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In 1991, Ireland reported the rearrangement of an allylic ester containing an allylic enol 
ether.
1
 This was followed by the publication of Kazmaier who reported the chelated 
enolate rearrangement of allylic amino esters.
2
 It was envisaged that the combination of 
these two fragments would lead to a suitable allylic enol ether amino ester substrate that 
upon rearrangement would deliver -hydroxy -amino acids. 
 
Initial efforts investigated the synthesis of the desired allylic enol ether amino esters 
with several routes being pursued. After significant investigation, synthesis of an allylic 
amino ester substrate was successfully completed. With the required substrate in hand 
significant investigation into employing Kazmaiers’ protocol was found to be 
detrimental to the desired rearrangement, instead promoting competitive decomposition 
pathways. Switching to imide nitrogen protection and employing a more traditional 
Ireland-Claisen protocol, the allylic amino ester underwent a syn-selective [3,3]-
sigmatropic rearrangement. This rearrangement was seen to be general, with a large 
range of O-functionality being investigated and offering yields of 50 – 81% and 
diastereoselectivites of ≥8:1.  
 
The rearrangement of several other allylic amino esters, containing other protecting 
groups lead to little or no selectivity being observed, however utilizing N-diboc glycine 
the rearrangent was observed to take place with diastereoselective control. A study of 
the formation of the silyl ketene acetals showed a correlation between the (E)/(Z) 
geometry of the silyl ketene acetal formed and the diastereoselectivity observed within 
the rearrangement of the methoxy enol ether derived allylic amino ether substrate. The 
rearrangement using N-diboc glycine based substrates was also seen to be general with a 
range of O-functionality offering yields of 40 – 80% all being obtained as single 
diastereomers. 
 
Access to the anti-diastereomer has been limited, being achieved in a 58% yield with a 
diastereoselectivity of 1.5:1. Several other transformations of the -alkoxy -amino 
esters products have also been shown. Finally the developed methodology was 
incorporated in a formal synthesis of furanomycin starting from (S)-butyn-2-ol, in 4.9% 
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Ac  acetyl 
app d  apparent doublet 
app t  apparent triplet 
aq  aqueous 
AQN  anthraquinone 
BINAP 2,2’-bis(diphenylphosphino)-1,1’-binapthyl 
Bn  benzyl 
Boc  tert-butyloxycarbonyl 
br  broad 
BTTP  tert-butyliminotri(pyrrolidino)-phosphorane 
Bz  benzoyl 
Cat  catalyst 




Cy  cyclohexyl 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DCC  N,N’-dicyclohexylcarbodiimide 
DCE  dichloroethane 
DCM  dichloromethane 
d  doublet 
dd  doublet of doublets 
ddd  doublet of doublet of doublets 
DET  diethyl tartrate 
DHQD  dihydroquinidine 
DIBAL-H diisobutyl aluminium hydride 
DMAP  4-dimethylamino pyridine 
DMF  dimethyl formamide 
DMS  dimethyl sulfide 
DMSO  dimethyl sulfoxide 
dr  diastereomeric ratio 
DTA  D-threonine aldolase 
DTT  dithiothretiol 
E  electrophile 
EDCi.HCl 1-ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride 
ee  enantiomeric excess 
Equiv  equivalents 
Et  ethyl 
Grubbs (I) benzylidene-bis(tricyclohexylphosphine)dichlororuthenium 
HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HMDS  hexamethyldisilazane 
HMPA  hexamethylphosphoramide 
HPLC  high pressure liquid chromatography 
hr  hour(s) 
Hz  hertz 
i
Pr  isopropyl 
  viii 
KHMDS potassium hexamethyldisilizide 
LiICA  lithium dicyclohexylamine 
LiHMDS lithium hexamethyldisilizide 
LDA  lithium diisopropylamine 
LTA  L-threonine aldolase 
m  multiplet 
Me  methyl 
MOM  methoxymethyl ether 
MPLC  medium pressure liquid chromatography 
MXn   metal 
m/z  mass charge ratio 
NaHMDS sodium hexamethyldisilizide 
NBS  N-bromosuccinimde 
NMM  N-methylmorpholine 
NMR  nuclear magnetic resonance 
NOe  nuclear overhauser effect 
P  protecting group 
Ph  phenyl 
PHAL  phthalazine  
PhH  benzene 
PhMe  toluene 
Phth  phthaloyl 
PLP  pyridoxal phosphate 
PMB  p-methoxybenyzl 
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RT  room temperature 
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TEMPO 2,2,6,6-tetramethylpiperidine-1-oxyl 
TFA  trifluoroacetic acid 
TFAA  trifluoroacetic anhydride 
TMS  trimethylsilyl 
TMSCl trimethylsilyl chloride
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CHAPTER 1 INTRODUCTION 
 
1.1 PEPTIDES 
Peptides are natural polymers consisting of a series of up to fifty amino acid monomers, 
linked via a peptide bond under nucleic control.
3
 Synthetic preparation either in vivo or 
in vitro, usually takes place via condensation reactions, however activation of the 
reaction differs (Scheme 1). 
 
 
Scheme 1: Peptide bond formation 
 
The structure of the peptides can be further elaborated by inter- and/or intra-chain 
interactions of side chains and therefore lead to a tertiary structure. With human 
biochemistry being regulated by peptic hormones and enzymatic pathways, it critical for 
stereochemical information contained upon the amino acids fragments to be retained 
during peptide synthesis.
3
 Vasopressin 4, a pituitary nonapeptide, was one of the first 
peptides to be prepared synthetically and displays an intra-molecular interaction with a 





Figure 1: Vasopressin 
 
Due to the overall complexity of peptides and proteins, a trivial system of naming has 
been developed. Each proteinogenic amino acid has been assigned a three letter code 
(Appendix 7.1). Using this system, individual amino acids along the protein chain can 
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easily be identified. Vasopressin 4 has again been represented below, using the 
abbreviated formula (Figure 2). 
 
 
Figure 2: Abbreviated representation of Vasopressin 
 
 1.1.1 Amino acids 
Amino acids are molecules that contain both carboxylic acid and amine functionalities. 
Proteinogenic amino acids are the twenty naturally occurring amino acids that are found 
within proteins and that are coded for in the standard genetic code.
4
 Proteinogenic 
literally means 'protein-building' and it is these amino acids that make up the peptides 




  Nomenclature of amino acids 
The most common type of amino acids found in nature are -amino acids. These amino 
acids comprise of both the carboxylic acid and amine functionalities bonded to the same 
-carbon. Other types of amino acids are classified by the number of carbon linkers 
separating the amine and carboxylic acid functional groups, as demonstarted below with 
alanine (Figure 3). 
 
 
Figure 3: Examples of - and -amino acids 
 
Another type of nomenclature refers to the specific enantiomer of an amino acid. The L- 
and D- nomenclature does not refer to the optical activity of the amino acid, instead this 
refers to the optical activity of the isomer of glyceraldehyde that the amino acid can 
theoretically be synthesized from (Figure 4).
6
 Alternatively, (R) or (S) designators can 
be used to indicate absolute stereochemistry of the specific amino acid. 
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Figure 4: Theoretical synthesis of L-serine 
 
  1.1.2 -Hydroxy -amino acids 
-Hydroxy -amino acids are seen as an important subgroup of amino acids. The 
importance of these molecules can be displayed with two key examples that represent 
10% of proteinogenic amino acids: threonine and serine. 
  
   Threonine  
Threonine is one of the eight essential amino acids, so called, since they must be 
obtained from food or other sources, since synthesis cannot occur within the body.
7
 The 
threonine moiety is susceptible to many post-translational modifications. The hydroxyl 
group can undergo O-linked glycosylation and also phosphorylation can occur through 
the action of threonine kinase. 
 
With two chiral centres, four possible stereoisomers of threonine can exist. L-threonine 
refers to one diastereomer whereas L-allo-threonine refers to the other. The same is 
applicable to D-threonine (Figure 5). 
 
 
Figure 5: Diastereomers of L-threonine 
 
Serine 
Serine is not considered an essential amino acid. In healthy adults, serine can be 
synthesized within the body via a condensation between glycine and activated 
formaldehyde. However, in clinical situations such as impaired kidney function, 
endogenous synthesis may not cover serine requirements and therefore supplements 
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1.2 -HYDROXY -AMINO ACIDS IN NATRUAL PRODUCTS 
The -hydroxy -amino acid moiety is prevalently distributed throughout a significant 
number of compounds isolated from natural products, with a sizeable proportion having 
biological activity.
9
 None of the examples detailed below include serine or threonine 
containing peptides and in all examples the -hydroxy -amino acid functionality 
highlighted in red. 

 1.2.1 -Hydroxy -amino acids 
The-hydroxy -amino acid moiety is found in large number natural products. For 
example, kaitocephalin 7 (Figure 6), was first isolated in 1997 by Shin-Ya and co-
workers from the filamentous fungus Eupenicillium shearii PF1191.
10
 This novel 
pyrrolidine based alkaloid is a naturally occurring glutamate receptor antagonist. Initial 
biological screening showed a suppression of kainic acid toxicity with an EC50 value of 
0.68 M concentration. These results prompted kaitocephalin to be examined as a 
potential lead compound in the development of therapeutic agents to treat neurological 





Figure 6: Kaitocephalin 
 
Sphingofungins were first isolated from Aspergillus and Paeciomyces in 1982 within 
the laboratories at Merck.
12
 This class of compounds has significant antifungal 
properties, acting as inhibitors of serine palmitoyl transferease.
13
 These novel 
polyhydroxyamino acids, containing four contiguous stereocentres makes these 
compounds particularly interesting as total synthesis targets. Sphingofungin E, 8 (Figure 
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Figure 7: Sphingofungin E 
 
Altemicidin 9 (Figure 8), a six-azainden monoterpene alkaloid was first isolated from 
the a group of gram-positive bacteria Actinomycete, in 1989 by Takeuchi and co-
workers.
15
 Strong acaricidal activity along with the inhibition of tumour cell growth 
shows the importance of this compound.  
 
 
Figure 8: Altemicidin 
 
1.2.2 -Alkoxy -amino acids 
Several natural products contain alkylated -hydroxy -amino acids. Brasilicardin A 
10 (Figure 9), was first isolated from the cultured broth of Nocardia brasiliensis 
IFM0406 by Kobayashi et al. in 1998.
16
 This compound consists of a -alkoxy -amino 
acid and a sugar moiety based upon a perhydrophenanthrene skeleton. Preliminary 
investigations showed strong immunosuppressive activity in a mouse mixed-
lymphocyte reaction assay system with an IC50 value of 0.057 g/mL.
17
 Brasilicardin A 
also exhibits strong antifungal activity against several other screens. When tested 
against 38 human tumour cell lines, brasilicardin A showed a striking pattern of 
differential cytotoxicity, however no significant correlations against known antitumor 
compounds were observed. 
 
Figure 9: Brasilicardin A 
Chapter 1                                                                                                          Introduction 
 6 
Renieramycin D 11 (Figure 10), is a member of a growing family of antimicrobaial 
metabolites isolated from a bright blue sponge of the genus Reniera in 1982 by 
Faulkner et al.
18





Figure 10: Renieramycin D 
 
Pauamides A and B, two cyclic depsipeptides that have been isolted from a collection of 
marine sponges Theneolla mirabilis and Theonella swinhoei in 1999, by Andersen et 
al.
20
 Structurally, pauamide A 12, comprises of a 22-membered macrocycle connected 
to a complex linear tetrapeptide through an amide bond (Figure 11). Several non-
proteinogenic amino acid residues are present and in particular several -alkoxy -
amino acid subunits including -methoxytyrosine.21 Recent interest in these molecules 
is due to their strong inhibitory effect on the infection of human T-lymphoblastoid cells 
by HIV-1RF, with an EC50 value of 4 ng/mL.  
 
 
Figure 11: Pauamide A 
 
Callipeltin A 13 (Figure 12), another cyclic depsipeptide was first isolated from a 
shallow water marine sponge of the genus Callipelta by Minale et al. in 1999.
22
 More 
recently the group of Luciani has shown that it acts as a powerful inhibitor of cardiac 
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Figure 12: Callipeltin A 
 
The family of cyclomarins were isolated from a marine bacterium in 1999 by Clardy et 
al.
24
 The major constituent, cyclomarin A 14 (Figure 13), displays significant anti-
cancer and anti-inflammatory activities both in, in vitro and in vivo assays. Intensive 
biological evaluation of cyclomarin C is somewhat limited due to the low availability of 
only 3% from nature.
25
 These cyclic heptapeptides each contain four non-coded amino 
acids, including -methoxyphenylalanine, another -alkoxy -amino acid subunit.  
 
 
Figure 13: Cyclomarin A 

1.2.3 -Aryloxy -amino acids 
There are also several examples of -aryloxy -amino acids within nature, typically 
based around a similar cyclopetide alkaloid structure. Sanjoinine G1 15 (Figure 14), is 
one cyclopeptide alkaloid that has been isolated from the seed of Zizyphus vulgaris var. 
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spinosus by Han et al. in 1989.
26
 These seeds have reportedly been used in the treatment 




    
Figure 14: Sanjoinine G1 
 
Adouetine Y 16 (Figure 15), another cyclopeptide alkaloid which was isolated from 
Melochia corchorifolia by Tschesche and Reutel in 1968.
28
 Extracts from this species of 
plant found in hot parts of India have been reported in folk law as medicines to cure 





Figure 15: Adouetine Y 
 
1.2.4 -Cyclic ether -amino acid derivatives 
Several examples of naturally occurring -hydroxy -amino acids have the -hydroxy 
functionality contained within a five/six member ring. Polyoxins are a class of 
pyrimidine nucleoside peptide antibiotics isolated from Streptomyces cacaoi var. 
asoensis by Isono et al. in 1969.
30
 Polyoxins have displayed noteworthy activity against 
phytopathogenic fungi whilst being ineffective against plants or animals, therefore 
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Figure 16: Polyoxin B 
 
Amipurimycin 18, (Figure 17) is a complex member of a family of peptidyl nucleosides 
isolated from Streptomyces novoguineensis sp. by Kishi et al. in 1976.
32
 Amipurimycin 
displays outstanding antifungal activity against several phytopathogenic fungi. In field 
tests, it showed exceptional control of blast disease of rice plants. However, only 
limited toxicity studies have been carried out. 
 
 
Figure 17: Amipurimycin 
 
Miharamycins A and B (Figure 18) were both isolated from Streptomyces miharaensis 
SF-489 by Niida et al. in 1967.
33
 The peptidyl nucleosides have also been to have strong 





Figure 18: Miharamycin B 

1.2.5 -Hydroxy -amino acid acyl derivatives 
Several -hydroxy -amino acid acyl moieties are present in a large number of 
biologically active molecules. Salinosporamide A 20 (Figure 19), a densely 
functionalized γ-lactam-β-lactone bicycle, was isolated by Feical and co-workers in 
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2003 as a bioactive product of a marine actinomyctete bacterium commonly found 
within ocean sediment.
34
 Biological testing of salinosporamide A showed it to be an 
extremely effective proteasome inhibitor, displaying high in vitro cytotoxic activity 
against several tumour cells lines with IC50 values of less then 10 nM.
35
 Such is the 
activity, this potential anticancer agent recently entered phase I of human clinical trials 





Figure 19: Salinosporamide A 
 
Oxazolomycin A 21 (Figure 20), was isolated from the fermented broth of Streptomyces 
sp. in 1985 by Uemura et al. during their study into molecules with inhibitory activity 
against Ehrlich ascites tumour.
37
 Oxazoloymcins exhibit a wide range of antibitotic 
activity against gram-positive bacteria, antiviral activity against vaccinia, herpes 





Figure 20: Oxazolomycin A 
 
Lactacystin 22 (Figure 21), a -lactam, was isolated from a cultured broth of 
Streptomyces sp. OM-6519 by Omura et al. in 1991.
39
 This compound induces neurite 
outgrowth in the neuroblastoma cell line therefore prompting a study in the use against 
neurologically related diseases such as Alzheimer’s.40 
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Figure 21: Lactacystin 
 
 
1.3 SYNTHESIS OF -HYDROXY -AMINO ACIDS 
Due to the importance of the -hydroxy -amino acid moiety and the large proportion 
of -hydroxy -amino acid containing natural products, there has been significant 
interest within the synthetic organic community towards the preparation of these 
compounds. As such, in recent years a significant number of protocols have been 
developed and existing methods have been improved, thus showing the importance of 
this class of compound. One of the major challenges of synthesizing the β-hydroxy-α-
amino acid unit is obtaining control of diastereo- and enantioselectivity. As a result, 
complete control in the synthesis of β-hydroxy-α-amino acids presents a challenging 
and desirable target to synthetic chemists. Several routes towards these compounds will 
now be discussed: 
 
1.3.1 Aldol reactions 
The first example of the use of an aldol condensation in the synthesis of -hydroxy -
amino acids was reported by Schöllkopf et al. in 1980 (Scheme 2).
41
 Starting from L-
alanine methyl ester and subjecting this to heat, afforded cyclic dimer 23. Reacting 
dimer 23 with trimethyloxonium tetrafluoroborate delivered the required bis-lactim 24. 
The ensuing aldol condensation between 24 and acetophenone, followed by acidic 
work-up generated the β-hydroxy-α-amino ester 25 in good yield and high 
diastereoselectivity with a moderate enantiomeric excess. Remaining L-alanine methyl 
ester starting material could also be recovered.  
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Scheme 2: Synthesis of the -hydroxy -amino acid moiety via an aldol condensation of L-alanine 
methyl ester 
 
Belokon et al. reported the condensation of formaldehyde with a Nickel (II) schiff base 
and chiral glycine derivative complex 26, to afford (S)-serine 27 in high enantiomeric 
excess in 1985 (Scheme 3).
42
 A switch in reactivity was observed to afford (R)-serine 
should the reaction be carried out in the of presence sodium methoxide at a 
concentration of greater than 0.2 N, however a reduced enantiomeric excess is obtained. 
  
 
Scheme 3: Aldol condensation utilizing a nickel schiff base complex 
 
Molinski and MacMillian developed a new approach to several enantioenriched 
diastereomers of -hydroxyleucine and -hydroxythreonine to aid in the determination 
of the absolute stereochemistry of the novel antifungal cyclododecapeptide, 
lobocyclamide B (Scheme 4).
43
 Treating the lithium enolate of N-
(diphenylmethylene)glycine tert-butyl ester 28, in the presence of (-)-sparteine with 
isobutyraldehyde afforded both the threo oxazolidine 29 and erythro imine 30 in good 
yields with high levels of asymmetric induction. 
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Scheme 4: Aldol condensation synthesis of -hydroxyleucine 
 
Compounds 29 and 30 were easily separable by chromatography and both showed 
enantioselectivities of 60% and 56% respectively. The individual compounds were 
converted through to their respective diastereomer of -hydroxyleucine. The 
configuration of each diastereomer was determined by comparison of optical rotations 
with literature values. Subsqently this methodology was applied to the synthesis of -
hydroxythreonine isomers starting from N-(diphenylmethylene)glycine tert-butyl ester 
28, and 2-(benzyloxy)acetaldehyde, where both were obtained in 58% and 56% ee. 
 
The aldol reaction between glycine-derived silicon enolates and aldehydes has been 
developed by Kobayashi et al. (Scheme 5).
44
 The aldol condensation between 
benzaldehyde 32 and silyl ketene acetal 33 with a chiral binolzirconium catalyst, 
prepared in situ proceeded through to the anti--hydroxy -amino acid 34 in high yield 
and excellent enantio- and diastereoselectivity. 
Scheme 5: Aldol condensation between an aldehyde and silyl ketene acetal 33 
 
In 2004, Barbas III et al. reported a highly enantioselective route to anti--hydroxy -
amino acids utilizing an organocatalytic approach (Scheme 6).
45
 Using L-proline, an 
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organocatalytic asymmetric aldol reaction between phthaloyl protected glycine aldehyde 
35 and isobutyraldehyde, afforded anti--hydroxy -amino aldehyde 36 in excellent 
diastereo- and enantioselectivity. Subsequent protection transformed 36 into protected 
anti--hydroxy -amino ester 37 to aid with isolation and purification. 
 
Scheme 6: Organocatalytic asymmetric aldol synthesis 
 
The use of phthaloyl protected glycine aldehyde 35 was critical for the success of this 
reaction. The enamine intermediate formed between 35 and proline is capable of 
reacting via one of two pathways (Scheme 7). Protection of the amine as a phthalamide 
allowed for a selective enamine reaction via path A, when compared to other more 
traditional orthogonal protecting groups such as tert-butyloxycarbonyl (Boc) and 
benzoyl (Bz). 
 
Scheme 7: Possible reaction pathways of an enamine intermediate with an electrophile 
 
Willis et al. reported a highly stereoselective synthesis of protected aryl-substituted β-
hydroxy-α-amino acids. (Scheme 8).46 Using a chiral magnesium catalyst and an amine 
base they generated a chiral glycine enolate. This enolate undergoes enantioselective 
addition to an aldehyde to form a protected aryl -hydroxy--amino acid in good yield 
with high enantioselectivity. 
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Scheme 8: Willis’ approach to protected aryl-substituted β-hydroxy-α-amino acids 
 
It was observed that substitution on the aryl ring had a profound impact on the 
diastereoselectivity. A wide range of electron rich and electron deficient substituents 
were tolerated in the para or meta position without significant changes to diastereo- and 
enantioselectivity. However, when ortho-tolualdehyde was used, enantioselectivity was 
retained, but a 1:1 diastereomeric mixture was obtained. 
 
Castle et al. developed several cinchona alkaloid phase transfer catalysts based upon the 
Park-Jew chiral quaternary ammonium salts for use in an aldol reaction (Scheme 9).
47
 
These catalysts exhibited reasonable yields with modest levels of enantioselectivity; 
however, poor diastereoselectivity was achieved. In the aldol reaction between 
hydrocinnamaldehyde 41, and tert-butyl glycinate benzophenone imine 42, catalyst 44 
gave the highest yield (86%), but with poor diastereomeric control. In comparison 
catalyst 45 gave a considerably better diastereoselectivity (1:4.7 syn/anti), however the 
desired product was obtained in a lower yield and very limited enantiomeric excess of 




Scheme 9: Cinchona alkaloid catalysts approach  
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Franck et al. have recently reported a simple aldol route to access protected syn--
hydroxy--amino acids derivatives (Scheme 10).48 
 
Scheme 10: Titanium mediated aldol condensation 
 
The reaction between the stable titanium enolate 47 and an aldehyde, delivered the syn-
aldol product 48, in good yield and excellent diastereoselectivity. Due to the sensitivity 
of the product, it was subjected to methanolysis to cleave the thiocarbamate auxiliary 
and afford the methyl ester 49. Notably a small degree of epimerisation occurred during 
this methanolysis.  
 
1.3.2 Enzymatic aldol reactions 
The use of enzymes in an aldol condensation is a popular method for the formation of 
the -hydroxy -amino acid moiety. Zhang and co-workers reported the use of serine 
hydroxyl-methyl transferase (SHMT) as a catalyst in an aldol condensation between 
glycine 50 and 4-pentenal 51 (Scheme 11).
49
 The enzyme successfully catalysed the 
reaction in good yield and excellent diastereoselectivity to obtain desired anti-β-
hydroxy-α-amino acid 52. Amino acid 52 was in turn used as a precursor in the total 
synthesis of loracarbef. 
 
Scheme 11: SHMT catalysed aldol condensation 
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In 2007, Griengl et al. investigated the enzymatic aldol reaction between substituted 
benzaldehydes and glycine using L-threonine aldolase (LTA) and D-threonine aldolase 
(DTA) (Scheme 12).
50
 They observed a strict requirement for glycine to be used as a 
donor, however a large range of aliphatic and aromatic aldehydes are tolerated. They 
found that LTA can operate within a range of pH (6-9). Using a sterically demanding 
aryl aldehyde, such as 2-chlorobenzaldehyde 32, high yield and moderate 
diastereomeric excess was achieved. 
 
 
Scheme 12: LTA catalysed aldol condensation  
 
Utilizing the same substituted benzaldehydes the aldol condensation was also 
investigated under optimised DTA conditions. In comparison, these condensations 
required a slightly higher and more consistent pH of 9.5 and the addition of 
stoichiometric manganese dichloride (Scheme 13). 
 
 
Scheme 13: DTA catalysed aldol condensation 
 
Comparable diastereoselectivities were obtained for all chloro- and 
bromobenzaldehydes. Under the DTA derived conditions, substituents on the aromatic 
ring had a more profound effect with meta substituted benzaldehydes affording higher 
yields and diastereoselectivites. All ortho substituted benzaldehydes delivered modest 
yields along with depleted selectivity at the -carbon. Therefore active site DTA must be 
more rigid and unable to occupy bulky benzaldehydes, especially ortho substituted 
variants.  
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Further investigation has lead to the enzymatic aldol reaction between sterically 
demanding aliphatic aldehydes such as halogenated acetaldehydes or long chain 
aldehydes and glycine, in the formation of L--threonines (Scheme 14).51 
 
 
Scheme 14: LTA catalysed aldol condensation utilizing sterically demanding aldehydes 
 
Diastereoselectivity for the halogenated aldehydes was excellent, however the use of 
acetaldehyde displayed no stereoselectivity at the -carbon. Long carbon chain 
aldehydes (C7 and greater) displayed a switch in selectivity, with the anti-diastereomer 
being preferentially formed, however a much reduced yield and diastereoselectivity was 
obtained. The switch in selectivity occurs due to the limiting size of the hydrophobic 
pocket of the enzyme. 
 
In a recent communication, Griengl et al. have shown the first example of a LTA 





Scheme 15: LTA catalysed aldol condensation utilizing serine 
 
A strict specificity of this reaction is the requirement of unnatural D-amino acids. Along 
with this only three amino acids, alanine, cysteine and serine have been shown to act as 
suitable donors. However this publication is one of the first reports of threonine aldolase 
promoted enzymatic aldol condenstations in the synthesis of -hydroxy -amino acids 
containing -quaternary centres. 
 
Riva et al. investigated the use of -carboxy-aldehydes in a LTA catalysed aldol 
reactions (Scheme 16).
53
 Glycoxylic acid 58, and a large excess of glycine 50, were 
Chapter 1                                                                                                          Introduction 
 19 
treated under optimised LTA conditions for 48 hours, resulting in the formation of -
carboxy--hydroxy--amino acid 60.  
 
 
Scheme 16: LTA catalysed aldol reaction of -carboxy-aldehydes 
 
Removal of excess glycine via ion-exchange chromatography, followed by 
lyophilization, allowed for the successful isolation of 59 in 68% yield as a 1:1 mixture 
of diastereomers. Derivatization of both diastereomers allowed separation of both 
isomers by flash chromatography. 
 
Fesko et al. have shown that a Y265A mutant of alanine racemase is a suitable catalyst 
for the synthesis of -hydroxy--amino acids (Scheme 17).54 In all cases, excellent 
enantio- and high diastereoselectivities were achieved, however in all examples low 
yields were obtained.  
 
Scheme 17: Y265A mutant of alanine racemase catalysed aldol reaction 
 
1.3.3 Strecker reaction 
Another route to -hydroxy -amino acids was developed by Davis et al. in 2000.55 An 
asymmetric route was established utilizing a sulfinimine-mediated Strecker reaction 
(Scheme 18). 
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Scheme 18: Strecker reaction approach to -hydroxy -amino acids  
 
Treatment of the protected aldehyde 63 with p-toluenesulfinamide 64 in the presence of 
of six equivalents of tetraethoxytitanium afforded the sulfinimine 65 in moderate yield. 
Upon subjection to ethylaluminium cyanoisopropoxide (generated in situ), the nitrile is 
added selectively to the re-face of the sulfinimine, due to the control of the sulfinyl 
group. The desired product 66 was afforded in excellent yield and good 
diastereoselectivity. Hydrolysis of the major diastereomer afforded anti-31, in 64% 
isolated yield and enantiomeric excess of greater than 95%. It should also be noted that 
the three other stereoisomers of 3-hydroxyleucine can also be synthesised via this 
method. 
 
1.3.4 Dihydroxylation approaches 
Alternative routes to -hydroxy -amino acid have utilized Sharpless enantioselective 





Scheme 19: Dihydroxylation approach to -hydroxy -amino acids 
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Riera utilized Sharpless’ syn-dihydroxylation protocol with olefin 67, to form diol 68. 
Subjecting diol 68 to sulfuryl chloride in the presence of triethylamine afforded the 
required sulfate 69. Ring opening with sodium azide, delivered the azido alcohol 70 in 
good yield. Hydrogenation followed by in situ boc-protection lead to the protected β-
hydroxy-α-amino ester 71 in a respectable yield. This route has the advantage of 
delivering an enantiopure diol in one step early in the synthesis, which in turn allows for 




Protocols have also been developed for the synthesis of -hydroxy -amino acids via 
Sharpless’ asymmetric aminohydroxylation of alkenes. One advantage of this protocol 
over the dihydroxylation methodology is the simultaneous introduction of amino and 
hydroxyl functionality.  
 
Panek reported the useof  this methodology in 1999, starting from ,-unsaturated aryl 
ester substrates (Scheme 20).
57
 Treatment of cinnamate 72 with Sharpless’ 
aminohydroxylation conditions delivered the protected -hydroxy -amino acid in good 
yield and high enantioselectivity, however only moderate regioselectivity was achieved. 
After several recrystallisations, both the regio- and enantioselectivities were improved 
to >20:1 and 99% respectfully.  
 
 
Scheme 20: Aminohydroxylation approach to -hydroxy -amino acids 
 
The use of an aromatic ester was vital to obtain high regioselectivity. Using an ethyl 
ester cinnamate a switch in regioselectivity was observed and the -hydroxy -amino 
ester was isolated as the sole regioisomeric product. The switch in regioselectivity is 
thought to arise from a change in conformation of the aryl ester substrate. NOE 
experiments were performed, and in the case of cinnamate 72 a significant NOE was 
observed between the ortho aryl protons and the -vinylic proton, indicating a s-cis 
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conformer (Figure 22). Since no NOE was observed between the -vinylic proton and 
the ethyl group for the ethyl ester substrate 74, this indicated a preference for the s-trans 




Figure 22: NOE confirmation of the change conformation between an aryl and an alkyl cinnamate  
 
Panek also postulated that more productive stacking interactions between the 
aromatic cinnamate and the (DHQ)2-AQN alkaloid ligand, also may account for the 
switch in regioselectivity. Further investigation using Hammett-type analysis of several 
para-substituted aromatic ester cinnamates showed that the level of enantioselectivity 
achieved can be directly related to the electronic properties of the olefinic substrate.  
 
Further work within this area was published by Zhou et al. in 2000.
58
 They showed that 
using heteroaromatic acrylate 76, along with the sodium salt of N-
chlorobenzylcarbamate under Sharpless’ aminohydroxylation conditions afforded the 
desired -hydroxy -amino acid moiety 77 in a high regio- and enantioselective fashion 
(Scheme 21). 
 
Scheme 21: Aminohydroxylation approach to -hydroxy -amino acids 
 
In particular, thienyl acrylates afforded that best regioselectivity, whereas the use of 
furyl derivatives lead to diminished selectivity. Pyrrolyl acrylates were inert under these 
reaction conditions. Subsequent protection and oxidation yielded the protected -
hydroxy -amino acid 78 in 68%. 
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1.3.6 Epoxidations 
Genet investigated a diastereoselective opening of epoxides with suitable nitrogen 
donors to afford β-hydroxy-α-amino acids (Scheme 22).59 Wittig olefination of the 
enantiopure - unsaturated aldehyde 79 gives the unsaturated ester, and subsequent 
DIBAL-H reduction furnishes a substituted allylic alcohol 80. Treatment with 
Sharpless’ asymmetric epoxidation catalyst delivered the epoxy-alcohol and ensuing 
PDC oxidation afforded epoxy carboxylic acid 81 in 81% yield. Treatment of 81 with 
methylamine afforded the N-substituted anti-β-hydroxy-α-amino acid 82 in a 24 % yield 




Scheme 22: Epoxide opening approach to anti-β-hydroxy-α-amino acids 
 
Similar methodology can be employed to obtain the syn-diastereomer (Scheme 23). 
Treating allylic alcohol 83 with Sharpless’ asymmetric epoxidation catalyst delivered 
the cis-epoxy alcohol 84 after a MPLC separation in a moderate diastereomeric excess 
of 70%. The desired syn-β-hydroxy-α-amino acid 86 was obtained by using the same 
oxidation and regioselective epoxide opening protocols used to access the anti-product. 
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Scheme 23: Epoxide opening approach to syn-β-hydroxy-α-amino acids 
 
1.3.7 Azomethine ylide 
Alker et al. reported the application of an azomethine ylide cycloaddition approach 
towards the synthesis of β-hydroxy-α-amino acids (Scheme 24).60 Taking (5S)-5-
phenylmorpholine-2-one 87 with an aldehyde under either Lewis acid or thermal 
conditions generates an azomethine ylide species as single isomer. A 1,3-dipolar 
cycloaddition with a second equivalent of an aldehyde delivers cycloadduct 88, which 
represents a protected β-hydroxy-α-amino acid. Subjecting 88 to hydrogenolysis 
conditions furnishes amino acid 89. 
 
 
Scheme 24: Azomethine ylide cycloaddition approach towards the synthesis of  
β-hydroxy-α-amino acids 
 
When alkyl aldehydes were subjected to the hydrogenolysis conditions, an inseparable 
mixture of the free amino acid and its N-alkylated counterpart were isolated. Upon 
investigation, refluxing cycloadduct 90 in methonolic hydrochloric acid led to the 
opening of the lactone with concomitant esterification to form the amino ester derivative 
91 (Scheme 25). Both methods delivered the desired products in moderate yield. 
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Scheme 25: Azomethine ylid cycloaddition approach utilizing alkyl aldehydes 
 
1.3.8 Hydrogenation and dynamic kinetic resolution 
Hamada et al. have shown that a stereoselective synthesis of anti--hydroxy--amino 
acids can be achieved via dynamic kinetic resolution (DKR) (Scheme 26).
61
 DKR of the 
-keto-ester 92 and subsequent protection afforded the protected anti--hydroxy--
amino acid 94 in good yield and excellent diastereoselectivity and enantiomeric excess.  
 
Scheme 26: Hamada’s dynamic kinetic resolution approach to anti--hydroxy--amino acids 
 
The use of -amino--keto ester substrates containing secondary carbon units  to the 
ketone, produced products with higher diastereo- and enantioselectivity, in comparison 
to primary alkyl chains. Aromatic substituents required more forcing conditions with 
the use of higher temperatures (Scheme 27).  
 
Scheme 27: DKR of aromatic derived substrates 
 
A greater yield and excellent diastereoselectivity was achieved with aromatic substrates, 
however with minimal chiral induction. These results suggest that hydrogenation with 
the Ru–BINAP catalyst is affected by the structure at the C4 position of the-amino--
keto ester. Nonetheless, these represent the first example of anti selective hydrogenation 
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of -amino--keto esters with high diastereo- and enantioselectivity through dynamic 
kinetic resolution. 
  
In 1981 Noyori reported the hydrogenation of 2-acetamido -ketoester 98 to form syn-






Scheme 28: Noyori’s hydrogenation of 2-acetamido -ketoester 
 
Zhang et al. reported in 2004 the application of a  similar methodology in the synthesis 
of enantiomerically pure phthaloyl (Phth) protected allo-threonine 101 (Scheme 29).
63
 
Starting from -phthalimido--keto ester 100, a ruthenium catalysed dynamic kinetic 




Scheme 29: Zhang’s hydrogenation for the synthesis of anti--hydroxy -amino esters 
 
These two communications show that with careful selection of catalyst and conditions, 
all four isomers of threonine can be selectively synthesized. 
 
1.3.9 Oxy-Michael additions 
Dixon et al. have recently described a three step sequence to β-aryl β-hydroxy-α-amino 
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Scheme 30: Oxy-Michael addition approach towards -hydroxy -amino acids 
 
Addition of KHMDS to (S)-6-methyltetrahydro-2H-pyran-2-ol 102, in the presence of 
18-crown-6 formed a chiral lactol alkoxide. Subsequent 1,4-addition to nitroalkene 103 
gave intermediate 104 after quenching with acetic acid. Treatment of 104, with Raney 
nickel and subsequent Boc-protection delivered amino ester 105 in good yield and high 
selectivity at the -centre. High facial selectivity is achieved during the addition to the 
nitro olefin, in favour with the syn-diastereomer. Interestingly, the olefin geometry of 
the Michael acceptor has no bearing on stereoselectivity at the -carbon.  
 
1.3.10 Photocycloadditions 
β-Hydroxy-α-amino acid derivatives can be prepared via a photoaldol route as reported 
by Griesbeck in 2003 (Scheme 31).
65
 Photocycloadditions of 5-methoxyoxazole 106, 
with an aldehyde led to bicyclic oxetane 107. This cycloadduct was hydrolysed in 
aqueous acid to deliver -acylamino -hydroxy carboxylic acid ester 108 in high yield 
and diastereoselectivty.  
 
 
Scheme 31: Photocycloaddition approach 
 
In all examples using both aliphatic and aromatic aldehydes, only the exo regioisomer is 
observed for the bicyclic oxetane. Furthermore, the formation of congested quaternary 
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1.3.11 Oxazolidinone 
The group of Tomasini has reported a novel approach to protected syn--hydroxy -
amino acids via 5-carboxymethyl oxazolidin-2-ones (Scheme 32).
66
 Reaction of the 
lithium dianion of N-protectected -amino ester 109 with iodine afforded the aziridine 
110 in good yield and selectivity. Treatment with copper (II) triflate gave the 
oxazolidinone 111 in excellent yields without any loss of selectivity. The protected 
product can be transformed to the syn--hydroxy -amino acid 112 by subsequent 
hydrolysis. 
 
Scheme 32: Synthesis of -hydroxy -amino acids via an oxazolidinone 
 
1.3.12 Sigmatropic rearrangements 
Few sigmatropic approaches to the β-hydroxy-α-amino acid functionality have been 
reported. Sutherland et al. have developed a MOM-ether directed, palladium-catalysed 
Overmann rearrangement that proceeds to the desired product with high 
diastereoselectivity and good yields (Scheme 33).
67
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Scheme 33: Palladium catalysed Overmann rearrangement to β-hydroxy-α-amino acid 
 
Starting from enantiopure -hydroxy acids, the Overmann substrate is synthesised in six 
steps. Treating allylic trichloroacetamide 114 with catalytic palladium, initiates a [3,3]-
sigmatropic rearrangement, delivering rearranged product 115 in good yield and 
moderate diastereoselectivity. Sharpless oxidation and subsequent deprotection 
delivered the required β-hydroxy-α-amino acid 117 without any loss of 
diastereoselectivity. Addition of p-benzoquinone improved the diastereoselectivity of 
the rearrangement further to 14:1, as well as suppressing any competing [1,3]-anti-
Claisen rearrangement products being formed.  
 
1.4 PERICYCLIC REACTIONS 
Pericyclic reactions take place through concerted cyclic mechanisms, with all bond 
forming and breaking occurring simultaneously and without any intermediates or no 
formal charges being formed.
68
 There are four main classes of pericyclic reactions: 
cycloadditions, electrocyclic reactions, group transfer reactions and sigmatropic 
rearrangements (Figure 23). 
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Figure 23: Examples of Pericyclic reactions 
 
All pericyclic reactions can be classified according to the change in the number -bonds 
within the system. Cycloadditions result in the formation or loss of two -bonds, 
electrocyclic and group transfers change of one -bond, whilst sigmatropic 
rearrangements show a migration of a -bond, therefore a change of zero. 
 
It was foreseen that the use of an Ireland-Claisen rearrangement as the key synthetic 
step in the synthesis of -alkoxy -amino acids would be beneficial. The versatility of 
the rearrangement, allowing access to either diastereomer, by changing the enolisation 
conditions or set alkene geometry and ease of substrate preparation were two vital 
aspects that made this methodology appealing. Along with mild reaction conditions and 
a large number of functional groups tolerated under this conditions, made the use of this 
[3,3]-sigmatropic rearrangement applicable for use in the formation of large complex 
molecules. 
 
1.4.1 Sigmatropic rearrangements 
During a sigmatropic rearrangement, a single -bond migrates from one location in a 
molecule to another. All sigmatropic rearrangements are assigned by a [i,j] numerical 
classification system, referring to the number of atoms that each end of the bond has 
migrated over. Examples of this numbering system can be seen in Figure 24. 
 
 




Figure 24: [i,j] Numerical classification 
 
1.4.1.1 Claisen rearrangement 
The first reported example of a sigmatropic rearrangement was published in 1912, by 
Claisen. He observed the thermal rearrangement of allyl phenyl ether 118 to afford allyl 





Scheme 34: Claisen rearrangement 
 
There are two main types of Claisen rearrangements; the aliphatic Claisen 
rearrangement and the main topic of his seminal paper the aromatic Claisen 
rearrangement.  
 
The aromatic Claisen is the rearrangement of allylic aryl ethers to allylphenols upon 
heating. During the rearrangement an allylic shift is observed with the allylic fragment 
migrates to the ortho position of the phenolic ring. Rearomatisation of the ring to a 





Scheme 35: Aromatic Claisen rearrangement 
 
Should both ortho positions already be substituted, rearomatisation via this mechanism 
is not possible. Instead, a second migration of the allyl fragment to the para position via 
a [3,3]-sigmatropic Cope rearrangement is observed, followed by rearomatisation to the 
phenol (Scheme 36). 
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Scheme 36: Aromatic Claisen rearrangement 
 
The aliphatic Claisen rearrangement involves the heating of an allyl vinyl ether 121 to 






Scheme 37: Aliphatic Claisen rearrangement 
 
In 1994, Paquette et al. utilized an aliphatic Claisen rearrangement to afford a ring 





Scheme 38: Aliphatic Claisen rearrangement 
 
The Claisen rearrangement is the only pericyclic reaction to be observed in a primary 
metabolic pathway.
72
 The enzymatic aliphatic Claisen rearrangement of chorismate 125 
affords prehenate 126; a precursor for two essential amino acids; tyrosine and 
phenylalanine (Scheme 39).
73
 Chorismate mutase, the key enzyme involved is 
responsible for a rate acceleration of approximately one million compared to the 





Scheme 39: Enzymatic aliphatic Claisen rearrangement 
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1.4.1.2 Variants of the Claisen rearrangement 
There have been many variations of the Claisen rearrangement reported. The most 
popular examples of these include: 
 
Meerwein-Eschenmoser-Claisen rearrangement 









 carbinol systems. Benzyl alcohol 127 is converted to ketene N,O-acetal 
intermediate 128 upon subjection to dimethylacetamide dimethyl acetal under refluxing 
conditions. In turn follows a [3,3]-sigmatropic rearrangement through to ,-unsaturated 
amide 129 (Scheme 40). 
 
 
Scheme 40: Meerwein-Eschenmoser-Claisen rearrangement 
 
The neutral conditions of this rearrangement allow for the use of sensitive substrates, as 
long as they are thermally stable.  
 
Johnson-Claisen rearrangement 
The Johnson-Claisen rearrangement is closely related to the Eschenmoser 
rearrangement (Scheme 41). This rearrangement proceeds via ketene acetal 131 which 
results from the condensation of an ortho-ester and allylic alcohol 130.
81
 The 




Scheme 41: Johnson-Claisen rearrangement 
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Overmann rearrangement 
The Overmann rearrangement involves the thermal or mercuric catalysed rearrangement 
of allylic trichloroacetimidate 134 to afford trichloroacetamide 135.
82
 The allylic 
trichloroactimidates are easily prepared in one step by treating an allylic alcohol with 
trichloroacetonitrile in the presence of catalytic amounts of base (Scheme 42). 
 
 
Scheme 42: Overmann rearrangement 
 
Carroll rearrangement 
The thermal or anionic [3,3]-sigmatropic rearrangement of -keto-allylic esters to -
keto acids is known as the Carroll rearrangement.
83-84
 Ensuing decarboxylation leads to 
the corresponding ,-unsaturated ketone.  
 
 
Scheme 43: Carroll rearrangement 
 
Aza-Claisen rearrangement 
The Aza-Claisen utilizes a variant of the Claisen substrate which sees the substitution of 
the oxygen atom for a nitrogen atom.
85
 The rearrangement is a thermal process and both 




Scheme 44: Aza-Claisen rearrangement 
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A major disadvantage of the Aza-Claisen rearrangement is the extremely harsh 
conditions required and as a consequence very few applications of this rearrangement 
have been published. The development of mild zwitterionic variants have allowed for 






Scheme 45: Zwitterionic aza-Claisen rearrangement 
 
Ireland-Claisen rearrangement 
The Ireland-Claisen rearrangement utilizes an allylic silyl ketene acetal as a substrate 
(Scheme 46).
88
 Typical conditions require an allylic ester and treating this with a 
lithium dialkylamide base and a silyl chloride. Enolisation occurs and subsequent 
trapping as a silyl ketene acetal allows for a [3,3]-sigmatropic rearrangement to take 
place upon warming, affording a ,-unsaturated carboxylic acid after protic quench. 
The use of the protocol developed by Ireland, allows for rearrangement to take place at 
significantly lower temperatures than the Claisen rearrangement.  
 
 
Scheme 46: Ireland-Claisen rearrangement 
 
Ireland reported that silylation of the enolate suppressed side reactions such as 
decompostition via ketene pathways or aldol condensations occurring. It is presumed 
that this rearrangement is diastereoselective, since the rearrangement was presumed to 
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1.5 IRELAND-CLAISEN REARRANGEMENT 
Irelands’ seminal paper was not the first reported example of an ester enolate Claisen 
rearrangement. In 1937, Tseou and Wang reported the formation of pent-4-enoic acid 





Scheme 47: First reported Ireland-Claisen type rearrangement promoted by sodium metal 
 
Between Tseou’s publication and Irelands’ first communication, multiple reports can be 
found in the literature of ester enolate Claisen rearrangements to the corresponding ,-
unsaturated carboxylic acids.
90





 or diethylaminemagnesium bromide
92
 as bases to achieve the rearrangement, 
all however, suffered from low yields and the use of high reaction temperatures. 
 
The Ireland-Claisen rearrangement has been widely used within the synthetic chemistry 
community. Ireland reported in his seminal paper the synthetic utility of the improved 
rearrangement by incorporating the developed methodology into the synthesis of 





Scheme 48: Irelands’ Claisen rearrangement approach to dihydrojasmine 152 
 
Today the Ireland-Clasien rearrangement is still widely used throughout organic 
synthesis and this can be highlighted by the communication of Iwabuchi et al.(Scheme 
49)
93
 They used an Ireland-Claisen rearrangement in an enantioselective construction of 
the BCD ring system of daphnicyclidin A 158 and obtained carboxylic acid 155 in good 
yield. Subsequent protection of the acid as the benzyl ester, followed by silyl 
deprotection afforded 156 in 70% yield over the three steps and diastereomeric ratio of 
9:1. 
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Scheme 49: An Ireland-Claisen rearrangement towards the synthesis of Daphnicyclin A 158 
 
The popularity of the Ireland-Claisen rearrangement is due to several factors, mild 
reaction conditions, the ease of preparation of allylic ester substrates, and the ability to 
control the geometry of both the alkene fragment and the ester enolate, which in turn 
can lead to total diastereomeric control. If chiral allylic alcohols are used chirality 
transfer is possible, and also the ability to form congested quaternary centres is 
achievable. 
 
1.5.1 Stereochemical aspects of the Ireland-Claisen 
rearrangement 
An attractive feature of the Ireland-Claisen rearrangement is the ability to consistently 
transfer stereochemistry to either of the newly formed sp
3
 centres as well as the resultant 
alkene formed. Stereoselectivity is crucial to the synthesis of syn or anti pentenoic acids 
from their appropriate substituted allyl silyl ketene acetals. The outcome of this is 
determined by two factors; the geometry of both the allylic alkene and silyl ketene 
acetal and whether the reaction proceeds via a chair or boat transition state. 
 
  Enolate and silyl ketene acetal (SKA) Geometry 
In 1975, Ireland reported that ester enolates of propionates and related esters could be 
stereoselectively generated to give either the (E)- or (Z)-SKA when trapped with tert-
butyldimethylsilyl chloride (TBSCl) (Table 1).
94
 When THF was used as a solvent, the 
(E)-SKA was predominately formed, however, upon the addition of 23% HMPA a 
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reversal of selectivity was observed which saw the (Z)-SKA prevail. (E)-Selectivity was 
generally higher, except in the case of phenyl acetates where the (Z)-SKA prevails. 
 







 THF THF/23% HMPA 
   ((E)-159 : (Z)-159) ((E)-159 : (Z)-159) 
1 Et Me 91:9 16:84 
2 
t
Bu Me 97:3 9:91 
3 Et 
t
Bu 95:5 23:77 
4 Ph Me 29:71 5:95 
 
 
Acyclic allyl silyl ketene acetals 
Ireland has also demonstrated that the anti-2,3-dimethyl pentenoic acid isomer could be 
obtained by either rearrangement of the (E)-SKA of the (E)-crotyl propionate or from 
the (Z)-SKA of the (Z)-crotyl propionate.
1,83,88,95
 It was noted that comparable levels of 
diastereoselectivity was achieved no matter whether the (E)-crotyl, (E)-SKA or the (Z)-
crotyl, (Z)-SKA route was utilized. Conversely, the syn-acid could be obtained from the 
(E)-SKA of the (Z)-crotyl propionate or the (Z)-SKA of the (E)-crotyl propionate. This 
time however the diastereoselectivites increased from 5:1 to 8:1 (Scheme 50). 
 




Scheme 50: Acyclic allyl silyl ketene acetals 
 
These stereochemical outcomes are consistent with the rearrangement proceeding 
through a chair transition state. Computational analysis has calculated the energy 
difference between a chair and boat transition state to be 2.3 kcal/mol, therefore 




 Cyclic allyl silyl ketene acetals 
The rearrangement of cyclic substrates can occur through either chair or boat transition 
states. It has been reported by Ireland has that this preference is highly dependant on 
ring size, ring constitution and substituent stereochemistry.
97-98
 In 1981, Bartlett and 
Pizzo reported that cyclohexyl propionates rearrange to the same major isomer under 
both sets of Irelands’ conditions (Scheme 51).99 They concluded that the (E)-SKA 
rearranges via a chair-like transition state, whereas the (Z)-SKA goes through a boat-
like transistion state. This has more recently been supported by further computational 




Chapter 1                                                                                                          Introduction 
 40 
 
Scheme 51: Cyclic silyl ketene acetals 
 
In the case of dihydropyran- and dihydrofuran-derived allylic esters the boat transition 
state is favoured, irrespective of the silyl ketene acetal geometry (Scheme 52).
98
 There 
have been several proposals put forward to this, including that a greater C-O bond 
cleavage in the transition state reduces steric interactions between the methyl group and 
the ring. Greater bond cleavage results in a more polarized transition state and due to the 
improved overlap of the allyl fragments in a boat transition state, dihydropyran- and 
dihydrofuran-derived allylic esters will preferentially rearrange via a boat transition 
state. However this theory has yet to be fully elucidated and no supporting 
computational analysis has been reported. 
 
 
Scheme 52: Geometries of dihydropyran allylic silyl ketene acetals 
  
 Alkene stereochemistry 
The rearrangement of allylic esters derived from primary alcohols leads to the formation 
of terminal alkenes. If the alcohol precursor is secondary or tertiary then there is the 
possibility of the formation of two alkene isomers. Again, due to the highly ordered 
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transition state for acyclic systems, the stereochemistry of these alkenes is highly 
predictable in secondary carbinol derived esters (Scheme 53).  
 
 
Scheme 53: Alkene stereochemistry 
 
The larger C4 substituent will be placed in a pseudo-equatorial position. This is 
illustrated by Katzenellenbogen in the synthesis of butterfly pheromone 162, in which 





Scheme 54: Katzenellenbogen synthesis of butterfly pheromone 162 
 
Allylic esters possessing one stereocentre:  
absolute stereocontrol 
Absolute stereocontrol can be achieved in an Ireland-Claisen rearrangement when a 
enantiopure chiral secondary alcohol is used. This will enable the transfer of chirality 
from the carbinol centre to the newly formed stereocentre(s) at C(2) and/or C(3) of the 
pentenoic acid product. The first example of this was demonstrated by Ireland utilizing 
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Scheme 55: Absolute stereocontrol 
 
 1.5.2 Glycinates and other higher amino esters 
Barlett and Barstow reported the first synthesis of -amino acids using an Ireland-





Scheme 56: Rearrangement of amino acid derived allylic esters 
 
Barlett observed that in all cases, except for crotyl glycinate 165, the rearrangement was 
successful with or without the use of a silylating agent. 
 
Barrett et al. also utilized an Ireland-Claisen rearrangement containing an allyic amino 
ester substrate combined with alkene metathesis in the synthesis of bicyclic -lactams 
(Scheme 57).
103
 The rearrangement proceeded in excellent yield, however no 
diastereoselectivity was achieved. The ring closing metathesis proceeded smoothly to 
afford 169 in a quantitative yield using 20 mol% of Grubbs first generation catalyst. 
 
 
Scheme 57: Use of an Ireland-Claisen rearrangement in the syntheis of bicyclic -lactam 169 
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 Chelated enolate Claisen rearrangements 
One other method for suppressing competing side reactions and ensuring 
diastereoselective control in the Ireland-Claisen rearrangement include the formation of 
a metal enolate. Should a heteroatom with a free pair of electrons or a formal negative 
charge be present either - or - to the ester, then metal chelation between the 
heteroatom, the enolate and a Lewis acidic metal is possible. This gives rise to either a 
five- or six-membered chelate, and these in turn afford highly selective formation of 
(Z)-enolate, irrespective of the addition of HMPA (Figure 25). 
 
 
Figure 25: Five and Six membered metal chealtes 
 
Chelate formation generally results in stabilization of the enolate, and allows for direct 
rearrangement.
104
 However, silylation and then rearrangement of the silyl ketene acetal, 
according to Irelands’ protocol is still possible. 
 
The rearrangement of N-protected amino allylic esters has been reported by Steglich et 
al. in 1975 (Scheme 58).
105
 Subjecting N-benzoyl amino acid allylic ester 170 to 
dehydrating agents (as in this case phosgene) results in the formation of oxazole 
intermediate 171, which in turn rearranges to afford allyloxazolinone 172. The fixed 
geometry of the alkene in the oxazole ring gives a strong preference for a chair-like 
transition state leading to high diastereoselectivies. Subsequent hydrolysis afforded the 
-alkylated amino acid 173. 
Scheme 58: Rearrangement of N-protected amino allylic esters 
 
However, this method is limited to only N-benzoyl protected amino acid esters, other 
commonly used nitrogen protecting groups do not allow the cyclization to the 
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intermediate allyloxazolinone, therefore the required substrate for the rearrangement to 
occur is not achieved. 
 
In 1994, Kazmaier investigated the effect of metal salts in the Ireland-Claisen 








Entry MXn Yield dr 
  (%) (syn:anti) 
1 None 0 - 
2 ZnCl2 90 95:5 
3 CoCl2 78 93:7 
4 MgCl2 85 91:9 
5 Al(O
i
Pr)3 75 90:10 
6 Ti(O
i
Pr)4 50 90:10 
7 Me2SiCl2 50 85:15 
8 Me3SiCl 60 83:17 
 
 
The corresponding lithium enolate (Entry 1) did not show any signs of rearrangement 
due decomposition side reactions occuring. In contrast, the addition of chelating metal 
salts allowed for successful rearrangement. The chelated enolates were more stable than 
their lithium counterparts, and therefore lead to successful rearrangement. Zinc 
dichloride (Entry 2) afforded the best result in terms of both yield and 
diastereoselectivity, however magnesium dichloride (Entry 4) gave comparable results 
in other substrates. Interestingly, it was shown that metal enolates were superior to silyl 
ketene acetals (Entries 7 & 8) both in terms of yield and diastereoselectivity. 
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Prior to commencing this research, two key rearrangements reported in the literature 
were significant. Firstly, Ireland’s allylic enol ether 176 was shown to rearrange to the 
anti--methoxy carboxylic acid 177 in good yield and diastereoselectivity (Scheme 59, 
equation 1).
1
 The second rearrangement was reported by Kazmaier, where he 
demonstrated the syn-selective rearrangement of allylic amino ester 178 to -substituted 
amino acid 179 via a metal chelated enolate in high yield and with excellent 





Scheme 59: Ireland’s allylic enol ether and Kazmaier’s allylic amino ester rearrangements 
 
It can be envisaged that a combination of Ireland’s allylic enol ether and Kazmaier’s 
amino ester fragments would provide a suitable substrate 180, that upon treating under 
Kazmaier’s optimised protocol, would rearrange to afford syn selective -alkoxy -
amino acids (Scheme 60). 
 
 
Scheme 60: Proposed Ireland-Claisen synthesis of -hydroxy -amino acids 
 
Furthermore, the use of Kazmaier’s protocol has also been shown to be effective in the 
formation of quaternary centres in a highly diastereoselective fashion, when using -
substituted amino acids as part of the allylic amino ester substrate (Scheme 61).
108
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Scheme 61: Proposed Ireland-Claisen synthesis of -hydroxy -amino acids containing -
quaternary centres 
 
Significantly amino acids containing quaternary -carbons are an important class of 
non-proteinogenic amino acids, and have been gathered a significantly amount of 




The use of protected allylic enol ethers, such as benzyl or p-methoxybenzyl, would 
enable the selective cleavage of these groups to form the free -hydroxy -amino acid 
moiety seen in many important biologically active products such as kaitocephalin 7 or 
to allow for further synthetic transformations such as a -lactonization as seen in 
salinosporamide A 20 (Figure 26). 
 
 
Figure 26: Examples of natural products for the incorporation of -hydroxy -amino acids 
 
 
2.2 IRELAND-CLAISEN SUBSTRATE SYNTHESIS 
2.2.1 Retrosynthesis 
With a clearly defined substrate 180 identified, retrosynthetic analysis identified readily 
available commercial starting precursors (Scheme 62). 
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Scheme 62: Substrate retrosynthetic analysis 
 
The retrosynthesis takes us back to one main, readily available class of alcohols such as 
188. Bromination followed by reduction affords the bromo allylic alcohol 186. A 
copper promoted cross coupling between 186 and a suitable alkoxide coupling partner, 
such as sodium methoxide would deliver the required alkoxy allylic enol ether 185. 
Subjecting 185 and N-Boc glycine 184 to carbodiimide coupling conditions would then 
afford the required allylic amino ester for the rearrangement in four steps. 
 
2.2.2 Forward synthesis 
Starting from 3-butyn-2-ol 189, bromoacetylene 190 was synthesised utilizing a silver 
nitrate catalysed, N-bromosuccinimide (NBS) bromination, adapted from the method 





Scheme 63: Attempted synthesis of vinyl bromide 191 
 
Several attempts to reduce the alkyne utilizing lithium aluminium hydride based 
protocols all yielded an intractable mixture of compounds, of which were sensitive to 
column chromatography.  
 
A sequential method of bromination followed by hydride reduction was reported by Polt 
et al. in 1999.
116
 Subjecting 189 to bromination utilizing potassium hypobromide 
(generated in situ), formed bromoacetylene 190. Without isolation or purification, 190 
was treated with lithium aluminium hydride in the presence of stoichiometric aluminum 
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trichloride to form vinyl bromide 191. The obtained product was not as desired, instead 




Scheme 64: Attempted synthesis of vinyl bromide 191 
 
Chemin et al. had shown that (E)-vinyl iodides could be synthesised employing 
hydrozirconation of terminal alkynes.
117
 Again starting from 3-butyn-2-ol 189, 
protection of the hydroxyl group as the TBS ether under standard protocols delivered 
the protected alcohol 192.
118
 Hydrozirconation utilizing Schwartz reagent (synthesised 
from zirconocene dichloride and lithium aluminium hydride) followed by iodolysis 
delivered the required protected (E)-vinyl iodide 193 (Scheme 65). 
 
 
Scheme 65: Synthesis of vinyl iodide 193 
 
Vinyl iodide 193 was obtained in low yield and was extremely sensitive to purification. 
Due to the sensitivity and the limited quantities of the product obtained, deprotection of 
the silyl ether was not investigated. Several attempts to substitute the iodine for 
bromine, to form the vinyl bromide via this procedure were also unsuccessful. 
 
In 2005, Walsh et al. published a synthetic route to alkoxy allylic enol ethers starting 
from terminal alkoxyalkynes.
119
 Subjecting ethoxy acetylene 194 to hydroboration 
conditions using borane THF complex, followed by transmetalation with diethyl zinc 
afforded vinyl zinc 195 in situ. A 1,2-addition to benzaldehyde in the presence of N-
methyl ephedrine should yield allylic enol ether (E)-196 (Scheme 66). However, even 
though complete consumption of starting material was observed by thin layer 
chromatography (TLC) analysis; none of the desired product was isolated from the 
complex reaction mixture.  
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Scheme 66: Attempted synthesis of allylic enol ether (E)-196 
 
Madduluno et al. reported the addition of lithiated enol ethers to aldehydes.
120
 Lithium 
halogen exchange using (Z)-1-bromo-2-ethoxyethene 197 affords the vinyl lithium 198, 
before the 1,2-addition to benzaldehyde affording alkoxy allylic enol ether (Z)-196 
(Scheme 67). Once again, none of the required product was observed and due to the use 




Scheme 67: Attempted synthesis of allylic enol ether (Z)-196 
 
Due to the inability to synthesise these alkoxy allylic enol ethers we thought about the 
reactivity of these compounds. In acidic media, these compounds act as vinylogous 
hemiacetals, with protonation of the hydroxyl group leading to elimination of water 
leading to oxonium cation 201. A 1,2-addition of the water into the oxonium cation 201 
forms hemiacetal 202, which in turn decomposes to form acrolein 203 and an alcohol 
(Scheme 68). 
 
Scheme 68: Decomposition of allylic enol ethers in acidic media 
 
It was proposed that reducing the ability of the allylic enol ethereal oxygen, to donate a 
lone pair of electrons into the -system of these compounds could potentially increase 
their stability and the ease of synthesis. The use of aromatic rings containing electron 
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withdrawing groups should reduce the donation of these lone pair of electrons by 
drawing the electron density into the aromatic -system.  
 
Liang et al. had shown that a 1,4-addition of various oxygen nucleophiles to activated 
alkynes, such as methyl propiolate, when catalysed by 1,4-diazabicyclo[2.2.2]octane 
(DABCO) afforded solely (E)-alkenoic acid esters.
121
 But-3-yn-2-ol 189 was therefore 
subjected to a Jones oxidation to afford the volatile but-3-yn-2-one. Without isolation, 
but-3-yn-2-one, was subjected to the 1,4-addition protocol developed by Liang using p-
nitrophenol, o-nitrophenol or 2,4-dinitrophenol as the oxygen nucleophile to afford the 




Scheme 69: Synthesis of 4-aryloxy but-3-en-2-ones 
 
Subsequent chemoselective reduction of the carbonyl was achieved, in moderate yield 
using sodium borohydride (Scheme 70). Purification of the obtained product was now 
achievable by recrystallisation and as a result, the aryloxy allylic enol ethers were bench 




Scheme 70: Reduction of 4-aryloxy but-3-en-2-ones 
 
Kazmaier has shown a large range of protected amino esters successfully rearrange via 
metal chelates to the desired -amino acids, with tert-butyl carbamate (Boc) protected 
glycine displaying excellent results.
2
 Taking aryloxy allylic enol ether 208 and N-boc 
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glycine under a typical dicyclohexylcarbodiimide (DCC) coupling protocol led to the 
formation of the required allylic amino ester as judged by 
1
H NMR analysis of the crude 









H NMR suggested the formation of the desired allylic amino ester, 
purification proved difficult and none of the desired product was isolated. It was seen 
that the amino ester substrate was sensitive to flash chromatography even using 
deactivated silica or basic grade alumina. Therefore, purification via this method to 
remove the excess DCC and the formed urea by-product was unsuitable. Further 
reviews of the literature showed that Sarabia et al. were able to synthesis the allylic 
amino ester 212 in good yield using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 





Scheme 72: Sarabias synthesis of 212 using EDCi 
 
The major benefit of switching EDCi is that excess EDCi and the urea formed during 
the reaction are both water soluble. Therefore, purification can be achieved by using 
acid/base washes rather than flash chromatography thus avoiding the degradation 
previously observed. Again taking aryloxy allylic enol ether 208 and N-boc glycine 184, 
the coupling was successful and delivered clean material (Scheme 73). After several 
attempts it was determined that two equivalents of all reagents and only 5 mol% of 4-
dimethylaminopyridine (DMAP) were required to ensure consumption of the starting 




Chapter 2                                                                                        Results and Discussion 
 52 
 
Scheme 73: Successful EDCi promoted esterification  
 
2.2.3 Rearrangement attempts 
With allylic amino ester 198 in hand investigation of the rearrangement was pursued. 
Traditional Ireland-Claisen rearrangements utilize a strong non-nucleophilic base to 
generate an enolate with subsquent silylation using a silylating agent, such as 
trimethylsilyl chloride (TMSCl). Kazmaier’s protocol, substitutes the silylating agent 
for a chelating metal. The formation of the enolate and a secondary anion in the 
presence of a chelating metal creates a chelated transition state. Thus high levels of 
metal chelate geometry selectivity can be achieved due to the fixed transition state 
(Figure 27). 
 
Figure 27: Comparison of transition states 
 
Due to high levels of diastereoselectivity observed by Kazmaier, it was decided to 
employ the metal chelated Ireland-Claisen rearrangement concept within our 
rearrangement (Table 3). 
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Table 3: Rearrangement optimization 
 
Entry Base Equiv. Additive Equiv. Yield 213 Major Product 
























 3 0 210 
5
a















 4 TMSCl 4 0 184 & 214 
 
a
 1M HCl quench used. 
b
 Methanol quench used. 
c
 1M solution in THF. 
d
 Solution of zinc chloride (1M in ether). 
 
Initial investigation examined the use of Kazmaier’s reported protocol (Entry 1).2 
Promisingly, TLC analysis showed the formation of new compounds, with spots more 
polar than the starting allylic amino ester. After complete consumption of the allylic 
amino ester, the reaction was worked up using an acidic aqueous procedure as reported 
by Kazmaier. None of the desired product was isolated from the aqueous wash, 
however, this was deemed a positive result, due to the high solubility of amino acids in 
aqueous environments. Repetition of the protocol (Entry 2) ensued, changing the 
workup procedure. The use of methanol as a protic quench yielded 3% of the rearranged 
product 213 amongst an intractable mixture of p-nitrophenol 214 and N-Bocglycine 
184. Significant quantities of insoluble zinc dichloride was present throughout the 
reaction, therefore suggesting incomplete formation of the zinc chelate, resulting in 
decomposition to the allylic amino ester’s constituent moieties. To help resolve 
incomplete dissolution of zinc dichloride, an ethereal solution of zinc dichloride was 
trialed along with a reduction in the equivalents of base used (Entry 3). Due to a 
reduction in base, incomplete consumption of allylic amino ester 210 was observed. 
Once again, none of the desired product 213 was isolated, however significant 
quantities of 214 was obtained from the reaction mixture. Other non-nucleophilic bases 
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LiHMDS and LDA (Entries 4 & 5) were also investigated. In both cases, quantitative 
return of the starting allylic amino ester 213 was observed, indicating that under these 
conditions, neither of these bases were appropriate in promoting the rearrangement. 
Kazmaier had also observed that TMSCl successfully promotes the rearrangement of a 
dianionic substrate, however with a reduction in diastereoselectivity. Switching our 
additive to TMSCl (Entry 6) only a quantitative return of 213 was observed. Increasing 
the equivalents of base and the additive used (Entries 7 & 8) also lead to decomposition 
products 184 and 214. 
 
The formation of 214 is thought to occur via a ketene pathway (Scheme 74). Enolisation 
of 210 and trapping as zinc enolate forms species 215. Decomposition of 215 leads to 
the formation of ketene 216, acetaldehyde 217, acetylene 218 and p-nitrophenoxide. 
With a sufficiently low pKa, p-nitrophenol would act as a suitable leaving group. Upon 
protic workup, hydrolysis reforms the parent amino acid 184 and p-nitrophenol 214, 
whilst volatile 217 and 218 are loss. One observation to support this theory is the strong 
yellow colour observed during the attempted rearrangements which can be attributed to 
the formation of p-nitrophenoxide. 
 
 
Scheme 74: Possible route for the formation of p-nitrophenol 214 and N-Bocglycine 184 
 
Due to the decomposition of the allylic amino ester under these conditions and/or the 
ability of p-nitrophenoxide to act as a leaving group, it was deemed necessary to re-





Chapter 2                                                                                        Results and Discussion 
 55 
2.2.4 Alkoxy Substrate Synthesis 
The reduction of 3-alkoxy ,-unsaturated ketones was deemed another feasible route 
into the required alkoxy allylic alcohols. Taking (1E)-1-methoxy-2-methyl-1-penten-3-
one 219, several protocols for the reduction of this ,-unsaturated ketone were 
investigated (Table 4). 
 
Table 4: Reduction of (1E)-1-methoxy-2-methyl-1-penten-3-one, 219 
 
Entry Reducing Agent Equiv. Solvent Yield (%) 
1
a
 DIBAL-H 2.5 Et2O 0 
2
a















5 LiAlH4 2 Et2O 41 
6 LiAlH4 4 Et2O 45 
7 LiAlH4 6 Et2O 60 
 
a
 DIBAL-H (1M in Hexane) 
 
The use of diisobutyl aluminium hydride (DIBAL-H) in ether as the reductant (Entry 1) 
failed to form the reduced product 220 with only the starting vinylogous methoxy 
ketone 219 being recovered, even with increased equivalents of DIBAL-H (Entry 2). 
Successful reduction utilizing hexane as solvent or a neat solution of DIBAL-H lead to 
successful reduction (Entries 3 & 4), however these reactions were low yielding and 
purification to remove excess aluminium salts was difficult. Switching hydride source 
to lithium aluminium hydride (Entry 5) saw an immediate improvement with the 
removal of aluminium salts made easier and a higher yield obtained, however complete 
consumption of the starting vinylogous ketone was never obtained when using two 
equivalents of hydride. Using more equivalents (Entries 6 & 7) further increased 
consumption of the starting vinylogous ketone and also the yield of the allylic enol 
ether. Utilizing a large excess of the hydride source had its inherent problems with 
purification to remove the aluminium salts becoming more difficult, and as such 
reproducibility of this reduction was very limited. Along with this, the stability of the 
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product was poor, decomposing rapidly even when cold storage at -18 °C was 
employed. 
 
Another 1,2-hydride reduction was attempted, this time on the simpler trans-4-
methoxy-3-buten-2-one 221. Utilizing lithium aluminium hydride in ether, ,-
unsaturated ketone 221 was successfully reduced to (E)-4-methoxybut-3-en-2-ol 222 in 




Scheme 75: Reduction of 221 to 222 
 
Taking both allylic enol ethers 220 & 222, esterification using the optimised conditions 
with N-Boc glycine did not yield any of the required allylic amino ester. 
 
Several groups had reported the synthesis of primary allylic enol ether (E)-3-
(methoxy)prop-2-enol 223 from a DIBAL-H mediated reduction of methyl trans-3-





Scheme 76: Pfaltz conditions for the reduction of 223 
 
Following the protocol described by Pfaltz et al. initial results showed that the 
formation of the correct product was achieved, however several side products were 
present and complete consumption of the starting alkoxyacrylate could not be obtained 
under these conditions. Purification of these sensitive products was even more 
challenging than the previous two alkoxy allylic alcohols synthesized. Careful 
consideration was required when assaying the product, since the relative acidity of 
CDCl3 was sufficient to promote the decomposition of the product to acrolein and 
methanol, therefore it was vital to switch to a non-protic deuterated solvent such as 
DMSO or acetone. Optimization of this protocol was required to obtain an appropriate 
quantity suitable for our synthesis. Increasing the equivalents of DIBAL-H to 2.5 and 
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changing the solvent to toluene afforded the correct product, with complete 
consumption of starting material, however no increase in yield was seen. Importantly, a 
slow syringe pump addition of DIBAL-H was also required, at a rate of 1 mL/min to 
help prevent the large exotherms being produced upon the mixing of reagents. Using 
these improved conditions, the quenching and work-up procedures were next 
investigated. Pfaltz had used a hydrolysis work-up procedure, leading to the formation 
of a thick slurry of aluminium salts. Filtration of these salts was slow and with the high 
viscosity of the salts the possibility arose of incomplete product isolation hence a low 
mass return from the reaction. Quenching at -78 °C with methanol produced a 
precipitate which was easier to filter and less aluminum salts were present in the final 
product. Careful purification by Kugelrohr bulb-to-bulb distillation yielded the product 
in an improved yield of 64%. Several groups have reported that the addition of saturated 
Rochelle salt solutions to their reduction mixture quenches the reaction whilst avoiding 
the formation of the notoriously difficult to remove aluminium salts.
126
 When used in 
our system this resulted in an extremely difficult separation with none of the desired 
product isolated. Cossey et al. reported the use of an inverse Rochelle salt quench, 
where the reduction mixture was added into a saturated solution of Rochelle salt, in 
their synthesis of allylic enol ethers.
127
 Following this workup protocol the required 
alkoxy allylic enol ether was obtained in a desirable 77% yield and even more 
significant, without the need for further purification (Scheme 77). 
 
 
Scheme 77: Optimized conditions for the reduction of 223 
 
With the required alkoxy allylic enol ether 224 in hand, the required allylic amino ester 
was synthesized using carbodiimide coupling to afford the required substrate in a 70% 
yield (Scheme 78). 
 
 
Scheme 78: Synthesis of allylic amino ester 180 
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Once again, the sensitivity of this substrate was clear to see. Should the esterification 
require purification, flash chromatography was inappropriate, causing the allylic amino 
ester to degrade. Instead, resubjecting to further aqueous washes was usually sufficient 
to afford 180 in sufficient purity to proceed. Furthermore, cold storage was also 
required to also prevent short term decomposition. 
 
2.2.5 Alkoxy substrate rearrangement attempts 
With substrate 180 in hand, the rearrangement to form -alkoxy -amino acids was 











 Yield (%) Major Product 
1 KHMDS ZnCl2 0 BocHN-Gly-OH 
2 LiHMDS ZnCl2 0 BocHN-Gly-OH 
 
a
 1M solution in THF. 
b
 1M solution in Et2O. 
 
The use of either KHMDS or LiHMDS none of the desired product was observed. 
Instead both promoted a decomposition pathway back to the parent amino acid, N-Boc 
glycine, consistent with that reported for the aryloxy allylic amino esters (Scheme 79). 
 
 
Scheme 79: Formation of N-Boc glycine 184 upon attempted rearrangement of 180 
 
Due to the lack of success of our desired rearrangement, a substrate reported by 
Kazmaier was prepared via a N,N’-dicyclohexylcarbodiimide (DCC) mediated coupling 
of crotyl alcohol 226 and N-Boc glycine 184 and the rearrangement was investigated. 
Subjecting allylic amino ester 227 to Kazmaier’s protocol yielded a successful 
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rearrangement to amino 3-methylpent-4-enoic acid 179 in good yield and 
diastereoselectivity (Scheme 80). This result is in line with the reported data by 
Kazmaier and prompted us to consider the suitability of our substrate in these 
rearrangements. 
 
Scheme 80: Repetition of a reported Kazmaier substrate 
 
Ireland reported that the addition of an enol ether leads to a stereoelectronic effect, 
affecting the relative stability of the chairlike transition.
1
 Hence donation of the ethereal 
oxygen’s lone pair of electrons leads to increased dipolar character in the transition 
state. Significantly this may cause a substantial increase in the rate of bond cleavage 
compared to bond formation. In our system, the degree of electron donation seems to be 
to such a high level that bond cleavage is observed instead of any sigmatropic 
rearrangement occurring, therefore leading to the degradation products observed. In 
addition to this, our system includes an electron rich nitrogen atom. Donation of the 
anionic charge build up on the nitrogen into the -system of the enolate and then 
subsequently into the C-O orbital can further increase the dipolar character of the 
transition state, and therefore further increase the rate of bond cleavage. Thus it can be 
considered that the formed intermediate is too high in energy, therefore becoming 
inherently unstable leading to decomposition of the allylic ester enolate system. 
 
The formation of this parent amino acid can be hypothesized to occur due to the 
presence of the dianionic nature of the intermediate enolate (Figure 28). Upon formation 
of the enolate of the allylic ester, the central C-O * orbital is overlapped by two 
highly electron rich -systems allowing a significant level of electron density to be 
donated into this C-O* orbital.  
 
Figure 28: Possible enolate instability 
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Should the instability of the allylic enolate be caused by the anionic nitrogen centre, 
then substituting the acidic N-H proton should allow for successful rearrangement. The 
major drawback and item to note is that the use of Kazmaier’s protocol would have to 
be swapped for more traditional Ireland-Claisen rearrangement protocols. 
 
2.3 SECOND-GENERATION IRELAND-CLAISEN SUBSTRATE 
After observing a significant increase in the stability of the aryl allylic enol ether by 
reducing the amount of electron pair donation, a similar setup was deemed suitable to 
prevent nitrogen lone pair donation. Taking this into account we decided to investigate 
the use of a phthalimde (Phth) protecting group. Protection of the amino nitrogen as an 
imide not only removes the acidic N-H proton and prevents the build up of an anionic 
charge, but should significantly reduce the ability of the nitrogen to donate the lone pair 
of electrons through the enolate -system in to the C-O. This in turn should hopefully 
reduce the rate of bond cleavage and the decomposition pathways.  
 
2.3.1 Forward synthesis 
Taking alkoxy allylic enol ether 224 and N-phthaloyl glycine 228, the required allylic 
amino ester was synthesized using carbodiimide coupling to afford the required 
substrate in 84% yield (Scheme 81). 
 
 
Scheme 81: Allylic amino ester 229 synthesis 
 
The stability of the allylic amino ester had been significantly increased by the addition 
of the phthalimde functionality. The substrate formed was a considerably easier to 
handle solid, and little degradation was seen with cold storage over several months. 
 
With the second generation allylic amino ester 229 in hand, we next turned our attention 
to the rearrangement. An initial attempt at rearrangement showed complete 
consumption of the starting allylic amino ester by TLC analysis (Scheme 82). 
1
H NMR 
analysis of the crude reaction mixture confirmed the consumption of allylic amino ester 
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229 along wtith the formation of a new compound consistent with the product obtained 
after rearrangement of Kazmaier’s allylic amino ester 227. Purification of the crude 
amino acid, proved difficult and therefore it was decided to derivatize the crude amino 
acid to its methyl ester,which significantly increased the stability of the product and 
allowed for chromatographic purification. 
 
 
Scheme 82: Successful rearrangement of 229 to 230 
 
After complete consumption of the starting allylic amino ester by TLC was observed, 
the reaction was quenched using 1M HCl solution and extracted with DCM. Upon 
isolation the residue was subjected to a methylation using potassium carbonate and 
methyl iodide (Scheme 83). There are several reports in the literature on the synthesis of 
amino methoxy esters from amino acids. Valle et al. used a protocol utilizing methyl 
iodide in the presence of potassium carbonate in their synthesis of Lucentamycin A.
128
 
None of the expected amino ester 231 was isolated. It was observed that a vast number 
of different phthalimide signals in the crude 
1
H NMR spectra. None of the required 
amino ester was recovered possibly due to degradation of the putative potassium 
carboxylate intermediate. 
 
Scheme 83: Rearrangement of 218 and attempted protection as the methyl ester 
 
A test reaction, subjecting phthaloyl glycine 228 to a methylation using the same 
conditions, confirmed this, since once more a large number of different phthalimide 
signals were present in the crude 
1
H NMR spectra, and none of the desired amino ester 
232 was isolated (Scheme 84). 
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Scheme 84: Attempted protection of N-phthaloyl glycine as the methyl ester 
 
Next we turned our attention to a significantly more rapid protocol utilizing 
diazomethane as reported by Molanski et al. in the synthesis of sagittamides A and B.
129
 
As observed before, complete consumption of the starting allylic amino ester was 
observed. The reaction was quenched using a 1M HCl/brine (1:1) solution and extracted 
with ethyl acetate and dichloromethane, then concentrated in vacuo. The crude residue 
treated with a freshly prepared ethereal solution of diazomethane to afford methyl ester 
231. After purification via flash chromatography compound 231 was isolated in a 21% 
yield (Scheme 85). 
 
 
Scheme 85: Successful rearrangement of 229 and protection forming 231 
 
Although low yielding, the desired product was isolated cleanly and therefore all 
subsequent rearrangements, were treated with diazomethane to aid purification and 
isolation. However, do to the low yield obtained, an optimization study was initiated 
(Table 6). 
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Table 6: Rearrangement optimization 
 
 
Entry Base Solvent Temperature Yield dr 
   (°C) (%)  
1 LiHMDS THF -78 0
a
 - 
2 NaHMDS THF -78 0
a
 - 
3 KHMDS THF -78 0
a
 - 
4 LiHMDS THF -95 74 11:1 
5 LiHMDS Et2O -95 65 9:1 
6 LiHMDS PhMe -95 0
a
 - 
7 NaHMDS THF -95 45 7:1 
8 KHMDS THF -95 34 6:1 










Intractable reaction mixture. 
b
 TIPSOTf used as a silylation additive. 
 
Due to the initial success where by obtaining rearranged material was obtained using 
1.3 equivalents of both base and silylating agent, it was decided to keep the equivalents 
used at this level. After considerable investigation it was determined that for efficient 
rearrangement to occur, LiHMDS was to be added over 15 minutes via syringe pump to 
a solution of allylic amino ester 229 and TMSCl in THF at -95 °C before warming to    
0 °C (Entry 4). When the reaction was initiated at higher temperatures (-78 °C, Entries 
1, 2 & 3) or when non-ethereal solvents such as toluene were used (Entry 6), the 
reaction yielded an intractable mixture of products. Crude 
1
H NMR analysis observed a 
mixture of the desired rearranged product along with elimination products, -silylation 
products and also unconverted starting allylic amino ester. The use of Na- (Entry 7) or 
KHMDS (Entry 8) at -95 °C, leads to successful rearrangement, however a significant 
drop in reaction quality was observed, in terms of both yield and diastereoselectivity. 
The use of another Li-amide base (LDA, Entry 9) or a different silylating agent 
(TIPSOTf, Entry 10) also lead to an intractable reaction mixture. 
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2.4 N-PHTHALIMIDE SUBSTRATES 
With the optimal reaction conditions identified, the generality of the rearrangement was 
investigated. A range of ethereal substrates were synthesized and investigated. 
 
 2.4.1 Substrate Synthesis 
With methyl trans-3-methoxyacrylate being the only commercially available 
vinylogous ester, a route to the synthesis of a range of analogues was investigated to 
keep our allylic amino ester synthesis consistent. Several reagents have been reported to 
catalyze the 1,4-addition of oxygen nucleophiles to activated acetylenes.
121,130-131
 With a 
selection investigated for the addition of isopropanol to methyl propiolate 232 (Table 7). 
 
Table 7: 1,4-Addition optimization 
 
 
Entry Catalyst Time Yield 233 
  (hr) (%) 
1 NMM 4 65 
2 P(
n
Bu)3 24 74 
3 DABCO 0.5 70 
 
N-Methylmorpholine (NMM, Entry 1) afforded vinylogous ester 233 in 65% yield, 
however, 20% of homo coupled product 234 was also obtained. The use of 
tri
n
butylphosphine (Entry 2), afforded 233 in 74% yield, however, required a 
significantly longer reaction time. This extended reaction time was required due to the 
necessity of opening the reaction to the air for 23 hours to oxidize the catalyst to aid 
removal. Filtration of the phosphine oxide was followed by distillation to remove any 
further traces. Finally, a DABCO mediated reaction (Entry 3), rapidly delivered the 
desired product in good yield. With significantly less of homo coupled product 234 
being obtained (<10%) with purification by flash chromatography sufficient to afford 
pure 233 in 70% yield. In all three trials only the (E)-isomer was obtained.  
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Although none of homo coupled product 234 was observed when using 
tri
n
butylphosphine as the catalyst, the long reaction times and the need for purification 
by distillation, would mean that a rapid synthesis of several different analogues via this 
method would be time consuming. Therefore the use of the DABCO catalysed protocol 
would be better employed. 
 
Having optimized the DABCO catalyzed 1,4-addition, several different alcohols were 
reacted with methyl propiolate to afford vinylogous esters 233, 235 - 246 (Table 8). 
 





 Product Yield  Entry OR
1
 Product Yield 
   (%)     (%) 
1 O
i
Pr 233 70  8 
 
240 91 















237 92  12 
 
244 98 









All alcohols successfully reacted with methyl propiolate to form the desired vinylogous 
ester in good to excellent yields (70 – 98%) with the exception of one. tert-Butanol 
(Entry 3), was the only alcohol where vinylogous carbonate formation was not 
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observed, and was most likely to be caused by the low nucleophilicity of tertiary 
alcohols. Only one example of a secondary alcohol used to form a secondary ethereal 
fragment was examined. 
 
Having previously optimized the DIBAL-H reduction, all vinylogous esters were 
successfully reduced to the required allylic enol ethers with these optimized conditions 
(Table 9). 
 





 Product Yield  Entry OR
1
 Product Yield 
   (%)     (%) 
1 OMe 224 77  8 
 
253 91 















250 92  12 
 
257 89 









All of the vinylogous esters were successfully reduced to the allylic enol ether in good 
yield (70 – 98%), none of which required further purification. All allylic enol ethers 
were extremely sensitive to a wide range of conditions and suitable precautions had to 
be taken to prevent decomposition. 
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Using the optimized carbodiimide promoted protocol the desired allylic amino esters 
were synthesized from either N-Phthaloyl glycine or N-Phthaloyl alanine (Table 10). 
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 Product Yield (%) 
1 OMe H 229 84 
2 OEt H 261 78 
3 O
i
Pr H - 0 
4 
 
H 262 61 
5 
 
H 263 76 
6  H 264 71 
7 
 
H 265 74 
8 
 
H 266 70 
9 
 
H 267 56 
10 
 
H 268 82 
11 
 
H 269 77 
12 
 
H 270 69 
13 
 
H 271 73 
14 
 
H 272 73 
15 OMe Me 273 95 
 
All of the allylic enol ethers coupled in good yield (56 – 91%) except for one, (Entry 3, 
R = isopropyl). In this case only an intractable mixture of products was obtained. Due to 
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the sensitivity of these products, purification or isolation of the desired allylic amino 
ester was not achievable. Although this protocol seems to be restricted to primary 
ethereal systems, importantly, the amino acid coupling partner is not restricted to 
glycine. Entry 15 shows the successful coupling of phthaloyl proctected alanine in 
excellent yield.  
 
2.4.2 Substrate rearrangement  
With a wide range of allylic amino esters in hand, the scope of the rearrangement could 
be investigated utilizing the optimized rearrangement protocol (Table 11). 
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Table 11: Scope of enol ether in rearrangement 
 
Entry Allylic amino OR1 R2 Product Yield drb 
 ester    (%)a (syn:anti) 
1c 229 OMe H 231 74 11:1 
2c 261 OEt H 274 79 9:1 
3c 262 
 
H 275 64 18:1 
4c 263 
 
H 276 78 13:1 
5c 264  H 277 70 10:1 
6c 265 
 
H 278 70 10:1 
7d 265 
 
H 278 64 2:1 
8c 266 
 
H 279 50 14:1 
9c 267 
 
H 280 63 8:1 
10c 268 
 















H 282 50 >25:1 
15c 273 OMe Me 283 71 24:1 
a Isolated yield. b Diastereomeric ratio measured by 1H NMR analysis of crude reaction mixtures. 
 c LiHMDS solution added over 15 minutes by syringe pump. d LiHMDS solution added over 1 minute by 
hand. e Intractable mixture. f  Starting allylic amino ester recovered in >95%. 
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The rearrangement is seen to be general, offering yields of 50 - 81% and 
diastereoselectivites of ≥8:1. A large range of O-functionality has been investigated and 
is tolerated, starting with simple alkyl substrates (Entries 1 & 2). Other alkyl groups 
such as isobutyl (Entry 3) and neopentyl (Entry 4) also successfully rearrange. Access 
to similar compounds containing isobutyl or neopentyl alkylated oxygens would be 
extremely difficult using more traditional alkylating methodologies, due to the 
requirement of extremely poor alkyating agents. A wide range of hydroxyl protecting 
groups (Entries 5, 6 & 9) were also tolerated. Importantly, substrates containing further 
synthetic handles (Entries 5, 8 & 14) also rearrange and provide excellent 
diastereoselectivity. Phenoxy derived amino allylic ester afford interesting 
chemoselectivity. Substrates containing electron-donating groups (Entry 11) saw 
complete consumption of the allylic amino ester, however furnishing a complex 
reaction mixture with the only identifiable component being diene 284 (Figure 29). It is 
believed diene 284 is resultant from successful rearrangement followed by a facile E1CB 
elimination of the -phenoxy -amino acid product. Confirmation of this was achieved 
by comparison to an independently prepared diene 284. Alkene geometry was 
confirmed by comparison of experimental data reported by Takahashi for diene 285 
(Figure 29).
132




Figure 29: Diene 284 and diene 285 
 
In contrast, electron-withdrawing substituents (Entries 12 & 13) inhibit the 
rearrangement. They were observed not to undergo rearrangement; instead complete 
recovery of the starting allylic amino ester was obtained from the reaction mixture. 
Substrates 268 and 272 (Entries 10 & 14) have no effect upon the rearrangement and 
proceeded to the rearranged products in high diastereoselectivity. Also satisfying was 
the rearrangement of an allylic amino ester derived form rac-alanine (Entry 15) with 
high levels of syn-selectivity once more being observed. More importantly this result 
now opens up a general diastereoselective route into synthesizing serine/alanine adducts 
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or further ,-substituted hybrid amino acid fragments utilizing this methodology. The 
synthesis of these amino acid residues are important due to the resemblence seen in 
several natural products such as sphingofungin F 286. 
 
 
Figure 30: Sphingofungin F 286 
 
The diastereoselectivity of this rearrangement appears to be particularly sensitive to 
initial rearrangement conditions. This is clearly seen for the benzyloxy substrate 265 
(Entry 6) with a 10:1 diastereoselectivity ratio observed when base addition was 
completed via syringe pump over 15 minutes. A much faster addition of base over 1 
minute by hand (Entry 7), led to a dramatic reduction in diastereoselectivity with an 
observed diastereoselectivity of 2:1. This observation could be consistent with a non-
concerted mechanism taking place. A possible scenario is the rate enhancement in the 
breaking of the C-Obond of intermediate enolate 287 into ion pair 288. 
Recombination of the lithium glycinate nucleophile with the acrolein oxonium 




Scheme 86: Possible selective or non-selective reactions of enolate 287 
 
Curran et al. have described polarized transition states and observed rate enhancement 
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Scheme 87: Curran’s Claisen rearrangement of methoxyallyl vinyl ether 289 
 
Kinetic studies have shown that methoxyallyl vinyl ether 289 rearranged more rapidly 
than unsubstituted allylvinyl ether (krel = 9.5 cf. 1.0). Switching to a hydrogen bonding 
solvent, in this case methanol, further enhances the rate of rearrangement (krel = 68 cf. 
1.7). The addition of the methoxy enol ether leads to rate enhancement due to two 
effects: enol ether resonance and vinylogous anomeric stabilization. Along with this an 
increase in dipolar character of the transition state is attributed to the increase in rate of 
reaction. Partial delocalization of a non-bonded pair of electrons from the enol ethereal 
oxygen leads to the formation of an enolate and oxonium ion pair, which stabilize the 
transition state to a greater extent than the ground state. Therefore, these enhanced rates 
might suggest that the rearrangement is proceeding through a two step non-concerted 
mechanism with ion pair 291, as the reactive intermediate (Scheme 88). It is thought 
that the effects seen in this report mirror the effect observed in our rearrangement and 
therefore low levels of diastereoselectivity observed upon rapid base addition can be 
attributed to a similar effect. 
 
 
Scheme 88: Curran’s Claisen rearrangement of methoxyallyl vinyl ether 289 throug ion pair 291 
 
The relative stereochemistry of the rearrangement was confirmed through X-ray 
crystallographic analysis of cesium carboxylate 292 (Figure 31). The observed 
diastereoselectivity suggests the reaction proceeds via the intermediate (Z)-SKA, 













Figure 31: ORTEP plot of cesium carboxylate 292 (ellipsoids shown at 30% probability) and chair 
transition state 293 
 
2.5 CONCLUSIONS 
We have developed a new Ireland-Claisen approach to -hydroxy -amino acids. From 
initially looking at metal chelated enolates, where none of the desired products were 
obtained, switching to a more traditional Ireland-Claisen type protocol, allowed for syn-
selective rearrangement. Although the rearrangement is particularly sensitive to a wide 
range of variables such as initiation temperature and base addition rate, a wide range of 
enol ethers can be tolerated to rearrange to the desired -hydroxy -amino acids in good 
yields and diastereoselectives. However the scope of the rearrangement is limited. Only 
allylic enol ethers containing primary or phenoxy based ethereal groups can be 
successfully coupled to form the required allylic amino ester. Can changing the N-
protecting group on the amino acid influence the carbodiimide promoted coupling and 
allow for the synthesis of secondary enol ether substrates? And also can greater 
























Chapter 3                                                                                        Results and Discussion 
 75 
CHAPTER 3 ALTERNATIVE NITROGEN PROTECTION
  
3.1 AMINO ACID INVESTIGATION 
Having obtained proof of principle in the desired rearrangement with N-phthaloyl allylic 
amino esters and assaying the scope of the enol ether, several key factors still required 
investigation. Although the phthaloyl protecting group was suitable, deprotection could 
not be achieved. Furthermore, incorporation of other nitrogen functionality could allow 
for further synthetic elaborations. Finally, the observed diastereoselectivity is good in 
some instances, however there seems to be considerable room for improvement. 
Therefore an investigation into the scope of the N-protection was initiated. 
 
 3.1.1 Amino acid synthesis 
It was observed early on that the electronic nature of the nitrogen protecting groups play 
a substantial part in stabilizing the enolate formed prior to silylation. Thus, by reducing 
the electron donating capability should allow for a decrease in lone pair overlap with the 
enolate -system allowing for a successful rearrangement to proceed. A broad range of 
protected glycines that were investigated included several commercially available 
derivatives, along with several synthesized variants where the electron withdrawing 
nature of the protecting group is suitable to stabilize the transition state of the 
rearrangement. 
 
Initial investigation was centred on a range of protected sarcosines. Following the 
protocol reported by Brimble et al. in 2005, sarcosine 294 was subjected to either 
methyl or benzyl chloroformate in the presence of sodium carbonate to yield the 





Scheme 89: Synthesis of methoxy and benzyloxy carbamate protected sarcosines 
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A toluene sulfonamide derivative was synthesized by the addition of tosyl chloride in 





Scheme 90: Tosyl protected sarcosine 
 
The synthesis of a trifluoroacetamide protected sarcosine proved considerably more 
complex. Several different sets of conditions were trialed until eventually utilizing the 
procedure described by Weygand. Amino acid 298 was synthesized using trifluoroacetic 
anhydride in trifluoroacetic acid at -20 °C in quantitative yield. The temperature at 





Scheme 91: Trifluroracetimide protected sarcosine 
 
Adapting this procedure, the reduced electron withdrawing acetamide functionality was 
installed in an 84% yield (Scheme 92). 
 
 
Scheme 92: Actetimide protected sarcosine 
 
With a range of protected sarcosines synthesized, a range of di substituted glycines 
where both groups can be considered as protecting groups (i.e. not a methyl group) were 
synthesized. In all cases, on of the groups was maintained as a Boc group. Firstly, 2-
(benzyl(tert-butoxycarbonyl)amino)acetic acid 301, was synthesized starting from N-
benzyl glycine ethyl ester 300. Subjecting 300 to di-tert-butyl dicarbonate in the 
presence of triethylamine followed by saponification utilizing lithium hydroxide 
afforded 301 in 82% over two steps (Scheme 93). 
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Scheme 93: N-Boc, benzyl glycine synthesis 
 
The addition of allyl bromide to N-Boc glycine methyl ester 302 in the presence of 
sodium hydride yielded the allyl protected amino ester. Saponifcation of the methyl 




Scheme 94: N-Boc, allyl glycine synthesis 
 
Although two different protecting groups allow for selective deprotection to the 
secondary amine, inclusion into a natural product synthesis requiring a primary amine 
would require two deprotections, therefore a selection of di-protected amino acids, with 
the same protecting groups were also synthesized. Using the protocol reported by 
Heimgartener, glycine was subjected to benzyl bromide and potassium hydroxide at 





Scheme 98: Dibenyl glycine synthesis 
 
The synthesis of a di-Boc protected glycine as reported by Gunnarson was more in-
depth (Scheme 99).
138
 Firstly, the cesium carboxylate of N-Boc glycine was treated with 
benzyl bromide, forming the benzyl ester. Taking the benzyl ester in acetonitrile and 
subjecting to di-tert-butyl dicarbonate in the presence of catalytic DMAP yielded the N-
diboc glycine benzyl ester. This in turn was subjected to hydrogenolysis in the presence 
of catalytic palladium on carbon to afford the N-diboc glycine in a 78% yield for the 
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four steps. Later the synthesis of 305 was reduced to three steps by utilizing an EDCi 
coupling between N-Boc glycine and benzyl alcohol to form the benzyl ester, again 
yielding 305 in 78% across the three steps. 
 
 
Scheme 99: Diboc glycine synthesis 
 
 
3.1.2 Substrate synthesis 
Initially investigation into different nitrogen protecting groups looked at rearrangements 
utilizing the methoxy allylic enol ether 224. The required substrates were synthesized 
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 Product Yield 
    (%) 
1 Boc Me 306 77 
2 CO2Me Me 307 87 
3 Cbz Me 308 97 
4 Ts Me 309 60 
5 Ac Me 310 73 
6 F3CCO Me - 0 
7 Boc Allyl 311 60 
8 Boc Bn 312 85 
9 Me Me - 0 
10 Bn Bn 313 76 
11 Boc Boc 314 70 
12 N-Boc Proline 315 65 
 
All products that contain a carbamate protecting group, except for N-diboc glycine were 
obtained as a rotameric mixture. Rotamers are conformational isomers arising from 
restriction of rotation around a bond.
139
 In particular, rotamers are observed upon the 
1
H 
NMR timescale and observed as two or more signals. The presence of rotamers can be 
confirmed by variable temperature (VT) 
1
H NMR analysis, heating the system, 
decreases the restriction within this rotation and therefore coalescence of the rotameric 
peaks being observed. All of our allylic amino esters and other products where rotamers 
were present were confirmed by the coalescence of these peaks via 
1
H VT NMR. 
 
Successful esterification of 224 with a range of amino acids was achieved, however, 
changing the N-protecting group had no bearing upon the stability of the allylic amino 
ester as they were still sensitive to purification. Only in two cases was the desired allylic 
amino ester was not obtained. When using the trifluororacetimide protected sarcosine 
(Entry 6), TLC analysis showed a successful coupling to the desired substrate. 
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However, upon workup or before analysis by 
1
H NMR could be carried out, degradation 
of the allylic amino ester substrate was observed to occur. To confirm a successful 
coupling had been achieved, a test coupling of amino acid 298 and with crotyl alcohol 
226 was undertaken (Scheme 100). 
 
 
Scheme 100: Successful coupling of 298 with 226 
 
Although a significantly longer reaction time was required, a successful coupling was 
performed, with comparable TLC analysis to that of the coupling utilizing methoxy 
allylic enol ether 224, showing a successful reaction had occurred, however, the allylic 
amino ester was unstable and degradation occurred before the rearrangement could be 
investigated. Also N-dimethyl glycine (Entry 9) failed to afford the coupled product, 
with a quantitative return of the parent amino acid being obtained.  
 
Carbamate protected sarcosines (Entries 1, 2 & 3) all coupled successfully in good yield 
with Cbz protected sarcosine in particular affording the desired allylic amino ester in 
near quantitative yield. N-Tosyl sarcosine (Entry 4) successfully coupled, although at a 
reduced yield along with the acetamide sarcosine (Entry 5). Both examples of glycine 
with two different protecting groups (Entries 7 & 8) successfully coupled in good yield. 
Two amino esters containing the same N-protecting group were also successfully 
synthesized (Entries 10 & 11), whilst finally, a second -functionalized amino acid in 
the form of proline was also successfully coupled (Entry 12). 
 
A significant number of important and relevant biologically active molecules contain 
secondary ethers such as Oseltamivir (Tamiflu) 317(Scheme 101). Due a significant 
requirement for stock piles of Oseltamivir, new synthetic routes for the synthesis of 317 
have become rife in the literature.
139-141
 It was felt that the synthesis of Oseltamivir 
could be achieved utilizing this methodology. 
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Scheme 101: Anticipated approach to Oseltamivir 317 
 
To allow for the synthesis of Tamiflu or another target containing a secondary ether 
using this methodology it would be required to synthesise and rearrange an allylic 
amino ester containing a secondary ethereal oxygen. All amino acids trailed in Table 12 
(vide supra) were also subjected to carbodiimide esterification utilizing isopropoxy 
allylic enol ether 239 (Table 13). 
 






 Product Yield 
    (%) 
1 Boc Me 320 49 
2 CO2Me Me 321 47 
3 Cbz Me - 0 
4 Ts Me - 0 
5 Ac Me - 0 
6 F3CCO Me - 0 
7 Boc Allyl - 0 
8 Me Me - 0 
9 Bn Boc - 0 
10 Bn Bn - 0 
11 Boc Boc 322 62 
 
Couplings utilizing isopropoxy allylic enol ether 284 were somewhat limited. Coupling 
with N-Boc sarcosine (Entry 1) and N-methoxy carbamate sarcosine (Entry 2) were 
successful affording the desired allylic amino esters. However, a significantly reduced 
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yield was achieved in comparison to the methoxy derived allylic amino ester. 
Interestingly, none of the desired product was obtained when utilizing N-Cbz sarcosine 
(Entry 3). Switching to the tosyl protected sarcosine (Entry 4), the desired product was 
obtained, however significant levels of impurities were also obtained. Several attempts 
at purification were examined, including more acid/base washes, flash chromatography 
on deactiviated silica and basic alumina and finally a Kugelrohr bulb-to-bulb 
distillation, with none improving the purity of the allylic amino ester. Both the 
acetamide and trifluoroacetamide protected sarcosine (Entries 5 & 6), failed to deliver 
the desired product, with an intractable mixture being achieved for the acetamide, whilst 
similar degradation products seen in with the methoxy derivatives was seen when using 
trifluoroacetamide. Utilizing N-boc allyl glycine (Entry 7) only the parent amino acid 
was recovered. When investigating the amino acids containing two of the same 
protecting groups, only one, N-diboc glycine coupled in 20%. It was observed that this 
allylic amino ester was sensitive to acid, so therefore, repetition of the coupling, 
omitting the citric acid wash increased the yield to a more synthetically useful 62%. 
After this observation, all allylic amino esters couplings that failed utilizing the 
isopropoxy allylic enol ether 284 were repeated, omitting the acid wash, however, still 
none of the desired allylic amino ester was yielded. 
 
3.1.3 Rearrangements 
With the allylic amino esters in hand, investigation of the rearrangements took place 
(Table 14). Initial investigation of the rearrangement different protected nitrogens will 
be based upon the optimized conditions developed for the N-phthalimide protected 
substrates. 
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Table 14: Methoxy derived allylic amino ester rearrangements  
 
 




 Product Yield dr
b
 
 ester     (%)
a
 (syn:anti) 
1 306 Boc Me 323 73 2:1 
2 307 CO2Me Me 324 42 1:1 
3 308 Cbz Me 325 41 2:1 
4 309 Ts Me 326 70 1:1 
5 310 Ac Me 327 58 1:1 
6 311 Boc Allyl 328 73 2:1 
7 312 Boc Bn 329 57 4:1 
8 313 Bn Bn - 0
c
 - 
9 314 Boc Boc 330 40 >25:1 
10 315 N-Boc Proline 331 95 >25:1 
 
a
 Isolated yield. 
b
 Diastereomeric ratio measured by 
1
H NMR analysis of crude reaction  
mixtures. 
c 
 Starting allylic amino ester recovered in >95%. 
 
In common with the starting allylic amino esters, rearranged products that contained a 
carbamate protecting group, except for N-diboc glycine were obtained as a rotameric 
mixture. The Boc-sarcosine based allylic amino ester (Entry 1) successfully rearranged 
to the desired product in a comparative yield to the phthalimide protected allylic amino 
ester 229, however, the diastereoselectivity of the rearrangement was significantly 
reduced. This trend in reduction of diastereoselectivity was also observed with other 
carbamate protected sarcosinate allylic amino esters (Entries 2 & 3), however, a 
significant decrease in isolated yield was also observed in these cases.  
 
Changing to a sulfonamide (Entry 4), offered no selectivity with a 1:1 diastereomeric 
mixture being obtained. An acetamide (Entry 5) also offered no selectivity. N-Boc, allyl 
allylic amino ester (Entry 6), affords the rearranged product in a comparative yield to 
some of the earlier investigated substrates, however once more, limited selectivity was 
observed. Importantly, the incorporation of the allyl group, not only serves as a 
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protecting group, but also as a functional handle, for the further manipulation of the 
rearranged products (vide infra). N-Boc benzyl allylic amino ester (Entry 7) showed an 
increase in diastereoselectivity, however the observed levels were significantly lower 
than those observed utilizing N-phthalimide allylic amino esters. The rearrangement of 
the N-dibenzyl based allylic amino ester (Entry 8), none of the rearranged product was 
observed under these conditions. Instead a quantitative return of the allylic amino ester 
was obtained. Switching to a N-diboc glycinate (Entry 9), complete conversion of the 
allylic amino ester is once again not observed, with only the starting allylic amino ester 
and the rearranged product being obtained, with the rearranged product as a single 
diastereomer.  
 
Similarly, the rearrangements of the isopropoxy derived allylic amino esters were 
investigated (Table 15). 
 
Table 15: Isopropoxy derived allylic amino ester rearrangements 
 
 




 Product Yield dr
b
 
 ester    (%)
a
 (syn:anti) 
1 320 Boc Me 332 62 2:1 
2 321 CO2Me Me 333 66 1:1 
3 322 Boc Boc 334 35 >25:1 
 
a
 Isolated yield. 
b
 Diastereomeric ratio measured by 
1
H NMR analysis of crude reaction  
mixtures. 
 
Rearranged products containing a carbamate protecting groups, except for N-Diboc 
glycine were obtained as rotameric mixtures. Pleasingly all three allylic amino esters 
rearranged successfully to the corresponding -isopropoxy -amino ester after 
methylation. 
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When either a tertiary butyl or a methyl carbamate (Entries 1 & 2) protected nitrogen 
was employed little to no selectivity was observed. Switching to N-Diboc glycinate 
(Entry 3), complete diastereoselective control was observed with the rearranged product 
being obtained as a single diastereomer, with no other side products. 
 
All three of these results are directly comparable to the respective methoxy derived 
allylic amino esters. 
 
It has been clearly demonstarted that changing the nitrogen protecting groups has a 
significant effect upon the developed rearrangement. These effects range from allylic 
amino ester synthesis, all the way through to the diastereoselectivity achieved upon 
rearrangement. The highest diastereoselectivites were achieved when using two 
carbonyl based protecting groups. Since the diastereoselectivity of the rearrangement is 
based solely upon the geometry of the SKA formed, and as the allylic geometry is fixed 
(vide supra, Scheme 50) changing the protecting group of the nitrogen is likely to 
influence the selectivity of the SKA formation.  
 
3.2 SILYL KETENE ACETAL (SKA) INVESTIGATION 
Due to such a large variation in diastereoselectivity observed for differently protected 
amino acids, it was decided to investigate the ratio of geometries of SKAs being 
formed. It was foreseen that there would be a direct correlation between the E/Z 
geometry of the SKA formed and the observed diastereoselectivity in the 
rearrangement. This in turn will allow determination of actual reaction pathway, 
whether its going through a truly concerted mechanism; a [3,3]-sigmatropic 
rearrangement, or a non-concerted mechanism and reacting via aldol type reactions. 
Due to the 
1
H NMR resonance of the SKA proton, investigations using our allylic 
amino esters such as 229 or 314, would be futile due to an overlap of the starting allylic 
ester signals, of rearranged material and the SKA signals, therefore making the 
assignment and determining the selectivity of the SKA formation tricky. Instead, since 
the rearrangement utilizes primary allylic esters, test substrates as the methoxy amino 
esters were prepared and isolation of the SKAs were investigated. The three test 
substrates were prepared by treating the required amino acid with an excess of 
diazomethane to form the required methoxy ester (Scheme 102). 
 




Scheme 102: Preparation of test substrates 
 
With the three methoxy esters in hand, each was subjected to LiHMDS in the presence 
of TMSCl at -95 °C before warming to room temperature. Samples were rapidly 
concentrated and assayed by 
1
H NMR to determine the SKA geometry ratio (Table 16). 
 




Entry Substrate SKA/SM Mass Return Z/E Rearrangement dr 
   (%)  (OMe, syn:anti) 
1  232 7:1 99 12:1 11:1 
2  335 4:1 100 2:1 2:1 
 3
a
 335 4:1 95 2:1 2:1 
4  336 1:3.5 72 >25:1 >25:1 
 
a
 6 equivalents of TMSCl used and allowed to warm to room temperature over 4 hours. 
 
Isolation of the SKA was successful in all cases with the major isomer being confirmed 
as the (Z)-SKA through NOeSY experiments (Appendix 7.2.1). This confirms that the 
rearrangement takes places, via the (Z)-SKA. Due to an observed syn-selectivity this 
suggests rearrangement takes place through a chairlike transistion state. Changing the 
nitrogen protecting groups (Entries 1, 2 & 4) has a dramatic effect on the selectivity of 
SKA formation. When di-Boc protection is employed (Entry 4) only a fraction of the 
starting amino ester is consumed to the SKA when the reaction is initiated at -95 °C 
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agreeing with the significant quantities of unreacted starting allylic amino ester 314 
being isolated after rearrangement after one hour. Moving to the Boc-sarcosine methyl 
ester (Entry 2), selectivity between the two SKAs is minimal, with only a 2:1 ratio being 
formed. The use of additional equivalents of TMSCl and increasing the reaction time to 
four hours (Entry 3), leads to no improvement in the selectivity. Importantly, in all cases 
the ratio of (E)/(Z)-SKA directly relates to the diastereoselectivity seen in the 
rearrangement of the methoxy based allylic amino ester. This in turn confirms that the 
rearrangement proceeds via a concerted mechanism through a chairlike transition state. 
 
It is clear to see that there is a correlation between the SKA ratios and the 
diastereoselectivity observed within our rearrangement. However rational behind this 
correlation is unknown at the present time. 
 
3.3 DIBOC SUBSTRATES 
Using N-Diboc glycine as the amino acid coupling partner, rearrangement was observed 
to form a single diastereomer in both the methoxy and isopropoxy derived allylic amino 
esters. This has been supported by the isolation of a single SKA geometry, however 
further investigation into the scope of using N-Diboc amino allylic esters is required to 
determine whether this is applicable to other substrates. Prior to investigating the scope, 
an optimization of the reaction conditions was carried out in order to increase the yield. 
 
3.3.1 Diboc optimization 
Although successful rearrangement of allylic amino ester 314 to amino ester 330 was 
observed, complete conversion of the starting allylic amino ester was not. More 
importantly, isolation of the desired product from the remaining allylic amino ester is 
not possible by flash chromatography due to co-elution of both starting allylic amino 
ester and product. Also a strong desire to increase the isolated yield to one more 
synthetically useful, led to an optimization of reaction conditions (Table 18).  
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Table 18: Rearrangement optimization 
 










 (equiv.) (equiv.) (°C) (%) (%) (syn:anti) 
1
a
 1.3 1.3 -95 60 40 >25:1 
2
a
 1.3 1.3 -78 50 45 >25:1 
3
a
 2 2 -95 75 56 >25:1 
4
af
 2 2 -95 100 62 >25:1 
5
a
 2 2 -78 100 72 >25:1 
6
b
 2 2 -78 100 30 >25:1 
 
a
 Syringe pump: addition via syringe pump at 3 mL/min. 
b
 Hand: addition by hand over 
20 seconds. 
c
 Measured by 
1
H NMR analysis of crude reaction mixtures after 24 hours. 
d
 Isolated yield. 
e
 Diastereomeric ratio measured by 
1
H NMR analysis of crude reaction 
mixtures. 
f
 time = 72 hours 
 
After repetition of the original protocol over an extended time period (Entry 1), a slight 
increase in conversion was observed (60% cf. 45%) however the isolated yield remained 
constant at 40%, this prompted us to investigate several other variables starting with the 
temperature of reaction initiation (Entry 2). Initiating the rearrangement at -78 °C, a 
greater isolated yield as a single diastereomer was obtained, however a reduction in 
conversion was observed. Therefore it was decided to increase the equivalents of base 
used. Allylic amino ester 314 was subjected to two equivalents of LiHMDS at -95 °C, 
and reacted for 24 hours (Entry 3) and 72 hours (Entry 4) respectively. In both cases, 
utilizing more base offered improved conversion of the starting allylic amino ester. 
With the increase in reaction time, complete conversion was seen, however this reaction 
time was less then desirable. Repetition of greater equivalents of base was carried out at 
-78 °C over 24 hours (Entry 5). Complete conversion of the starting allylic amino ester 
was observed during this time period, along with an increase in isolated yield to 72%. 
One final variation was carried out to determine the sensitivity of the reaction to rapid 
base addition (Entry 6). Utilizing the optimized conditions (Entry 5), LiHMDS was 
added by hand over 20 seconds, rather than by syringe pump at 3mL/min. Unlike with 
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the phthaloyl derived allylic amino ester 229, no reduction in diastereoselectivity was 
observed, however a significant reduction in the isolated yield was observed. 
 
Once more a SKA investigation was attempted, investigating the difference in SKA 
formation, dependant upon the temperature of initiation (Table 19). 
 
Table 19: SKA investigation of initiation temperature 
 
 
Entry Temp SKA/SM Mass retur Z/E Rearrangement dr 
 (°C)  (%)  (OMe, syn:anti) 
1 -95 1:3.5 72 >25:1 >25:1 
2 -78 1.4:1 89 >25:1 >25:1 
 
From the SKA investigation it has been observed that initiation of the reaction at a 
higher temperature (Entry 2) immediately generates a significantly greater quantity of 
the SKA, and therefore, coupled with an extended reaction time, allowed for complete 
consumption of the allylic amino ester substrate. 
 
3.3.2 Diboc substrate synthesis 
Having optimized the rearrangement, the generality was investigated using several of 
the allylic enol ethers previously synthesized, along with several derived from 
secondary alcohols. Firstly, new vinylogous carbonates were synthesized by a DABCO 
catalysed 1,4-additon of alcohol to methyl propiolate 232 (Table 20). 
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 Product Yield   Entry OR
1
 Product Yield  
   (%)     (%) 
1 
 











342 98      
 
Due to the successful synthesis and rearrangement of the isopropoxy derived allylic 
amino ester, other secondary alcohols were also successfully reacted with methyl 
propiolate. Isopentyl alcohol (Entry 1) and cyclohexyl alcohol (Entry 2) were both 
successfully reacted with methyl propiolate to form the desired vinylogous carbonates. 
Cyclohexyl alcohol yielded the desired product in a significantly reduced yield in 
comparison to all other DABCO catalyzed 1,4-additions. Moreso,the product was 
significantly more sensitive than previously synthesized products. One secondary 
system, comprising of a chiral -carbon was synthesized using (S)-1-phenyl ethanol to 
allow for the investigation into the effects of chirality transfer within our rearrangement. 
Other alcohols to successfully coupled were, propargyl alcohol (Entry 3) where upon 
rearrangement will deliver a terminal alkyne, suitable for enyne metathesis reactions, 
whilst 2,6-dichlorobenzyl alcohol (Entry 4) would act as a protecting group, which is 
particularly susceptible to dry acid. 
 
Following the synthesis of the vinylogous carbonates, DIBAL-H reduction afforded the 
allylic enol ethers (Table 21). 
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 Product Yield   Entry OR
1
 Product Yield  
   (%)     (%) 
1 
 










347 75      
 
All of the vinylogous esters were successfully reduced to the allylic enol ether in good 
yield (67 – 75%), with none requiring further purification. Once more, all allylic enol 
ethers were extremely sensitive to a wide range of conditions and suitable precautions , 
such as cold storage under nitrogen had to be taken to prevent rapid decomposition. 
 
Using the optimized carbodiimide promoted protocol the desired allylic amino esters 
were synthesized from N-Diboc glycine (Table 22). 
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Table 22: Allylic amino ester synthesis 
 
Entry Allylic  OR
1
 Yield Product  Entry Allylic  OR
1
 Yield  Product 
 enol ether  (%)    enol ether  (%)  
1 224 OMe 70 314  9 252 
 
63 356 




















71 353  14 256 
 
79 361 






85 355       
 
All of the allylic enol ethers coupled in good yield (45 – 96%), however not all of the 
couplings were sufficiently high in purity to use in the rearrangement. The benzyloxy 
derived substrate 357 required flash chromatography on basic alumina, whilst 
purification of the cyclohexyl derivative 346 was even more detrimental, therefore the 
allylic amino ester was taken through crude and immediately subjected to the 
rearrangement protocol. Suitable precautions such as cold storage under nitrogen were 
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3.3.3 Diboc substrate rearrangement 
With a wide range of allylic amino esters in hand, the scope of the rearrangement could 
be investigated utilizing the optimized rearrangement protocol (Table 23). 
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Table 23: Scope of enol ether in rearrangement 
 
Entry Allylic amino ester OR1 Product Yield(%)a 
drb 
(syn:anti) 
1c 314 OMe 330 72 >25:1 















365 80 >25:1 














370 78 >25:1 
12c 359 
 












 f - 
a Isolated yield. b Diastereomeric ratio measured by 1H NMR analysis of crude reaction mixtures. 
c LiHMDS solution added over 15 minutes by syringe pump. d 20% methyl N-diboc glycinate isolated 
e 10% methyl N-diboc glycinate isolated f Only diene 272 was isolated.g Isolated as trimethylsilyl alkyne. 
h 40% methyl N-diboc glycinate isolated i  Starting allylic amino ester recovered in >95%. 
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Once more, the rearrangement is seen to be general offering yields of 42 – 80%, whilst 
all rearrangements proceeded with complete diastereocontrol affording the rearranged 
products as a single diastereomer. A large range of O-functionalities have been 
investigated and are tolerated through the synthesis of our allylic amino esters and the 
rearrangement, starting with simple alkyl substrates (Entries 1 & 2). Secondary ethereal 
systems (isopropyl, entry 3) and (isopentyl, entry 4) both rearrange in 50% and 45% 
respectively. Interestingly, using cyclohexyl derived allylic amino ester, didn’t 
rearrange as expected. Instead decomposition of rearranged product to form diene 372 
was observed (Scheme 103). The formation of 372 is likely to arise from a successful 





Scheme 103: Rearrangement of 352 leading to the formation of diene 372 via an E1cb elimination 
pathway 
 
Access to alkylated oxygens containing a neopentyl group (Entry 6) is once more 
possible and is achieved in a comparable yield to the phthaloyl protected allylic amino 
ester 263, whilst incorporation of the allyl group is also successful (Entry 7). Moving to 
the propargylic ether, different reactivity was observed. Utilizing the optimized 
protocol, complete conversion of the allylic amino ester was not observed. Instead, 
silylation of the terminal acetylene of the rearranged product was also observed, 
therefore increasing the equivalents of LiHMDS and TMSCl to three, complete 
conversion of allylic amino ester 355 rearranged to afford the C-silylated product 367 in 
a 71% yield and as a single diastereomer (Scheme 104). 
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Scheme 104: Trimethylsilyl alkyne 367 obtained from the rearrangement of allylic amino ester 355 
 
Subsequent silyl deprotection of the by subjecting acetylene 367 to methanolysis in the 
presence of potassium carbonate,  was unsuccessful (Scheme 105).  
 
 
Scheme 105: Diene afforded from attempted trimethylsilyl deprotection 
 
Diene 372 was afforded as as single product 367 in quantitative yield via an E1cb 
elimination similar to that seen after the rearrangement of allylic amino ester 353. 
 
All three benzyl protecting groups (Entries 9 – 11), were tolerated, with each affording 
the desired product in good yield, with the 2,6-dichlorobenyl ether in a greater 
synthetically useful yield. 
 
Once again, interesting chemoselectivity was observed with the phenoxy based allylic 
amino esters (Entries 13 – 15), with only starting allylic amino ester being recovered. 
Each of these rearrangements was repeated utilizing LDA instead of LiHMDS under the 
same developed protocol. In all three examples, complete consumption of the starting 
allylic amino ester was observed, however, none of the desired product  
 
When the (S)-1-phenyl ethanol derived allylic amino ester 359 was rearranged, a 2.25:1 
diastereomeric mixture of both syn-diastereomers was obtained. To determine the major 
product, it was required to manipulate the rearranged product to a known compound to 
allow a direct comparison of experimental data (Scheme 106). Firstly 371 was subjected 
to hydrogenolysis in the presence of catalytic palladium on carbon to afford the 
deprotected amino ester 373. Subjecting 373 to TFA (2 equivalents) in DCM, mono-
deprotected the amine functionality to afford the threonine analogue 374. 
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Scheme 106: Rearrangement of 359 and subsequent elaboration to determine major product 
 
Comparison of the optical rotations of the synthesized 374 and the literature value as 
reported by Misiti et al. show the same direction of optical rotation, therefore 




The -facial selectivity observed is similar to the selectivity observed by Greene et al. 
when they reported the use of chiral enol ethers in an asymmetric [2+2] cycloaddition 
for the synthesis of -oxygenated lactones (Scheme 107).141 Starting from (S)-1-
phenylethanol 375 the corresponding enol ether 376 was synthesized in two steps. 
Subjecting 376 to a [2+2] cycloaddition with dichloroketene in the presence of zinc 
metal afforded -benzyloxy cyclopentanone 377 in a diastereoselectivity of 3:1. 
 
Scheme 107: Greene’s synthesis of -benzyloxy cyclopentanone 
 
The extent of -facial selectivity observed by Greene is comparable to the level of 
diastereoselectivity observed within rearrangement of 359 (2.25:1). Greene et al. 
rationalize their selectivity using computer simulation. It was predicted and observed 
that the cycloaddition takes place, in a highly selective manner on the C-re face. 
Applying the conformational model to the rearrangement of 359, our observed 
selectivity is predicted by the transition state geometry in Figure 32. 




Figure 32: Plausible model for the observed diastereoselectivity in the rearrangement of chiral 




Utilizing several allylic amino ester substrates containing common protecting groups, a 
range of methoxy derived allylic amino esters have been shown to rearrange, utilizing 
two equivalents of LiHMDS in the presence of two equivalents pof trimethylsilyl 
chloride. The diastereoselectivity of the rearrangement was extremely varied, with most 
examples offering little to no selectivity. N-Diboc glycine however, rearranged with 
complete diastereocontrol, affording the rearranged product as a single diastereomer. 
Promising this observation was also seen within an allylic amino ester containing a 
secondary ether fragment. With such a range of diastereoselectivities being achieved, an 
investigation into isolating the SKA of three amino esters was investigated. All three, 
returned a ratio of (E)- and (Z)-SKA in direct comparison to the diastereoselectivity 
observed within the rearrangement of the methoxy derived allylic amino esters. Finally 
the scope of the N-Diboc glycinate allylic amino esters was investigated where a large 
range of ethereal functional groups were tolerated, rearranging in good yield and 
affording a single diastereomer. Also important to note is the selectivity achieved when 
rearranging allylic amino esters containing a chiral centre. Allylic amino ester 359 
rearranged in 42% yield with a diastereoselectivity of 2.25:1. This level of selectivity is 
comparable to the selectivity observed by Greene et al. in their synthesis of -
oxygenated lactones.  
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CHAPTER 4 PRODUCT ELABORATION AND 
NATURAL PRODUCT SYNTHESIS 
 
4.1 PRODUCT ELABORATION 
Having investigated the influence and scope of both O- and N-substitution, a number of 
key substrate structural features were explored. A key motivation for developing this 
new Ireland-Claisen protocol for the synthesis of -hydroxy -amino acids was the 
diastereo- and enantioselective control, along with the synthetic handles that are formed 
in situ. These in turn allow for synthetic conversions of these groups and for the use in 
natural product synthesis. To demonstrate the synthetic utility of these rearranged 
products, several transformations were performed. 
 
 4.1.1 Diastereocontrol 
Synthesis of the anti-diastereomer as the major product would not only complement our 
previous work but would allow us access to either diastereomer of a desired-hydroxy 
-amino acid or ester for use in synthetic projects. There are two ways of accessing this, 
either by changing the geometry of the silyl ketene acetal formed or the geometry of the 
allylic double bond (vide supra). Initial attempts looked at changing the geometry of the 
silyl ketene acetal formed. 
 
Having previously synthesized allylic amino ester 229 and subsequently rearranging to 
the syn-product 231 in high yield and diastereoselectivity, it was first investigated 
whether changing the geometry of the silyl ketene acetal formed would allow us access 
to the anti-diastereomer.  
 
Subjecting allylic amino ester 229 to our optimized rearrangement conditions in the 
presence of HMPA, should afford the anti-diastereomer (Scheme 108).
95
 The rate of 
reaction was significantly slower than observed in previous rearrangements and full 
consumption of the starting allylic amino ester wasn’t achieved in the same time frame. 
Upon workup only an intractable mixture of degradation products was obtained. This is 
likely to be caused by the HMPA. 
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Scheme 108: Unsuccessful formation of the anti-diastereomer 
 
A brief investigation into the SKA that is formed under these reaction conditions was 
undertaken using amino ester 232 (Scheme 109). 
 
 
Scheme 109: SKA investigation using HMPA 
 
Although a significant increase in the formation of the (E)-SKA is observed, the (Z)-
SKA is still the major product. Utilizing these conditions, a significantly lower 
conversion of amino ester 232 is observed. In addition to this, a whole series of 
unidentifiable side products are visible in the 
1
H NMR spectra. With such a low 
conversion of the allylic amino ester to the desired (E)-SKA and a significant quantity 
of side products being formed, this clearly is not a viable route for the synthesis of the 
anti-diastereomer. Due to this, we investigated routes into the anti-diastereomer via 
changing the geometry of the allylic double bond. 
 
The required (Z)-allylic amino ester substrate was prepared by treating methyl 
propiolate 232 with silver (I) triflate in methanol for 16 hours to promote a trans-
selective addition of methanol across the alkyne to afford (Z)-methyl methoxyacrylate 
(Z)-223 in a 81% and as a single geometric isomer.
142
 Subsequent DIBAL-H reduction 
and subsequent carbodiimide promoted coupling, furnished the desired allylic amino 
ester (Z)-229 in three steps (Scheme 110). 
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Scheme 110: Synthesis of NPhth substrate with Z-allylic double bond 
 
With allylic amino ester (Z)-229 in hand, rearrangement utilizing our standard 
conditions was attempted (Scheme 111). Again, this rearrangement required a longer 
reaction time and displayed a complex reaction profile in comparison to an (E)-allylic 
amino ester rearrangement. Upon work-up, an intractable mixture of starting materials, 
diene 284 and a small trace of the desired diastereomer was present, however neither 
could be isolated cleanly. 
 
 
Scheme 111: Unsuccessful rearrangement of (Z)-229 
 
However, due to the successful rearrangement of several di-Boc protected amino allylic 
ester substrates to single diastereomers, it was decided to utilize a N-di-Boc substrate to 
access the anti-diastereomer, hopefully with complete diastereoselective control as 
previously seen. Substrate (Z)-313 was prepared via a carbodiimide coupling using 




Scheme 112: Synthesis of NBoc2 substrate with Z-allylic double bond 
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With the required allylic amino ester in hand, the rearrangement was again investigated 
(Scheme 113). Utilizing the optimized conditions developed for di-Boc protected allylic 
amino ester substrates, rearrangement took place, again at a slower rate, with only 75% 
conversion of starting material within the same time frame as the (E)-allylic amino 
ester. However the reaction profile was significantly cleaner than previous attempts 
using HMPA or allylic amino ester (Z)-229. The rearrangement afforded amino ester 
anti-330 as a diastereomeric mixture of 1.5:1 (anti/syn). Whilst this result is 
disappointing, the desired diastereomer was obtained as the major product and with 
further optimization of the reaction conditions, greater conversion and 
diastereoselectivity can hopefully be achieved. 
 
 
Scheme 113: Rearrangement to the anti-diastereomer 
 
A slower rearrangement with the (Z)-allylic enol ether, is likely to caused by a less 
stable chairlike transition state (Figure 33). With the (E)-allylic enol ether, both the 
large amino functionality and the enol ether are placed in favourable pseudo equatorial 
positions around the chair. Switching to the (Z)-allylic enol ether, the enol ether, is 
placed in a unfavourable axial position. This transition state is likely to be significantly 
higher in energy than for the 314 due to a significant 1,3-transannular interaction 
between the lone pairs of electrons of the SKA and the allylic enol ether.  
 
 
Figure 33: Comparison of transition states of the (E)- and (Z)-allylic enol ether 
 
The generation of a mixture of diastereomers also provided an interesting result. We 
have observed that utilizing N-Diboc allylic amino ester substrates a single (Z)-SKA 
geometry is generated. Due to the synthesis of (Z)-314 a single geometry of allylic 
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alkene has been installed. Therefore a plausible explanation to obtaining the syn-
diastereomer is likely to be caused by the unfavourable 1,3-transannular interactions 
forcing the rearrangement to take place through a less favourable but possibly lower in 
energy boat transition state (Figure 34). 
 
 
Figure 34: Chair and boat transistion states for the (Z)-allylic amino ester rearrangement 
 
Alternatively, the enol ether alkene geometry may undergo interconversion from (Z) to 
(E) and subsequent rearrangement take place via a chair transition state or that a non-
concerted mechanism is taking place. 
 
4.1.2 Allylic enol ethers processing secondary hydroxy groups 
Expanding the scope of the allylic enol ethers to containing secondary hydroxyl groups 
would lead to the formation of 1,2-disubstituted alkenes. Investigation into the synthesis 
of this type of allylic amino ester started by taking allylic enol ether 222 under our 
EDCi promoted coupling utilizing several different amino acids. In all cases none of the 
desired allylic amino ester was obtained, although TLC analysis showed complete 
consumption of 222 (Scheme 114). After several attempts at each esterification either an 
intractable mixture of products, of which all were sensitive to purification or the starting 
amino acids were obtained. 
 
 
Scheme 114: Attempted synthesis of allylic amino esters containing secondary hydroxy 
functionality via a carbodiimide promoted esterification 
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Other routes into these substrates were also investigated, including a mixed anhydride 
approach (Scheme 115). Irreversible deprotonation 222 to form the sodium or lithium 
alkoxide was followed by treatment with mixed anhydride 381 (generated in situ from 
amino acid 304 and pivaloyl chloride). Crude 
1
H NMR analysis showed that a 
successful coupling reaction had taken place, however a significant number of 
impurities were present. Several attempts at purification, only lead to decomposition. 
 
 
Scheme 115: Attempted synthesis of allylic amino esters containing secondary hydroxy 
functionality via a mixed anhydride approach 
 
Previously we have shown that a p-nitrophenoxy derived secondary allylic enol ether 
208 had previously been successfully coupled to furnished allylic amino ester 210. Due 
to the unsuccessful the application of Kazmaier’s protocol, it was deemed the use of an 
allylic aryloxy enol ether would not be applicable for this protocol. 
 
4.1.3 Deprotection 
4.1.3.1 -Hydroxyl deprotection 
Deprotection of the -hydroxy group affording the free hydroxyl group is important for 
further synthetic transformations. Subjecting product 371, to hydrogenation conditions 
in the presence of catalytic palladium on carbon cleaves the 2-methyl benzyl moiety 
affording the free hydroxyl group as well as alkene reduction to the alkane, to afford -
hydroxy -amino ester 373 in 73% yield (Scheme 116). 
 
 
Scheme 116: Selective -hydroxyl group deprotection 
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4.1.3.2 Methyl ester deprotection 
Saponification of the ester functionality would be vital for the incorporation of the 
synthesized amino acid residue into peptide structures. Subjecting amino ester 330 to an 
alkali metal hydrolysis, similar to the one used during the amino acid synthesis, did not 
achieve the desired transformation (Scheme 117). Instead, a base promoted E1cb 
elimination ensued, delivering diene 372 in quantitative yield. 
 
 
Scheme 117: Unsuccessful ester cleavage 
 
Baldwin has reported the saponification of methyl esters using the relatively mild 
conditions of potassium trimethylsilanolate in a protic solvent to afford the carboxylic 
acid.
143
 Importantly this cleavage is sufficiently mild enough to be utilized with 
compounds that are particularly sensitive to alkali metal hydrolysis. Following the 
reported procedure, amino ester 330 was treated with ten equivalents of potassium 
trimethylsilanolate (Scheme 118). Saponification of the ester functionality was 
observed, however, with such a large excess of potassium trimethylsilanolate another 
elimination reaction was observed. Also under these conditions, mono deprotection of 
the amine was observed affording diene 383 in quantitative yield. Utilizing reduced 




Scheme 118: Unsuccessful ester cleavage 
 
Another useful transformation is the reduction of the ester to the primary alcohol, 
affording amino alcohols. Taking amino ester 330, with lithium aluminium hydride, 
selectively reduces the ester to the alcohol in good yield (Scheme 119). Reduction of the 
ester moiety reduces the conformational restraints upon the product, and therefore a 
rotameric nature of amino alcohol 384 is observed. 
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Scheme 119: Selective reduction of the ester 
 
4.1.3.3 Deprotection of the amine 
Deprotection of the amine functionality is also important for the incorporation of the -
hydroxy -amino acid moiety into large peptide structures. Initially the deprotection of 
the phthalimde group was investigated. Traditionally, deprotection of phthalimde 
moieties is through the use of hydrazine. Following the procedure as described by 
Danishefsky et al., amino ester 231 was subjected to hydrazine monohydrate in 
methanol for 3 days (Scheme 120).
144




Scheme 120: Deprotection of the amine 
 
Investigating the deprotection utilizing amino ester 330, excellent selectivity was 
observed. Subjecting 330 to two equivalents of TFA in DCM for 30 minutes as reported 
by Rodríguez et al., afforded mono protected amino ester 386 in 78% (Scheme 121). 
 
 
Scheme 121: Mono boc deprotection  
 
4.1.4 Alkene functionalisation  
Reduction of the alkene has already been shown utilizing hydrogenation conditions 
(vide supra, Scheme 116) however, there are an appreciable number of transformations 
that can make use of the resultant alkene in the product. Diene 277 was subjected to a 
ring-closing metathesis reaction (RCM). The diene was observed to undergo efficient 
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ring closure when promoted by the Grubbs first-generation catalyst to form 
dihydrofuran 387 in excellent yield, without any loss of diastereoselectivity (Scheme 
122). The core structure of norfuranomycin was formed during this reaction, however 
subsequent depropection of the methyl ester and of the phthalimide protecting group 
(vide supra) were ineffective, leading to decomposition products or incomplete removal 
of the protecting groups. 
 
 
Scheme 122: RCM to form protected norfuranomycin 
 
Another RCM has been shown using N-Boc, allyl glycine as the parent amino acid in 
the rearrangement. Again, subjecting diene 328 to Grubbs first-generation catalyst, it 
was observed to undergo ring closure to afford tetrahydropyridine 388, in good yield 
(Scheme 123).  
 
 
Scheme 123: RCM to form a convenient scaffold for the synthesis of iminosugars such as 1-
deoxymojorimycin 389 
 
Although a poor diastereoselectivity was achieved during the sigmatropic 
rearrangement, the synthetic utility of 328 allows for a rapid formation of convenient 
common intermediate scaffold 388 for the synthesis of iminosugars such as 1-
deoxynojorimycin 389, should an appropriate protecting group be used on the -
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4.2 NATURAL PRODUCT SYNTHESIS 
4.2.1 Furanomycin 
Furanomycin 390 (Figure 35), a naturally occurring -amino acid containing a 
dihydrofuran ring was first isolated by Katagiri et al. in 1967 from Streptomyces 
threomyceticus.
145
 Initial biological screening by Katagiri showed furanomycin to be 





Figure 35: Furanomycin 
 
Following extensive biological analysis furanomycin has been shown to demonstrate 
excellent antibiotic activity as well as being one of the smallest natural antibiotic 
products.
146
 The antibiotic nature arises from the in vitro incorporation of furanomycin 




 4.2.2 Previous Syntheses 
To date, several syntheses of furanomycin and derivatives thereof have been reported, 
including that by the group of Joullié, who reported their synthesis in 1980 (Scheme 
124).
148
 Starting from D-glucose, furanose 391 was prepared following the procedure 
detailed by Ogawa et al.
149
 Treatment with excess sodium phenylselenide afforded 392, 
and subsequent exposured to Raney nickel, reductively removed the phenylselenyl 
group. This transformation also delivered the required methyl group at C(5). Tosylation 
followed by base mediated elimination delivered the dihydrofuran 394. Acid mediated 
acetal deprotection to the sensitive aldehyde was followed by the addition of the amine 
functionality via treatment with -methyl benzylamine. Subsquent protection as the 
benzoyl amide afforded dihydrofuran 395. No selectivity was achieved during this step, 
providing a 1:1 mixture of diastereomers. Chromatographic separation of the 
diastereomers, followed by debenzylation using formic acid and acid mediated 
hydrolysis lead to the formation of 390. 
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Scheme 124: Joullié’s synthesis of furanomycin 
 
Kang et al. reported the first highly enantioselective synthesis in 1998 (Scheme 125).
150
 
The 16 step synthesis started with the deprotection of silyl ether 396, followed by 
iodination yielding iodide 397 quantitatively. The addition of vinylmagnesium bromide 
in the presence of copper (I) bromide, followed by acetonide deprotection afforded 
diene diol 398. Mercury cation mediated cyclisation followed by an in situ reductive 
demercuration afforded the tetrahydrofuran ring 399 in 83% and as an inseparable 9:1 
mixture of diastereomers. Conversion to the trichloroacetimidate 400, allowed 
chromatographic separation to yield the required diastereomer in 83% yield. A second 
mercuric cyclisation delivered 401 in 95% after an aqueous potassium bromide workup. 
Treatment with 2,2,6,6-trimethylpiperidine-1-oxyl (TEMPO) and lithium borohydride 
in the presence of triethylborane afforded the protected oxidized product 402. Acid 
catalysed hydrolysis, followed by subsequent protection led to protected amino alcohol 
403. Conversion of the hydroxyl group to iodine allowed a regioselective base mediated 
elimination to afford the dihydrofuran ring 404. Removal of the TEMP group and 
subsequent two step oxidation afforded protected product 405. Subsequent deprotection 
completed the synthesis of 390 in an overall yield of 25%. 
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Scheme 125: Kang’s synthesis of furanomycin 
 
Clive et al. used a radical cyclisation approach to the synthesis of 390 (Scheme 126).
151
 
L-Xylose 406 was converted to its methyl glycoside, acylated, subjected to acetolysis 
conditions and then treated with benzeneselenol to form 407, in a 77% yield over the 
four steps, without the isolation of any intermediates. Mild basic hydrolysis deprotected 
the hydroxyl groups before selective protection of the C(4) and C(5) hydroxyl groups as 
ketal 408 in good yield. Carbodiimide mediated coupling formed hydrazone ester 410, 
which in the presence of acid lead to deprotection of the ketal. Selenation of the primary 
hydroxyl group afforded 412 which underwent a radical cyclisation to generate lactone 
413. Under these conditions, conversion of C(5) to the required methyl group was also 
achieved. No selectivity was observed, however isolation of the required diastereomer 
was possible by chromatography. Lithium aluminium hydride reduction yielded a triol 
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before selective protection of the primary hydroxyl group. Acidic hydrogenation 
followed by acylation delivered the protected amino alcohol 415. Both remaining 
hydroxyl groups were removed by treatment with triphenylphosphine and iodoform to 
form dihydrofuran ring 416. Hydroxyl deprotection followed by a two step oxidation 
and amine deprotection delivered 390 in an overall yield of 15%. 
 
Scheme 126: Clive’s synthesis of furanomycin 
 
Standaert et al. reported a seven step synthesis in 2000 starting from (R)-Garner 
aldehyde 417 (Scheme 127).
152
 A 1,2-additon of lithiated acetylene (R)-192 to 417 in 
the presence of zinc bromide yielded 418 in a 9:1 mixture of diastereomers. Separation 
via flash chromatography isolated the major isomer in a 77% yield. Hydroxyl-directed 
reduction proved problematic with several reducing agents delivering unidentifiable 
products. The use of lithium aluminum hydride (6 equivalents of hydride) delivered 
allenic alcohol 419 in poor yield. Cyclisation of 420 proceeded smoothly in the 
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presence of silver nitrate yielding dihydrofuran 420 in almost quantitative yield. 
Selective N,O-acetonide deprotection, followed by a two-step oxidation afforded 422 
and a final Boc-deprotection yielded 390, in an overall yield of 12%. 
 
Scheme 127: Standaert’s synthesis of furanomycin 
 
4.2.3 Reterosynthetic analysis 
It was envisaged that the dihydrofuran ring of 390 could be installed from a RCM from 
diene 423, the product of the Ireland-Claisen rearrangement of 424. The required allylic 
amino ester 424 can be prepared utilizing a carbodiimide promoted coupling of 305 and 
425. Allylic enol ether 425 will be generated from a functional group interconversion of 
426, synthesized from the 1,4-addition of 427 to 232 (Scheme 128). 
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Scheme 128: Retrosynthetic analysis of furanomycin utilizing an Ireland-Clasien rearrangement 
 
4.2.4 Forward synthesis 
Due to the required enantiopure allylic alcohol not being commercially available and 
recent reports of the synthesis of 427 proving challenging due to its volatility, it was 





Figure 36: Required allylic alcohol and allylic amino ester 
 
The added mass to this compound would reduce the volatility thus making allylic 
alcohol 428 easier to work with and the added steric bulk on the alkene should not 
impede the RCM significantly. Phenyl substituted alkenes such as 430 have been show 






Scheme 129: A recent example of a phenyl substituted alkene in a RCM 
 
The synthesis of furanomycin started by taking (S)-butyn-2-ol (S)-189 under Songashira 
coupling conditions with iodobenzene as reported by Knochel et al. to yield propargylic 
alcohol 432, quantitatively (Scheme 130).
155
 Following a reported Red-Al reduction by 
Ma et al., reduction of the of the alkyne moiety proceed smoothly to the allylic alchol 
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428 in 97% yield after flash chromatography purification.
156
 The 1,4-addition proceeded 
slowly, however returned the vinylogous ester 433 in a yield of 65%. Reduction using 
DIBAL-H delivered the required alkoxy allylic enol ether 434, however significant level 
of unidentifiable impurities were observed. Purification by Kugelrohr bulb to bulb 
distillation lead to decomposition of the allylic alcohol, therefore subsequent material 
was taken through crude. Carbodiimde coupling yielded the required allylic amino ester 
429 in a satisfactory yield. Once more this substrate proved sensitive to purification. 
Subjecting 429 to the developed Ireland-Claisen protocol, a successful rearrangement 




Scheme 130: Synthesis of diene 435 
 
With the required substrate in hand, we next turned our attention to the RCM to form 
the dihydrofuran ring (Scheme 131). 
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Scheme 131: Unsuccessful RCM to form dihydrofuran 436 
 
Following the successful dihydrofuran ring synthesis (vide supra, Scheme 122), the 
same procedure was utilized in an attempt to synthesis 436. Treating diene 435 with 
Grubbs first-generation catalyst in DCM at reflux did not furnish any of the desired 
product with only recovery of the starting diene possible. Changing the catalyst to 
Grubbs second-generation catalyst at reflux in toluene, still none of the desired product 
was observed. Finally, Hovedya-Grubbs first-generation catalyst in 10 mol% loading, at 
reflux in toluene was employed. Again no conversion of the starting diene 435 to 
dihydrofuran 436 was seen.  
 
Although Feringa had reported the formation of ,-unsaturated-dihydro--lactone 431 
via a RCM, this is the only report of a RCM containing a phenyl substituted alkene 
affording a 5-member ring. 
 
Due to the lack of success with the RCM, it was decided to synthesis a substrate without 
steric bulk surrounding the alkene. A DABCO catalysed 1,4-addition of enantiopure 
(S)-butyn-2-ol to methyl propiolate afforded vinylogous ester 437, in excellent yield. 
This in turn was also more stable and easy to handle than the required allylic alcohol. 
Subsequent reduction of the alkyne functionality to the required alkene was 
investigated. Hydrogenation using Lindlar’s catalyst in the presence of quinoline 
yielded rac-426 in 88%, however racemisation of the chiral centre was seen. Along with 
this 10% of over reduction to the alkane was also observed. 
 
 
Scheme 132: Racemisation of the chiral centre under hydrogenation 
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Alkyne reduction of vinylogous ester 437 was investigated without the presence of 
quinoline (Scheme 133). When subjected to these conditions, no selectivity was 
observed with reduction to alkane 438. Interestingly, no epimerization of the chiral 
centre was observed. Due to the lack of selectivity or epimerization occurring 




Scheme 133: Over reduction without the use of quinoline 
 
Direct hydrogenation of (S)-butyn-2-ol (S)-189, in the presence of Lindlar’s catalyst, 
only yielded fully reduced alkane 439 (Scheme 134). In the presence of quinoline, none 
reduced material was isolated, possibly due to the volatility of the product.  
 
 
Scheme 134: Over reduction of (S)-butyn-2-ol  
 
Secondly, a hydride mediated reduction of the alkyne moiety was investigated. Treating 
(S)-189 with lithium aluminium hydride in ether at reflux for 48 hours afforded 
enantiopure (S)-buten-2-ol, in a modest yield, however comparable to literature values 
(Scheme 135).
153
 Although complete consumption of the alkyne was not observed, no 
over reduction to the alkane was seen. Crude (S)-buten-2-ol was immediately subjected 
to a 1,4-addition with methyl propiolate to afford vinylogous ester 426. It was at this 
stage where purification to separate the alkyne and alkene was carried out and afforded 
the required vinylogous ester 426 in 24% yield over the two steps. Selective reduction 
of 426 to the allylic enol ether afforded 425 in 80%. Carbodiimide coupling with N-
diBocglycine 305 proceeded smoothly to afford the required allylic amino ester 424 in 
98% without the need for purification. Utilizing the optimized protocol, the 
rearrangement was observed to be successful yielding the required diene 423 in a 60% 
and a 2.5:1 mixture of diastereomers. Several different conditions were tried to increase 
the diastereoselectivity of the rearrangement however none of these were fruitful. RCM 
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using Grubbs first generation catalyst was observed to be slower than previous RCMs, 
however the required dihydrofuran 436 was obtained in good yield and with retention of 
diastereoselectivity. It was at this stage that the major diastereomer was confirmed as 
the desired product by NOe spectroscopy due to the through space interaction between 
the C(5) methyl and the C(2) proton, indicating an syn arrangement of these two groups 
(Appendix 7.2.2). Subjecting 436 to potassium trimethylsilanolate resulted in 
decomposition of dihydrofuran 436, with only a small trace (<5%) of unreacted 436 
being isolated from the reaction. 
 
 
Scheme 135: Forward synthesis of 436 
 
Since there is a significant array of different protocols for the deprotection of methyl 
esters with alkali metal hydroxides in the literature, several different hydroxides were 
trailed to deprotect 436 (Scheme 136).
157-159
 
Chapter 4                                                                                        Results and Discussion 
 118 
 
Scheme 136: Different hydrolysis approaches 
 
In each case, none of the desired product 440 was isolated. In all four examples, 
complete consumption of 436 was observed by TLC analysis, although a significant 
number of new spots were observed. After workup, crude 
1
H NMR analysis showed 
alkene signals consistent with those expected for 440, however a vast quantity of other 
alkene signals and impurities were present. All attempts at purification by flash 
chromatography using deactiviated silica resulted in none of the desired product being 
isolated. Refering to the synthesis by Standaert et al., after oxidation of N-Boc 
furanomycinol 421 to N-Boc furanomcyin 422, no purification is used.
152
 Instead the 
422 is taken through crude to the final deprotection before purification. Although not 
stated, reasons behind this maybe the instability of 422, leading to degradation similar 
to what we have observed. 
 
To try and follow the saponifcation closely, it was tried to monitor the reaction in a 
NMR tube using cesium hydroxide. Unfortunately due to the low solubility of 436 in 
deuterium oxide, this was not possible. Even with the addition of THF, monitoring the 
reaction was difficult. Instead the reaction was run as normal, and aliquots subjected to 
mini work-ups and immediated analysed by 
1
H NMR. However, due to the small scale 
of the reaction, this method of reaction monitoring provided insufficient information 
about the reaction profile. 
 
A possible route to prevent this decomposition is not adding the methyl ester therefore 
removing the requirement to deprotect the methyl ester. After the Ireland-Claisen 
rearrangement of 424, the crude diene was isolated from the reaction mixture and 
immediately subjected to an RCM utilizing Grubbs first generation catalyst (Scheme 
137). Unfortunately, none of the required dihydrofuran 440 was obtained. Instead, an 
intractable mixture of identifiable products all containing significant amounts of 
ruthenium based complexes making assignment difficult. 




Scheme 137: Attempts at RCM utilizing crude 441 
 
Having previously shown that mono deprotection of the amine functionality and 
selective ester reduction of amino ester 330 could be achieved, it was decided to 
concentrate upon the formal synthesis of furanomycin, up to immediate 421 as reported 
by Standaert et al.
152
 First 436 was subjected to two equivalents of TFA in DCM at 0 °C 
for 4 hours afforded 442 in 79% yield. Although a longer reaction time was required, 
none of the free amine was observed. Subsquently 442 was treated with two equivalents 
of lithium aluminum hydride to reduce the amino ester to amino alcohol 421 in 65% 
yeild. Therefore a formal synthesis of furanomycin was completed, starting from (S)-
butyn-2-ol (S)-189 to N-Boc furanomycinol 421, in 4.9% yield over 8 steps. 
 
 
Scheme 138: Formal synthesis of N-Boc Furanomycinol 421 
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4.3 CONCLUSIONS 
Access to the anti-diastereomer has been shown to be limited. The SKA investigations 
show that the (Z)-SKA is the major geometry formed, therefore the use of HMPA to 
change the SKA geometry would not have been applicable. Instead, switching to a (Z)-
allylic enol ether, led to the anti-diastereomer, however limited diastereoselectivity was 
observed. 
 
Key transformations such as amine deprotection can be selectively achieved utilizing 
the N-Diboc products, along with the removal of protecting groups sensitive to 
hydrogenolysis (such as 2-methyl benzyl) has also been shown. Saponification of the 
methyl ester has however proved more difficult due to the sensitivity of these 
compounds towards alkali bases and other protocols such as utilizing potassium 
trimethylsilanote have also proved ineffective. Further functionalisation of the resultant 
alkene has been explored utilizing RCM methodology, resulting in the formation of the 
main core of norfuranomycin 387 and a key intermediate for the synthesis of 
iminosugars. 
 
Finally, several of these transformations have been incorporated into a formal synthesis 
of furanomycin starting from (S)-butyn-2-ol, in 4.9% in 8 steps. 
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CHAPTER 5 CONCLUSIONS AND FUTURE WORK 
 
5.1 CONCLUSIONS 
A new synthetic approach to -hydroxy -amino acids has been established utilizing the 
Ireland-Claisen rearrangement of allylic amino esters generated, from an amino acid and 
an allylic enol ether (Scheme 139). 
 
Scheme 139: Ireland-Claisen rearrangement of allylic amino esters to -hydroxy -amino acids 
 
The development of this methodology initially centred on utilizing the protocol 
developed by Kazmaier of metal chelated enolates. However, none of the desired 
rearranged product was obtained; instead decomposition back to the starting 
components was observed (Scheme 140). This has been postulated to occur due to the 
significant dipolar character of the transition state.  
 
 
Scheme 140: Decomposition utilizing Kazmaier’s protocol 
 
Switching to a more traditional Ireland-Claisen type protocol utilizing N-Phthaloyl 
glycine, successfully allowed for a syn-selective rearrangement, with a wide scope of 
ethereal groups tolerated producing good yields and diastereoselectivities (Scheme 141). 
The rearrangement has been observed to be sensitive to a wide range of variables such 
as initiation temperature and base addition rate. One limitation to the use of a 
phthalimde protecting group is that only allylic enol ethers containing primary or 
phenoxy based ethereal groups can be successfully coupled to form the required allylic 
amino ester. The rearrangement of an allylic amino ester derived from rac-alanine was 
also accomplished with high levels of syn-selectivity. This opens up a general 
diastereoselective route into synthesizing serine/alanine adducts or further ,-
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substituted hybrid amino acid fragments resembling the -hydroxy -amino acid seen in 
several natural products such as sphingofungin F. 
 
 
Scheme 141: Successful rearrangement using a phthalimde protected nitrogen under traditional 
Ireland-Claisen rearrangement conditions 
 
Switching the study from the ethereal oxygen, N-substitution using several commonly 
used protecting groups was investigated. A range of amino acids were synthesised and 
investigated with all but one displaying little to no selectivity. N-Diboc glycine was 
observed to rearrange in a syn-selective fashion to afford the desired -alkoxy -amino 
ester products as single diastereomers. Importantly, this was also observed to be 
applicable to allylic amino esters containing secondary ethereal oxygens. 
 
Due to a large variation in selectivity being observed an investigation into the formation 
of the SKA was invoked. This provided a large insight into the relative formation of 
SKA geometries through to the diastereoselectivity and mechanism of the 
rearrangement. With three amino esters investigated, the ratio of E/Z geometries of the 
SKAs formed showed a direct correlation with the diastereoselectivity obtained utilizing 
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Table 24: SKA investigation 
 
 
Entry Substrate Temp SKA/SM Yield SKA Z/E Rearrangement dr 
  (°C)  (%)  (OMe, syn:anti) 
1 232 -95 7:1 87 12:1 11:1 
2 335 -78 1.4:1 51 >25:1 >25:1 
3 336 -95 4:1 81 2:1 2:1 
 
The scope of the rearrangement was once again investigated using the N-diboc glycine 
as the amino acid coupling partner. Again a large range of ethereal functional groups 
were tolerated, rearranging in good yield as a single diastereomer (Scheme 142). Also 
important to note is the selectivity achieved when rearranging allylic amino esters 
containing a chiral centre.  
 
Scheme 142: Successful rearrangement using N-Diboc glycine affording -hydroxy -amino acids 
as a single diastereomer 
 
Access to the anti-diastereomer has been shown to be limited. The SKA investigations 
show that the (Z)-SKA is the major geometry formed, therefore the use of HMPA to 
change the SKA geometry would not have been applicable. Instead, switching to a (Z)-
allylic enol ether, led to the anti-diastereomer, however limited diastereoselectivity was 
observed (Scheme 143). 
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Scheme 143: Limited access to the anti-diastereomer 
 
Key transformations such as amine deprotection can be selectively achieved utilizing 
the N-diboc products, whilst removal of protecting groups sensitive to hydrolysis has 
also been shown. Saponification of the methyl ester has however proved more difficult 
due to the sensitivity of these compounds towards alkali bases. Further functionalisation 
of the resultant alkene has been expored utilizing RCM methodology, resulting in the 
formation of the main core of norfuranomycin and a key intermediate for the synthesis 
of iminosugars being achieved (Scheme 144).  
 
 
Scheme 144: Several functionalisations of the -alkoxy -amino esters 
 
Finally, several of these transformations have been incorporated into a formal synthesis 
of furanomycin starting from (S)-butyn-2-ol, in 4.9% in 8 steps (Scheme 145). 
 
Scheme 145: Synthesis of N-Boc furanomycinol 
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5.2 FUTURE WORK 
5.2.1 Chiral enol ethers 
Greene et al. have reported the use of chiral enol ethers in an asymmetric [2+2] 
cycloaddition for the synthesis of -oxygenated lactones.141 When starting from (S)-1-
phenylethanol (R=H) the -benzyloxy cyclopentanone was obtained in a 
diastereoselectivity of 3:1 (Scheme 146). 
 
Scheme 146: Greene’s observations of increasing diastereoselctive control with increasing steric 
benzyl enol ether 
 
They observed greater -facial selectivity was achieved and hence improved 
diastereoselective control when utilizing substitued benzyl chiral enol ethers.  
 
Utilzing this observation, increasing the steric bulk upon chiral benzylic allylic enol 
ethers to substituents such as isopropyl groups could might allow the rearrangement to 
proceed in a completly diastereoselective manner (Scheme 147). 
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5.2.2 Chiral phosphates 





Scheme 148: Funk’s enol phosphate rearrangement 
 
Utilizing Funk’s procedure, substituting the diethyl phosphorochloridate for a chiral 
variant (Scheme 149), should lead to a diastereo- and enantioselective rearrangement of 
our allylic amino ester substrate. 
 
 
Scheme 149: Possible use of chiral phosphorochloride to induce absolute chirality within our 
rearrangement 
 
Although our substrate has been shown to be sensitive to HMPA, initial investigation 
with other solvents could allow for a successful rearrangement and therefore proof of 
concept can be obtained. 
 
5.2.3 Alkene substitution 
Several natural products containing -hydroxy -amino acids moieties contain 
contiguous stereocentres. Utilizing substitution on the alkene unit coupled with 
substituted amino acids, will lead to the generation of two new stereocentres. More so, 
Kato et al. have recently reported the synthesis of -methoxyacrylates starting from 
terminal acetylenes. Utilizing his methodology to synthese -methoxyacrylates would 








Scheme 150: Kato synthesis of -methoxyacrylates leading to contiguous stereocentres after 
rearrangement of the allylic amino ester. 
 
5.2.4 Natural product synthesis 
Primary investigation into natural product synthesis should concentrate upon improving 
and completing the synthesis of furanomycin. First, since protection of the carboxylic 
acid functionality is required after rearrangement to allow for flash chromatographic 
purification, protection as either a tert-butyl ester or p-methoxybenzyl ester should 
allow for a global deprotection, therefore also reducing the number of steps in the 
synthesis. Also improvement of the rearrangement diastereoselectivity, to afford the 
desired amino ester as a single diastereomer would considerably improve the synthesis. 
Changing the substitution of the ethereal fragment however is very limited. Since the 
addition of the bulk phenyl ring not only yielded similar diastereoselectivities, but also 
impeded the RCM. Alternatives would see a large group at this position instead of the 
methyl group, however, further manipulation of this group is required to yield a methyl 
group for the final compound. 
 
Several more natural products can be synthesized via this methodology. More 
importantly the key substrates and rearrangements have already been investigated and 
have been shown to proceed successfully to the required intermediates for the synthesis 
of both these compounds (Figure 36). 
 
 
Figure 36: Two further natural product targets: 1-deoxymojorimycin 389 and oseltamivir 317. 
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CHAPTER 6 EXPERIMENTAL 
 
6.1 GENERAL EXPERIMENTAL 
Reactions were carried out using anhydrous solvents and under an inert atmosphere of 
nitrogen. All reaction vessels were flame dried prior to use. Anhydrous acetonitrile, 
diethyl ether, dichloromethane, hexane, toluene and tetrahydrofuran were obtained by 
passing through anhydrous alumina columns using an Innovative Technology Inc. PS-
400-7 solvent purification system. All other commercially available compounds were 
used as obtained from the chemical suppliers and used without purification. 
Triethylamine and methyl trans-3-methoxyacrylate were freshly distilled, 
diisopropylamine was freshly distilled from sodium hydroxide pellets and 
chlorotrimethylsilane was freshly distilled from 10 % quinoline. Zinc chloride was dried 
at 130 °C and 1.2 torr for 90 minutes prior to use. Diazomethane was generated by the 
addition of potassium hydroxide solution (37%) to N-nitroso-N-methylurea in ether. All 
distilled materials were stored under nitrogen at 4 
o
C or less. All reactions were 
monitored by thin layer chromatography (TLC) using pre-coated MN Alugram Sil 
G/UV254 silica gel 60 aluminium backed plates. Plates were developed using standard 
techniques, UV light (at 254 nm) followed by a chemical dip, usually KMnO4 and 
gentle heating. Flash chromatography was performed on chromatography grade, silica 
60Å particle size 35-70 micron from Fisher Scientific or chromatography grade basic 
Brockmann I grade alumina particle size 50 – 200 micron from Acros Organics using 
the solvent system as stated. Samples were pre-absorbed onto silica/alumina or loaded 
as saturated solutions in an appropriate solvent. Ether refers to diethyl ether and petrol 





C NMR was performed on Brüker Avance 250 (
1
H 250 MHz), Brüker Avance 
300 (
1
H 300 MHz and 
13
C 75 MHz), Brüker Avance 400 (
1
H 400 MHz and 
13
C 100 
MHz) and Brüker Avance 500 (
1
H 500 MHz and 
13
C 125 MHz) as stated. Chemical 
shifts are reported in parts per million (ppm) relative to tetramethylsilane (TMS) (
0.00). Coupling constants are reported in Hertz (Hz) and signal multiplicity as denoted. 
Rotamers were confirmed by variable temperature (VT) 
1
H NMR and ratios determined 
at room temperature using either Brüker Avance 400 (
1
H 400 MHz and 
13
C 100 MHz) 
or Brüker Avance 500 (
1
H 500 MHz and 
13
C 125 MHz) as stated. Where rearranged 
products are obtained as a diastereomeric and rotameric mixture,data reported 
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corresponds to both sets of rotamers for the major diastereomer only, regardless of ratio. 
Mass spectroscopy was performed on a a Brüker Daltonics micrOTOF using 
electrospray ionisation (ESI) in either positive or negative ionization as stated. Infra-red 
spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer, using a 
Universal ATR accessory for sampling. Melting points were determined using a Bibby 
Scientific Melting point apparatus Stuart SMP10 digital and are reported as uncorrected. 
X-ray data was collected at 150 K on a Nonius KappaCCD area detector diffractometer 
using Mo-Kα radiation (λ = 0.71073 Å), and all structures were solved by direct 
methods and refined on all F2 data using SHELXL-97 suite of programs, with hydrogen 
atoms included in idealized positions and refined using the riding model. 
 
6.2 GENERAL PROCEDURES 
General Procedure 1  Synthesis of 4-aryloxy but-3-en-2-ones 
 
To a stirred solution of chromium (VI) oxide (4.00 g, 40 mmol, 1.45 equiv.) in H2SO4 
(20% v/v, 150 mL) was added 3-butyn-2-ol (2.2 mL, 27.5 mmol, 1 equiv.) in H2SO4 
(20% v/v, 150 mL) at 0 °C and stirred for 4 hours. The reaction was extracted with 
DCM (3 × 100 mL). The combined organics were washed with 1:1 saturated 
bicarb/water solution (3 × 100 mL), dried over Na2SO4 and filtered. The crude ketone 
was added dropwise over 1 hour to a solution of an alcohol (1 equiv.) and DABCO 
(0.31 g, 2.75 mmol, 0.1 equiv.) in DCM (10 mL) at 0 °C, warmed to room temperature 
and stirred for a further 64 hours. The resulting solution was concentrated in vacuo to 
c.a. 100 mL, washed with water (3 × 75 mL), dried over Na2SO4, filtered and 
concentrated in vacuo to afford the title compound. 
 
General Procedure 2  Synthesis of 4-aryloxy but-3-en-2-ols 
 
To a stirred to solution of 4-aryloxy but-3-en-2-one (2.35 g, 11.4 mmol, 1 equiv) in 
methanol and water (1:1, 10 mL) at 0 °C was added sodium borohydride (0.91 g, 22.8 
mmol, 2 equiv.) portionwise. The resultant suspension was stirred at room temperature 
for 5 hours before extracting with DCM (3 × 25 mL). The organic fractions were 
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combined and washed with saturated bicarbonate solution (3 × 50 mL) and brine (3 × 50 
mL), dried over Na2SO4, filtered and concentrated in vacuo to afford the title 
compound.  
 
General Procedure 3  Synthesis of amino esters substrates 
 
To a stirred solution of EDCi.HCl (2 equiv.) in DCM (50 mL) was added triethylamine 
(2 equiv.), amino acid (2 equiv.), catalytic DMAP (5 mol %) and allylic alcohol (1 
equiv.). The reaction is stirred at room temperature for 4 hours or until consumption of 
allylic alcohol is complete by TLC. Dilution with DCM to 100 mL, followed by 
washing with saturated sodium bicarbonate solution (3 × 100 mL), citric acid (10% 
solution, 3 × 100 mL) and brine (3 × 100 mL), dried over Na2SO4, filtered and 
concentrated in vacuo to afford amino esters without any further purification, unless 
stated.  
 
General Procedure 4  Synthesis of vinylogous esters  
 
To a stirred solution of 1,4-diazabicyclo[2.2.2]octane (0.1 equiv.) and alcohol (1.1 
equiv.) in THF (150 mL) at room temperature was added methyl propiolate (1 equiv.) 
via syringe pump over 10 minutes, before stirring at room temperature for a further 30 
minutes. Sodium hydroxide (10% solution, 200 mL) was added and the aqueous was 
extracted with DCM (4 × 100 mL), combined, washed with brine (3 × 150 mL), dried 
over Na2SO4, filtered and concentrated in vacuo. The product ester was isolated after 
subsequent purification on silica gel by flash chromatography. 
 
General Procedure 5  Synthesis of allylic alcohols 
 
To a stirred solution of the ester (1 equiv.) in toluene (100 mL) at -78 °C was added 
diisobutylaluminium hydride solution (1M in toluene, 2.5 equiv.) at a rate of 1 mL    
min
-1
. After addition the reaction was stirred at -78 °C for 6 hours, before pouring onto 
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a Rochelle’s salt solution (sat., 100 mL) followed by the addition of EtOAc (100 mL). 
The biphasic mixture was vigorously stirred for 2 hours before separating and extracting 
with EtOAc (3 × 100 mL). The organics were combined, dried over Na2SO4, filtered 
and concentrated in vacuo to afford the primary allylic alcohol product without further 
purification, unless stated. 
 
General Procedure 6  Ireland-Claisen rearrangements 
 -- Phthamide protected substrates 
 
To a stirred solution of the amino ester (1 equiv.) in THF (1 mL) at -95 °C is added 
TMSCl (1.3 equiv.) and stirred for 10 minutes. LiHMDS (1M in THF, 1.3 equiv.) was 
added via syringe pump at a rate of 3 mL hr
-1
 and the mixture stirred at -95 °C for a 
further 10 minutes before warming to 0 °C and stirring for 30 minutes. The reaction is 
quenched by the addition of 1M HCl and brine solution (1:1, 2 mL). The reaction 
mixture is extracted with DCM (3 × 10 mL) and ethyl acetate (3 × 10 mL). The 
combined organic phases were dried over Na2SO4, filtered and concentrated in vacuo to 
afford the crude acid. Treatment with excess diazomethane (generated from NMU in 
situ) in ether afforded the methyl ester. Purification was achieved by flash 
chromatography to afford the title compound as an inseparable mixture of 
diastereomers. 
 
General Procedure 7  Ireland-Claisen rearrangements 
 -- Di-boc protected substrates 
 
To a stirred solution of the amino ester (1 equiv.) in THF (1 mL) at -78 °C is added 
TMSCl (2 equiv.) and stirred for 10 minutes. LiHMDS (1M in THF, 2 equiv.) was 
added via syringe pump at a rate of 3 mL hr
-1
 and the mixture stirred at -78 °C for a 
further 10 minutes before warming to room temperature and stirring for 24 hours. The 
reaction is quenched by the addition of methanol (10 mL). Treatment with excess 
diazomethane (generated from NMU in situ) in ether afforded the methyl ester. 
Chapter 6  Experimental 
 132 
Purification was achieved by flash chromatography to afford the title compound as a 
single diastereomer. 
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6.3 COMPOUND CHARATERISATION 
4-Bromo-3-butyn-2-ol (190) 
 
To a stirred solution of N-bromosuccinimide (5.07 g, 28.5 mmol, 1 equiv.) and silver 
nitrate (1.00 g, 5.9 mmol, 0.2 equiv.) in acetone (30 mL) was added 3-butyn-2-ol 189 
(2.24 mL, 28.5 mmol, 1 equiv.). After 1 hour, the reaction mixture was concentrated in 
vacuo to approximately 10 mL, filtered through a pad of silica and washed through with 
DCM (50 mL). The solution was then concentrated in vacuo to afford the title 
compound as a yellow oil and used without any further purification (3.30 g, 75%). 
1
H 
NMR (250 MHz, CDCl3) : 1.39 (d, 3H, J = 6.6 Hz, BrC≡CCH(OH)CH3), 3.51 (br s, 
1H, BrC≡CCH(OH)CH3), 4.48 (q, 1H, J = 6.6 Hz, BrC≡CCH(OH)CH3); 
13
C NMR (75 





To a stirred solution of 3-butyn-2-ol 189 (5.60 mL, 71.3 mmol, 1 equiv.) in THF (50 
mL) was added DMAP (0.81 g, 7.1 mmol, 0.1 equiv.), triethylamine (19.8 mL, 143 
mmol, 2 equiv.) and tert-butylchlorodimethylsilane (10.75 g, 71.3 mmol, 1 equiv.). The 
solution was stirred for 16 hours at room temperature, filtered through a pad of silica 
and washed through with THF (50 mL) and concentrated in vacuo. The crude product 
was taken up in DCM (100 mL) and filtered through a second pad of silica and 
concentrated in vacuo to afford the title compound as a yellow oil and used without any 
further purification (8.36 g, 64%). 
1
H NMR (250 MHz, CDCl3) : 0.08 (s, 3H, 
Si(CH3)2(C(CH3)3), 0.12 (s, 3H, Si(CH3)2C(CH3)3), 0.90 (s, 9H, Si(CH3)2C(CH3)3), 1.44 
(d, 3H, J = 6.6 Hz, CCH(OSi)CH3), 2.38 (d, 1H, J = 2.0 Hz, HC≡CCH(OSi)CH3), 4.52 
(qd, 1H, J = 6.6, 2.0 Hz, HC≡CCH(OSi)CH3); 
13
C NMR (75 MHz, CDCl3) : -4.3, -3.2, 










To a stirred solution of bis(cyclopentadienyl)zirconium(IV) hydrochloride (0.26 g, 1 
mmol, 1 equiv.) in toluene (5 mL) was added  (but-3-yn-2-yloxy)(tert-
butyl)dimethylsilane 192 (0.18 g, 1 mmol, 1 equiv.) in THF (15 mL). After 15 minutes 
a further portion of bis(cyclopentadienyl)zirconium(IV) hydrochloride (0.26 g, 1 mmol, 
1 equiv.) in toluene/THF (3:1, 20 mL) was added. After a further 2 hours, iodine (0.25 
g, 1 mmol, 1 equiv.) was added before stirring for 16 hours. The mixture was diluted 
with hexane (25 mL), filtered through a pad of silica and concentrated in vacuo to afford 
the title compound as a yellow oil (0.08 g, 25%). FTIR (film/cm
-1) υmax: 3012.5, 2958.3, 
1659.7; 
1
H NMR (250 MHz, CDCl3) : 0.00 (m, 6H, Si(CH3)2C(CH3)3), 0.84 (s, 9H, 
Si(CH3)2C(CH3)3), 1.15 (d, 3H, J = 6.6 Hz, CHCH(OSi)CH3), 4.21 (qt, 1H, J = 6.6, 1.2 
Hz, ICH=CHCH(OSi)CH3), 6.17 (app. dd, 1H, J = 13.7, 1.2 Hz, 
ICH=CHCH(OSi)CH3), 6.49 (dd, 1H, J = 13.7, 1.2 Hz, ICH=CHCH(OSi)CH3); 
13
C 




According to general procedure 1, the title compound was synthesised using 4-
nitrophenol (3.83 g, 27.5 mmol, 1 equiv.). Purification was achieved by recrystalisation 
from hot methanol, affording the title compound as pale yellow crystals (3.00 g, 53%). 
MP: 70 – 71 °C; FTIR (nujol mull/cm-1) υmax: 3088.3, 1702.8, 1643.7; 
1
H NMR (250 
MHz, CDCl3) : 2.22 (s, 3H, =CHCOCH3), 6.10 (d, 1H, J = 10.2 Hz, 
ArOCH=CHCOCH3), 7.16 (dt, 2H, J = 9.2, 3.3 Hz, Ar-H Ph), 7.70 (d, 1H, J = 10.2 Hz, 
ArOCH=CHCOCH3), 8.25 (dt, 2H, J = 9.2, 3.3 Hz, Ar-H Ph); 
13
C NMR (75 MHz, 
CDCl3) : 29.1, 113.8, 117.8, 126.1, 144.5, 155.5, 160.2, 196.7; HRMS (ESI, +ve) m/z: 










According to general procedure 1, the title compound was synthesised using 2-
nitrophenol (3.83 g, 27.5 mmol, 1 equiv.). Purification was achieved by recrystalisation 
from hot methanol, affording the title compound as pale yellow crystals (2.53 g, 40%). 
MP: 65 – 67 °C; FTIR (nujol mull/cm-1) υmax: 3085.7, 1647.3; 
1
H NMR (250 MHz, 
CDCl3) : 2.17 (s, 3H, =CHCOCH3), 5.83 (d, 1H, J = 12.4 Hz, ArOCH=CHCOCH3), 
7.25 (m, 2H, Ar-H Ph), 7.59 (dt, 2H, J = 7.9, 2.1 Hz, Ar-H Ph), 7.91 (d, 1H, J = 12.4 
Hz, ArOCH=CHCOCH3); 
13
C NMR (75 MHz, CDCl3) : 29.1, 113.3, 126.2, 126.4, 
139.8, 141.6, 148.6, 150.8, 158.2, 197.0; HRMS (ESI, +ve) m/z: calcd. for C10H10NO4 






According to general procedure 1, the title compound was synthesised using 2,4-
dinitrophenol (5.06 g, 27.5 mmol, 1 equiv.). The crude compound was recrystalised 
from hot methanol, affording the title compound as pale yellow crystals (4.57 g, 66%). 
MP: 70 – 72 °C; FTIR (nujol mull/cm-1) υmax: 3055.7, 1667.3; 
1
H NMR (250 MHz, 
CDCl3) : 2.22 (s, 3H, =CHCOCH3), 6.12 (d, 1H, J = 12.2 Hz, ArOCH=CHCOCH3), 
7.44 (m, 3H, Ar-H Ph), 7.64 (d, 1H, J = 12.2 Hz, ArOCH=CHCOCH3); 
13
C NMR (75 
MHz, CDCl3) : 29.1, 112.8, 117.2, 128.8, 139.5, 142.4, 145.9, 148.0, 154.0, 197.7; 







According to general procedure 2, the title compound was synthesised using (E)-4-(4-
nitrophenoxy)but-3-en-2-one 205. Purification was achieved by recrystalisation from 
chloroform/petrol, affording the title compound as pale white powder (1.85 g, 77%). 
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MP: 78 – 80 °C; FTIR (nujol mull/cm-1) υmax: 3305.4; 
1
H NMR (250 MHz, CDCl3) : 
1.31 (d, 3H, J = 6.3 Hz, =CH(OH)CH3), 1.62 (br, 1H, =CH(OH)CH3), 4.40 (quin, 1H, J 
= 6.3 Hz, =CH(OH)CH3), 5.56 (dd, 1H, J = 12.0 Hz, OCH=CHCH(OH)CH3), 6.65 (d, 
1H, J = 12.0 Hz, OCH=CHCH(OH)CH3), 7.02 (m, 2H, Ar-H Ph), 8.18 (m, 2H, Ar-H 
Ph); 
13
C NMR (75 MHz, CDCl3) : 24.6, 65.8, 116.6, 120.6, 126.4, 141.5, 143.3, 162.1; 




According to general procedure 2, the title compound was synthesised using (E)-4-(2-
nitrophenoxy)but-3-en-2-one 206. Purification was achieved by recrystalisation from 
chloroform/petrol, affording the title compound as pale white powder (1.65 g, 70%). 
MP: 80 – 81 °C; FTIR (nujol mull/cm-1) υmax: 3310.6; 
1
H NMR (250 MHz, CDCl3) : 
1.39 (d, 1H, J = 6.3 Hz, OCH=CHCH(OH)CH3)), 1.54 (br, 1H, OCH=CH(OH)CH3), 
4.47 (quin, 1H, J = 6.3 Hz, OCH=CHCH(OH)CH3), 5.58 (dd, 1H, J = 12.8, 6.3 Hz, 
OCH=CHCH(OH)CH3)), 6.70 (d, 1H, J = 12.8 Hz, OCH=CHCH(OH)CH3)), 7.18 – 
7.95 (m, 4H, Ar-H Ph); 
13
C NMR (75 MHz, CDCl3) : 23.6, 64.6, 112.2, 119.7, 123.8, 
127.6, 135.5, 136.3, 139.8, 142.0; HRMS (ESI, -ve) m/z: calcd. for C10H10NO4 





EDCi.HCl (1.33 g, 7.00 mmol), triethylamine (1.00 mL, 7.00 mmol), N-boc glycine 
(1.22 g, 7.00 mmol), catalytic DMAP and (E)-4-(4-nitrophenoxy)but-3-en-2-ol 208 
(0.74 g, 3.50 mmol) were combined according to general procedure 3, to afford the title 
compound as a yellow oil (0.90 g, 70%). FTIR (nujol mull/cm
-1) υmax: 3010.7, 2980.3, 
1757.6, 1718.0, 1671.7; 
1
H NMR (250 MHz, CDCl3) : 1.35 – 1.40 (m, 12H, 
(CH3)3COCON & OCH(CH3)CH=CHO), 3.83 (d, 2H, J = 5.8 Hz, NCH2CO2), 4.94 (br, 
1H, NH), 5.38 – 5.49 (m, 2H, OCH(CH3)CH=CHO & OCH(CH3)CH=CHO), 6.78 (dt, 
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1H, J = 11.7, 4.9 Hz, OCH(CH3)CH=CHO), 6.98 – 7.04 (m, 2H, Ar-H Ph), 8.13 - 8.20 
(m, 2H, Ar-H Ph);
13
C NMR (75 MHz, CDCl3) : 21.1, 28.7, 43.1, 69.3, 80.3, 115.2, 
116.8, 126.3, 143.5, 144.6, 156.2, 161.7, 170.2; HRMS (ESI, -ve) m/z: calcd. for 




To a stirred solution of lithium aluminium hydride (0.91 g, 24 mmol, 6 equiv.) in ether 
(5 mL) was added (1E)-1-methoxy-2-methyl-1-penten-3-one 219 (0.53 mL, 4 mmol, 1 
equiv.) dropwise at -78 °C and stirred for 8 hours. The mixture was warmed room 
temperature and stirred for a further 16 hours before quenching with water (0.9 mL), 
sodium hydroxide (15%, 0.9 mL) and further water (2.7 mL). The slurry was filtered 
through a pad of celite and concentrated in vacuo to afford the title compound as a 





H NMR (250 MHz, CDCl3) : 0.85 (t, 3H, J = 7.6 Hz, CH3CH2CH(OH)), 
1.58 (m, 5H, CH3CH2CH(OH) & EtCH(OH)C(CH3)C=CH), 3.60 (s, 3H, OCH3), 3.83 
(td, 1H, J = 7.0, 3.1 Hz, CH3CH2CH(OH)C), 6.02 (s, 1H, C=CHOCH3); 
13
C NMR (75 




To a stirred solution of lithium aluminium hydride (0.57 g, 15 mmol, 1.5 equiv.) in 
ether (200 mL) at -78 °C was added a solution of (E)-4-methoxy-3-buten-2-one 221 
(1.00 g, 10 mmol, 1 equiv.) in ether (10 mL) via syringe pump. The mixture was stirred 
at -78 °C for 4 hours, before diluting with ether and quenching with ethyl acetate, 
followed by stirring with saturated Rochelle salt solution for 2 hours. The mixture was 
extracted with EtOAc (2 × 50 mL) dried over Na2SO4, filtered and concentrated in 
vacuo to afford the title compound as a colourless oil (0.82 g 80%). FTIR (film/cm
-1
) 
υmax: 3367.0, 2970.1, 2932.1, 2835.0, 1652.8; 
1
H NMR (500 MHz, d6-acetone) : 1.19 
(d, 3H, J = 6.4 Hz, CH3CH(OH)), 3.48 (s, 3H, OCH3), 4.17 – 4.23 (m, 1H, 
CH3CH(OH)), 4.83 (dd, 1H, J = 12.7, 5.2 Hz, CH3CH(OH)CH=CHOCH3), 6.50 (d, 1H, 
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J = 12.7 Hz, CH3CH(OH)CH=CHOCH3);
 13
C NMR (125 MHz, d6-acetone) : 24.4, 




(E)-Methyl 3-(methoxy)acrylate 223 (2.00 g, 17.2 mmol) was reduced according to 
general procedure 5 to afford the product as a yellow oil (1.17 g, 77%). FTIR (film/cm
-
1
) υmax: 3354.8, 2957, 2873.9, 1657.1; 
1
H NMR (500 MHz, d6-acetone ) δ: 3.35 (t, 1H, J 
= 5.7 Hz, CH3OCH=CHCH2OH), 3.51 (s, 3H, CH3O), 3.96 (t, 2H, J = 7.0 Hz, 
CH3OCH=CHCH2OH) 4.96 (dt, 1H, J = 12.7, 7.0 Hz, CH3OCH=CHCH2OH), 6.51 (d, 
1H, J = 12.7 Hz, CH3OCH=CHCH2OH); 
13
C NMR (125 MHz, d6-acetone ) δ: 55.1, 




(E)-3-Methoxyallyl 2-((tert-butoxycarbonyl)amino)acetate (180) 
 
EDCi.HCl (2.50 g, 17.0 mmol), triethylamine (1.6 mL, 17.0 mmol), N-Boc-Gly-OH 184 
(2.24 g, 17.0 mmol) and (E)-3-(methoxy)prop-2-enol 224 (0.75 g, 8.51 mmol) were 
combined according to general procedure 3, to afford the title compound as a colourless 
oil (1.45 g, 70%). FTIR (film/cm
-1) υmax: 2880.3, 1736.1, 1717.6, 1673.9; 
1
H NMR (500 
MHz, CDCl3) : 1.38 (s, 9H, (CH3)3COCON), 3.51 (s, 3H, OCH2CH=CHOCH3), 3.83 
(app. q, 2H, J = 5.6 Hz, NCH2CO2), 4.51 (d, 2H, J = 7.8 Hz, OCH2CH=CHOCH3), 4.89 
(dt, 1H, J = 12.7, 7.8 Hz, OCH2CH=CHOCH3), 4.99 (br, 1H, NH), 6.59 (d, 1H, J = 12.7 
Hz, OCH2CH=CHOCH3); 
13
C NMR (125 MHz, CDCl3) : 28.4, 42.7, 55.1, 66.3, 80.2, 
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(E)-But-2-en-1-yl 2-((tert-butoxycarbonyl)amino)acetate (227) 
 
To a solution of N-Boc-Gly-OH 184 (1.05 g, 6.0 mmol, 1 equiv.), catalytic DMAP and 
crotyl alcohol 226 (1.54 mL, 18 mmol, 3 equiv.) in DCM (5 mL) was added a solution 
of N,N’-dicyclohexylcarbodiimide (1.40 g, 6.6 mmol, 1.1 equiv.) in DCM (5 mL) and 
stirred at room temperature for 20 hours. The slurry was diluted with ether (40 mL) and 
filtered through a pad of celite. The filtrate was washed with aqueous HCl (1 N, 3 × 50 
mL), saturated sodium bicarbonate solution (3 × 50 mL) and brine (3 × 50 mL), dried 
over Na2SO4, filtered and concentrated in vacuo. The residue was taken up in ether (50 
mL), filtered through a second pad of celite and concentrated in vacuo to afford the title 
compound as a brown oil and was used without any further purification (1.25 g, 92%). 
1
H NMR (250 MHz, CDCl3) : 1.45 (s, 9H, (CH3)3COCON), 1.73 (d, 3H, J = 6.5 
Hz,OCH2CH=CHCH3), 3.92 (d, 2H, J = 5.2 Hz, OCH2CH=CHCH3), 4.58 (d, 2H, J = 
6.6 Hz, NHCH2CO2), 4.99 (br, 1H, NH), 5.59 (m, 1H, OCH2CH=CHCH3), 5.80 (m, 1H, 
OCH2CH=CHOCH3); 
13
C NMR (75 MHz, CDCl3) : 18.1, 28.7, 42.8, 66.3, 80.2, 124.9, 





(2R,3S)-2-((tert-Butoxycarbonyl)amino)-3-methylpent-4-enoic acid (179) 
 
Butyllithium (2 mL, 3.3 mmol, 1.6 M solution in hexane) was added to a solution of 
diisopropylamine (0.56 mL, 4 mmol) in THF (3 mL) at -20 °C. This solution was stirred 
for 20 minutes, then cooled to -78 °C and a solution of (E)-but-2-en-1-yl 2-((tert-
butoxycarbonyl)amino)acetate 227 (0.22 g, 1.5 mmol) in THF (1.5 mL) was added. 
After 5 minutes a solution of zinc chloride (1.7 mL, 1 M in ether) was added and then 
warmed to room temperature. After 4 hours and completion was observed by TLC, a 
solution of hydrochloric acid (1 N, 3 mL) was added and then concentrated in vacuo. 
The residue was taken up in ether (10 mL), washed with a solution of hydrochloric acid 
(1 N, 2 × 10 mL). The ether was then extracted with NaOH (1 N, 2 × 10 mL), and the 
aqueous phases combined, acidified to pH 4 with acetic acid and extracted with ether (3 
× 10 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford the title 
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compound as a colourless oil (0.18 g, 84%, dr >25:1). 
1
H NMR (250 MHz, CDCl3) : 
1.10 (d, 3H, J = 6.0 Hz, H2C=CHCHCH3), 2.68 – 2.71 (m, 1H, H2C=CHCHCH3), 4.20 
– 4.24 (m, 1H, NCHCO2), 4.96 – 5.1 (m, 2H, H2C=CHCHCH3), 5.4 – 5.8 (m, 1H, 
H2C=CHCHCH3); 
13
C NMR (75 MHz, CDCl3): 14.9, 28.1, 40.2, 57.3, 79.7, 115.9, 





(E)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate (229) 
 
EDCi.HCl (2.18 g, 11.4 mmol), triethylamine (1.57 mL, 11.4 mmol), phthaloyl glycine 
228 (2.33 g, 11.4 mmol), catalytic DMAP and (E)-3-(methoxy)prop-2-enol 224 (0.50 g, 
5.70 mmol) were combined according to general procedure 3, to afford the title 
compound as a white solid (1.30 g, 84%). MP: 55 - 58 °C; FTIR (film/cm
-1) υmax: 
2993.7, 2880.3, 1757.6, 1736.1, 1718.0, 1671.7; 
1
H NMR (500 MHz, CDCl3) : 3.58 (s, 
3H, OCH3), 4.43 (s, 2H, NCH2CO2), 4.61 (d, 2H, J = 8.2 Hz, OCH2CH=CHO), 4.92 (dt, 
1H, J = 12.6, 8.2 Hz, OCH2CH=CHO), 6.65 (d, 1H, J = 12.6 Hz, OCH2CH=CHO), 7.77 
– 7.73 (m, 2H, Ar-H Phth), 7.91 – 7.88 (m, 2H, Ar-H, Phth); 13C NMR (125 MHz, 
CDCl3) : 39.0, 56.2, 64.2, 96.3, 123.6, 132.1, 134.2, 154.0, 167.3, 167.5; HRMS (ESI, 




(±)-(2R,3R)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-methoxypent-4-enoate (231) 
 
(E)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate 229 (0.28 g, 1.03 mmol, 1 
equiv.), TMSCl (0.15 g, 1.34 mmol, 1.3 equiv.) and LiHMDS (1.24 mL, 1.24 mmol, 1.3 
equiv) were combined according to general procedure 6. Treatment with diazomethane 
and purification by flash chromatography (4:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.22 g, 74%, dr 11:1). FTIR (film/cm
-1) υmax: 3086.6, 
2987.0, 2954.1, 2828.2, 1778.0, 1750.5, 1720.0, 1644.7, 1613.9; 
1
H NMR (500 MHz, 
CDCl3) syn δ: 3.21 (s, 3H, OCH3), 3.71 (s, 3H, CO2CH3), 4.53 (app. t, 1H, J = 8.2 Hz, 




=CHCHO), 4.87 (d, 1H, J = 8.2 Hz, NCHCO
2
), 5.38 (dt, 1H, J = 10.1, 1.3 Hz, 
CH
2
=CHCH), 5.43 (dt, 1H, J = 17.1, 1.3 Hz, CH
2
=CHCH), 5.85 (ddd, 1H, J = 17.1, 
10.1, 8.2 Hz, CH
2
=CHCH), 7.72 -- 7.75 (m, 2H, Ar-H Phth), 7.84 -- 7.89 (m, 2H, Ar-H 
Phth); anti δ: 3.39 (s, 3H, OCH
3




), 4.67 (t, 1H, J = 9.1 Hz, 
H
2
C=CHCHO), 5.00 (d, 1H, J = 9.1 Hz, NCHCO
2
), 5.16 (dt, 1H, J = 10.7, 1.2 Hz, 
H
2
C=CHCH), 5.25 (dt, 1H, J = 17.7, 1.2 Hz, H
2
C=CHCHO), 5.59 (ddd, 1H, J = 17.7, 
10.7, 6.8 Hz, H
2
C=CHCHO), 7.72 -- 7.75 (m, 2H, Ar-H Phth), 7.84 -- 7.89 (m, 2H, Ar-H 
Phth); 
13
C NMR (125 MHz, CDCl3) syn δ: 52.5, 55.7, 56.7, 78.2, 119.9, 123.5, 131.8, 
134.1, 135.0, 167.5, 167.8; 
 
anti δ: 52.7, 54.0, 56.9, 80.4, 120.7, 123.6, 132.0, 133.7, 





(E)-Methyl 3-isopropoxyacrylate (233) 
 
DABCO (0.26 g, 2.38 mmol) in THF (40 mL), 2-propanol (1.43 g, 2.62 mmol) and 
methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (10:1 Pet/EtOAc) to 
afford the title compound as a colourless oil (2.4 g, 70%). 
1
H NMR (500 MHz, CDCl3) 
: 1.22 (d, 6H, J = 6.4 Hz, (CH3)2CHO), 3.63 (s, 3H, CO2CH3), 4.17 (sept, 1H, J = 6.4 
Hz, (CH3)2CHO), 5.17 (d, 1H, J = 12.9 Hz, OCH=CHCO2CH3), 7.47 (d, 1H, J = 12.9 
Hz, OCH=CHCO2CH3); 
13
C NMR (125 MHz, CDCl3) : 21.9, 50.9, 75.6, 96.8, 161.6, 




(E)-Dimethyl hex-2-en-4-ynedioate (234) 
 
FTIR (film/cm
-1) υmax: 3025.4, 3019.7, 2195.0, 1709.1, 1695.3; 
1
H NMR (500 MHz, 
CDCl3) : 3.80 (s, 3H, CO2CH3), 3.83 (s, 3H, CO2CH3), 6.48 (d, 1H, J = 16.0 Hz, 
H3COCOCH=CHC≡C), 6.79 (d, 1H, J = 16.0 Hz, H3COCOCH=CHC≡C); 
13
C NMR 
(125 MHz, CDCl3) : 52.3, 53.0, 81.8, 86.7, 121.7, 135.0, 153.5, 165.1; HRMS (ESI, 
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(E)-Methyl 3-ethoxyacrylate (235) 
 
DABCO (0.26 g, 2.38 mmol) in THF (40 mL), ethanol (1.09 g, 26.2 mmol) and methyl 
propiolate 232 (2.00 g, 23.8 mmol) were combined according to general procedure 4. 
Purification was achieved by flash chromatography (10:1 Pet/EtOAc) to afford the title 
compound as a colourless oil (2.73 g, 88%). FTIR (film/cm
-1) υmax: 3095.5, 2986.2, 
2952.0, 2903.0, 2846.8, 1712.1, 1626.8; 
1
H NMR (500 MHz, CDCl3) : 1.31 (t, 3H, J = 
7.0 Hz, CH3CH2O), 3.66 (s, 3H, CO2CH3), 3.88 (q, 2H, J = 7.0 Hz, CH3CH2O), 5.17 (d, 
1H, J = 12.6 Hz, OCH=CHCO2CH3), 7.56 (d, 1H, J = 12.6 Hz, OCH=CHCO2CH3); 
13
C 
NMR (125 MHz, CDCl3) : 14.4, 51.0, 66.7, 96.0, 162.4, 168.3; HRMS (ESI, +ve) m/z: 




(E)-Methyl 3-isobutoxyacrylate (236) 
 
DABCO (0.27 g, 2.38 mmol) in THF (150 mL), 2-methyl-1-propanol (1.93 g, 26.2 
mmol) and methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to 
general procedure 4. Purification was achieved by flash chromatography (15:1 
Pet/EtOAc) to afford the title compound as a colourless oil (3.37 g, 86%). FTIR 
(film/cm
-1) υmax: 2961.6, 2877.0, 1712.3, 1628.0; 
1
H NMR (500 MHz, CDCl3) : 0.91 
(d, 6H, J = 6.7 Hz, (CH3)2CHCH2O), 1.95 (oct, 1H, J = 6.7 Hz, (CH3)2CHCH2O), 3.56 
(d, 2H, J = 6.7 Hz, (CH3)2CHCH2O), 3.64 (s, 3H, CO2CH3), 5.14 (d, 1H, J = 12.7 Hz, 
OCH=CHCO2CH3), 7.55 (d, 1H, J = 12.7 Hz, OCH=CHCO2CH3); 
13
C NMR (125 
MHz, CDCl3) : 18.8, 28.0, 50. 9, 77.4, 95.8, 162.8, 168.2; HRMS (ESI, +ve) m/z: 
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(E)-Methyl 3-(neopentyloxy)acrylate (237) 
 
DABCO (0.27 g, 2.38 mmol) in THF (150 mL), neopentyl alcohol (2.31 g, 26.2 mmol) 
and methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (10:1 Pet/EtOAc) to 
afford the title compound as a colourless oil (3.98 g, 92%). FTIR (film/cm
-1) υmax: 
2958.5, 2871.7, 1715.5, 1645.5, 1627.5; 
1
H NMR (500 MHz, CDCl3) : 0.97 (s, 9H, 
(CH3)3CCH2O), 3.50 (s, 2H, (CH3)3CCH2O), 3.71 (s, 3H, CO2CH3), 5.20 (d, 1H, J = 
12.6 Hz, OCH=CHCO2CH3), 7.63 (d, 1H, J = 12.6 Hz, OCH=CHCO2CH3);
 13
C NMR 
(125 MHz, CDCl3) : 26.3, 31.8, 51.0, 81.1, 95.7, 163.3, 168.4; HRMS (ESI, +ve) m/z: 




(E)-Methyl 3-(allyloxy)acrylate (238) 
 
DABCO (0.26 g, 2.38 mmol) in THF (200 mL), allyl alcohol (1.37 g, 26.2 mmol) and 
methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (10:1 Pet/EtOAc) to 
afford the title compound as a colorless oil (2.85 g, 85%). FTIR (film/cm
-1
) υmax: 
3092.8, 2922.1, 2952.2, 2876.0, 2846.9, 1713.9, 1625.7; 
1
H NMR (500 MHz, CDCl3) : 
3.60 (s, 3H, CO2CH3), 4.30 (dt, 2H, J = 5.3, 1.6 Hz, CH2=CHCH2O), 5.16 (d, 1H, J = 
12.6 Hz, OCH=CHCO2CH3), 5.22 (dq, 1H, J = 10.3, 1.6 Hz, CH2=CHCH2O), 5.28 (dq, 
1H, J = 17.2, 1.6 Hz, CH2=CHCH2O), 5.85 (ddt, 1H, J = 17.2, 10.3, 5.3 Hz, 
CH2=CHCH2O), 7.49 (d, 1H, J = 12.6 Hz, OCH=CHCO2CH3); 
13
C NMR (125 MHz, 
CDCl3) : 50.9, 71.5, 96.8, 118.7, 131.7, 161.9, 167.9; HRMS (ESI, +ve) m/z: calcd. for 
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(E)-Methyl 3-(benzyloxy)acrylate (239) 
 
DABCO (0.11 g, 1.00 mmol) in THF (40 mL), benzyl alcohol (1.08 g, 11.0 mmol) and 
methyl propiolate 232 (0.84 g, 10.0 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (10:1 Pet/EtOAc) to 
afford the title compound as a colourless oil (1.65 g, 86%). FTIR (film/cm
-1) υmax: 
3092.1, 3065.9, 3034.0, 2950.5, 2882.2, 2844.8, 1712.2, 1644.4, 1625.0; 
1
H NMR (500 
MHz, CDCl3) : 3.71 (s, 3H, CO2CH3), 4.91 (s, 2H, PhCH2O), 5.34 (d, 1H, J = 12.7 Hz, 
OCH=CHCO2CH3), 7.42 – 7.34 (m, 5H, Ar-H Ph), 7.69 (d, 1H, J = 12.7 Hz, 
OCH=CHCO2CH3); 
13
C NMR (125 MHz, CDCl3) : 51.1, 72.9, 97.2, 127.7, 128.5, 
128.7, 135.2, 162.1, 168.0; HRMS (ESI, +ve) m/z: calcd. for C11H12O3Na 215.0684, 
found 215.0676 (M+Na)
+




(E)-Methyl 3-(2-iodobenzyloxy)acrylate (240) 
 
DABCO (0.27 g, 2.38 mmol) in THF (40 mL), 2-iodobenzyl alcohol (6.12 g, 26.2 
mmol) and methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to 
general procedure 4. Purification was achieved by flash chromatography (6:1 
Pet/EtOAc) to afford the title compound as a white solid (6.85 g, 91%). MP: 40 – 42 °C; 
FTIR (film/cm
-1) υmax: 3091.4, 3052.3, 2947.4, 2909.9, 2855.8, 1713.2, 1640.0, 1623.3; 
1
H NMR (500 MHz, CDCl3) : 3.73 (s, 3H, CO2CH3), 4.91 (s, 2H, ArCH2O), 5.37 (d, 
1H, J = 12.5 Hz, OCH=CHCO2CH3), 7.07 – 7.04 (m, 1H, Ar-H Ph), 7.40 – 7.36 (m, 2H, 
Ar-H Ph), 7.71 (d, 1H, J = 12.5 Hz, OCH=CHCO2CH3)), 7.87 (d, 1H, J = 8.1 Hz, Ar-H 
Ph); 
13
C NMR (125 MHz, CDCl3) : 51.2, 76.4, 97.4, 97.5, 128.5, 128.8, 130.1, 137.5, 
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(E)-Methyl 3-(4-methoxybenzyloxy)acrylate (241) 
 
DABCO (0.11 g, 1.00 mmol) in THF (40 mL), 4-methoxybenzyl alcohol (1.38 g, 11.0 
mmol) and methyl propiolate 232 (0.84 g, 10.0 mmol) were combined according to 
general procedure 4. Purification was achieved by flash chromatography (10:1 
Pet/EtOAc) to afford the title compound as a colourless oil (1.73 g, 78%). FTIR 
(film/cm
-1) υmax: 3092.5, 3000.2, 2951.2, 2910.2, 2838.7, 1711.3, 1624.5, 1586.5; 
1
H 
NMR (500 MHz, CDCl3) : 3.71 (s, 3H, CO2CH3), 3.83 (s, 3H, CH3OAr), 4.84 (s, 2H, 
ArCH2O), 5.32 (d, 1H, J = 12.5 Hz, OCH=CHCO2CH3), 6.92 (m, 2H, Ar-H Ph), 7.28 
(m, 2H, Ar-H Ph), 7.67 (d, 1H, J = 12.5 Hz, OCH=CHCO2CH3); 
13
C NMR (125 MHz, 
CDCl3) : 51.1, 55.3, 72.8, 97.0, 114.1, 127.2, 129.6, 159.9, 162.2, 168.1; HRMS (ESI, 




(E)-Methyl 3-phenoxyacrylate (242) 
 
DABCO (0.27 g, 2.38 mmol) in THF (100 mL), phenol (2.46 g, 26.2 mmol) and methyl 
propiolate 232 (2.00 g, 23.8 mmol) were combined according to general procedure 4. 
Purification was achieved by flash chromatography (10:1 Pet/EtOAc) to afford the title 
compound as a colourless oil (4.35 g, 98%). FTIR (film/cm
-1) υmax: 3078.8, 3044.2, 
2994.4, 2952.0, 2906.4, 2845.6, 1715.4, 1649.1, 1589.8; 
1
H NMR (500 MHz, CDCl3) : 
3.74 (s, 3H, CO2CH3), 5.58 (d, 1H, J = 12.4 Hz, PhOCH=CHCO2CH3), 7.08 (d, 2H, J = 
8.0 Hz, Ar-H Ph), 7.21 (t, 1H, J = 8.0 Hz, Ar-H Ph), 7.39 (t, 2H, J = 8.0 Hz, Ar-H Ph), 
7.83 (d, 1H, J = 12.4 Hz, PhOCH=CHCO2CH3); 
13
C NMR (125 MHz, CDCl3) : 51.3, 
101.8, 118.0, 125.0, 130.0, 155.9, 159.2, 167.6; HRMS (ESI, +ve) m/z: calcd. for 
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(E)-Methyl 3-(4-methoxyphenoxy)acrylate (243) 
 
DABCO (0.27 g, 2.38 mmol) in THF (150 mL), 4-methoxyphenol (3.24 g, 26.2 mmol) 
and methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (6:1 Pet/EtOAc) to 
afford the title compound as a colourless oil (4.30 g, 82%). FTIR (film/cm
-1) υmax: 
3078.4, 2994.2, 2948.4, 2843.3, 1715.3, 1649.8, 1629.6, 1573.9; 
1
H NMR (500 MHz, 
CDCl3) : 3.73 (s, 3H, CO2CH3), 3.81 (s, 3H, CH3OAr), 5.48 (d, 1H, J = 12.6 Hz, 
OCH=CHCO2CH3), 6.89 (m, 2H, Ar-H Ph), 7.00 (m, 2H, Ar-H Ph), 7.76 (d, 1H, J = 
12.6 Hz, OCH=CHCO2CH3);
 13
C NMR (125 MHz, CDCl3) : 51.7, 56.1, 101.3, 115.3, 
119.8, 149.9, 157.3, 160.8, 168.2; HRMS (ESI, +ve) m/z: calcd. for C11H12O4Na 




(E)-Methyl 3-(4-nitrophenyloxy)acrylate (244) 
 
DABCO (0.28 g, 2.51 mmol) in THF (40 mL), 4-nitrophenol (3.85 g, 27.6 mmol) and 
methyl propiolate 232 (2.11 g, 25.1 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (6:1 Pet/EtOAc) to 
afford the title compound as a yellow solid (5.72 g, 98%). MP: 133 – 136 °C; FTIR 
(film/cm
-1) υmax: 3505.5, 2987.7, 1717.0, 1653.9; 
1
H NMR (500 MHz, CDCl3) : 3.78 
(s, 3H, CO2CH3), 5.79 (d, 1H, J = 12.5, OCH=CHCO2CH3)), 7.18 – 7.24 (m, 2H, Ar-H 
Ph), 7.82 (d, 1H, J = 12.5, OCH=CHCO2CH3), 8.28 - 8.31(m, 2H, Ar-H Ph); 
13
C NMR 
(125 MHz, CDCl3) : 51.64, 105.08, 117.60, 126.09, 144.38, 155.92, 160.18, 166.76; 
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(E)-Methyl 3-(4-trifluoromethylphenyloxy)acrylate (245) 
 
DABCO (0.05 g, 0.45 mmol) in THF (150 mL), 4-trifluoromethylphenol (0.80 g, 4.97 
mmol) and methyl propiolate 232 (0.38 g, 4.52 mmol) were combined according to 
general procedure 4. Purification was achieved by flash chromatography (15:1 
Pet/EtOAc) to afford the title compound as a white solid (1.10 g, 93%). MP: 60 – 61 °C; 
FTIR (film/cm
-1) υmax: 3121.9, 3080.6, 3037.8, 3004.5, 2959.9, 1713.7, 1663.7, 1614.8; 
1
H NMR (500 MHz, CDCl3) : 3.74 (s, 3H, CO2CH3), 5.66 (d, 1H, J = 12.2 Hz, 
OCH=CHCO2CH3), 7.16 (m, 2H, Ar-H Ph), 7.64 (m, 2H, Ar-H Ph), 7.80 (d, 1H, J = 
12.2 Hz, OCH=CHCO2CH3); 
13
C NMR (75 MHz, CDCl3) : 51.4, 103.6, 117.8, 122.7, 
124.9, 126.7, 128.4 (q, J = 4.0 Hz), 157.2, 158.1; HRMS (ESI, +ve) m/z: calcd. for 




(E)-Methyl 3-(2-iodophenyloxy)acrylate (246) 
 
DABCO (0.09 g, 0.83 mmol) in THF (150 mL), 2-iodophenol (2.00 g, 9.16 mmol) and 
methyl propiolate 232 (0.70 g, 8.33 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (6:1 Pet/EtOAc) to 
afford the title compound as a colourless oil (2.52 g, 93%). FTIR (film/cm
-1) υmax: 
3081.0, 2995.6, 2949.8, 1715.4, 1650.5, 1630.4; 
1
H NMR (500 MHz, CDCl3) : 3.74 (s, 
3H, CO2CH3), 5.52 (d, 1H, J = 12.4 Hz, OCH=CHCO2CH3), 6.96 (t, 1H, J = 7.8 Hz, 
Ar-H Ph), 7.07 (d, 1H, J = 7.8 Hz, Ar-H Ph), 7.38 (t, 1H, J =  7.8 Hz, Ar-H Ph), 7.72 (d, 
1H, J = 12.4 Hz, OCH=CHCO2CH3), 7.85 (d, 1H, J =  7.8 Hz, Ar-H Ph);
 13
C NMR (125 
MHz, CDCl3) : 51.4, 87.8, 102.3, 119.1, 127.0, 130.0, 140.0, 155.1, 159.0, 167.3; 










(E)-Methyl 3-ethoxyacrylate 235 (1.59 g, 12.2 mmol) was reduced according to general 
procedure 5 to afford the title compound as a colourless oil (0.90 g, 75%). FTIR 
(film/cm
-1) υmax: 3355.9, 2980.9, 2877.4, 1672.3, 1654.1; 
1
H NMR (500 MHz, d6-
DMSO) δ: 1.19 (t, 3H, J = 7.1 Hz, CH3CH2O), 3.70 (q, 2H, J = 7.1 Hz, CH3CH2O), 
3.83 (ddd, 2H, J = 6.9, 5.6, 1.3 Hz, OCH=CHCH2OH), 4.40 (t, 1H, J = 5.6 Hz, OH), 
4.86 (dt, 1H, J = 12.9, 6.9 Hz, OCH=CHCH2OH), 6.42 (d, 1H, J = 12.9 Hz, 
OCH=CHCH2OH); 
13




(E)-Methyl 3-(isopropoxy)acrylate 233 (2.00 g, 13.8 mmol) was reduced according to 
general procedure 5 to afford the title compound as a yellow oil (1.19 g, 74%). FTIR 
(film/cm
-1) υmax: 3371.8, 2976.5, 2931.2, 2874.6, 1670.6, 1650.9.
 1
H NMR (500 MHz, 
d6-acetone) : 1.15 (d, 6H, J = 6.2 Hz, (CH3)2CHO), 3.81 (app. t, 2H, J = 6.5 Hz, 
OCH=CHCH2OH), 4.00 (quin, 1H, J = 6.2 Hz, (CH3)2CHO), 4.36 (t, 1H, J = 6.5 Hz, 
OCH=CHCH2OH), 4.88 (dt, 1H, J = 12.5, 6.5 Hz, OCH=CHCH2OH), 6.33 (d, 1H, J = 
12.5 Hz, OCH=CHCH2OH). 
13





(E)-Methyl 3-(isobutyloxy)acrylate 236 (1.38 g, 8.72 mmol) was reduced according to 
general procedure 5 to afford the title compound as a colourless oil (0.57 g, 85%). FTIR 
(film/cm
-1) υmax: 3346.3, 2958.9, 2932.0, 2873.9, 1671.6, 1653.0; 
1
H NMR (300 MHz, 
d6-acetone ) δ: 0.79 (d, 6H, J = 6.7 Hz, (CH3)2CHCH2O), 1.77 (oct, 1H, J = 6.7 Hz, 
(CH3)2CHCH2O), 3.15 (t, 1H, J = 5.5 Hz, OH) 3.32 (d, 2H, J = 6.7 Hz, 
(CH3)2CHCH2O), 3.81 (ddd, 2H, J = 7.0, 5.5, 1.1 Hz, OCH=CHCH2OH), 4.82 (dt, 1H, 
J = 12.6, 7.0 Hz, OCH=CHCH2OH), 6.35 (d, 1H, J = 12.6 Hz, OCH=CHCH2OH); 
13
C 
NMR (125 MHz, d6-acetone) δ: 19.7, 29.3, 60.7, 76.5, 104.9, 150.3.  




(E)-Methyl 3-(neopentyloxy)acrylate 237 (1.36 g, 7.90 mmol) was reduced according to 
general procedure 5 to afford the title compound as a colourless oil (0.92 g, 86%). FTIR 
(film/cm
-1) υmax: 3343.4, 3063.7, 2957.6, 2904.4, 2869.8, 1670.6, 1653.0; 
1
H NMR (500 
MHz, d6-acetone ) δ: 0.94 (s, 9H, (CH3)3CCH2O), 3.30 (t, 1H, J = 7.1 Hz, OH), 3.36 (s, 
2H, (CH3)3CCH2O), 3.95 (app. t, 2H, J = 7.1 Hz, OCH=CHCH2OH), 4.96 (dt, 1H, J = 
12.7, 7.1 Hz, OCH=CHCH2OH), 6.52 (d, 1H, J = 12.7 Hz, OCH=CHCH2OH); 
13
C 




(E)-Methyl 3-(allyloxy)acrylate 238 (1.38 g, 9.71 mmol) was reduced according to 
general procedure 5 to afford the title compound as a yellow oil (0.78 g, 71%). FTIR 
(film/cm
-1) υmax: 3350.6, 2923.2, 2869.7, 1671.8, 1654.4; 
1
H NMR (500 MHz, d6-
DMSO) δ: 3.83 (ddd, 2H, J = 7.0, 5.5, 1.2 Hz, CH2=CHCH2O), 4.21 (dt, 2H, J = 5.2, 
1.7 Hz, OCH=CHCH2OH), 4.43 (t, 1H, J = 5.5 Hz, CH2OH), 4.92 (dt, 1H, J = 13.8, 6.9 
Hz, OCH=CHCH2OH), 5.20 (dq, 1H, J = 10.4, 1.8 Hz, CH2=CHCH2O), 5.31 (dq, 1H, J 
= 17.3, 1.8 Hz, CH2=CHCH2O), 5.94 (ddt, 1H, J = 17.3, 10.4, 5.4 Hz, CH2=CHCH2O), 
6.44 (d, 1H, J = 13.8 Hz, OCH=CHCH2OH); 
13
C NMR (125 MHz, d6-DMSO) δ: 58.5, 




(E)-Methyl 3-(benzyloxy)acrylate 239 (2.15 g, 11.2 mmol) was reduced according to 
general procedure 5 to afford the title compound as a colourless oil (1.56 g, 80%). FTIR 
(film/cm
-1
) υmax: 3348.7, 3064.7, 3033.4, 2926.1, 2871.1, 1670.6, 1652.6; 
1
H NMR (500 
MHz, d6-DMSO) δ: 3.86 (t, 2H, J = 5.3 Hz, OCH=CHCH2OH), 4.47 (t, 1H, J = 5.3 Hz, 
CH2OH), 4.75 (s, 2H, PhCH2O), 5.02 (m, 1H, OCH=CHCH2OH), 6.55 (d, 1H, J = 13.1 
Hz, OCH=CHCH2OH), 7.32 – 7.39 (m, 5H, Ar-H Ph); 
13
C NMR (125 MHz, d6-DMSO) 
δ: 58.9, 71.0, 105.4, 126.9, 127.1, 128.2, 128.5, 128.8, 137.7, 148.4. 
 




(E)-Methyl 3-(2-iodobenzyloxy)acrylate 240 (1.08 g, 3.40 mmol) was reduced 
according to general procedure 5 to afford the product as a colourless oil (0.88 g, 89%). 
FTIR (film/cm
-1
) υmax: 3391.9, 3062.1, 2924.5, 2873.2, 1774.8, 1746.7, 1718.4, 1670.1, 
1652.1; 
1
H NMR (500 MHz, d6-acetone) δ: 3.44 (t, 1H, J = 7.0 Hz, CH2OH), 4.01 (t, 
1H, J = 7.0 Hz, OCH=CHCH2OH), 4.78 (s, 2H, ArCH2O), 5.14 (dt, 1H, J = 12.3, 7.0 
Hz, OCH=CHCH2OH), 6.63 (d, 1H, J = 12.3 Hz, OCH=CHCH2OH), 7.11 (td, 1H, J = 
7.6, 1.7 Hz, Ar-H Ph), 7.43 – 7.50 (m, 2H, Ar-H Ph), 7.91 (dd, 1H, J = 7.6, 1.0 Hz, Ar-
H Ph); 
13
C NMR (125 MHz, d6-acetone) δ: 59.2, 74.6, 97.2, 105.2, 128.4, 129.0, 129.7, 




(E)-Methyl 3-(4-methoxybenzyloxy)acrylate 241 (1.02 g, 4.59 mmol) was reduced 
according to general procedure 5 to afford the title compound as a colourless oil (0.78 g, 
72%). FTIR (film/cm
-1) υmax: 3303.5, 2922.6, 2872.5, 1650.2, 1613.5, 1586.9; 
1
H NMR 
(500 MHz, d6-DMSO) δ: 3.75 (s, 3H, CH3OAr), 3.84 (t, 2H, J = 7.1 Hz, 
OCH=CHCH2OH), 4.45 (t, 1H, J = 7.1 Hz, CH2OH), 4.66 (s, 2H, ArCH2O), 4.98 (dt, 
1H, J = 12.8, 7.1 Hz, OCH=CHCH2OH), 6.52 (d, 1H, J = 12.8 Hz, OCH=CHCH2OH), 
6.93 – 7.01 (m, 2H, Ar-H Ph), 7.29 – 7.35 (m, 2H, Ar-H Ph); 13C NMR (125 MHz, d6-




(E)-Methyl 3-(phenyloxy)acrylate 242 (1.02 g, 5.72 mmol) was reduced according to 
general procedure 5 to afford the title compound as a colourless oil (0.60 g, 53%). FTIR 
(film/cm
-1
) υmax: 3343.9, 3030.2, 2924.9, 2864.2, 1673.5, 1592.3; 
1
H NMR (500 MHz, 
d6-acetone ) δ: 3.70 (t, 1H, J = 6.6 Hz, CH2OH), 4.11 (app. t, 2H, J = 6.6 Hz, 
OCH=CHCH2OH), 5.49 (dt, 1H, J = 12.3, 6.6 Hz, OCH=CHCH2OH), 6.81 (d, 1H, J = 
12.3 Hz, OCH=CHCH2OH), 7.04 (d, 2H, J = 7.5 Hz, Ar-H Ph), 7.08 (t, 1H, J = 7.5 Hz, 
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Ar-H Ph), 7.36 (d, 2H, J = 7.5 Hz, Ar-H Ph); 
13
C NMR (125 MHz, d6-acetone) δ: 58.4, 




(E)-Methyl 3-(4-methoxyphenyloxy)acrylate 243 (1.15 g, 5.52 mmol) was reduced 
according to general procedure 5, to afford the title compound as a colourless oil (0.64 
g, 64%). FTIR (film/cm
-1) υmax: 3348.5, 3048.5, 3002.8, 2950.5, 2836.4, 1672.4, 1609.4, 
1592.4; 
1
H NMR (500 MHz, d6-acetone) δ: 4.10 (t, 1H, J = 5.6 Hz, CH2OH), 4.28 (s, 
3H, CH3OAr), 4.58 (t, 2H, J = 5.6 Hz, OCH=CHCH2OH), 5.88 (dt, 1H, J = 12.2, 5.6 
Hz, OCH=CHCH2OH), 7.22 (d, 1H, J = 12.2 Hz, OCH=CHCH2OH), 7.40 – 7.44 (m, 
2H, Ar-H Ph), 7.46 – 7.49 (m, 2H, Ar-H Ph); 13C NMR (125 MHz, d6-acetone) δ: 55.0, 




(E)-Methyl 3-(4-nitrophenyloxy)acrylate 244 (2.23 g, 10 mmol) was reduced according 
to general procedure 5 to afford the title compound as a yellow solid (1.93 g, 89%). 
FTIR (film/cm
-1) υmax: 3012.7, 3017.3, 2977.1, 1674.9, 1614.8;
 1
H NMR (500 MHz, d6-
DMSO) δ: 4.18 (dd, 2H, J = 6.5, 1.5 Hz, OCH=CHCH2OH), 5.72 (dt, 1H, J = 12.1, 6.5 
Hz, OCH=CHCH2OH), 6.97 (d, 1H, J = 12.1 Hz, OCH=CHCH2OH), 7.25 – 7.29 (m, 
2H, Ar-H Ph), 8.25 – 8.29 (m, 2H, Ar-H Ph); 13C NMR (125 MHz, d6-DMSO) δ: 58.1, 




(E)-Methyl 3-(4-trifluoromethylphenyloxy)acrylate 245 (0.63 g, 2.56 mmol) was 
reduced according to general procedure 5 to afford the title compound as a yellow oil 
(0.54 g, 85%). FTIR (film/cm
-1) υmax: 3336.9, 2930.5, 2878.6, 1676.3, 1615.1, 1516.1; 
1
H NMR (500 MHz, d6-acetone) δ: 3.76 (br, 1H, CH2OH), 3.96 (dd, 2H, J = 6.5, 1.3 Hz, 
OCH=CHCH2OH), 5.43 (dt, 1H, J = 12.0, 6.5 Hz, OCH=CHCH2OH), 6.66 (dt, J = 
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12.0, 1.3 Hz, OCH=CHCH2OH), 6.95 – 7.01 (m, 2H, Ar-H Ph), 7.42 – 7.46 (m, 2H, Ar-
H, Ph); 
13
C NMR (125 MHz, d6-acetone) δ: 59.6, 116.0, 117.7, 125.3, 127.6, 128.4 (q, J 




(E)-Methyl 3-(2-iodophenyloxy)acrylate 246 (1.34 g, 4.41 mmol) was reduced 
according to general procedure 5 to afford the title compound as a colourless oil (1.00 g, 
82%). FTIR (film/cm
-1) υmax: 3429.2, 2950.0, 2837.1, 1649.1, 1504.3; 
1
H NMR (500 
MHz, d6-acetone) δ: 3.59 (t, 1H, J = 5.7 Hz, CH2OH), 3.99 (dt, 2H, J = 6.6, 1.4 Hz, 
OCH=CHCH2OH), 5.40 (dt, 1H, J = 12.1, 6.6 Hz, OCH=CHCH2OH), 6.63 (dt, 1H, J = 
12.1, 1.4 Hz, OCH=CHCH2OH), 6.77 (dt, 1H, J = 7.5, 1.4 Hz, Ar-H Ph), 6.97 (dd, 1H, 
J = 7.5, 1.4 Hz, Ar-H Ph), 7.25 – 7.31 (m, 1H, Ar-H Ph), 7.72 (dd, 1H, J = 7.9, 1.4 Hz, 
Ar-H Ph); 
13
C NMR (125 MHz, d6-acetone) δ: 59.6, 87.4, 115.0, 117.7, 126.2, 131.2, 
141.0, 144.9, 157.6. 
 
(E)-3-Ethoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate (261) 
 
EDCi.HCl (1.58 g, 5.02 mmol), triethylamine (1.15 mL, 5.02 mmol), phthaloyl glycine 
228 (1.70 g, 5.02 mmol), catalytic DMAP and (E)-3-(ethoxy)prop-2-enol 247 (0.54 g, 
2.51 mmol) were combined according to general procedure 3, to afford the title 
compound as a yellow solid (0.93 g, 78%). MP: 58 – 60 °C; FTIR (film/cm-1) υmax: 
2983.7, 2939.4, 2890.3, 1777.8, 1745.3, 1717.9, 1671.7, 1671.7, 1653.8; 
1
H NMR (500 
MHz, CDCl3) : 1.29 (t, 3H, J = 7.0 Hz, OCH2CH3), 3.79 (q, 2H, J = 7.0 Hz, 
OCH2CH3), 4.43 (s, 2H, NCH2CO2), 4.60 (d, 2H, J = 7.5 Hz, OCH2CH=CHO), 4.93 (dt, 
1H, J = 12.9, 7.5 Hz, OCH2CH=CHO), 6.59 (d, 1H, J = 12.9 Hz, OCH2CH=CHO), 7.76 
– 7.74 (m, 2H, Ar-H Phth), 7.90 – 7.88 (m, 2H, Ar-H Phth); 13C NMR (125 MHz, 
CDCl3) : 14.5, 39.0, 64.4, 65.1, 96.9, 123.6, 123.6, 132.0, 134.2, 153.1, 167.3, 167.5; 
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(E)-3-Isobutoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate (262) 
 
EDCi.HCl (1.69 g, 8.82 mmol), triethylamine (1.22 mL, 8.82 mmol), phthaloyl glycine 
228 (1.88 g, 8.82 mmol), catalytic DAMP and (E)-3-(isobutyloxy)prop-2-enol 249 (0.57 
g, 4.41 mmol) were combined according to general procedure 3 to afford the title 
compound as a yellow solid (0.85 g, 61%). MP: 65 -- 66 °C; FTIR (film/cm
-1
) υmax: 
3066.7, 2959.9, 2874.6, 1777.4, 1723.5, 1670.9, 1652.7, 1616.1; 
1
HNMR (500 MHz, 




















(d, 2H, J = 8.2 Hz, OCH
2
CH=CHO), 4.91 (dt, 1H, J = 12.9, 8.2 Hz, OCH
2
CH=CHO), 
6.60 (d, 1H, J = 12.9 Hz, OCH
2
CH=CHO), 7.73 -- 7.75 (m, 2H, Ar-H Phth), 7.87 -- 7.89 
(m, 2H, Ar-H Phth); 
13
C NMR(125 MHz, CDCl3) : 19.1, 28.1, 39.0, 64.5, 75.9, 96.6, 
123.6, 132.0, 134.2, 153.0,167.3, 167.5; HRMS (ESI, +ve) m/z calcd. for C17H19NO5Na 




(E)-3-(Neopentyl)oxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate (263) 
 
EDCi.HCl (2.68 g, 14.0 mmol), triethylamine (2.00 mL, 14.0 mmol), phthaloyl glycine 
228 (2.86 g, 14.0 mmol), catalytic DMAP and (E)-3-(neopentyloxy)prop-2-enol 
250(1.00 g) were combined according to general procedure 3 to afford the title 
compound as a white solid (1.75 g, 76%). MP: 70 -- 73 °C; FTIR (film/cm
-1
) υmax: 
3062.5, 2958.1, 2870.0, 1777.7, 1723.9, 1670.8, 1651.4, 1616.3; 
1
H NMR (500 MHz, 

















), 4.53 (d, 2H, J = 8.4 Hz, OCH
2
CH=CHO), 4.85 (dt, 1H, J = 12.7, 8.4 Hz, 
OCH
2
CH=CHO), 6.58 (d, 1H, J = 12.7 Hz, OCH
2
CH=CHO), 7.65 -- 7.69 (m, 2H, Ar-H 
Phth), 7.78 -- 7.81 (m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) : 26.4, 31.6, 39.0, 
64.4, 79.8, 96.3, 123.5, 132.0, 134.2, 153.8, 167.2, 167.3; HRMS (ESI, +ve) m/z calcd. 





(E)-3-(Allyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate (264) 
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EDCi.HCl (2.23 g, 11.6 mmol), triethylamine (1.62 mL, 11.6 mmol), phthaloyl glycine 
228 (2.39 g, 11.6 mmol), catalytic DMAP and (E)-3-(allyloxy)prop-2-enol 251 (0.67 g, 
5.81 mmol) were combined according to general procedure 3 to afford the title 
compound as a yellow solid (1.24 g, 71%). MP: 73 -75 °C; FTIR (film/cm
-1
) υmax: 
3077.4, 2981.4, 2946.5, 2888.4, 2867.7, 1776.6, 1746.6, 1722.0, 1671.7, 1654.0; 
1
H 









), 4.59 (d, 2H, J = 8.0 Hz, OCH
2
CH=CHO), 4.94 -- 5.00 (m, 1H, 
OCH
2













), 6.59 (d, 1H, J = 
12. 6 Hz, OCH
2
CH=CHO), 7.73 -- 7.77 (m, 2H, Ar-H Phth), 7.86 -- 7.91 (m, 2H, Ar-H 
Phth). 13C NMR (125 MHz, CDCl3) : 39.0, 64.2, 70.3, 97.7, 118.1, 123.6, 132.0, 
132.6, 134.3, 152.8, 167.3, 167.5; HRMS (ESI, +ve) m/z calcd. for C16H15NO5Na 




(E)-3-Benzyloxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate (265) 
 
EDCi.HCl (2.12 g, 11.1 mmol), triethylamine (1.53 mL, 11.1 mmol), phthaloyl glycine 
228 (2.26 g, 11.1 mmol), catalytic DMAP and (E)-3-(benzyloxy)prop-2-enol 252 (0.91 
g, 5.53 mmol) were combined according to general procedure 3 to afford the title 
compound as a white solid (1.43 g, 74%). MP: 90 -- 92 °C; FTIR (film/cm
-1
) υmax: 
3035.3, 2936.1, 1777.4, 1744.2, 1716.1, 1651.8, 1614.3; 
1
H NMR (500 MHz, CDCl3) : 




), 4.62 (d, 2H, J = 8.0 Hz, OCH
2
CH=CHO), 4.79 (s, 2H, 
OCH
2
Ph), 5.07 (dt, 1H, J = 12.5, 8.0 Hz, OCH
2
CH=CHO), 6.70 (d, 1H, J = 12.5 Hz, 
OCH
2
CH=CHO), 7.31 -- 7.40 (m, 5H, Ar-H Ph), 7.77 -- 7.74 (m, 2H, Ar-H Phth), 7.88 -- 
7.91 (m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) : 39.0, 64.2, 71.5, 97.9, 123.6, 
123.6, 127.7, 128.2, 128.3, 128.5, 128.6, 128.7, 132.1, 136.2, 152.8, 167.3, 167.5; 
HRMS (ESI, +ve) m/z calcd. for C20H17NO5Na 374.1004, found 374.0998. (M+Na)
+
. 
(E)-3-(2-Iodobenzyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate (266) 
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EDCi.HCl (1.15 g, 6.00 mmol), triethylamine (0.84 mL, 6.00 mmol), phthaloyl glycine 
228 (1.23 g, 6.00 mmol), catalytic DMAP and (E)-3-(2-iodobenzyloxy)prop-2-enol 253 
(0.88 g) were combined according to general procedure 3, to afford the title compound 
as a white solid. (1.00 g, 70%). MP: 82 – 84 °C; FTIR (film/cm-1) υmax: 3060.4, 2944.7, 
2889.8, 1776.6, 1721.1, 1654.0, 1615.8; 
1





), 4.63 (d, 2H, J = 7.9 Hz, OCH
2
CH=CHO), 4.76 (s, 2H, OCH
2
Ar), 5.09 (dt, 
1H, J = 12.8, 7.9 Hz, OCH
2
CH=CHO), 6.71 (d, 1H, J = 12.8 Hz, OCH
2
CH=CHO), 6.99 
-- 7.04 (m, 1H, Ar-H Ph), 7.41 -- 7.33 (m, 2H, Ar-H Phth), 7.71 -- 7.75 (m, 2H, Ar-H 
Phth), 7.82 -- 7.84 (m, 1H, Ar-H Ph), 7.86 -- 7.89 (m, 2H, Ar-H Phth); 
13
C NMR (125 
MHz, CDCl3) : 39.0, 64.0, 75.1, 97.3, 98.4, 123.6, 128.4, 128.7, 129.7, 132.0, 134.2, 
138.5, 139.3, 152.5, 167.3, 167.4; HRMS (ESI, +ve) m/z: calcd. for C20H16INO5Na, 




(E)-3-(4-Methoxybenzyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate (267) 
 
EDCi.HCl (1.53 g, 7.98 mmol), triethylamine (1.10 mL, 7.98 mmol), phthaloyl glycine 
228 (1.66 g, 7.98 mmol), catalytic DMAP and (E)-3-(4-methoxybenzyloxy)prop-2-enol 
254 (0.77 g, 3.99 mmol) were combined according to general procedure 3, to afford the 
title compound as a white solid. (0.76 g, 56%). MP: 72 – 76 °C; FTIR (film/cm-1) υmax: 
3057.9, 3002.0, 2942.3, 2838.7, 1775.3, 1720.1, 1653.9, 1613.2: 
1
H NMR (500 MHz, 
CDCl3) : 3.81 (s, 3H, ArOCH3), 4.47 (d, 2H, J = 5.1 Hz, OCH2Ar), 4.61 (d, 2H, J = 7.8 
Hz, OCH
2




), 5.05 (dt, 1H, J = 12.7, 7.8 Hz, 
OCH
2
CH=CHO), 6.67 (d, 1H, J = 12.7 Hz, OCH
2
CH=CHO), 6.90 (m, 2H, Ar-H Ph), 
7.28 (m, 2H, Ar-H Ph), 7.73 -- 7.76 (m, 2H, Ar-H Phth), 7.87 -- 7.90 (m, 2H, Ar-H 
Phth); 
13
C NMR (125 MHz, CDCl3) : 39.0, 55.3, 64.3, 71.3, 97.8, 114.0, 123.6, 128.3, 
129.4, 132.0, 134.2, 152.8, 159.6, 167.3, 167.5; HRMS (ESI, +ve) m/z: calcd. for 
C21H19NO6Na 404.1110, found 404.1076 (M+Na)
+
.  
(E)-3-(Phenyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate (268) 
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EDCi.HCl (1.53 g, 7.98 mmol), triethylamine (1.10 mL, 7.98 mmol), phthaloyl glycine 
228 (1.64 g, 7.98 mmol), catalytic DMAP and (E)-3-(phenyloxy)prop-2-enol 255 (0.60 
g, 3.99 mmol) were combined according to general procedure 3, to afford the title 
compound as a white solid. (1.10 g, 82%). MP: 124 - 127 °C; FTIR (film/cm
-1) υmax: 
3058.1, 2988.7, 2950.3, 1775.7, 1724.0, 1676.6, 1654.6, 1593.1; 
1
H NMR (500 MHz, 
CDCl3) : 4.47 (s, 2H, NCH2CO2), 4.69 (d, 2H, J = 8.1 Hz, OCH2CH=CHO), 5.45 (dt, 
1H, J =12.1, 8.1 Hz, OCH
2
CH=CHO), 6.81 (d, 1H, J = 12.1 Hz, OCH
2
CH=CHO), 7.01 
(d, 2H, J = 7.9 Hz, Ar-H Ph), 7.12 (t, 1H, J = 7.9 Hz, Ar-H Ph), 7.34 (t, 2H, J = 7.9 Hz, 
Ar-H Ph), 7.75 -- 7.78 (m, 2H, Ar-H Phth), 7.89 -- 7.82 (m, 2H, Ar-H Phth); 
13
C NMR 
(125 MHz, CDCl3) : 39.0, 63.1, 104.6, 117.2, 123.6, 129.7, 132.0 134.3, 149.0, 156.5, 





(E)-3-(4-Methoxyphenoxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate (269) 
 
EDCi.HCl (1.35 g, 7.04 mmol), triethylamine (1.10 mL, 7.04 mmol), phthaloyl glycine 
228 (1.44 g, 7.04 mmol), catalytic DMAP and (E)-3-(4-methoxyphenyloxy)prop-2-enol 
256 (0.63 g, 3.52 mmol) were combined according to general procedure 3 , to afford the 
title compound as a yellow solid. (1.20 g, 77%). MP: 80 – 82 °C; FTIR (film/cm-1) υmax: 
3063.9, 2945.9, 1776.6, 1749.7, 1723.4, 1675.4, 1613.0;  
1
H NMR (500 MHz, CDCl3) 
: 3.74 (s, 3H, ArOCH
3




), 4.63 (d, 2H, J = 8.2 Hz, 
OCH
2
CH=CHO), 5.30 (dt, 1H, J = 12.1, 8.2 Hz, OCH
2
CH=CHO), 6.71 (d, 1H, J = 12.1 
Hz, OCH
2
CH=CHO), 6.82 (m, 2H, Ar-H Ph), 6.90 (m, 2H, Ar-H Ph), 7.69 -- 7.73 (m, 
2H, Ar-H Phth), 7.83 -- 7.86 (m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) : 30.9, 
39.0, 53.5, 55.6, 63.2, 103.3, 114.7, 118.7, 123.6, 132.0, 134.2, 150.3, 155.9, 167.2, 




(E)-3-(4-Nitrophenoxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate (270) 
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EDCi.HCl (1.17 g, 6.10 mmol), triethylamine (0.80 mL, 6.10 mmol), phthaloyl glycine 
228 (1.17 g, 6.10 mmol), catalytic DMAP and (E)-3-(4-nitrophenyloxy)prop-2-enol 257 
(0.60 g, 3.05 mmol) were combined according to general procedure 3, to afford the title 
compound as a yellow solid. (0.75 g, 69%). MP: 80 -- 82 °C;  FTIR (film/cm
-1) υmax: 
3087.3, 3006.6, 2965.3, 2921.2, 1774.0, 1702.3, 1654.2, 1774.0, 1702.3, 1654.2, 
1591.4;
 1
H NMR (500 MHz, CDCl3) : 4.49 (s, 2H, NCH2CO2), 4.74 (d, 2H, J = 7.7 Hz, 
OCH
2
CH=CHO), 5.65 (dt, 1H, J = 12.1, 7.7 Hz, OCH
2
CH=CHO), 6.84 (d, 1H, J = 12.1 
Hz, OCH
2
CH=CHO), 7.08 -- 7.11 (m, 2H, Ar-H Ph), 7.76 --7.80 (m, 2H, Ar-H Phth), 
7.90 -- 7.93 (m, 2H, Ar-H Phth), 8.23 -- 8.27 (m, 2H, Ar-H Ph);
 13
C NMR (125 MHz, 
CDCl3) : 39.0, 62.1, 108.8, 116.6, 123.7, 126.0, 132.0, 134.3, 143.4, 146.1, 161.1, 





(E)-3-(4-Trifluoromethylphenyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate (271) 
 
EDCi.HCl (0.88 g, 4.59 mmol), triethylamine (0.64 mL, 4.59 mmol), phthaloyl glycine 
228 (0.94 g, 4.59 mmol), catalytic DMAP and (E)-3-(4-trifluoromethylphenyloxy)prop-
2-enol 258 (0.50 g, 2.30 mmol) were combined according to general procedure 3, to 
afford the title compound as an off-white solid. (0.68 g, 73%). MP: 114 – 115 °C; FTIR 
(film/cm
-1) υmax: 3078.4, 2948.1, 1777.3, 1750.8, 1724.0, 1677.7, 1613.4; 
1
H NMR (500 
MHz, CDCl3) : 4.48 (s, 2H, NCH2CO2), 4.72 (d, 2H, J = 8.0 Hz, OCH2CH=CHO), 5.56 
(dt, 1H, J = 12.4, 8.0 Hz, OCH
2
CH=CHO), 6.81 (d, 1H, J = 12.4 Hz, OCH
2
CH=CHO), 
7.09 (m, 2H, Ar-H Ph), 7.61 (m, 2H, Ar-H Ph), 7.76 -- 7.79 (m, 2H, Ar-H Phth), 7.89 -- 
7.93 (m, 2H Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) : 39.0, 62.5, 106.9, 116.9, 
121.9, 123.7, 127.2 (q, J = 3.6 Hz), 132.0, 134.3, 134.5, 147.3, 158.9, 167.2, 167.4; 




(E)-3-(2-Iodophenyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate (272) 
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EDCi.HCl (1.39 g, 7.25 mmol), triethylamine (1.00 mL, 7.25 mmol), phthaloyl glycine 
228  (1.50 g, 7.25 mmol), catalytic DMAP and (E)-3-(4-methoxybenzyloxy)prop-2-enol 
259 (1.00 g, 3.63 mmol) were combined according to general procedure 3, to afford the 
title compound as a cream solid. (1.22 g, 73%). MP: 81 – 85 °C; FTIR (film/cm-1) υmax: 
3061.8, 2945.2, 1776.0, 1748.4, 1723.5, 1673.7, 1615.2, 1579.0; 
1
H NMR (500 MHz, 
CDCl3) : 4.45 (s, 2H, NCH2CO2), 4.67 (d, 2H, J = 7.7 Hz, OCH2CH=CHO), 5.44 (dt, 
1H, J = 12.2, 7.7 Hz, OCH
2
CH=CHO), 6.71 (d, 1H, J = 12.2 Hz, OCH
2
CH=CHO), 6.84 
(t, 1H, J = 8.1 Hz, Ar-H Ph), 6.95 (d, 1H, J = 8.1 Hz, Ar-H Ph), 7.30 (t, 1H, J = 8.1 Hz, 
Ar-H Ph), 7.71 -- 7.74 (m, 2H, Ar-H Phth), 7.77 (dd, 1H, J = 8.1, 1.4 Hz, Ar-H Ph), 7.84 
-- 7.88 (m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) : 39.0, 62.7, 87.2, 105.7, 
117.5, 123.6, 125.6, 129.7, 132.0, 134.3, 139.8, 148.5, 155.6, 167.2, 167.4; HRMS 




2-(1,3-dioxoisoindolin-2-yl)propanoic acid (260) 
 
DL-alanine (1.00 g, 11.2 mmol, 1 equiv.) and phthalic anhydride (1.66 g, 11.2 mmol, 1 
equiv.) were refluxed in toluene (50 mL) under Dean-Stark conditions for 5 days, 
cooled and solvent removed in vacuo to afford a white solid. Purification was achieved 
by recystallisation from water to afford the title compound as white needles. (1.80 g, 
73%). MP: 165 – 167 °C, Lit: 162.5 – 163 °C;165 1H NMR (500 MHz, CDCl3) : 1.68 
(d, 3H, J = 7.5 Hz, NCH(CH3)CO2H), 4.90 (br, 1H, CO2H), 4.97 (q, 1H, J = 7.5 Hz, 
NCH(CH3)CO2H), 7.85 – 7.81 (m, 2H, Ar-H Phth), 7.90 – 7.87 (m, 2H, Ar-H Phth);
 13
C 
NMR (125 MHz, CDCl3) : 14.0, 47.2, 122.9, 131.8, 134.2, 167.6, 171.8. All analytical 








 (E)-3-Methoxyallyl 2-(1,3-dioxoisodolin-2-yl)propanote (273) 
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EDCi.HCl (1.23 g, 6.43 mmol), triethylamine (0.77 mL, 6.43 mmol), 2-(1,3-
diocoisoindoin-2-yl)propanoic acid 260 (1.23 g, 6.43 mmol), catalytic DMAP and (E)-
3-(methoxy)prop-2-enol 224 (0.25 g, 3.21 mmol) were combined according to general 
procedure 3, to afford the title compound as a colourless oil. (0.78 g, 95%). FTIR 
(film/cm
-1) υmax: 2997.5, 2944.0, 1780.1, 1713.9, 1654.1, 1612.1; 
1
H NMR (500 MHz, 
CDCl3) : 1.68 (d, 3H, J = 7.3 Hz, NCH(CH3)CO2), 3.53 (s, 3H, OCH3), 4.53 -- 4.60 (m, 
2H, OCH
2
CH=CHO), 4.87 (dt, 1H, J = 13.1, 7.6 Hz, OCH
2





), 6.59 (d, 1H, J = 13.1 Hz, OCH
2
CH=CHO), 7.71 -- 7.74 (m, 2H, 
Ar-H Phth), 7.83 -- 7.87 (m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) : 15.2, 
27.6, 47.6, 47.7, 53.4, 56.1, 64.1, 96.5, 123.5, 131.9, 132.0, 134.1, 153.7, 167.5, 169.7; 




(±)-(2R,3R)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-ethoxypent-4-enoate (274) 
 
(E)-3-Ethoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate 261 (0.206 g, 0.71 mmol, 1 
equiv.), TMSCl (0.11 mL, 0.92 mmol, 1.3 equiv.) and LiHMDS (0.85 mL, 0.85 mmol, 
1.3 equiv.) were combined according to general procedure 6. Treatment with 
diazomethane and purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) 
afforded the title compound as a yellow oil. (0.17 g, 79%, dr 9:1). FTIR (film/cm
-1
) 
υmax: 3062.5, 2977.4, 2955.5, 2928.3, 2896.7, 1778.0, 1753.4, 1719.1, 1672.1, 1612.4; 
1













), 4.63 (app. t, 1H, 
J = 7.1 Hz, CH
2
=CHCHO), 4.86 (d, 1H, J = 7.1 Hz, NCHCO
2
), 5.33 (d, 1H, J = 10.5 
Hz, CH
2
=CHCHO), 5.43 (d, 1H, J = 17.2 Hz, CH
2
=CHCHO), 5.91 (ddd, 1H, J = 17.2, 
10.5, 7.1 Hz, CH
2
=CHCHO), 7.72 -- 7.76 (m, 2H, Ar-H Phth), 7.86 -- 7.89 (m, 2H, Ar-H 

















), 4.65 (app. t, 1H, J = 7.1 Hz, 
CH
2
=CHCHO), 4.89 (d, 1H, J = 7.1 Hz, NCHCO
2
), 5.11 (d, 1H, J = 10.5 Hz, 




=CHCHO), 5.23 (d, 1H, J = 17.2 Hz, CH
2
=CHCHO), 5.63 (ddd, 1H, J = 17.2, 10.5, 
7.1 Hz, CH
2
=CHCHO), 7.72 -- 7.76 (m, 2H, Ar-H Phth), 7.86 -- 7.89 (m, 2H, Ar-H 
Phth); 
13
C NMR (125 MHz, CDCl3) syn δ: 15.0, 52.5, 55.9, 64.4, 76.2, 119.1, 123.5, 
131.8, 134.1, 135.8, 167.5, 167.9; anti δ: 15.2, 52.6, 54.2, 64.7, 78.5, 120.0, 123.6, 
131.7, 134.2, 134.5, 167.1, 168.2; HRMS (ESI, +ve) m/z: calcd. for C16H18NO5 




(±)-(2R,3S)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-isobutoxypent-4-enoate (275) 
 
(E)-3-Isobutoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate 262 (0.13 g, 0.40 mmol, 1 
equiv.), TMSCl (0.07 mL, 0.51 mmol, 1.3 equiv.) and LiHMDS (0.47 mL, 0.47 mmol, 
1.3 equiv.) were combined according to general procedure 6. Treatment with 
diazomethane and purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) 





υmax: 2956.5, 2921.7, 2878.8, 1777.9, 1750.0, 1718.8, 1644.1; 
1
H NMR (500 MHz, 













O), 3.30 (dd, 1H, J = 










), 4.58 (app. t, J = 9.1 Hz, 
CH
2
=CHCHO), 4.87 (d, 1H, J = 9.1 Hz, NCHCO
2
), 5.35 (d, 1H, J = 10.7 Hz, 
CH
2
=CHCHO), 5.44  (d, 1H, J = 17.4 Hz, CH
2
=CHCHO), 5.90 (ddd, 1H, J = 17.4, 10.7, 
9.1 Hz, CH
2
=CHCHO), 7.73 -- 7.76 (m, 2H, Ar-H Phth), 7.86 -- 7.90 (m, 2H, Ar-H 






























), 4.64 (app. t, 1H, J = 8.8 Hz, 
CH
2
=CHCHO), 4.92 (d, 1H, J = 6.1 Hz, NCHCO
2
), 5.12 (d, 1H, J = 10.1 Hz, 
CH
2
=CHCHO), 5.23 (d, 1H, J = 17.2 Hz, CH
2
=CHCHO), 5.62 (ddd, 1H, J = 17.2, 10.1, 
6.1 Hz, CH
2
=CHCHO), 7.73 -- 7.76 (m, 2H, Ar-H Phth), 7.86 -- 7.90 (m, 2H, Ar-H 
Phth); 
13
C NMR (125 MHz, CDCl3) syn δ: 19.0, 28.3, 52.5, 55.8, 75.6, 76.5, 119.3, 
123.4, 131.9, 134.1, 135.8, 167.5, 167.9; HRMS (ESI, +ve) m/z: calcd. for 









(E)-3-(Neopentyl)oxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate 263 (0.18 g, 0.53 mmol, 
1 equiv.), TMSCl (0.09 mL, 0.69 mmol, 1.3 equiv.) and LiHMDS (0.64 mL, 0.64 
mmol, 1.3 equiv.) were combined according to general procedure 6. Treatment with 
diazomethane and purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) 
afforded the title compound as a colourless oil. (0.14 g, 78%, dr 13:1). FTIR (film/cm
-1
) 
υmax: 3087.0, 2955.9, 2901.7, 2868.5, 1778.2, 1719.2, 1645.5, 1614.5; 
1
H NMR (500 

















), 4.53 -- 
4.57 (m, 1H, CH
2
=CHCHO), 4.86 (d, 1H, J = 10.3 Hz, NCHCO
2
), 5.32 -- 5.35 (m, 1H, 
CH
2
=CHCHO), 5.43 (dt, 1H, J = 17.1, 1.5 Hz, CH
2
=CHCHO), 5.88 (ddd, 1H, J = 17.1, 
10.3, 6.7 Hz, CH
2
=CHCHO), 7.71 -- 7.74 (m, 2H, Ar-H Phth), 7.83 -- 7.88 (m, 2H, Ar-H 























), 4.62 (app. t, 1H, J = 8.6 Hz, 
CH
2
=CHCHO), 4.92 (d, 1H, J = 8.6 Hz, NCHCO
2
), 5.09 -- 5.12 (m, 1H, CH
2
=CHCHO), 
5.20 -- 5.24 (m, 1H, CH
2
=CHCHO), 5.60 (ddd, 1H, J = 17.5, 10.3, 8.6 Hz, 
CH
2
=CHCHO), 7.71 -- 7.74 (m, 2H, Ar-H Phth), 7.83 -- 7.88 (m, 2H, Ar-H Phth); 
13
C 
NMR (125 MHz, CDCl3) syn δ: 26.4, 31.6, 52.4, 55.7, 76.3, 79.2, 119.1, 123.4, 131.9, 
134.1, 135.8, 167.4, 167.9; anti δ: 26.7, 31.9, 52.5, 54.5, 78.8, 79.6, 119.8, 123.6, 131.7, 








(±)-(1R,2R)-2-(allyloxy)-1-(1,3-dioxoisoindolin-2-yl)but-3-enyl acetate (277) 
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(E)-3-(Allyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate 264 (0.24 g, 0.78 mmol, 1 
equiv.), TMSCl (0.13 mL, 1.01 mmol, 1.3 equiv.) and LiHMDS (0.93 mL, 0.93 mmol, 
1.3 equiv.) were combined according to general procedure 6. Treatment with 
diazomethane and purification by flash chromatography (4:1 Pet/EtOAc + 1% NEt3) 
afforded the title compound as a colourless oil. (0.17 g, 70%, dr 10:1). FTIR (film/cm
-1
) 
υmax: 3082.3, 2985.4, 2954.3, 2921.8, 2865.3, 1777.8, 1750.0, 1718.6, 1646.1, 1613.0; 
1
H NMR (500 MHz, CDCl3) syn and anti δ: 3.72 (s, 3H), 4.96 -- 4.90 (m, 1H), 4.97 (dq, 
1H, J = 10.5, 1.7 Hz), 5.07 (dq, 1H, J = 17.2, 2.1 Hz), 5.38 (dt, 1H, J = 10.8, 0.91 Hz), 
5.15 -- 5.33 (m, 1H), 5.45 (dt, 1H, J = 17.1, 1.4 Hz), 5.62 -- 5.71 (m, 1H), 5.91 (ddd, 1H, 
J = 17.1, 10.6, 6.9 Hz), 7.73 -- 7.76 (m, 2H), 7.86 -- 7.89 (m, 2H); 
13
C NMR (125 MHz, 
CDCl3) syn δ: 52.5, 55.7, 69.5, 75.9, 116.6, 119.7, 123.5, 131.9, 134.1, 134.3, 135.3, 
167.4, 167.8; anti δ: 52.7, 54.2, 70.1, 78.1, 117.1, 120.5, 123.6, 131.7, 134.2, 135.3, 





(±)-(2R,3R)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-benzyloxypent-4-enoate (278) 
 
(E)-3-(Benzyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate 265 (0.13 g, 0.37 mmol, 1 
equiv.), TMSCl (0.06 mL, 0.48 mmol, 1.3 equiv.) and LiHMDS (0.44 mL, 0.44 mmol, 
1.3 equiv) were combined according to general procedure 6. Treatment with 
diazomethane and purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) 
afforded the title compound as a colourless oil. (0.10 g, 70%, dr 10:1). FTIR (film/cm
-1
) 
υmax: 3035.8, 2999.3, 2954.3, 2839.3, 1749.8, 1718.9, 1645.5; 
1
H NMR (500 MHz, 
CDCl3) syn δ: 3.72 (s, 3H, CO2CH3), 4.47 -- 4.61 (m, 2H, OCH2Ph), 4.73 (app. t, 1H, J = 
8.6 Hz, CH
2
=CHCHO), 4.93 (d, 1H, J = 8.6 Hz, NCHCO
2
), 5.41 -- 5.43 (m, 1H, 
CH
2
=CHCHO), 5.49 -- 5.53 (m, 1H, CH
2
=CHCHO), 5.98 (ddd, 1H, J = 17.3, 10.7, 8.6 




=CHCHO), 7.05 -- 7.15 (m, 5H, Ar-H Ph), 7.73 -- 7.75 (m, 2H, Ar-H Phth), 7.83 




), 4.61 -- 4.47 (m, 2H, OCH
2
Ph), 
4.81 (app. t, 1H, J = 8.4 Hz, CH
2
=CHCHO), 5.01 (d, 1H, J = 8.4 Hz, NCHCO
2
), 5.18 -- 
5.21 (m, 1H, CH
2
=CHCHO), 5.28 -- 5.32 (m, 1H, CH
2
=CHCHO), 5.71 (ddd, 1H, J = 
17.3, 10.7, 8.4 Hz, CH
2
=CHCHO), 7.34 -- 7.38 (m, 5H, Ar-H Ph), 7.73 -- 7.75 (m, 2H, 
Ar-H Phth), 7.83 -- 7.87 (m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) syn δ: 38.8, 
52.5, 55.7, 70.6, 76.2, 123.5, 127.5, 128.1, 128.3, 128.7, 131.9, 134.0, 135.3, 167.4, 
167.7; anti δ: 39.0, 52.7, 54.3, 67.6, 77.4, 123.7, 127.3, 128.0, 128.3, 128.5, 132.0, 








(E)-3-(2-Iodobenzyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate 266 (0.25 g, 0.51 
mmol, 1 equiv.), TMSCl (0.08 mL, 0.66 mmol, 1.3 equiv.) and LiHMDS (0.61 mL, 
0.61 mmol, 1.3 equiv) were combined according to general procedure 6. Treatment with 
diazomethane and purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) 
afforded the title compound as a colourless oil. (0.12 g, 50%, dr 14:1). FTIR (film/cm
-1
) 
υmax: 3063.2, 2953.1, 1777.1, 1751.6, 1719.5, 1642.4, 1613.1, 1587.7, 1565.5;
 1
H NMR 
(500 MHz, CDCl3) syn δ: 3.72 (s, 3H, CO2CH3), 4.47 -- 4.56 (m, 2H, OCH2Ar), 4.80 
(app. t, 1H, J = 8.9 Hz, CH
2
=CHCHO), 4.98 (d, 1H, J = 8.9 Hz, NCHCO
2
), 5.45 (app. d, 
1H, J = 17.1 Hz, CH
2
=CHCHO), 5.56 (dt, 1H, J = 17.2, 1.8 Hz, CH
2
=CHCHO), 6.00 
(ddd, 1H, J = 17.2, 10.5, 8.9 Hz, CH
2
=CHCHO), 6.86 (td, 1H, J = 7.8, 1.5 Hz, Ar-H 
Ph), 7.13 (td, 1H, J = 7.8, 1.5 Hz, Ar-H Ph), 7.19 (dd, 1H, J = 7.8, 1.5 Hz, Ar-H Ph), 
7.64 (dd, 1H, J = 7.8, 1.5 Hz, Ar-H Ph), 7.72 -- 7.75 (m, 2H, Ar-H Phth), 7.83 -- 7.86 




), 4.59 -- 4.62 (m, 2H, OCH
2
Ar), 4.88 
(app. t, 1H, J = 8.2 Hz, CH
2
=CHCHO), 5.06 (d, 1H, J = 8.2 Hz, NCHCO
2
), 5.22 (app. d, 
1H, J = 10.2 Hz, CH
2
=CHCHO), 5.35 (app. d, 1H, J = 17.1 Hz, CH
2
=CHCHO), 5.74 
(ddd, 1H, J = 17.1, 10.2, 8.1 Hz, CH
2
=CHCHO), 6.86 (td, 1H, J = 7.7, 1.5 Hz, Ar-H 
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Ph), 7.13 (td, 1H, J = 7.7, 1.5 Hz, Ar-H Ph), 7.19 (dd, 1H, J = 7.7, 1.5 Hz, Ar-H Ph), 
7.64 (dd, 1H, J = 7.7, 1.5 Hz, Ar-H Ph), 7.75 -- 7.77 (m, 2H, Ar-H Phth), 7.92 -- 7.98 
(m, 2H, Ar-H Phth);
13
C NMR (125 MHz, CDCl3) syn δ: 38.8, 52.6, 74.2, 76.4, 123.5, 
128.0, 128.8, 129.0, 131.9, 134.1, 134.3, 134.9, 138.9, 167.3, 167.6; anti δ: 38.9, 52.7, 
74.9, 78.9, 123.6, 128.4, 129.0, 129.1, 132.0, 133.8, 137.5, 139.6, 140.1, 167.4, 167.7; 






(E)-3-(4-Methoxybenzyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate 267 (0.13 g, 0.34 
mmol), TMSCl (0.06 mL, 0.44 mmol) and LiHMDS (0.40 mL, 0.40 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil. (0.08 g, 63%, dr 8:1). FTIR (film/cm
-1) υmax: 3064.0, 
3001.2, 2954.3, 2838.6, 1777.1, 1749.0, 1720.0, 1642.9, 1613.2, 1586.4;
 1
H NMR (500 
MHz, CDCl3) syn δ: 3.71 (s, 3H, ArOCH3), 3.72 (s, 3H, CO2CH3), 4.46 -- 4.51 (m, 2H, 
OCH
2
Ar), 4.70 (app. t, 1H, J = 8.4 Hz, CH
2
=CHCHO), 4.90 (d, 1H, J = 8.4 Hz, 
NCHCO
2
), 5.41 (d, 1H, J = 10.2 Hz, CH
2
=CHCHO), 5.50 (d, 1H, J = 17.0 Hz, 
CH
2
=CHCHO), 5.98 (ddd, 1H, J = 17.0, 10.2, 8.4 Hz, CH
2
=CHCHO), 6.62 (m, 2H, Ar-
H Ph), 6.97 (m, 2H, Ar-H Ph), 7.72 -- 7.78 (m, 2H, Ar-H Phth), 7.86 -- 7.81 (m, 2H, Ar-
H Phth); anti δ: 3.71 (s, 3H, ArOCH
3




), 4.46 -- 4.51 (m, 2H, 
OCH
2
Ar), 4.78 (app. t, 1H, J = 8.4 Hz, CH
2
=CHCHO), 4.99 (d, 1H, J = 8.4 Hz, 
NCHCO
2
), 5.18 (d, 1H, J = 10.1 Hz, CH
2
=CHCHO), 5.28 (d, 1H, J = 17.9 Hz, 
CH
2
=CHCHO), 5.70 (ddd, 1H, J = 17.9, 10.1, 8.4 Hz, CH
2
=CHCHO), 6.62 (m, 2H, Ar-
H Ph), 6.89 (m, 2H, Ar-H Ph), 7.72 -- 7.77 (m, 2H, Ar-H Phth), 7.88 -- 7.91 (m, 2H, Ar-
H Phth); 
13
C NMR (125 MHz, CDCl3) syn δ: 52.5, 55.1, 55.7, 70.3, 75.8, 113.5, 114.0, 
119.6, 123.4, 129.2, 130.3, 131.9, 134.0, 158.9, 167.3, 167.8; anti δ: 52.7, 54.2, 55.3, 
71.0, 78.4, 113.8, 113.9, 120.5, 123.6, 129.6, 130.0, 132.0, 134.2, 159.9, 167.5, 168.1; 
HRMS (ESI, +ve) m/z: calcd. for C22H21NO5Na 396.1447, found 418.1283 (M+Na)
+
. 
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(±)-(2R,3S)-Methyl 2-(1,3-dioxoisoindolin-2-yl)-3-phenoxypent-4-enoate (281) 
 
(E)-3-(4-Phenyloxybenzyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate 268 (0.11 g, 
0.33 mmol, 1 equiv.), TMSCl (0.06 mL, 0.43 mmol, 1.3 equiv.) and LiHMDS (0.40 
mL, 0.40 mmol, 1.3 equiv) were combined according to general procedure 6. Treatment 
with diazomethane and purification by flash chromatography (6:1 Pet/EtOAc + 1% 
NEt3) afforded the title compound as a colourless oil. (0.10 g, 81%, dr 14:1). FTIR 
(film/cm
-1) υmax: 3864.2, 3848.9, 2954.0, 2849.6, 1727.4, 1750.6, 1720.2, 1646.5, 
1596.0; 
1
H NMR (500 MHz, CDCl3) syn δ: 3.76 (s, 3H, CO2CH3), 5.10 (d, 1H , J = 5.6 
Hz, CH
2
=CHCHO), 5.36 (d, 1H, J = 5.6 Hz, NCHCO
2
), 5.50 (d, 1H, J = 17.2 Hz, 
CH
2
=CHCHO), 5.57 (app. t, 1H, J = 8.6 Hz, CH
2
=CHCHO), 6.17 (ddd, 1H, J = 17.2, 
10.6, 5.6 Hz, CH
2
=CHCHO), 6.80 -- 7.17 (m, 5H, Ar-H Ph), 7.72 -- 7.78 (m, 2H, Ar-H 




), 5.19 (t, 1H , J = 
8.0 Hz, CH
2
=CHCHO), 5.34 (d, 1H, J = 10.6 Hz, NCHCO
2
), 5.42 -- 5.46 (m, 2H, 
CH
2
=CHCHO), 5.79 -- 5.86 (m, 1H, CH
2
=CHCHO), 6.80 - 7.17 (m, 5H, Ar-H Ph), 7.72 
-- 7.78 (m, 2H, Ar-H Phth), 7.84 -- 7.87 (m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, 
CDCl3) syn δ: 39.0, 52.7, 55.7, 75.0, 116.4, 119.6, 123.7, 129.7, 131.7, 134.2, 149.0, 
157.4, 167.3, 167.5; anti δ: 39.1, 52.9, 54.3, 63.1, 117.2, 121.7, 123.7, 129.5, 132.0, 
134.3, 150.3, 156.5, 167.2, 167.4; HRMS (ESI, +ve) m/z: calcd. for C20H17NO5Na 
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(E)-3-(2-Iodophenyloxy)allyl 2-(1,3-dioxoisoindolin-2-yl)acetate 272 (0.11 g, 0.22 
mmol, 1 equiv.), TMSCl (0.04 mL, 0.29 mmol, 1.3 equiv.) and LiHMDS (0.27 mL, 
0.27 mmol, 1.3 equiv) were combined according to general procedure 6. Treatment with 
diazomethane and purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) 
afforded the title compond as a colourless oil. (0.05 g, 50%, dr 17:1). FTIR (film/cm
-1
) 
υmax: 3090.3, 3060.4, 2954.3, 2923.8, 2846.3, 1777.7, 1750.1, 1719.7, 1611.0, 1581.6; 
1
H NMR (500 MHz, CDCl3) syn and anti δ: (s, 3H, CO2CH3), 5.19 (d, 1H, J = 9.5 Hz, 
CH
2
=CHCHO), 5.41 (d, 1H, J = 10.7 Hz, NCHCO
2
), 5.51 (d, 1H, J = 17.7 Hz, 
CH
2
=CHCHO), 5.68 (dd, 1H, J = 10.7, 4.4 Hz, CH
2
=CHCHO), 6.24 (ddd, 1H, J = 17.7, 
10.7, 9.5 Hz, CH
2
=CHCHO), 6.64 (t, 1H, J = 7.7 Hz, Ar-H Ph), 6.84 (d, 1H, J = 7.7 Hz, 
Ar-H Ph), 7.21 (app. t, 1H, J = 7.7 Hz, Ar-H Ph), 7.60 (app. d, 1H, J = 7.7 Hz, Ar-H 
Ph), 7.72 -- 7.76 (m, 2H, Ar-H Phth), 7.85 -- 7.88 (m, 2H, Ar-H Phth);
13
C NMR (125 
MHz, CDCl3) syn and anti δ: 52.8, 55.4, 74.7, 86.5, 113.9, 120.2, 123.0, 123.7, 129.2, 
132.1, 134.1, 134.2, 139.4, 155.6, 167.3, 167.5; HRMS (ESI, +ve) m/z: calcd. for 







(E)-3-Methoxyallyl 2-(1,3-dioxoisodolin-2-yl)propanote 273 (0.22 g, 0.74 mmol, 1 
equiv.), TMSCl (0.12 mL, 0.96 mmol, 1.3 equiv.) and LiHMDS (0.89 mL, 0.89 mmol, 
1.3 equiv) were combined according to general procedure 6. Treatment with 
diazomethane and purification by flash chromatography (6:1 Pet/EtOAc + 1% NEt3) 
afforded the title compound as a colourless oil. (0.16 g, 71%, dr 24:1). FTIR (film/cm
-1
) 
υmax: 3082.2, 2990.9, 2950.5, 2826.4, 1781.6, 1718.2, 1639.6, 1612.5; 
1
H NMR (500 





), 4.48 (dt, 1H, J = 7.8, 0.6 Hz, CH
2
=CHCHO), 5.31 -- 5.33 (m, 1H, 




=CHCHO), 5.33 -- 5.36 (m, 1H, CH
2
=CHCHO), 5.99 (ddd, 1H, J = 17.1, 10.3, 7.8 
Hz, CH
2
=CHCHO), 7.70 -- 7.71 (m, 2H, Ar-H Phth), 7.78 -- 7.80 (m, 2H, Ar-H Phth); 




), 3.32 (s, 3H, OCH
3




), 4.60 (dt, 
1H, J = 8.62, 0.84 Hz, CH
2
=CHCHO), 5.26 -- 5.30 (m, 2H, CH
2
=CHCHO), 5.73 (ddd, 
1H, J = 17.1, 10.3, 7.7 Hz, CH
2
=CHCHO), 7.70 -- 7.71 (m, 2H, Ar-H Phth), 7.78 -- 7.80 
(m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) syn δ: 19.5, 52.4, 57.2, 65.5, 83.7, 
120.5, 123.2, 131.7, 133.5, 134.0, 168.2, 170.6; anti δ: 19.3, 52.5, 56.8, 65.2, 83.1, 
121.1, 123.4, 131.9, 133.0, 134.2, 168.3, 169.7; HRMS (ESI, +ve) m/z: calcd. for 




(Z)-Methyl 2-(1,3-dioxoisoindolin-2-yl)penta-2,4-dienoate (284) 
 
FTIR (film/cm
-1) υmax: 3025.4, 3003.7, 2985.9, 1704.2, 1689.8; 
1
H NMR (500 MHz, 
CDCl3) δ: 3.71 (s, 3H, CO2CH3), 5.14 – 5.27 (m, 2H, H2C=CHCH=C), 6.35 (dt, 1H, J = 
16.8, 10.5 Hz, H2C=CHCH=C), 7.61 (d, 1H, J = 10.5 Hz, H2C=CHCH=C), 7.78 – 7.80 
(m, 2H, Ar-H Phth), 7.91 – 7.93 (m, 2H, Ar-H Phth); 13C NMR (125 MHz, CDCl3) δ: 
52.7, 124.0, 129.1, 132.0, 133.8, 134.3, 134.4, 142.2, 163.4, 167.1; HRMS (ESI, +ve) 




2-(Methoxycarbonyl(methyl)amino)acetic acid (295) 
 
To a stirred solution of sarcosine 294 (3.49 g, 39.1 mmol, 1 equiv.) in water (140 mL) at 
0 °C was added sodium carbonate (12.5 g, 117 mmol, 3 equiv.). To this solution was 
added a solution of methyl chloroformate (8.3 mL, 107 mmol, 2.75 equiv.) in dioxane 
(40 mL) via a dropping funnel over 5 minutes. The reaction was stirred for a further 30 
minutes at 0 °C before warming to room temperature and stirring for a further 20 hours. 
The slurry was washed with ether (2 × 50 mL) and the aqueous acidified with 10% HCl 
to pH 1-2 and extracted with EtOAc (4 × 50 mL). Organic fractions were combined, 
dried over MgSO4, filtered and concentrated in vacuo to afford the title compound as a 
colourless oil (4.20 g, 73%, 1.2:1 rotamers). FTIR (film/cm
-1) υmax: 3019.8, 2956.0, 
1701.2, 1666.1; 
1
H NMR (500 MHz, CDCl3) : 2.92 & 2.93 (2s, 3H, CH3OCON), 3.65 
& 3.68 (2s, 3H, CH3N), 3.96 & 4.02 (2s, 2H, NCH2CO2H), 11.37 (s, 1H, CO2H); 
13
C 
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NMR (125 MHz, CDCl3) : 35.2, 35.9, 50.1, 50.4, 53.2 (×2), 157.0, 157.7, 173.6, 





2-((Benzyloxycarbonyl)(methyl)amino)acetic acid (296) 
 
To a stirred solution of sarcosine 294 (4.00 g, 44.9 mmol, 1 equiv.) in water (140 mL) at 
0 °C was added sodium carbonate (14.3 g, 134 mmol, 3 equiv.). To this solution was 
added a solution of benzyl chloroformate (7 mL, 123 mmol, 2.75 equiv.) in dioxane (40 
mL) via a dropping funnel over 5 minutes. The reaction was stirred for a further 30 
minutes at 0 °C before warming to room temperature and stirring for a further 20 hours. 
The slurry was washed with ether (2 × 50 mL) and the aqueous acidified with 10% HCl 
to pH 1-2 and extracted with EtOAc (4 × 50 mL). Organic fractions were combined, 
dried over MgSO4, filtered and concentrated in vacuo to afford the crude acid as an oil. 
Upon storage at -18 °C solidification occurred to afford the title compound as an off-
white solid (8.96 g, 90%, 1.3:1 rotamers). MP: 58 – 59 °C; lit. 58 - 59 °C;167 1H NMR 
(500 MHz, CDCl3) : 3.03 (s, 3H, CH3NCH2), 4.06 & 4.11 (2s, 2H, NCH2CO2H), 5.15 
& 5.18 (2s, 2H, PhCH2OCON), 7.29 – 7.39 (m, 5H, Ar-H Ph), 11.37 (s, 1H, CO2H); 
13
C 
NMR (125 MHz, CDCl3) : 35.4, 36.0, 50.2, 50.6, 67.6, 67.7, 127.9, 128.1, 128.5, 





2-(N,4-Dimethylphenylsulfonamido)acetic acid (297) 
 
To a stirred solution of sarcosine 294 (5.00 g, 56.1 mmol, 1 equiv.) in water (50 mL) 
was added potassium hydroxide (9.4 g, 168.4 mmol, 3 equiv.). To this was added a 
solution of p-toluenesulfonyl chloride (11.7 g, 61.7 mmol, 1.1 equiv.) in THF (250 mL) 
via a dropping funnel over 10 minutes. The reaction was stirred at room temperature for 
20 hours, before acidifying with 10% HCl to pH 1-2 and extracting with EtOAc (5 × 
100 mL), drying over MgSO4, filtering and concentrating in vacuo. Purification was 
Chapter 6  Experimental 
 169 
achieved by recrystalisation from acetone/hexane to afford the title compound as 
colourless solid (12.2 g, 90%). MP: 152 – 153 °C, Lit: 147 – 150 °C; FTIR (film/cm-1) 
υmax: 3070.5, 2958.3, 2932.6, 2895.8, 2858.0, 1728.9; 
1
H NMR (500 MHz, CDCl3) : 
2.45 (s, 3H, CH3C6H4SO2N), 2.89 (s, 3H, NCH3), 4.00 (s, 2H, NCH2CO2H), 7.31 – 7.34 
(m, 2H, Ar-H Ts), 7.70 – 7.72 (m, 2H, Ar-H Ts); 13C NMR (125 MHz, CDCl3) : 21.5, 
35.8, 50.7, 127.4, 129.7, 135.0, 143.9, 173.6; HRMS (ESI, +ve) m/z: calcd. for 
C10H13NO4SNa 266.0463, found 266.0461 (M+Na)
+
. All analytical data is in 




2-(2,2,2-Trifluoro-N-methylacetamido)acetic acid (298) 
 
To a cooled solution of sarcosine 294 (2.22 g, 25.0 mmol, 1 equiv.) in dry 
trifluoroacetic acid (15 mL) at -10 °C, was added trifluoroacetic anhydride (4.4 mL, 
30.0 mmol, 1.2 equiv.) over 30 minutes via syringe pump. After addition, the mixture 
was cooled to -20 °C and stirred for 16 hours, then at room temperature for 1 hour. 
Excess reagents and solvent were removed in vacuo before azeotroping with toluene 
(200 mL) to afford the title compound as a yellow solid (4.96 g, 100%, 2.9:1 rotamers). 
MP: 53 – 54 °C, Lit: 54.5 - 55.5 °C; 1H NMR (500 MHz, CDCl3) : 3.14 & 3.26 (2s, 
3H, NCH3), 4.24 & 4.27 (2s, 2H, NCH2CO2H), 9.12 (br, 1H, NCH2CO2H); 
13
C NMR 
(125 MHz, CDCl3) : 36.4, 36.5, 50.4, 115.0, 117.3, 158.0 (q, J = 37.6 Hz), 159.9 (q, J 
= 37.6 Hz), 172.8, 172.9; HRMS (ESI, +ve) m/z: calcd. for C16H17F3NO3Na 208.0197, 
found 208.0175 (M+Na)
+





2-(N-methylacetamido)acetic acid (299) 
 
To a cooled solution of sarcosine 294 (5.0 g, 56.1 mmol, 1 equiv.) in dry acetic acid (60 
mL) at 0 °C, was added acetic anhydride (6.35 mL, 67.1 mmol, 1.2 equiv.) over 30 
minutes via syringe pump. After addition, the mixture was stirred at 0 °C for 16 hours, 
then at room temperature for 1 hour. Excess reagents and solvent were removed in 
vacuo before azetroping with toluene (200 mL) to afford the title compound as a white 
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solid (6.15 g, 84%, 2.2:1 rotamers). MP: 138 – 140 °C, Lit: 134 - 134.5 °C;171 1H NMR 
(500 MHz, CDCl3) : 2.06 & 2.15 (2s, 3H, CH3CON), 2.96 & 3.13 (2s, 3H, 
CH3CON(CH3)), 4.11 & 4.19 (2s, 2H, NCH2CO2H); 
13
C NMR (125 MHz, CDCl3) : 
19.7, 19.8, 33.7, 36.3, 48.7, 51.6, 170.9, 171.2, 172.7, 172.8. All analytical data is in 




2-(Benzyl(tert-butoxycarbonyl)amino)acetic acid (301) 
 
To a solution of N-benzyl glycine ethyl ester 300 (6.24 g, 32.3 mmol, 1 equiv.) in water 
(200 mL) was added triethylamine (13.5 mL, 96.9 mmol, 3 equiv.) and di-tert-butyl 
dicarbonate (8.45 g, 38.7 mmol, 1.2 equiv.) and stirred at room temperature for 24 
hours. The reaction was quenched with aqueous HCl (10%, 100 mL) and extracted with 
EtOAc (5 × 100 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford 
the ethyl 2-benzyl(tert-butoxycarbonyl)amino)acetate as a yellow oil (7.73 g, 82%, 
1.3:1 rotamers). FTIR (film/cm
-1) υmax: 2979.5, 1749.0, 1697.7; 
1
H NMR (500 MHz, 
CDCl3) : 1.26 (t, 3H, J = 7.2 Hz, CO2CH2CH3), 1.48 (s, 9H, (CH3)3COCON), 3.78 & 
3.93 (2s, 2H, PhCH2N), 4.17 (q, 2H, J = 7.2 Hz, CO2CH2CH3), 4.53 & 4.57 (2s, 2H, 
NCH2CO2), 7.21 – 7.37 (m, 5H, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) : 14.2, 28.3, 
48.1, 51.5, 61.0, 80.7, 127.4, 127.6, 128.2, 128.6, 137.6, 155.8, 170.0; HRMS (ESI, 




To a solution of ethyl 2-benzyl(tert-butoxycarbonyl)amino)acetate (7.73 g, 26.3 mmol, 
1 equiv.) in THF/water (200 mL, 1:1) was added lithium hydroxide (2.20 g, 52.7 mmol, 
2 equiv.) and was stirred at room temperature for 3 hours. Acetic acid was added until 
pH 4 was reached then the solution was extracted with EtOAc (4 × 100 mL). The 
organics were dried over MgSO4, filtered, concentrated in vacuo to afford a yellow 
solid. Toluene (200 mL) was added to azeotrope excess acetic acid. Purification was 
achieved by recrystallisation from cyclohexane to afford the title compound as a yellow 
solid (7.08 g, 100%, 1.3:1 rotamers). MP: 134 – 135 °C, Lit. 107 °C; 1H NMR (500 
MHz, CDCl3) : 1.48 (s, 9H, (CH3)3COCON), 3.82 & 3.93 (2s, 2H, NCH2CO2H), 4.51 
& 4.55 (2s, 2H, PhCH2N), 7.16 – 7.35 (m, 5H, Ar-H Ph), 8.34 (br, 1H, CO2H); 
13
C 
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NMR (125 MHz, CDCl3) : 28.3, 28.4, 47.8, 48.1, 50.8, 51.6, 80.8, 81.1, 125.3, 127.5, 
128.1, 128.2, 128.6, 129.0, 137.2, 137.3, 155.7, 156.3, 175.2, 175.5. All analytical data 




2-(Allyl(tert-butoxycarbonyl)amino)acetic acid (303) 
 
To a solution of N-(tert-butoxycarbonyl)glycine methyl ester 302 (2.00 g, 10.6 mmol, 1 
equiv.) in DMF (100 mL) at 0 °C was added allyl bromide (1.34 mL, 15.9 mmol, 1.5 
equiv.). Dried sodium hydride (0.30 g, 12.7 mmol. 1.2 equiv.) was added portionwise 
and the reaction stirred for 4 hours. The reaction was quenched with saturated NH4Cl 
(100 mL) and extracted with EtOAc (4 × 50 mL), washed with saturated LiCl solution 
(2 × 50 mL) and brine  (2 × 50 mL), dried over MgSO4, filtered and concentrated in 
vacuo to afford methyl 2-(allyl(tert-butoxycarbonyl)amino)acetate as a yellow oil (1.55 
g, 64%, 1:1 rotamers). 
1
H NMR (500 MHz, CDCl3) : 1.45 & 1.48 (2s, 9H, 
(CH3)3COCON), 3.73 & 3.75 (2s, 3H, CO2CH3), 3.86 & 3.89 (2d, 2H, J = 5.6 Hz, 
NCH2CO2), 3.94 – 3.98 (m, 2H, NCH2CH=CH2), 5.10 – 5.19 (m, 2H, NCH2CH=CH2), 
5.72 - 5.85 (m, 1H, NCH2CH=CH2);
13
C NMR (125 MHz, CDCl3) : 28.5, 47.7, 48.1, 
50.5, 51.0, 52.1, 80.6, 117.0, 117.8, 133.8, 133.9, 155.3, 155.8, 170.8. All analytical 




To a solution of 2-(allyl(tert-butoxycarbonyl)amino)acetate (0.93 g, 4.00 mmol, 1 
equiv.) in THF/water (20 mL, 1:1) was added lithium hydroxide (0.34 g, 8.00 mmol, 2 
equiv.) and was stirred at room temperature for 3 hours. Acetic acid was added until pH 
4 was reached then the solution was extracted with ethyl acetate (4 × 100 mL). The 
organics were dried over MgSO4, filtered, concentrated in vacuo to afford a yellow 
solid. Toluene (200 mL) was added to azeotrope excess acetic acid to afford the title 
compound as a yellow solid (0.86 g, 100%, 1:1 rotamers). 
1
H NMR (500 MHz, CDCl3) 
: 1.44 & 1.46 (2s, 9H, (CH3)3COCON), 3.89 (s, 2H, NCH2CO2), 3.95 – 3.99 (m, 2H, 
NCH2CH=CH2), 5.14 – 5.18 (m, 2H, NCH2CH=CH2), 5.74 – 5.83 (m, 1H, 
NCH2CH=CH2); 
13
C NMR (125 MHz, CDCl3) : 28.1, 47.6, 50.2, 50.8, 80.8, 117.1, 
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2-(Dibenzylamino)acetic acid (304) 
 
To a stirred solution of glycine 50 (1.29 g, 17.1 mmol, 1 equiv.) in water and ethanol 
(20 mL, 1:1) was added potassium hydroxide (3.46 g, 60.1 mmol, 3.5 equiv) followed 
by benzyl bromide (4.08 mL, 34.2 mmol, 2 equiv.) dropwise. The reaction was stirred at 
room temperature for 24 hours, then refluxed for 30 minutes. The mixture is cooled and 
ethanol removed in vacuo before acidifying with acetic acid to pH 6. The white solid 
was collected by filtration. Purification was achieved by recrystalisation from water to 
afford a white powder (2.33 g, 100%). MP: 198 – 200 °C, Lit: 192 – 194 °C;176 1H 
NMR (500 MHz, d6-DMSO) : 3.16 (s, 2H, NCH2CO2H), 3.75 (s, 4H, PhCH2N), 7.24 – 
7.37 (m, 10H, Ar-H Ph), 12.32 (br, 1H, CO2H); 
13
C NMR (125 MHz, d6-DMSO) : 





Di-(tert-butoxycarbonyl)aminoacetic acid (305) 
 
To a stirred solution of N-Boc-Gly-OH 184 (0.88 g, 5 mmol, 1 equiv.) in ethanol and 
water (25 mL, 7:3) was added a 1M CsCO3 solution dropwise until pH 7 was reached. 
The solvents were removed in vacuo and the white salt dried under vacuum. The cesium 
salt was taken up in DMF (25 mL), treated with benzyl bromide (0.65 mL, 5.5 mmol, 
1.1 equiv.) and stirred for 18 hours at room temperature. Solvent was removed in vacuo 
and the residue taken up in water (100 mL) and extracted with EtOAc (3 × 75 mL). 
Organics were washed with water (2 × 50 mL), dried over Na2SO4, filtered and 
concentrated in vacuo to afford benzyl 2-(tert-butoxycarbonylamino)acetate as a cream 
solid (1.32 g, 100%). MP: 73 – 77 °C, Lit: 72 – 73 °C;177 1H NMR (500 MHz, CDCl3) 
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: 1.46 (s, 9H, (CH3)3COCON), 3.97 (d, 2H, J = 5.8 Hz, NCH2CO2), 5.04 (br, 1H, 
(CH3)3COCONH), 5.20 (s, 2H, PhCH2O2C), 7.33 – 7.40 (m, 5H, Ar-H Ph); 
13
C NMR 
(125 MHz, CDCl3) : 28.3, 42.5, 67.1, 80.1, 128.4, 128.5, 128.6, 135.3, 155.7, 170.3. 




To a solution of benzyl 2-(tert-butoxycarbonylamino)acetate (1.27 g, 4.8 mmol, 1 
equiv.) and DMAP (0.06 g, 0.5 mmol, 0.1 equiv.) in acetonitrile was added a solution of 
di-tert-butyl dicarbonate (1.15 g, 5.3 mmol, 1.1 equiv.) in acetonitrile (2.6 mL). The 
solution was stirred at room temperature 16 hours before concentrating in vacuo. The 
residue was taken up in EtOAc (50 mL) and washed with brine (2 × 50 mL), dried over 
Na2SO4, filtered and concentrated in vacuo to afford benzyl 2-(bis(tert-
butoxycarbonyl)amino)acetate as a yellow oil (1.35 g, 78%). FTIR (film/cm
-1) υmax: 
3034.6, 2981.3, 2934.9, 1797.0, 1759.5, 1698.1; 
1
H NMR (500 MHz, CDCl3) : 1.48 (s, 
18H, (CH3)3COCON), 4.39 (s, 2H, NCH2CO2), 5.20 (s, 2H, CO2CH2Ph), 7.31 - 7.40 
(m, 5H, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) : 28.0, 47.4, 66.9, 83.1, 128.3, 128.4, 
128.5, 151.9, 169.1; HRMS (ESI, +ve) m/z: calcd. for C19H27NO6Na 388.1736, found 
388.1716 (M+Na)
+





To a solution of benzyl 2-(bis(tert-butoxycarbonyl)amino)acetate (1.35 g, 3.7 mmol, 1 
equiv.) in methanol (20 mL) was added catalytic palladium/carbon under an atmosphere 
of hydrogen and stirred at room temperature for 16 hours. Filtration through celite and 
concentrating in vacuo affords a cream solid. This solid was taken up in ether (100 mL) 
and washed with saturated sodium bicarbonate solution (3 × 50 mL). The aqueous was 
acidified with 1M HCl solution to pH 1, and extracted with ether, dried over MgSO4, 
filtered and concentrated in vacuo to afford the title compound as a colourless 
crystalline product (1.01 g, 100%). MP: 115 – 117 °C; Lit: 113.5 – 114 °C; 1H NMR 
(500 MHz, CDCl3) : 1.47 (s, 18H, (CH3)3COCON), 4.36 (s, 2H, NCH2CO2), 11.18 (br, 
1H, CO2H); 
13
C NMR (125 MHz, CDCl3) : 27.9, 47.0, 83.4, 151.7, 175.2; HRMS 
(ESI, +ve) m/z: calcd. for C12H21NO6Na 298.1267, found 298.1260. All analytical data 
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(E)-3-Methoxyallyl 2-(tert-butoxycarbonyl(methyl)amino)acetate (306) 
 
EDCi.HCl (3.81 g, 19.9 mmol), triethylamine (2.75 mL, 19.9 mmol), Boc-Sar-OH 294 
(3.76 g, 19.9 mmol), catalytic DMAP and (E)-3-(methoxy)prop-2-enol 224 (0.88 g, 9.94 
mmol) were combined according to general procedure 3, to afford the title compound as 
a yellow oil (3.79 g, 77%, 1.1:1 rotamers). FTIR (film/cm
-1) υmax: 3006.0, 2976.4, 
2933.5, 2841.2, 1746.0, 1695.0, 1653.9; 
1
H NMR (500 MHz, CDCl3) : 1.42 & 1.47 
(2s, 9H, (CH3)3COCON), 2.91 & 2.93 (2s, 3H, N(CH3)CH2CO2), 3.57 (s, 3H, 
OCH2CH=CHOCH3), 3.87 & 3.96 (2s, 3H, NCH2CO2), 4.57 (app. dd, 2H, J = 7.9, 2.9 
Hz, OCH2CH=CHO), 4.88 – 4.96 (m, 1H, OCH2CH=CHO), 6.64 (app. t, 1H, J = 11.3 
Hz, OCH2CH=CHO); 
13
C NMR (125 MHz, CDCl3) : 28.2, 28.4, 35.5, 35.6, 50.4, 51.2, 
56.1, 63.2, 80.1, 96.6, 153.5, 153.7, 155.5, 156.1, 169.9 (×2); HRMS (ESI, +ve) m/z: 




(E)-3-Methoxyallyl 2-(methoxycarbonyl(methyl)amino)acetate (307) 
 
EDCi.HCl (1.48 g, 7.74 mmol), triethylamine (1.1 mL, 7.74 mmol), 2-
(methoxycarbonyl(methyl)amino)acetic acid 295 (1.14 g, 7.74 mmol), catalytic DMAP 
and 3-methoxyprop-2-en-1-ol 224 (0.34 g, 3.89 mmol) were combined according to 
general procedure 3, to afford the title compound as a yellow oil (0.73 g, 87%, 1.2:1 
rotamers). FTIR (film/cm
-1) υmax: 2958.4, 2839.0, 1744.2, 1701.0, 1654.0; 
1
H NMR 
(500 MHz, CDCl3) : 2.96 & 2.99 (2s, 3H, NCH3), 3.58 (s, 3H, OCH2CH=CHOCH3), 
3.69 & 3.74 (2s, 3H, CH3OCON), 3.95 & 4.02 (2s, 2H, NCH2CO2), 4.58 (d, 2H, J = 7.6 
Hz, OCH2CH=CHOCH3), 4.93 (dt, 1H, J = 12.5, 7.6 Hz, OCH2CH=CHOCH3), 6.65 (d, 
1H, J = 12.5 Hz, OCH2CH=CHOCH3); 
13
C NMR (125 MHz, CDCl3) : 35.2, 35.9, 
50.5, 50.7, 52.9 (×2), 61.1 (×2), 63.3, 96.5 (×2), 153.6, 153.7, 156.7, 157.3, 169.5, 
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(E)-3-Methoxyallyl 2-(((benzyloxy)carbonyl)(methyl)amino)acetate (308) 
 
EDCi.HCl (1.41 g, 7.35 mmol), triethylamine (1.0 mL, 7.35 mmol), 2-
((benzyloxycarbonyl)(methyl)amino)acetic acid 296 (1.604 g, 7.35 mmol), catalytic 
DMAP and 3-methoxyprop-2-en-1-ol 224 (0.32 g, 3.68 mmol) were combined 
according to general procedure 3, to afford the title compound as a yellow oil (1.05 g, 
97%, 1.2:1 rotamers). FTIR (film/cm
-1) υmax: 3015.2, 2985.9, 2843.7, 1734.2, 1695.0, 
1659.3; 
1
H NMR (500 MHz, CDCl3) : 3.01 & 3.02 (2s, 3H, NCH3), 3.55 & 3.58 (2s, 
3H, OCH2CH=CHOCH3), 3.99 & 4.05 (2s, 2H, NCH2CO2), 4.54 & 4.59 (2d, 2H, J = 
7.9 Hz, OCH2CH=CHOCH3), 4.87 & 4.92 (2dt, 1H, J = 12.6, 7.9 Hz, 
OCH2CH=CHOCH3), 5.14 & 5.17 (2s, 2H, PhCH2O), 6.64 (app. t, 1H, J = 12.6 Hz, 
OCH2CH=CHOCH3), 7.29 – 7.39 (m, 5H, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) : 
35.3, 36.1, 50.7, 50.8, 56.1, 63.4 (×2), 67.4 (×2), 67.5, 96.4, 96.5, 127.7, 127.8, 128.0 
(×2), 128.4, 128.5, 136.6 (×2), 153.7 (×2), 156.1, 156.7, 169.5, 169.6; HRMS (ESI, 




(E)-3-Methoxyallyl 2-(N,4-dimethylphenylsulfonamido)acetate (309) 
 
EDCi.HCl (1.61 g, 8.40 mmol), triethylamine (1.2 mL, 8.40 mmol), 2-(N,4-
dimethylphenylsulfonamido)acetic acid 297 (2.07 g, 8.40 mmol), catalytic DMAP and 
(E)-3-(methoxy)prop-2-enol 224 (0.38 g, 4.20 mmol) were combined according to 
general procedure 3, to afford the title compound as a yellow oil (0.80 g, 60%). FTIR 
(film/cm
-1) υmax: 2963.7, 2938.1, 2891.0, 2837.7, 1747.1, 1654.7; 
1
H NMR (500 MHz, 
CDCl3) : 2.42 (s, 3H, CH3C6H4SO2), 2.86 (s, 3H, NCH3), 3.55 (2, 3H, 
OCH2CH=CHOCH3), 3.94, (s, 2H, NCH2CO2), 4.48 (d, 2H, J = 8.1 Hz, 
OCH2CH=CHO), 4.84 (dt, 1H, J = 12.5, 8.1 Hz, OCH2CH=CHO), 6.56 (d, 1H, J = 12.5 
Hz, OCH2CH=CHO), 7.30 (m, 2H, Ar-H Ph), 7.69 (m, 2H, Ar-H Ph); 
13
C NMR (125 
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MHz, CDCl3) : 21.5, 35.7, 51.1, 56.2, 63.5, 96.3, 127.5, 129.6, 135.2, 143.5, 153.8, 





(E)-3-Methoxyallyl 2-(N-methylacetamido)acetate (310) 
 
EDCi.HCl (0.76 g, 3.96 mmol), triethylamine (0.55 mL, 3.96 mmol), 2-(N-
methylacetamido)acetic acid 299 (0.52 g, 3.96 mmol), catalytic DMAP and (E)-3-
(methoxy)prop-2-enol 224 (0.18 g, 1.98 mmol) were combined according to general 
procedure 3, to afford the title compound as a yellow oil (0.23 g, 73%, 2.5:1 rotamers). 
FTIR (film/cm
-1
) υmax: 3006.0, 2977.0, 2933.5, 2879.8, 1703.6, 1695.1, 1669.7; 
1
H 
NMR (500 MHz, CDCl3) : 2.05 & 2.15 (2s, 3H, CH3CON), 2.97 & 3.08 (2s, 3H, 
NCH3), 3.58 & 3.59 (2s, 3H, OCH2CH=CHOCH3), 4.01 & 4.12 (2s, 2H, NCH2CO2), 
4.57 & 4.61 (2d, 2H, J = 8.0 Hz, OCH2CH=CHOCH3), 4.89 – 4.96 (m, 1H, 
OCH2CH=CHOCH3), 6.62 – 6.68 (m, 1H, OCH2CH=CHOCH3); 
13
C NMR (125 MHz, 
CDCl3) : 21.3, 21.4, 34.7, 37.2, 49.2, 52.6, 56.1, 56.2, 63.4, 63.8, 96.2, 96.6, 153.6, 
154.2, 168.9, 169.3, 171.0, 171.3; HRMS (ESI, +ve) m/z: calcd. for C9H16NO4Na 




(E)-3-Methoxyallyl 2-(allyl(tert-butoxycarbonyl)amino)acetate (311) 
 
EDCi.HCl (0.60 g, 3.15 mmol), triethylamine (0.45 mL, 3.15 mmol), 2-(allyl(tert-
butoxycarbonyl)amino)acetic acid 303 (0.52 g, 3.96 mmol), catalytic DMAP and (E)-3-
(methoxy)prop-2-enol 224 (0.18 g, 1.98 mmol) were combined according to general 
procedure 3, to afford the title compound as a yellow oil (0.34 g, 60%, 1:1 rotamers). 
FTIR (film/cm
-1) υmax: 3006.1, 2963.9, 2945.4, 1739.7, 1698.9, 1650.4; 
1
H NMR (500 
MHz, CDCl3) : 1.44 & 1.47 (2s, 9H, (CH3)3COCON), 3.58 (s, 3H, 
OCH2CH=CHOCH3), 3.82 – 3.97 (m, 4H, NCH2CO2 & NCH2CH=CH2), 4.56 (d, 2H, J 
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= 7.6 Hz, OCH2CH=CHOCH3), 4.89 – 4.96 (m, 1H, OCH2CH=CHOCH3), 5.11 – 5.19 
(m, 2H, NCH2CH=CH2), 5.75 – 5.84 (m, 1H, NCH2CH=CH2), 6.65 (app. t, 1H, J = 11.6 
Hz, OCH2CH=CHOCH3); 
13
C NMR (125 MHz, CDCl3) : 28.2, 28.3, 47.8, 48.2, 50.3, 
50.7, 56.1(×2), 63.1, 63.2, 80.3 (×2), 96.7, 96.9, 116.8, 117.6, 133.7, 133.8, 153.5, 
153.7, 155.2, 155.6, 170.0, 170.1; HRMS (ESI, +ve) m/z: calcd. for C14H23NO5Na 




(E)-3-Methoxyallyl 2-(benzyl(tert-butoxycarbonyl)amino)acetate (312) 
 
EDCi.HCl (0.92 g, 4.81 mmol), triethylamine (0.66 mL, 4.81 mmol), 2-(benzyl(tert-
butoxycarbonyl)amino)acetic acid (1.28 g, 4.81 mmol), catalytic DMAP and (E)-3-
(methoxy)prop-2-enol 224 (0.21 g, 2.41 mmol) were combined according to general 
procedure 3, to afford the title compound as a yellow oil. (0.69 g, 85%, 1.2:1 rotamers). 
FTIR (film/cm
-1) υmax: 2976.8, 2939.3, 2836.4, 1745.2, 1697.0, 1654.0; 
1
H NMR (500 
MHz, CDCl3) : 1.47 & 1.48 (2s, 9H, (CH3)3COCON), 3.57 (s, 3H, 
OCH2CH=CHOCH3), 3.77 & 3.92 (2s, 2H, NCH2CO2), 4.50 – 4.56 (m, 4H, 
OCH2CH=CHOCH3 & PhCH2N), 4.86 – 4.92 (m, 1H, OCH2CH=CHOCH3), 6.63 (dd, 
1H, J = 12.9, 4.4 Hz, OCH2CH=CHOCH3), 7.21 – 7.35 (5H, m, Ar-H Ph); 
13
C NMR 
(125 MHz, CDCl3) : 28.3 (×2), 47.8, 48.2, 51.0, 51.5, 56.1(×2), 63.2 (×2), 80.5, 80.7, 
96.6 (×2), 127.4, 127.5 (×2), 128.1 (×2), 128.6 (×2), 137.3, 137.6, 153.5, 153.7, 155.6, 





(E)-3-Methoxyallyl 2-(dibenzylamino)acetate (313) 
 
EDCi.HCl (0.98 g, 5.12 mmol), triethylamine (0.72 mL, 5.12 mmol), 2-
(dibenzylamino)acetic acid 304 (1.34 g, 5.12 mmol), catalytic DMAP and 3-
methoxyprop-2-en-1-ol 224 (0.23 g, 2.60 mmol) were combined according to general 
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procedure 3, to afford the title compound as a cream oil (0.68 g, 76%). FTIR (film/cm
-1
) 
υmax: 3004.2, 3000.1, 2967.1, 1743.1, 1701.0, 1655.0; 
1
H NMR (500 MHz, CDCl3) : 
3.21 (s, 2H, NCH2CO2), 3.50 (s, 3H, OCH2CH=CHOCH3), 3.74 (s, 4H, PhCH2N), 4.45 
(d, 2H, J = 7.7 Hz, OCH2CH=CHO), 4.84 (dt, 1H, J = 12.5, 7.7 Hz, OCH2CH=CHO), 
6.57 (d, 1H, J = 12.5 Hz, OCH2CH=CHO), 7.14 – 7.34 (m, 10H, Ar-H Ph); 
13
C NMR 
(125 MHz, CDCl3) : 54.0, 56.5, 58.1, 62.8, 97.4, 127.5, 128.7, 129.3, 139.4, 153.8, 





(E)-3-Methoxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate (314) 
 
EDCi.HCl (1.01 g, 5.27 mmol), triethylamine (0.74 mL, 5.27 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (1.15 g, 5.27 mmol), catalytic DMAP and (E)-3-
methoxyprop-2-enol 224 (0.31 g, 2.63 mmol) were combined according to general 
procedure 3 to afford the title compound as a yellow oil (0.85 g, 70%). FTIR (film/cm
-1
) 
υmax: 2980.8, 2936.5, 1732.0, 1697.3; 
1
H NMR (500 MHz, CDCl3) : 1.49 (s, 18H, 
(CH3)3COCON), 3.55 (s, 3H, OCH2CH=CHOCH3), 4.30 (s, 2H, NCH2CO2), 4.56 (d, 
2H, J = 7.9 Hz, OCH2CH=CHOCH3), 4.91 (dt, 1H, J = 12.7, 7.9 Hz, 
OCH2CH=CHOCH3), 6.63 (d, 1H, J = 12.7 Hz, OCH2CH=CHOCH3); 
13
C NMR (125 
MHz, CDCl3) : 28.0, 47.4, 56.1, 63.3, 83.0, 96.6, 151.9, 153.6, 169.2; HRMS (ESI, 




(S,E)-1-tert-Butyl 2-(3-methoxyallyl) pyrrolidine-1,2-dicarboxylate (315) 
 
EDCi.HCl (1.52 g, 7.95 mmol), triethylamine (1.10 mL, 7.95 mmol), Boc-L-Pro-OH 
(1.71 g, 7.95 mmol), catalytic DMAP and (E)-3-methoxyprop-2-enol 224 (0.35 g, 3.97 
mmol) were combined according to general procedure 3. Purifcation was achieved by 
flash chromatography (4:1 Pet/EtOAC + 2% NEt3) to afford the title compound as a 
colourless oil (0.73 g, 65%).[] 20D
 
-54° (c 1, DCM); FTIR (film/cm
-1) υmax: 3072.0, 
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2976.1, 2882.9, 1744.7, 1698.3, 1656.2; 
1
H NMR (500 MHz, CDCl3) : 1.35 & 1.40 
(2s, 9H, (CH3)3COCON), 1.72 – 2.23 (m, 4H, CH2CH2CH), 3.23 – 3.55 (m, 2H, NCH2), 
3.50 & 3.51 (2s, 3H, OCH3), 4.08 – 4.17 & 4.19 – 4.27 (2m, 1H, NCH), 4.44 – 4.55 (m, 
2H, OCH2CH=CHO), 4.78 – 4.92 (m, 1H, OCH2CH=CHO), 6.56 & 6.58 (2d, 1H, J = 
12.6 Hz, OCH2CH=CHO); 
13
C NMR (125 MHz, CDCl3) : 14.4, 14.5, 24.0, 24.7, 28.7, 
28.8, 30.2, 31.2, 46.7, 46.9, 59.3, 59.6, 60.8, 63.4, 77.0, 77.4, 77.6, 77.8, 80.0, 80.2, 





(E)-But-2-enyl 2-(2,2,2-trifluoro-N-methylacetamido)acetate (316) 
 
EDCi.HCl (0.21 g, 1.10 mmol), triethylamine (0.15 mL, 1.10 mmol), 2-(2,2,2-trifluoro-
N-methylacetamido)acetic acid 298 (0.20 g, 1.10 mmol), catalytic DMAP and crotyl 
alcohol 226 (0.05 mL, 0.55 mmol) were combined according to general procedure 3, 
with a reaction time of 48 hours, to afford the title compound as a yellow oil. (0.08 g, 
60%, 2.4:1 rotamers). FTIR (film/cm
-1) υmax: 3022.6, 2951.3, 1747.9, 1694.6; 
1
H NMR 
(500 MHz, CDCl3) : 1.76 (d, 3H, J = 6.3 Hz, OCH2CH=CHCH3), 3.13 & 3.24 (2s, 3H, 
NCH3), 4.19 (s, 2H, NCH2CO2), 4.63 (app. t, 2H, J = 6.7 Hz, OCH2CH=CHCH3), 5.57 
– 5.65 (m, 1H, OCH2CH=CHCH3), 5.81 – 5.91 (m, 1H, OCH2CH=CHCH3); 
13
C NMR 
(125 MHz, CDCl3) : 17.8, 36.2, 50.5, 66.4, 66.6, 111.9, 112.0, 114.8, 114.9, 117.6, 
117.7, 120.5, 120.6, 124.0, 124.2, 132.6, 132.9, 157.7 (q, J = 37.2 Hz), 167.3, 167.4; 




(E)-3-Isopropoxyallyl 2-((tert-butoxycarbonyl)(methyl)amino)acetate (320) 
 
EDCi.HCl (0.68 g, 3.50 mmol), triethylamine (0.48 mL, 3.50 mmol), Boc-Sar-OH 294 
(0.68 g, 3.5 mmol), catalytic DMAP and 3-isopropoxyprop-2-en-1-ol 248 (0.21 g, 1.75 
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mmol) were combined according to general procedure 3 omitting the citric acid wash, to 
afford the title compound as a colourless oil (0.25 g, 49%, 1:1 rotamers). FTIR 
(film/cm
-1) υmax: 2977.4, 2939.1, 2878.8, 1744.3, 1701.7, 1668.1; 
1
H NMR (500 MHz, 
CDCl3) : 1.16 (d, 6H, J = 6.0 Hz, OCH(CH3)2), 1.35 & 1.40 (2s, 9H, (CH3)3COCON), 
2.84 & 2.85 (2s, 3H, NCH3), 3.79 & 3.88 (2s, 2H, NCH2CO2), 3.98 (sept, 1H, J = 6.0 
Hz, OCH(CH3)2), 4.47 (d, 2H. J = 8.5 Hz, OCH2CH=CHO), 4.86 – 4.97 (m, 1H, 
OCH2CH=CHO), 6.40 (dd, 1H, J = 12.5, 6.3 Hz, OCH2CH=CHO); 
13
C NMR (125 
MHz, CDCl3) : 22.4, 28.4, 35.9, 52.2, 63.7, 73.6, 80.4, 99.1, 136.5, 152.2, 170.2; 




(E)-3-Isopropoxyallyl 2-(methoxycarbonyl(methyl)amino)acetate (321) 
 
EDCi.HCl (1.20 g, 6.26 mmol), triethylamine (0.90 mL, 6.26 mmol), 2-
(methoxycarbonyl(methyl)amino)acetic acid 295 (0.92 g, 6.26 mmol), catalytic DMAP 
and 3-isopropoxyprop-2-en-1-ol 248 (0.34 g, 3.12 mmol) were combined according to 
general procedure 3 omitting the citric acid wash, to afford the title compound as a 
yellow oil. (0.36 g, 47%, 1.1:1 rotamers) FTIR (film/cm
-1) υmax: 2977.0, 2933.5, 2879.8, 
1745.4, 1703.6, 1669.7; 
1
H NMR (500 MHz, CDCl3) : 1.25 (d, 6H, J = 6.1 Hz, 
OCH2CH=CHOCH(CH3)2), 2.96 & 2.98 (2s, 3H, NCH3), 3.69 & 3.73 (2s, 3H, 
CH3OCON), 3.95 & 4.02 (2s, 2H NCH2CO2), 4.07 (quin, 1H, J = 6.1 Hz, 
OCH2CH=CHOCH(CH3)2), 4.56 (d, 2H, J = 8.0 Hz, OCH2CH=CHOCH(CH3)2), 5.01 
(dt, 1H, J = 12.4, 8.0 Hz, OCH2CH=CHOCH(CH3)2), 6.48 (dd, 1H, J = 12.4, 5.3 Hz, 
OCH2CH=CHOCH(CH3)2); 
13
C NMR (125 MHz, CDCl3) : 22.0, 35.2, 35.9, 50.6, 
50.8, 52.9, 53.0, 63.6, 73.4 (×2), 98.6, 151.8, 151.9, 157.4, 169.5, 169.6; HRMS (ESI, 
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(E)-3-Isopropyloxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate (322) 
 
EDCi.HCl (0.79 g, 4.12 mmol), triethylamine (0.60 mL, 4.12 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (1.13 g, 4.12 mmol), catalytic DMAP and (E)-3-
(isopropoxy)prop-2-enol 248 (0.24 g, 2.06 mmol) were combined according to general 
procedure 3 omitting the citric acid wash, to afford the title compound as a brown oil 
(0.72 g, 94%). FTIR (film/cm
-1) υmax: 2978.5, 2936.4, 1757.1, 1736.3, 1697.0, 1671.0; 
1
H NMR (500 MHz, CD2Cl2) : 1.21 (d, 6H, J = 6.3 Hz, (CH3)2CHO), 1.49 (s, 18H, 
(CH3)3COCON), 4.12 (sept, 1H, J = 6.3 Hz, (CH3)2CHO), 4.27 (s, 2H, NCH2CO2), 4.55 
(d, 2H, J = 7.8 Hz, OCH2CH=CHO), 4.97 (dt, 1H, J = 12.8, 7.8 Hz, OCH2CH=CHO), 
6.62 (d, 1H, J = 12.8 Hz, OCH2CH=CHO); 
13
C NMR (125 MHz, CD2Cl2) : 21.4, 27.3, 
47.1, 63.1, 72.9, 82.1, 98.6, 151.8, 152.0, 168.8; HRMS (ESI, +ve) m/z: calcd. for 







(E)-3-Methoxyallyl 2-((tert-butoxycarbonyl)(methyl)amino)acetate 306 (0.13 g, 0.49 
mmol), TMSCl (0.08 mL, 0.64 mmol) and LiHMDS (0.64 mL, 0.64 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (8:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.07 g, 73%, dr 2:1 obtained as a mixture of 2:1 
rotamers). FTIR (film/cm
-1) υmax: 3012.4, 2998.6, 1704.2, 1659.4; 
1
H NMR (500 MHz, 
CDCl3) syn-323: 1.42 – 1.45 (m, 9H, (CH3)3COCON), 2.84 - 2.94 (m, 3H, NCH3), 
3.27 – 3.30 (m, 3H, OCH3), 3.73 & 3.74 (2s, 3H, CO2CH3), 4.02 – 4.25 (m, 1H, 
H2C=CHCHOCH3), 4.31 - 5.04 (4 app. d, 1H, J = 5.4 Hz, NCHCO2), 5.28 – 5.36 (m, 
2H, H2C=CHCHOCH3), 5.68 (app. ddd, 1H, J = 6.9, 6.5, 3.5 Hz, H2C=CHCHOCH3); 
13
C NMR (125 MHz, CDCl3)  syn-323: 28.3 (×2), 32.4, 32.8, 51.9, 52.0, 57.1, 57.4, 
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62.5, 62.7, 79.9, 80.2, 81.8, 82.0, 118.6, 119.1, 133.9, 134.4, 155.5, 156.6, 170.1, 170.3. 







(E)-3-Methoxyallyl 2-((methoxycarbonyl)(methyl)amino)acetate 307 (0.11 g, 0.52 
mmol), TMSCl (0.09 mL, 0.68 mmol) and LiHMDS (0.68 mL, 0.68 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (8:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.05 g, 42% dr 1:1 obtained as a mixture of 2:1 rotamers). 
FTIR (film/cm
-1) υmax: 2998.2, 2997.7, 1708.2, 1657.4; 
1
H NMR (500 MHz, CDCl3) 
syn-324: 2.88 & 2.99 (2s, 3H, NCH3), 3.28 & 3.30 (2s, 3H, OCH3), 3.66 – 3.76 (m, 
6H, CO2CH3 & NCO2CH3), 4.01 – 4.28 (m, 1H, H2C=CHCHO), 4.55 – 5.08 (app. d, 
1H, J = 5.4 Hz, NCHCO2), 5.32 – 5.39 (m, 2H, H2C=CHCHO), 5.63 – 5.78 (m, 1H, 
H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3)  syn-324: 32.4 (×2), 52.1, 53.0, 56.7, 
57.5, 61.9, 62.1, 81.4,  81.5, 81.9 (×2), 119.0, 120.2, 133.7, 134.6, 156.5, 158.1, 170.1, 








(E)-3-Methoxyallyl 2-((benzyloxycarbonyl)(methyl)amino)acetate 308 (0.12 g, 0.39 
mmol), TMSCl (0.07 mL, 0.52 mmol) and LiHMDS (0.52 mL, 0.52 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (8:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil. (0.07 g, 41%, dr 2:1 obtained as a mixture of 2:1 
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rotamers). FTIR (film/cm
-1) υmax: 3014.2, 2988.7, 2985.3, 1704.5, 1698.2; 
1
H NMR 
(500 MHz, CDCl3) syn-325: 2.91 & 2.93 (2s, 3H, NCH3), 3.29 & 3.30 (2s, 3H, 
OCH3), 3.70 & 3.76 (2s, 3H, CO2CH3), 4.00 – 4.29 (m, 1H, H2C=CHCHO), 4.60 – 5.10 
(4 app. d, 1H, J = 8.6 Hz, NCHCO2), 5.11 – 5.19 (m, 2H, PhCH2O), 5.27 – 5.38 (m, 2H, 
H2C=CHCHO), 5.54 – 5.77 (m, 1H, H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3)  
syn-325: 32.6, 32.7, 52.1, 52.2, 56.7, 57.2, 61.6, 62.0, 67.4, 67.5, 81.5, 81.9, 119.0, 
119.5, 120.3, 120.6, 127.7, 127.9, 133.7, 134.0, 136.5, 136.6, 156.2, 156.6, 169.7, 








(E)-3-Methoxyallyl 2-(N,4-dimethylphenylsulfonamido)acetate 309 (0.17 g, 0.53 
mmol), TMSCl (0.09 mL, 0.69 mmol) and LiHMDS (0.69 mL, 0.69 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (8:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.12 g, 70% dr 1:1). FTIR (film/cm
-1) υmax: 2952.4, 
2944.8, 2830.0, 1742.5, 1598.6; 
1
H NMR (500 MHz, CDCl3) syn-326: 2.43 (s, 3H, 
CH3Ph), 2.88 (s, 3H, NCH3), 3.25 (s, 3H, OCH3), 3.50 (s, 3H, CO2CH3), 3.88 (app. t, 
1H, J = 9.2 Hz, H2C=CHCHO), 4.59 (d, 1H, J = 9.2 Hz, NCHCO2), 5.31 – 5.38 (m, 2H, 
H2C=CHCHO), 5.70 – 5.78 (m, 1H, H2C=CHCHO), 7.27 – 7.29 (m, 2H, Ar-H Ph), 7.66 
– 7.68 (m, 2H, Ar-H Ph); 13C NMR (125 MHz, CDCl3)  syn-326: 21.5, 31.0, 51.9, 
56.7, 61.5, 81.7, 120.7, 127.5, 129.4, 134.2, 136.0, 143.4, 169.1; HRMS (ESI, +ve) m/z: 
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(±)-(2R,3S)-Methyl 3-methoxy-2-(N-methylacetamido)pent-4-enoate (327) 
 
(E)-3-Methoxyallyl 2-(N-methylacetamido)acetate 310 (0.10 g, 0.48 mmol), TMSCl 
(0.08 mL, 0.62 mmol) and LiHMDS (0.62 mL, 0.62 mmol) were combined according to 
general procedure 6. Treatment with diazomethane and purification by flash 
chromatography (2:1 Pet/EtOAc + 1% NEt3) afforded the title compound as a colourless 
oil (0.06 g, 58%, dr 1:1 obtained as a mixture of 1:1 rotamers). FTIR (film/cm
-1) υmax: 
2992.4, 2974.8, 1724.9, 1587.1; 
1
H NMR (500 MHz, CDCl3) syn-327: 2.10 & 2.12 
(2s, 3H, CH3CON), 2.98 & 3.02 (2s, 3H, NCH3), 3.30 &3.31 (2s, 3H, OCH3), 3.75 & 
3.76 (2s, 3H, CO2CH3), 4.03 – 4.10 (m, 1H, H2C=CHCHO), 4.29 – 4.38 (m, 1H, 
NCHCO2), 5.29 – 5.35 (m, 2H, H2C=CHCHO), 5.61 – 5.71 (m, 1H, H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3)  syn-327: 21.4, 33.9, 45.7, 57.7, 60.4, 81.9, 118.4, 133.7, 








(E)-3-Methoxyallyl 2-(allyl(tert-butoxycarbonyl)amino)acetate 311 (0.17 g, 0.59 
mmol), TMSCl (0.10 mL, 0.77 mmol) and LiHMDS (0.77 mL, 0.77 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (10:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.13 g, 73%, dr 1:1 obtained as a mixture of 1:1 
rotamers). FTIR (film/cm
-1) υmax: 3007.2, 3001.8, 2985.7, 1704.2, 1698.2, 1689.7; 
1
H 
NMR (500 MHz, CDCl3) δ syn-328: 1.43 & 1.45 (2s, 9H, (CH3)3COCON), 3.26 (s, 3H, 
OCH3), 3.71 & 3.76 (2s, 3H, CO2CH3), 4.03 – 4.10 (m, 1H, H2C=CHCHO), 4.18 – 4.20 
(m, 2H, H2C=CHCH2N), 4.31 – 4.35 (m, 1H, NCHCO2), 5.05 – 5.20 (m, 2H, 
H2C=CHCH2N), 5.28 – 5.37 (m, 2H, H2C=CHCHO), 5.72 – 5.83 (m, 1H, 
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H2C=CHCH2N), 5.87 – 5.97 (m, 1H, H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3) δ 
syn-328: 28.3, 50.0, 51.9, 56.7, 61.8, 80.3, 81.5, 115.3, 119.2, 134.5, 136.8, 156.3, 








(E)-3-Methoxyallyl 2-(benzyl(tert-butoxycarbonyl)amino)acetate 312 (0.12 g, 0.36 
mmol), TMSCl (0.06 mL, 0.46 mmol) and LiHMDS (0.46 mL, 0.46 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (10:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.07 g, 57%, dr 4:1 obtained as a mixture of 2:1 
rotamers). FTIR (film/cm
-1) υmax: 3102.5, 2998.4, 2897.5, 1715.2, 1704.8, 1695.2, 
1666.7; 
1
H NMR (500 MHz, CDCl3) δ syn-312: 1.36 & 1.47 (2s, 9H, (CH3)3COCON), 
3.17 & 3.22 (2s, 3H, OCH3), 3.57 & 3.63 (2s, 3H, CO2CH3), 4.01 – 4.94 (m, 4H, 
H2C=CHCHO, NCHCO2 & PhCH2N), 5.20 – 5.34 (m, 2H, H2C=CHCHO), 5.61 – 5.75 
(m, 1H, H2C=CHCHO), 7.19 – 7.36 (m, 5H, Ar-H Ph);
13
C NMR (125 MHz, CDCl3) δ 
syn-312: 28.1, 47.5, 52.0, 56.6, 62.3, 74.9, 81.1, 119.4, 127.0, 127.8, 128.6, 134.8, 








(E)-3-Methoxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate 314 (0.10 g, 0.28 mmol), 
TMSCl (0.07 mL, 0.55 mmol) and LiHMDS (0.55 mL, 0.55 mmol) were combined 
according to general procedure 7. Treatment with diazomethane and purification by 
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flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title compound as a 
colourless oil (0.07 g, 72%, as a single diastereomer). FTIR (film/cm
-1) υmax: 2986.3, 
2938.0, 1752.4, 1698.1, 1649.9; 
1
H NMR (500 MHz, CDCl3) δ syn-330: 1.51 (s, 18H, 
(CH3)3COCON), 3.27 (s, 3H, CHOCH3), 3.70 (s, 3H, CO2CH3), 4.18 (app. t, 1H, J = 7.8 
Hz, H2C=CHCHOCH3), 4.87 (d, 1H, J = 7.8 Hz, NCHCO2), 5.33 (dq, 1H, J = 10.4, 1.2 
Hz, H2C=CHCHOCH3), 5.42 (dq, 1H, J = 17.1, 1.2 Hz, H2C=CHCHOCH3), 5.88 (ddd, 
1H, J = 17.1, 10.4, 7.8 Hz, H2C=CHCHOCH3); 
13
C NMR (125 MHz, CDCl3) δ syn-
330: 30.0, 52.0, 56.8, 61.4, 79.1, 82.9, 118.6, 136.4, 152.2, 169.4; HRMS (ESI, +ve) 




(S)-1-tert-Butyl 2-methyl 2-((S)-1-methoxyallyl)pyrrolidine-1,2-dicarboxylate (331) 
 
(S,E)-1-tert-Butyl 2-(3-methoxyallyl) pyrrolidine-1,2-dicarboxylate 315 (0.14 g, 0.50 
mmol), TMSCl (0.13 mL, 1.00 mmol) and LiHMDS (1.00 mL, 1.00 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.14 g, 95%, as a single diastereomer as a 2:1 mixture of 
rotamers). FTIR (film/cm
-1) υmax: 3001.2, 2988.4, 2875.3, 1715.2, 1698.2; 
1
H NMR 
(500 MHz, CDCl3) δ syn-331: 1.35 & 1.37 (2s, 9H, (CH3)3COCON), 1.30 – 1.67 (m, 
4H, CH2CH2CH), 3.16 – 3.75 (m, 2H, NCH2), 3.23 & 3.25 (2s, 3H, OCH3), 3.60 & 3.61 
(2s, 3H, CO2CH3), 4.28 – 4.36 & 4.53 – 4.60 (2m, 1H, H2C=CHCHO), 5.11 – 5.33 (m, 
2H, H2C=CHCHO), 5.88 – 6.06 (m, 1H, H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3) 
δ syn-331: 23.3, 23.9, 28.8, 30.1, 32.4, 33.9, 18.8, 48.8, 48.9, 52.2, 52.3, 58.3, 58.6, 
70.2, 70.7, 79.9, 80.5, 82.0, 117.2, 117.3, 135.6, 135.7, 153.5, 154.3, 173.7 (×2); HRMS 














(E)-3-Isopropoxyallyl 2-((tert-butoxycarbonyl)(methyl)amino)acetate 320 (0.18 g, 0.62 
mmol), TMSCl (0.10 mL, 0.81 mmol) and LiHMDS (0.81 mL, 0.81 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (8:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.10 g, 62%, dr 2:1 obtained as a mixture of 2:1 
rotamers). FTIR (film/cm
-1) υmax: 2999.3, 2978.6, 1715.2, 17.04.2, 1659.8; 
1
H NMR 
(500 MHz, CDCl3) δ syn-332: 1.05 & 1.09 (2d, 6H, OCH(CH3)2), 1.42 & 1.43 (2s, 9H, 
(CH3)3COCON), 2.85 & 2.94 (2s, 3H, NCH3), 3.57 & 3.67 (2quin, 1H, J = 6.0 Hz, 
CH(CH3)2), 3.71 (s, 3H, CO2CH3), 4.25 – 4.42 (m, 1H, H2C=CHCHO), 4.48 - 4.99 (m, 
1H, NCHCO2), 5.19 – 5.34 (m, 2H, H2C=CHCHO), 5.66 – 5.79 (m, 1H, 
H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3) δ syn-332: 21.4, 28.3, 33.1, 51.7, 61.6, 
70.5, 79.7, 117.4, 135.7, 156.7, 170.3; HRMS (ESI, +ve) m/z: calcd. for C15H27NO5Na 







(E)-3-Isopropoxyallyl 2-(methoxycarbonyl(methyl)amino)acetate 321 (0.14 g, 0.58 
mmol), TMSCl (0.11 mL, 0.85 mmol) and LiHMDS (0.85 mL, 0.85 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (10:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil. (0.07 g, 66%, dr 1:1 obtained as a mixture of 2:1 
rotamers). FTIR (film/cm
-1) υmax: 3001.2, 2988.7, 1704.9, 1659.3; 
1
H NMR (500 MHz, 
CDCl3) δ: 1.04 & 1.08 (2d, 6H, J = 6.3 Hz, OCH(CH3)2), 2.87 & 3.00 (2s, 3H, NCH3), 
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3.65 – 3.67 (m, 1H, OCH(CH3)2), 3.68 (s, 3H, NCO2CH3), 3.71 (s, 3H, CO2CH3), 4.21 – 
4.52 (m, 1H, H2C=CHCHO), 4.54 -5.05 (m, 1H, NCHCO2), 5.22 – 5.34 (m, 2H, 
H2C=CHCHO), 5.64 – 5.78 (m, 1H, H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3) δ: 
21.1, 31.5, 32.8, 51.8, 61.5, 70.3, 77.9, 117.7, 135.4, 158.1, 170.1; HRMS (ESI, +ve) 







(E)-3-Isopropoxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate 322 (0.10 g, 0.31 
mmol), TMSCl (0.08 mL, 0.61 mmol) and LiHMDS (0.61 mL, 0.61 mmol) were 
combined according to general procedure 6. Treatment with diazomethane and 
purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil. (0.05 g, 50% as a single diastereomer). FTIR (film/cm
-1
) 
υmax: 2979.2, 2937.1, 1798.7, 1750.2, 1698.2; 
1
H NMR (500 MHz, CDCl3) δ: 1.09 (dd, 
6H, J = 11.0, 6.1 Hz, OCH(CH3)2), 1.51 (s, 18H, (CH3)3COCON), 3.63 (sept, 1H, J = 
6.1 Hz, OCH(CH3)2), 3.70 (s, 3H, CO2CH3), 4.41 – 4.44 (m, 1H, H2C=CHCHOCH3), 
4.80 (d, 1H, J = 9.4 Hz, NCHCO2), 5.24 (dq, 1H, J = 10.5, 0.8 Hz, H2C=CHCHO), 5.44 
(dq, 1H, J = 15.4, 0.8 Hz, H2C=CHCHO), 6.03 (ddd, 1H, J = 15.4, 10.5, 6.3 Hz, 
H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3) δ: 21.4, 28.0, 52.1, 62.1, 69.9, 74.9, 83.1, 





Methyl 2-(1,3-dioxoisoindolin-2-yl)acetate (232) 
 
To a stirred solution of phthaloyl glycine 228 (0.58 g, 2.82 mmol) in methanol (20 mL) 
was added an ethereal solution of diazomethane until a yellow colour persisted. The 
reaction was quenched with acetic acid and concentrated in vacuo. Purification was 
achieved by flash chromatography (4:1 Petrol/EtOAc) to afford the title compound as a 
colourless solid (0.36 g, 58%). MP: 111 – 113 °C, Lit: 112 – 113 °C; 1H NMR (500 
MHz, CDCl3) δ: 3.78 (s, 3H, CO2CH3), 4.46 (s, 2H, NCH2CO2), 7.74 – 7.78 (m, 2H, 
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Ar-H Phth), 7.88 – 7.91 (m, 2H, Ar-H Phth); 13C NMR (125 MHz, CDCl3) δ: 38.8, 52.7, 





Methyl 2-((tert-butoxycarbonyl)(methyl)amino)acetate (335) 
 
To a stirred solution of Boc-Sar-OH 294 (0.58 g, 3.07 mmol) in methanol (20 mL) was 
added an ethereal solution of diazomethane until a yellow colour persisted. The reaction 
was quenched with acetic acid and concentrated in vacuo. Purification was achieved by 
flash chromatography (4:1 Petrol/EtOAc) to afford the title compound as a colourless 
oil (0.46 g, 74%, 1:1 rotamers). FTIR (film/cm
-1) υmax: 2977.5, 2933.2, 1752.1, 1694.1; 
1
H NMR (500 MHz, CDCl3) δ: 1.36 & 1.41 (2s, 9H, (CH3)3COCON), 2.86 & 2.87 (2s, 
3H, NCH3), 3.67 & 3.68 (2s, 3H, CO2CH3), 3.85 & 3.92 (2s, 2H, NCH2CO2); 
13
C NMR 
(125 MHz, CDCl3) δ: 28.1, 28.2, 35.4, 50.0, 50.8, 51.8, 80.0, 155.3, 156.0, 170.3; 




Methyl 2-(bis(tert-butoxycarbonyl) amino)acetate (336) 
 
To a stirred solution of di-(tert-butoxycarbonyl)aminoacetic acid 305 (0.60 g, 2.18 
mmol) in methanol (20 mL) was added an ethereal solution of diazomethane until a 
yellow colour persisted. The reaction was quenched with acetic acid and concentrated in 
vacuo. Purification was achieved by flash chromatography (1:1 Petrol/EtOAc) to afford 
the title compound as a colourless oil (0.34 g, 54%). 
1
H NMR (500 MHz, CDCl3) δ: 
1.42 (s, 18H, (CH3)3COCON), 3.66 (s, 3H, CO2CH3), 4.25 (s, 2H, NCH2CO2); 
13
C 
NMR (125 MHz, CDCl3) δ: 27.9, 47.0, 51.9, 82.9, 151.8, 169.5. All data is in 














To a stirred solution of methyl 2-(1,3-dioxoisoindolin-2-yl)acetate 232 (0.05 g, 0.24 
mmol, 1 equiv.) in THF (0.5 mL) at -95 °C was added TMSCl (0.06 mL, 0.48 mmol, 2 
equiv.) and stirred for 10 minutes. LiHMDS (1M in THF, 0.48 mL, 0.48 mmol, 2 
equiv.) was added via syringe pump and then the solution was allowed to warm to room 
temperature. Rapid concentration in vacuo afforded the title compound as a yellow solid 
(0.06 g, 87%, Z/E 12:1). FTIR (film/cm
-1) υmax: 3119.3, 3024.9, 2977.4, 1780.6, 1719.1, 
1669.9, 1659.7; 
1
H NMR (400 MHz, CDCl3) δ Z-337: 0.22 (s, 9H, 
NCH=C(OSi(CH3)3)OCH3)), 3.80 (s, 3H, NCH=C(OSi(CH3)3)OCH3), 4.69 (s, 1H, 
NCH=C(OSi(CH3)3)OCH3), 7.73 – 7.75 (m, 2H, Ar-H Phth), 7.88 – 7.90 (m, 2H, Ar-H 
Phth); δ E-337: 0.22 (s, 9H, NCH=C(OSi(CH3)3)OCH3)), 3.81 (s, 3H, 
NCH=C(OSi(CH3)3)OCH3), 4.74 (s, 1H, NCH=C(OSi(CH3)3)OCH3), 7.73 – 7.75 (m, 
2H, Ar-H Phth), 7.88 – 7.90 (m, 2H, Ar-H Phth); 13C NMR (100 MHz, CDCl3) δ Z-337: 
5.5, 55.5, 71.8, 123.1, 132.4, 133.8, 159.6, 168.1; HRMS (ESI, +ve) m/z: calcd. for 




(Z)-tert-Butyl (2-methoxy-2-((trimethylsilyl)oxy)vinyl)(methyl)carbamate (338) 
 
To a stirred solution of methyl 2-((tert-butoxycarbonyl)(methyl)amino)acetate 235 (0.06 
g, 0.26 mmol, 1 equiv.) in THF (0.5 mL) at -95 °C was added TMSCl (0.06 mL, 0.52 
mmol, 2 equiv.) and stirred for 10 minutes. LiHMDS (1M in THF, 0.52 mL, 0.52 mmol, 
2 equiv.) was added via syringe pump and then the solution was allowed to warm to 
room temperature. Rapid concentration in vacuo afforded the title compound as a 
yellow oil (0.05 g, 81%, Z/E 2:1, 2:1 rotamers). FTIR (film/cm
-1) υmax: 2955.1, 1756.9, 
1698.7; 
1
H NMR (400 MHz, CDCl3) δ Z-338: 0.22 & 0.26 (2s, 9H, 
NCH=C(OSi(CH3)3)OCH3) 1.49 & 1.51 (2s, 9H, (CH3)3COCON), 2.99 & 3.00 (2s, 3H, 
CH3N), 3.58 & 3.60 (2s, 3H, NCH=C(OSi(CH3)3)OCH3), 4.88 & 4.93 (2br, 1H, 
NCH=C(OSi(CH3)3)OCH3); δ E-338: 0.22 & 0.26 (2s, 9H, NCH=C(OSi(CH3)3)OCH3) 
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1.49 & 1.51 (2s, 9H, (CH3)3COCON), 2.99 & 3.00 (2s, 3H, CH3N), 3.58 & 3.60 (2s, 
3H, NCH=C(OSi(CH3)3)OCH3), 4.99 & 5.08 (2br, 1H, NCH=C(OSi(CH3)3)OCH3); 
13
C 
NMR (100 MHz, CDCl3) δ Z-338: 5.5, 28.5, 55.2, 87.7, 164.1, 179.3; HRMS (ESI, +ve) 




(Z)-Bis(tert-butyl (2-methoxy-2-((trimethylsilyl)oxy)vinyl))carbamate (339) 
 
To a stirred solution of methyl 2-(bis(tert-butoxycarbonyl) amino)acetate (0.06 g, 0.22 
mmol, 1 equiv.) in THF (0.5 mL) at -78 °C was added TMSCl (0.06 mL, 0.44 mmol, 2 
equiv.) and stirred for 10 minutes. LiHMDS (1M in THF, 0.44 mL, 0.44 mmol, 2 
equiv.) was added via syringe pump and then the solution was allowed to warm to room 
temperature. Rapid concentration in vacuo afforded the title compound as a yellow oil 
(0.05 g, 51%, Z/E >25:1). FTIR (film/cm
-1) υmax: 2980.5, 2900.9, 1736.9, 1739.8, 
1700.0; 
1
H NMR (400 MHz, CDCl3) δ Z-339: 0.19 (s, 9H, NCH=C(OSi(CH3)3)OCH3), 
1.47 (s, 18H, (CH3)3COCON), 3.72 (s, 3H, NCH=C(OSi(CH3)3)OCH3), 4.33 (s, 1H, 
NCH=C(OSi(CH3)3)OCH3); 
13
C NMR (100 MHz, CDCl3) δ Z-339: 5.6, 28.1, 55.2, 





(E)-Methyl 3-(pentan-3-yloxy)acrylate (340) 
 
DABCO (0.26 g, 2.38 mmol) in THF (40 mL), 3-pentanol (2.09 g, 2.62 mmol) and 
methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (12:1 Pet/EtOAc) to 
afford the title compound as a colourless oil (3.05 g, 75%). FTIR (film/cm
-1) υmax: 
2971.6, 2944.9, 2881.6 2846.7, 1713.4, 1641.7; 
1
H NMR (500 MHz, CDCl3) : 0.90 (t, 
6H, J = 7.6 Hz, (CH3CH2)2CHO), 1.61 (quin, 4H, J = 7.6 Hz, (CH3CH2)2CHO), 3.68 (s, 
3H, CO2CH3), 3.75 (quin, 1H, J = 7.6 Hz, (CH3CH2)2CHO), 5.23 (d, 1H, J = 12.8 Hz, 
OCH=CHCO2CH3), 7.53 (d, 1H, J = 12.8 Hz, OCH=CHCO2CH3); 
13
C NMR (125 
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MHz, CDCl3) : 9.5, 26.7, 50.9, 86.9, 96.4, 163.1, 168.7; HRMS (ESI, +ve) m/z: calcd. 




(E)-Methyl 3-(cyclohexyloxy)acrylate (341) 
 
DABCO (0.27 g, 2.38 mmol) in THF (300 mL), cyclohexanol (2.62 g, 26.2 mmol) and 
methyl propiolate 232 (2.12 mL, 23.8 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (20:1 Pet/EtOAc) to 
afford the pure title compound as a colourless oil (0.99 g, 23%). FTIR (film/cm
-1) υmax: 
2937.0, 2860.6, 1707.3, 1638.3, 1619.3; 
1
H NMR (500 MHz, CDCl3) : 1.23 – 1.56 (m, 
6H, Cy-H), 1.72 – 1.76 (m, 2H, Cy-H), 1.89 – 1.93 (m, 2H, Cy-H), 3.69 (s, 3H, 
CO2CH3), 3.93 (sept, 1H, J = 4.1 Hz, CHOCH=CHCO2CH3), 5.25 (d, 1H, J = 12.7 Hz, 
OCH=CHCO2), 7.56 (d, 1H, J = 12.7 Hz, OCH=CHCO2); 
13
C NMR (125 MHz, CDCl3) 
: 23.4, 25.2, 31.8, 51.0, 81.0, 96.8, 161.8, 168.6; HRMS (ESI, +ve) m/z: calcd. for 




(E)-Methyl 3-(prop-2-ynyloxy)acrylate (342) 
 
 
DABCO (0.40 g, 3.57 mmol) in THF (300 mL), propagylic alcohol (2.3 mL, 3.93 
mmol) and methyl propiolate 232 (3.2 mL, 35.7 mmol) were combined according to 
general procedure 4. Purification was achieved by flash chromatography (10:1 
Pet/EtOAc) to afford the title compound as a colourless oil (5.10 g, 98%). FTIR 
(film/cm
-1) υmax: 3293.2, 3096.0, 2998.8, 2953.6, 2124.5, 1704.9, 1646.0, 1624.3; 
1
H 
NMR (500 MHz, CDCl3) : 2.60 (t, 1H, J = 2.6 Hz, HC≡CCH2O), 3.71 (s, 3H, 
CO2CH3), 4.53 (d, 2H, J = 2.6 Hz, HC≡CCH2O), 5.35 (d, 1H, J = 12.7 Hz, 
OCH=CHCO2CH3), 7.58 (d, 1H, J = 12.7 Hz, OCH=CHCO2CH3); 
13
C NMR (125 
MHz, CDCl3) : 51.2, 58.1, 76.6, 77.0, 98.3, 160.6, 167.6; HRMS (ESI, +ve) m/z: calcd. 
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(E)-Methyl 3-(2,6-dichlorobenzyloxy)acrylate (343) 
 
DABCO (0.27 g, 23.8 mmol) in THF (300 mL), 2,6-dichlorobenzyl alcohol (4.63 g, 
26.2 mmol) and methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to 
general procedure 4. Purification was achieved by flash chromatography (10:1 
Pet/EtOAc) to afford title compound as a colourless oil (3.82 g, 62%). FTIR (film/cm
-1
) 
υmax: 3090.0, 2951.1, 2892.8, 1706.6, 1644.1, 1620.7, 1583.0, 1565.4; 
1
H NMR (500 
MHz, CDCl3) : 3.73 (s, 3H, CO2CH3), 5.16 (s, 2H, ArCH2O), 5.39 (d, 1H, J = 12.6 Hz, 
OCH=CHCO2CH3), 7.25 – 7.28 (m, 1H, Ar-H Ph) 7.35 (s, 1H, Ar-H Ph), 7.37 (s, 1H, 
Ar-H Ph), 7.71 (d, 1H, J = 12.6 Hz, OCH=CHCO2CH3); 
13
C NMR (125 MHz, CDCl3) 
: 51.2, 67.5, 97.1, 128.5, 130.7, 131.0, 137.0, 162.1, 167.9; HRMS (ESI, +ve) m/z: 




(S,E)-Methyl 3-(1-phenylethoxy)acrylate (344) 
 
DABCO (0.26 g, 2.38 mmol) in THF (200 mL), (S)-1-phenylethanol (2.90 g, 26.2 
mmol) and methyl propiolate 232 (2.00 g, 23.8 mmol) were combined according to 
general procedure 4. Purification was achieved by flash chromatography (30:1 
Pet/EtOAc) to afford the title compound as a white solid (4.0 g, 81%). [] 20D = -113° (c 
1, DCM); MP: 38 – 39 °C; FTIR (film/cm-1) υmax: 2993.6, 2950.2, 1713.4, 1643.4; 
1
H 
NMR (500 MHz, CDCl3) : 1.60 (d, 3H, J = 7.2 Hz, OCH(CH3)Ph), 3.65 (s, 3H, 
CO2CH3), 5.04 (q, 1H, J = 7.2 Hz, OCH(CH3)Ph), 5.25 (d, 1H, J = 12.5 Hz, 
OCHCHC(O)), 7.39 – 7.29 (m, 5H, Ar-H Ph), 7.52 (d, 2H, J = 12.5 Hz, OCHCHC(O)); 
13
C NMR (125 MHz, CDCl3) : 23.4, 51.0, 80.5, 98.1, 125.7, 128.2, 128.8, 141.2, 










(E)-Methyl 3-(pentan-3-yloxy)acrylate 340 (1.32 g, 10.4 mmol) was reduced according 
to general procedure 5 to afford the title compound as a colourless oil. (1.05 g, 68%). 
FTIR (film/cm
-1) υmax: 3347.2, 2966.1, 2937.3, 2878.9, 1699.1, 1650.3. 
1
H NMR (500 
MHz, d6-acetone) : 0.89 (t, 6H, J = 7.4 Hz, (CH3CH2)2CHO), 1.55 (m, 4H, 
(CH3CH2)2CHO), 3.31 (t, 1H, J = 5.8 Hz, OCH=CHCH2OH), 3.54 (quin, 1H, J = 5.9 
Hz, (CH3CH2)2CHO), 4.00 (dd, 2H, J = 7.6, 1.0 Hz, OCH=CHCH2OH), 5.08 (dt, 1H, J 
= 12.3, 7.6 Hz, OCH=CHCH2OH), 6.37 (d, 1H, J = 12.3 Hz, OCH=CHCH2OH). 
13
C 




(E)-Methyl 3-(cyclohexyloxy)acrylate 341 (0.84 g, 4.55 mmol) was reduced according 
to the general procedure 5 to afford the title compound as a yellow oil (0.53 g, 74%). 
FTIR (film/cm
-1) υmax: 3338.1, 2932.0, 2858.9, 1669.8, 1649.4; 
1
H NMR (500 MHz, d6-
acetone) : 1.21 – 1.56 (m, 6H, Cy-H), 1.67 – 1.77 (m, 2H, Cy-H), 1.79 – 1.91 (m, 2H, 
Cy-H), 3.27 (t, 1H, J = 5.6 Hz,OCH=CHCH2OH), 3.71 – 3.79 (m, 1H, OCH), 3.91 – 
3.97 (m, 2H, OCH=CHCH2OH), 5.01 (dt, 1H, J = 12.4, 7.2 Hz, OCH=CHCH2OH), 
6.39 (d, 1H, J = 12.4 Hz, OCH=CH2OH); 
13
C NMR (125 MHz, d6-acetone) : 23.3, 




(E)-Methyl 3-(prop-2-ynyloxy)acrylate 342 (1.03 g, 7.35 mmol) was reduced according 
to general procedure 5 to afford the title compound as a colourless oil (0.63 g, 75%). 
FTIR (film/cm
-1
) υmax: 3380.5, 3289.2, 2926.0, 2869.7, 2120.7, 1671.8, 1653.0; 
1
H 
NMR (500 MHz, d6-acetone) : 2.60 (dt, 1H, J = 2.4, 0.8 Hz, HC≡CCH2O), 4.06 (d, 
2H, J = 7.2 Hz, OCH=CHCH2OH), 4.43 (d, 2H, J = 2.4 Hz, HC≡CCH2O), 5.17 (dt, 1H, 
J = 12.7, 7.2 Hz, OCH=CHCH2OH), 6.52 (d, 1H, J = 12.7 Hz, OCH=CHCH2OH); 
13
C 
NMR (125 MHz, d6-acetone) : 57.0, 60.1, 75.3, 78.5, 105.4, 148.1. 




(E)-Methyl 3-(2,6-dichlorobenzyloxy)acrylate 343 (1.25 g, 4.79 mmol) was reduced 
according to the general procedure to afford the title compound as a white solid (0.74 g, 
67%). MP: 80 – 83 °C; FTIR (film/cm-1) υmax: 3300.2, 3078.3, 2945.4, 2863.0, 1672.2, 
1583.1, 1563.1; 
1
H NMR (500 MHz, d6-acetone) : 3.46 (t, 1H, J = 5.6 Hz, 
OCH=CHCH2OH), 4.02 (m, 2H, OCH=CHCH2OH), 5.03 (s, 2H, ArCH2O), 5.18 (dt, 
1H, J = 12.6, 7.2 Hz, OCH=CHCH2OH), 6.63 (d, 1H, J = 12.6 Hz, OCH=CHCH2OH), 
7.41 – 7.45 (m, 1H, Ar-H Ph), 7.49 – 7.51 (m, 2H, Ar-H Ph); 13C NMR (125 MHz, d6-




(S,E)-Methyl 3-(1-phenylethoxy)acrylate 344 (2.65 g, 12.9 mmol) was reduced 
according to general procedure 5 to afford the title compound as a colourless oil (1.72 g, 
75%). [] 20D
 
-68° (c 1, DCM); FTIR (film/cm
-1) υmax: 3347.2, 3086.6, 3062.8, 3031.0, 
2977.6, 2930.0, 2872.4, 1670.1, 1671.2, 1651.2; 
1
H NMR (500 MHz, d6-DMSO) : 1.42 
(d, 3H, J = 6.5 Hz, PhCH(CH3)O), 3.75 (app. t, 2H, J = 6.6 Hz, OCH=CHCH2OH), 4.38 
(t, 1H, J = 5.4 Hz, OCH=CHCH2OH), 4.88 – 4.95 (m, 2H, OCH=CCH2OH & 
PhCH(CH3)O), 6.33 (d, 1H, J = 12.4 Hz, OCH=CHCH2OH), 7.30 – 7.38 (m, 5H, Ar-H 
Ph); 
13
C NMR (125 MHz, d6-DMSO) : 23.8, 58.8, 77.7, 106.6, 126.3, 127.9, 128.9, 
143.4, 147.4. 
 
(E)-3-Ethyloxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate (350) 
 
EDCi.HCl (0.75 g, 3.91 mmol), triethylamine (0.54 mL, 3.91 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (1.07 g, 3.91 mmol) , catalytic DMAP and (E)-3-
ethoxyprop-2-enol 247 (0.20 g, 1.96 mmol) were combined according to general 
procedure 3, to afford the title compound as a yellow oil (0.64 g, 91%). FTIR (film/cm
-
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1) υmax: 2980.6, 2935.6, 1755.7, 1743.7, 1697.4, 1652.9; 
1
H NMR (500 MHz, CDCl3) : 
1.20 (t, 3H, J = 6.8 Hz, OCH2CH3), 1.43 (s, 18H, (CH3)3COCON), 3.69 (q, 2H, J = 6.8 
Hz, OCH2CH3), 4.23 (s, 2H, NCH2CO2), 4.48 (d, 2H, J = 7.9 Hz, CO2CH2CH=CHO), 
4.85 (dt, 1H, J = 12.7, 7.9 Hz, CO2CH2CH=CHO), 6.51 (d, 1H, J = 12.7 Hz, 
CO2CH2CH=CHO); 
13
C NMR (125 MHz, CDCl3) : 14.5, 27.9, 47.3, 63.4, 64.9, 82.8, 





(E)-3-(Pentan-3-yloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (351) 
 
EDCi.HCl (0.62 g, 3.23 mmol), triethylamine (0.45 mL, 3.23 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.89 g, 3.23 mmol), catalytic DMAP and (E)-3-
(pentan-3-yloxy)prop-2-enol 345 (0.24 g, 1.62 mmol) were combined according to 
general procedure 3 omitting the citric acid wash, to afford the title compound as a 
brown oil (0.49 g, 75%). FTIR (film/cm
-1) υmax: 2978.7, 2937.9, 2881.5, 1798.9, 1755.9, 
1736.3, 1697.7, 1669.7; 
1
H NMR (500 MHz, d6-acetone) : 0.90 (t, 6H, J = 7.5 Hz, 
(CH3CH2)2CHO), 1.49 – 1.50 (m, 22H, (CH3)3COCON) & (CH3CH2)2CHO)), 3.70 
(quin, 1H, J = 5.8 Hz, (CH3CH2)2CHO), 4.28 (s, 2H, NCH2CO2), 4.55 (d, 2H, J = 7.9 
Hz, OCH2CH=CHO), 4.99 (dt, 1H, J = 12.2, 7.9 Hz, OCH2CH=CHO), 6.66 (d, 1H, J = 
12.2 Hz, OCH2CH=CHO); 
13
C NMR (125 MHz, d6-acetone) : 8.9, 26.3, 27.3, 47.1, 
63.2, 82.1, 83.6, 98.2, 151.8, 153.2, 168.9; HRMS (ESI, +ve) m/z: calcd. for 




(E)-3-(Cyclohexyloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (352) 
 
EDCi.HCl (0.49 g, 2.56 mmol), triethylamine (0.36 mL, 2.56 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.70 g, 2.56 mmol), catalytic DMAP and (E)-3-
(cyclohexyloxy)prop-2-en-1-ol 346 (0.20 g, 1.28 mmol) were combined according to 
general procedure 3 omitting the citric acid wash, to afford the title compound as a 
brown oil (0.26 g, 45%). FTIR (film/cm
-1) υmax: 2998.3, 2996.2, 1798.6, 1736.9, 1697.5, 




H NMR (500 MHz, d6-acetone) : 1.21 – 1.56 (m, 24H, (CH3)3COCON & Cy-
H), 1.67 – 1.77 (m, 2H, Cy-H), 1.79 – 1.91 (m, 2H, Cy-H), 3.81 – 3.86 (m, 1H, OCH), 
4.27 (s, 2H, NCH2CO2), 4.54 (d, 2H, J = 7.9 Hz, OCH2CH=CHO), 5.00 (dt, 1H, J = 
12.4, 7.9 Hz, OCH2CH=CHO), 6.65 (d, 1H, J = 12.4 Hz, OCH2CH=CHO); 
13
C NMR 
(125 MHz, d6-acetone) : 23.3, 25.2, 27.3, 31.7, 47.1, 63.1, 78.2, 82.1, 98.6, 151.8, 





(E)-3-(Neopentyloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (353) 
 
EDCi.HCl (0.45 g, 2.33 mmol), triethylamine (0.32 mL, 2.33 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.64 g, 2.33 mmol), catalytic DMAP and (E)-3-
(neopentyloxy)prop-2-en-1-ol 250 (0.17 g, 1.16 mmol) were combined according to 
general procedure 3 to afford the title compound as a yellow oil (0.33 g, 71%). FTIR 
(film/cm
-1) υmax: 2979.9, 2868.7, 1796.5, 1756.3, 1736.1, 1698.4, 1651.9; 
1
H NMR (500 
MHz, CDCl3) : 0.92 (s, 9H, OCH2C(CH3)3), 1.48 (s, 18H, (CH3)3COCON), 3.32 (s, 
2H, OCH2C(CH3)3), 4.28 (s, 2H, NCH2CO2), 4.55 (d, 2H, J = 7.8 Hz, OCH2CH=CHO), 
4.89 (dt, 1H, J = 12.6, 7.8 Hz, OCH2CH=CHO), 6.61 (d, 1H, J = 12.6 Hz, 
OCH2CH=CHO); 
13
C NMR (125 MHz, CDCl3) : 26.4, 28.0, 43.0, 47.4, 63.6, 79.3, 
82.9, 96.6, 151.8, 153.6, 169.2; HRMS (ESI, +ve) m/z: calcd. for C20H35NO7Na 




(E)-3-(Allyloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (354) 
 
EDCi.HCl (0.53 g, 2.76 mmol), triethylamine (0.40 mL, 2.76 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.76 g, 2.76 mmol), catalytic DMAP and (E)-3-
(allyloxy)prop-2-enol 251 (0.16 g, 1.38 mmol) were combined according to general 
procedure 3, to afford the title compound as a yellow oil (0.40 g, 78%). FTIR (film/cm
-
1) υmax: 2981.3, 2936.0, 1755.8, 1735.8, 1698.0, 1673.1, 1654.7; 
1
H NMR (500 MHz, 
CDCl3) : 1.51 (s, 18H, (CH3)3COCON), 4.26 (dt, 2H, J = 5.6, 1.5 Hz, OCH2CH=CH2) 
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4.32 (s, 2H, NCH2CO2), 4.58 (d, 2H, J = 7.8 Hz, OCH2CH=CHO), 4.99 (dt, 1H, J = 
12.7, 7.8 Hz, OCH2CH=CHO), 5.26 (dq, 1H, J = 10.5, 1.5 Hz, OCH2CH=CH2), 5.34 
(dq, 1H, J = 17.2, 1.5 Hz, OCH2CH=CH2), 5.90 – 5.98 (m, 1H, OCH2CH=CH2), 6.60 
(d, 1H, J = 12.7 Hz, OCH2CH=CHO); 
13
C NMR (125 MHz, CDCl3) : 28.0, 47.4, 63.4, 
70.3, 83.0, 98.1, 118.0, 132.7, 151.9, 152.3, 169.2; HRMS (ESI, +ve) m/z: calcd. for 




(E)-3-(prop-2-yn-1-yloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (355) 
 
EDCi.HCl (1.09 g, 5.69 mmol), triethylamine (0.80 mL, 5.69 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (1.57 g, 5.69 mmol), catalytic DMAP and (E)-3-
(prop-2-yn-1-yloxy)prop-2-en-1-ol 347 (0.32 g, 2.84 mmol) were combined according 
to general procedure 3, to afford the title compound as a yellow oil (0.90 g, 85%). FTIR 
(film/cm
-1) υmax: 2980.4, 2940.0, 2146.1, 1796.1, 1753.6, 1734.5, 1696.5, 1654.5; 
1
H 
NMR (500 MHz, CDCl3) : 1.47 (s, 18H, CH3)3COCON), 2.52 (t, 1H, J = 2.5 Hz, 
OCH2C≡CH), 4.28 (s, 2H, NCH2CO2), 4.36 (d, 2H, J = 2.5 Hz, OCH2C≡CH), 4.55 (dd, 
2H, J = 7.9, 0.6 Hz, OCH2CH=CHO), 5.05 (dt, 1H, J = 12.7, 7.9 Hz, OCH2CH=CHO), 
6.55 (d, 1H, J = 12.7 Hz, OCH2CH=CHO); 
13
C NMR (125 MHz, CDCl3) : 27.9, 47.3, 
57.0, 62.9, 75.9, 77.7, 83.0, 99.5, 150.9, 151.8, 169.1; HRMS (ESI, +ve) m/z calcd. for 




(E)-3-(Benzyloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (356) 
 
EDCi.HCl (0.94 g, 4.90 mmol), triethylamine (0.70 mL, 4.90 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (1.35 g, 4.90 mmol), catalytic DMAP and (E)-3-
bezyloxyprop-2-enol 252 (0.20 g, 2.45 mmol) were combined according to general 
procedure 3. Purifcation was achieved by flash chromatography (Al2O, 10:1 
Petrol/EtOAc) to afford the title compound as a colourless oil (0.32 g, 63%) FTIR 
(film/cm
-1) υmax: 2980.4, 2938.6, 1757.7, 1736.4, 1698.3; 
1
H NMR (500 MHz, CDCl3) 
: 1.51 (s, 18H, (CH3)3COCON), 4.33 (s, 2H, NCH2CO2), 4.60 (d, 2H, J = 7.8 Hz, 
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OCH2CH=CHO), 4.78 (s, 2H, PhCH2O), 5.08 (dt, 1H, J = 12.4, 7.8 Hz, 
OCH2CH=CHO), 6.71 (d, 1H, J = 12.4 Hz, OCH2CH=CHO), 7.33 – 7.41 (m, 5H, Ar-H 
Ph); 
13
C NMR (125 MHz, CDCl3) : 28.0, 47.4, 63.4, 71.4, 83.1, 98.2, 127.7, 128.2, 
128.6, 136.2, 151.9, 152.5, 169.2; HRMS (ESI, +ve) m/z calcd. for C22H31NO7Na 




(E)-3-(4-Methoxybenzyloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (357) 
EDCi.HCl (0.44 g 2.31 mmol), triethylamine (0.32 mL, 2.31 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.64 g, 2.31 mmol), catalytic DMAP and (E)-3-
((4-methoxybenzyl)oxy)prop-2-en-1-ol 252 (0.22 g, 1.15 mmol) were combined 
according to general procedure 3 to afford the title compound as a yellow oil (0.73 g, 
70%). FTIR (film/cm
-1) υmax: 3054.2, 3026.5, 2998.7, 2968.1, 1759.6, 1731.9, 1698.3; 
1
H NMR (500 MHz, CDCl3) : 1.49 (s, 18H, (CH3)3COCON), 3.80 (s, 3H, ArOCH3), 
4.31 (s, 2H, NCH2CO2), 4.57 (d, 2H, J = 7.6 Hz, OCH2CH=CHO), 4.68 (s, 2H, 
OCH2Ar), 5.04 (dt, 1H, J = 12.6, 7.6 Hz, OCH2CH=CHO), 6.66 (d, 1H, J = 12.6 Hz, 
OCH2CH=CHO), 6.86 – 6.90 (m, 2H, Ar-H Ph), 7.24 – 7.29 (m, 2H, Ar-H Ph); 
13
C 
NMR (125 MHz, CDCl3) : 28.0, 47.4, 55.3, 63.4, 71.2, 83.0, 98.1, 114.0, 128.3, 129.4, 





(E)-3-((2,6-dichlorobenzyl)oxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (358) 
 
EDCi.HCl (0.55 g, 2.87 mmol), triethylamine (0.40 mL, 2.87 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.79 g, 2.87 mmol), catalytic DMAP and (E)-3-
(2,6-dichlorobenzyloxy)prop-2-enol 348 (0.34 g, 1.43 mmol) were combined according 
to general procedure 3 to afford the title compound as a yellow oil (0.74 g, 94%). FTIR 
(film/cm
-1) υmax: 2980.9, 2939.7, 2887.4, 1754.9, 1735.3, 1696.7, 1651.4; 
1
H NMR (500 
MHz, CDCl3) : 1.52 (s, 18H, (CH3)3COCON), 4.34 (s, 2H, NCH2CO2), 4.62 (d, 2H, J 
= 8.8 Hz, OCH2CH=CHOAr), 5.03 (s, 2H, OCH2Ar), 5.13 (dt, 1H, J = 12.7, 7.8 Hz, 
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OCH2CH=CHOAr), 6.73 (d, 1H, J = 12.7 Hz, OCH2CH=CHOAr), 7.23 – 7.36 (m, 3H, 
Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) : 28.0, 47.4, 63.2, 66.1, 83.0, 98.4, 128.4, 
130.6, 131.7, 136.9, 151.9, 152.3, 169.2; HRMS (ESI, +ve) m/z: calcd. for 




(S,E)-3-(1-Phenylethoxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (359) 
 
EDCi.HCl (0.56 g, 2.90 mmol), triethylamine (0.40 mL, 2.90 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.80 g, 2.90 mmol), catalytic DMAP and (S,E)-
3-(1-phenylethoxy)prop-2-enol 349 (0.26 g, 1.45 mmol) were combined according to 
general procedure 3 to afford the title compound as a yellow oil (0.31 g, 49%). [] 20D = -
60° (c 1 DCM); FTIR (film/cm
-1) υmax: 3002.5, 2999.3, 2985.2, 1754.6, 1734.2, 1698.2, 
1651.7; 
1
H NMR (500 MHz, d6-acetone) : 1.02 – 1.13 (m, 3H, OCH(CH3)Ph), 1.37 (s, 
18H, (CH3)3COCON), 4.14 (s, 2H, NCH2CO2), 4.38 (d, 2H, J = 7.9 Hz, 
OCH2CH=CHO), 4.85 – 4.97 (m, 2H, OCH2CH=CHO & OCH(CH3)Ph), 6.53 (d, 1H, J 
= 12.7 Hz, OCH2CH=CHO), 7.08 – 7.34 (m, 5H, Ar-H Ph); 
13
C NMR (125 MHz, d6-
acetone) : 23.9, 28.4, 46.4, 58.8, 77.7, 82.6, 106.6, 125.7, 127.9, 128.9, 143.4, 147.4, 





(E)-3-Phenoxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate (360) 
 
EDCi.HCl (0.58 g, 3.03 mmol), triethylamine (0.42 mL, 3.03 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.84 g, 3.03 mmol), catalytic DMAP and (E)-3-
phenoxyprop-2-enol 255 (0.23 g, 1.51 mmol) were combined according to general 
procedure 3 to afford the title compound as a yellow oil (0.62 g, 95%). FTIR (film/cm
-1
) 
υmax: 2980.1, 2936.0, 1755.7, 1735.9, 1697.0; 
1
H NMR (500 MHz, CDCl3) : 1.51 (s, 
18H, (CH3)3COCON), 4.35 (s, 2H, NCH2CO2), 4.67 (d, 2H, J = 7.9 Hz, 
OCH2CH=CHOPh), 5.45 (dt, 1H, J = 12.4, 7.9 Hz, OCH2CH=CHOPh), 6.82 (d, 1H, J = 
12.4 Hz, OCH2CH=CHOPh), 7.01 (d, 2H, J = 8.3 Hz, Ar-H Ph), 7.11 (t, 1H, J = 8.3 Hz, 
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Ar-H Ph), 7.34 (t, 2H, J = 8.3 Hz, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) : 28.4, 47.6, 
62.6, 83.0, 105.1, 117.2, 123.6, 130.0, 148.5, 152.0, 156.8, 169.3; HRMS (ESI, +ve) 




(E)-3-(4-Methoxyphenyloxy)allyl 2-bis(tert(butoxycarbonyl)amino)acetate (361) 
 
EDCi.HCl (0.41 g, 2.14 mmol), triethylamine (0.30 mL, 2.14 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.59 g, 2.14 mmol), catalytic DMAP and (E)-3-
(4-methoxyphenyloxy)prop-2-enol 256 (0.20 g, 1.07 mmol) were combined according 
to general procedure 3 to afford the title compound as a yellow oil (0.41 g, 79%). FTIR 
(film/cm
-1) υmax: 2979.9, 2940.1, 1796.2, 1755.6, 1735.3, 1697.3, 1673.1; 
1
H NMR (500 
MHz, CDCl3) : 1.47 (s, 18H, (CH3)3OCON), 3.75 (s, 3H, CH3OPh), 4.30 (s, 2H, 
NCH2CO2), 4.60 (d, 2H, J = 7.7 Hz, OCH2CH=CHO), 5.29 (dt, 1H, J = 12.2, 7.7 Hz, 
OCH2CH=CHO), 6.72 (d, 1H, J = 12.2 Hz, OCH2CH=CHO), 6.82 (app. dt, 2H, J = 8.9, 
2.9 Hz, Ar-H Ph), 6.90 (app. dt, 2H, J = 8.9, 2.9 Hz, Ar-H Ph); 
13
C NMR (125 MHz, 
CDCl3) : 27.9, 47.4, 55.6, 62.4, 83.1, 103.7, 114.7, 118.6, 150.0, 150.3, 151.8, 155.9, 








EDCi.HCl (0.33 g, 1.72 mmol), triethylamine (0.22 mL, 1.72 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.47 g, 1.72 mmol), catalytic DMAP and (E)-3-
bezyloxyprop-2-enol 258 (0.19 g, 0.86 mmol) were combined according to general 
procedure 3 to afford the title compound as a colourless oil (0.40 g, 96%). FTIR 
(film/cm
-1) υmax: 3013.2, 2937.1, 1795.5, 1756.0, 1735.2, 1698.6, 1612.7; 
1
H NMR (500 
MHz, CDCl3) : 1.51 (s, 18H, (CH3)3COCON), 4.36 (s, 2H, NCH2CO2), 4.69 (dd, 2H, J 
= 7.6, 1.0 Hz, OCH2CH=CHO), 5.55 (dt, 1H, J = 12.2, 7.6 Hz, OCH2CH=CHO), 6.82 
(dt, 1H , J = 12.2, 1.0 Hz, OCH2CH=CHO), 7.09 (app. d, 2H, J = 8.6 Hz, Ar-H Ph), 
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7.60 (app. d, 2H, J = 8.6 Hz, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) 28.0, 47.3, 
61.7, 83.2, 107.3, 116.9, 125.4, 125.7, 127.2 (q, J = 3.8 Hz), 146.9, 152.0, 158.9, 169.1; 




(±)-(2R,3S)-Methyl 2-(bis(tert-butoxycarbonyl)amino)-3-ethoxypent-4-enoate (363) 
 
(E)-3-Ethoxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate 350 (0.10 g, 0.27 mmol), 
TMSCl (0.07 mL, 0.53 mmol) and LiHMDS (0.53 mL, 0.53 mmol) were combined 
according to general procedure7. Treatment with diazomethane and purification by flash 
chromatography (10:1 Pet/EtOAc + 1% NEt3) afforded the title compound as a 
colourless oil. (0.07 g, 56% as a single diastereomer). FTIR (film/cm
-1) υmax: 2980.4, 
2937.3, 1794.1, 1748.2, 1698.2; 
1
H NMR (500 MHz, CDCl3) : 1.14 (t, 3H, J = 7.0 Hz, 
OCH2CH3), 1.52 (s, 18H, (CH3)3COCON), 3.30 (dq, 1H, J = 9.2, 7.0 Hz, OCH2CH3), 
3.59 (dq, 1H, J = 9.2, 7.0 Hz, OCH2CH3), 3.71 (s, 3H, CO2CH3), 4.32 (dd, 1H, J = 9.0 
2.4 Hz, H2C=CHCHO), 4.86 (d, 1H, J = 9.0 Hz, NCHCO2), 5.28 (dq, 1H, J = 10.4, 1.0 
Hz, H2C=CHCHO), 5.42 (dq, 1H, J = 17.2, 1.0 Hz, H2C=CHCHO), 5.96 (ddd, 1H, J = 
17.2, 10.4, 2.4 Hz, H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3) : 15.2, 28.0, 47.2, 
51.9, 61.6, 64.6, 82.7, 117.7, 137.2, 152.24, 169.5; HRMS (ESI, +ve) m/z: calcd. for 







(E)-3-(Pentan-3-yloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate 351 (0.22 g, 0.55 
mmol), TMSCl (0.14 mL, 1.10 mmol) and LiHMDS (1.10 mL, 1.10 mmol) were 
combined according to general procedure 7. Treatment with diazomethane and 
purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.10 g, 45% as a single diastereomer). FTIR (film/cm
-1
) 
υmax: 2980.0, 2937.7, 2879.8, 1797.7, 1751.0, 1698.6; 
1
H NMR (500 MHz, d6-acetone) 
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δ: 0.84 (t, 6H, J = 7.6 Hz, ((CH3CH2)2CHO), 1.48 – 1.51 (m, 22H, (CH3)3COCON & 
((CH3CH2)2CHO), 3.31 (quin, 1H, J = 5.9 Hz, (CH3CH2)2CHO), 3.66 (s, 3H, CO2CH3), 
4.45 (dd, 1H, J = 9.2, 2.3 Hz, H2C=CHCHO), 4.84 (d, 1H, J = 9.2 Hz, NCHCO2), 5.25 
(dd, 1H, J = 10.5, 1.7 Hz, H2C=CHCHO), 5.39 (d, 1H, J = 17.1 Hz, H2C=CHCHO), 
5.94 (ddd, 1H, J = 17.1, 10.5, 9.2 Hz, H2C=CHCHO); 
13
C NMR (125 MHz, d6-acetone) 
δ: 8.0, 9.2, 24.2, 25.7, 27.3, 51.2, 61.8, 75.0, 78.2, 82.0, 117.3, 138.5, 152.2, 168; 







(E)-3-(Neopentyloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate 353 (0.10 g, 0.25 
mmol), TMSCl (0.06 mL, 0.49 mmol) and LiHMDS (0.49 mL, 0.49 mmol) were 
combined according to general procedure 7. Treatment with diazomethane and 
purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil. (0.08 g, 80% as a single diastereomer). FTIR (film/cm
-1
) 
υmax: 2979.6, 2955.0, 1796.3, 1749.2, 1698.4; 
1
H NMR (500 MHz, CDCl3) δ: 0.88 (s, 
9H, OCH2C(CH3)3), 1.51 (s, 18H, (CH3)3COCON), 2.80 (d, 1H, J = 8.4 Hz, 
OCH2C(CH3)3), 3.23 (d, 1H, J = 8.4 Hz, OCH2C(CH3)3), 3.70 (s, 3H, CO2CH3), 4.28 
(dd, 1H, J = 9.0, 2.4 Hz, H2C=CHCHO) 4.94 (d, 1H, J = 9.0 Hz, NCHCO2), 5.30 (dd, 
1H, J = 10.3, 1.9 Hz, H2C=CHCHO), 5.43 (dt, 1H, J = 17.4, 1.9 Hz, H2C=CHCHO), 
5.90 (ddd, 1H, J = 17.4, 10.3, 8.4 Hz, H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3) δ: 
26.8, 28.1, 32.0, 51.9, 61.7, 77.3, 79.4, 82.8, 118.1, 137.6, 152.0, 169; HRMS (ESI, 
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(E)-3-Allyloxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate 354 (0.12 g, 0.21 mmol), 
TMSCl (0.05 mL, 0.41 mmol) and LiHMDS (0.41 mL, 0.41 mmol) were combined 
according to general procedure 7. Treatment with diazomethane and purification by 
flash chromatography (10:1 Pet/EtOAc + 1% NEt3) afforded the title compound as a 
colourless oil (0.08 g, 65% as a single diastereomer). FTIR (film/cm
-1) υmax: 2981.7, 
2935.6, 1747.9, 1698.3; 
1
H NMR (500 MHz, CDCl3) δ: 1.51 (s, 18H, (CH3)3COCON), 
3.70 (s, 3H, CO2CH3), 3.81 (ddt, 1H J = 12.9, 5.7, 1.6 Hz, H2C=CHCH2O), 4.07 (ddt, 
1H, J = 12.9, 5.7, 1.6 Hz, H2C=CHCH2O), 4.36 – 4.40 (m, 1H, H2C=CHCHO), 4.91 (d, 
1H, J = 8.9 Hz, NCHCO2), 5.12 (dq, 1H, J = 10.5, 1.6 Hz, H2C=CHCHO), 5.24 (dq, 
1H, J = 17.2, 1.6 Hz, H2C=CHCHO), 5.32 (dq, 1H, J = 10.5, 1.0 Hz, H2C=CHCH2), 
5.43 (dq, 1H, J = 17.2, 1.0 Hz, H2C=CHCH), 5.80 – 5.88 (m, 1H, H2C=CHCH2O), 5.94 
(ddd, 1H, J = 17.2, 10.5, 6.8 Hz, H2C=CHCHO); 
13
C NMR (125 MHz, CDCl3) δ:28.0, 
51.9, 61.5, 69.6, 74.9, 82.9, 116.4, 118.4, 134.7, 136.7, 152.2, 169.4; HRMS (ESI, +ve) 







(E)-3-(Prop-2-yn-1-yloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate 355 (0.10 g, 
0.30 mmol, 1 equiv.), TMSCl (0.10 mL, 0.89 mmol, 3 equiv.) and LiHMDS (0.89 mL, 
0.89 mmol, 3 equiv.) were combined according to general procedure 7. Treatment with 
diazomethane and purification by flash chromatography (10:1 Pet/EtOAc + 1% NEt3) 
afforded the title compound as a colourless oil (0.10 g, 71% as a single diastereomer). 
FTIR (film/cm
-1) υmax: 2979.7, 2867.7, 2182.2, 1794.0, 1749.6, 1700.7; 
1
H NMR (500 
MHz, CDCl3) : 0.16 (s, 9H, Si(CH3)3), 1.52 (s, 18H, (CH3)3COCON), 3.70 (s, 3H, 
CO2CH3), 4.05 (d, 1H, J = 15.6 Hz, OCH2C≡CSi), 4.17 (d, 1H, J = 15.6 Hz, 
OCH2C≡CSi), 4.51 (app. t, 1H, J = 8.0 Hz, H2C=CHCHO), 4.93 (d, 1H, J = 8.0 Hz, 
NCHCO2), 5.36 (d, 1H, J = 10.6 Hz, H2C=CHCHO), 5.48 (d, 1H, J = 17.2 Hz, 
H2C=CHCHO), 5.86 (ddd, 1H, J = 17.2, 10.6, 8.0 Hz, H2C=CHCHO); 
13
C NMR (125 
MHz, CDCl3) : -0.2, 28.0, 51.9, 56.6, 61.2, 76.5, 82.9, 90.9, 101.6, 119.8, 135.7, 152.1, 
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(±)-(2R,3S)-Methyl 2-(bis(tert-butoxycarbonyl)amino)-3-(benzyloxy) pent-4-enoate 
(368) 
 
(E)-3-Benzyloxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate 356 (0.09 g, 0.22 
mmol), TMSCl (0.05 mL, 0.43 mmol) and LiHMDS (0.43 mL, 0.43 mmol) were 
combined according to general procedure 7. Treatment with diazomethane and 
purification by flash chromatography (10:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil. (0.05 g, 55% as a single diastereomer). FTIR (film/cm
-1
) 
υmax: 2980.7, 2890.6, 1750.9, 1700.6; 
1
H NMR (500 MHz, CDCl3) δ: 1.45 (s, 18H, 
(CH3)3COCON), 3.71 (s, 3H, CO2CH3), 4.33 (d, 1H, J = 11.6 Hz, OCH2Ph), 4.47 (dd, 
1H, J = 9.1, 2.1 Hz, H2C=CHCHO), 4.61 (d, 1H, J = 11.6 Hz, OCH2Ph), 4.99 (d, 1H, J 
= 9.1 Hz, NCHCO2), 5.38 (dd, 1H, J = 10.4, 1.4 Hz, H2C=CHCHO), 5.49 (dd, 1H, J = 
17.3, 1.4 Hz, H2C=CHCHO), 5.89 (ddd, 1H, J = 17.3, 10.4, 9.1 Hz, H2C=CHCHO), 
7.23 – 7.39 (m, 5H, Ar-H Ph); 13C NMR (125 MHz, CDCl3) δ: 27.9, 52.0, 61.6, 70.5, 
77.2, 82.9, 118.9, 127.3, 127.7, 128.1, 136.6, 138.3, 152.3, 169.3; HRMS (ESI, +ve) 







(E)-3-(4-Methoxybenzyloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate 357 (0.14 g, 
0.31 mmol), TMSCl (0.08 mL, 0.62 mmol) and LiHMDS (0.62 mL, 0.62 mmol) were 
combined according to general procedure 7. Treatment with diazomethane and 
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purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.06 g, 40% as a single diastereomer). FTIR (film/cm
-1
) 
υmax: 3010.5, 2955.0, 1794.7, 1751.3, 1697.4; 
1
H NMR (500 MHz, CDCl3) δ: 1.45 (s, 
18H, (CH3)3COCON), 3.70 (s, 3H, OCH2PhOCH3), 3.80 (s, 3H, CO2CH3), 4.26 (d, 1H, 
J = 9.7, OCH2Ar), 4.44 (dd, 1H, J = 8.5, 6.9 Hz, H2C=CHCHO), 4.53 (d, 1H, J = 9.7 
Hz, OCH2Ar), 4.95 (d, 1H, J = 8.5 Hz, NCHCO2), 5.37 (dd, 1H, J = 10.4, 1.1 Hz, 
H2C=CHCHO), 5.47 (dd, 1H, J = 17.7, 1.1 Hz, H2C=CHCHO), 5.98 (ddd, 1H, J = 17.7, 
10.4, 6.9 Hz, H2C=CHCHO), 6.84 (d, 2H, J = 8.4 Hz, Ar-H Ph), 7.23 (d, 2H, J = 8.4 
Hz, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) δ: 27.9, 51.9, 55.2, 61.7, 65.8, 70.2, 82.9, 
113.6, 118.7, 129.3, 130.2, 130.5, 136.7, 152.2, 159.0, 169.3; HRMS (ESI, +ve) m/z: 







(E)-2,6-Dichlorobenzyloxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate 358 (0.07 g, 
0.15 mmol), TMSCl (0.04 mL, 0.30 mmol) and LiHMDS (0.30 mL, 0.30 mmol) were 
combined according to general procedure 7. Treatment with diazomethane and 
purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.06 g, 78% as a single diastereomer). FTIR (film/cm
-1
) 
υmax: 2979.9, 2933.7, 1796.6, 1749.3, 1697.7; 
1
H NMR (500 MHz, CDCl3) δ: 1.38 (s, 
18H, (CH3)3COCON), 3.70 (s, 3H, CO2CH3), 4.51 – 4.54 (m, 2H, NCHCO2 & 
H2C=CHCHO), 4.89 (dd, 2H, J = 36.6, 9.6 Hz, OCH2Ar), 5.42 (dd, 1H, J = 10.7, 0.6 
Hz, H2C=CHCHO), 5.61 (dq, 1H, J = 17.4, 0.6 Hz, H2C=CHCHO), 6.05 (ddd, 1H, J = 
17.4, 10.7, 6.9 Hz, H2C=CHCHO), 7.15 (dd, 1H, J = 8.7, 0.9 Hz, Ar-H Ph), 7.28 (d, 2H, 
J = 8.7 Hz, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) δ: 27.8, 51.9, 62.0, 65.3, 77.7, 82.6, 
118.9, 128.1, 129.7, 133.7, 136.5, 137.1, 152.0, 169.1; HRMS (ESI, +ve) m/z: calcd. for 











(S,E)-3-(1-Phenylethoxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate 359 (0.24 g, 
0.54 mmol), TMSCl (0.14 mL, 1.08 mmol) and LiHMDS (1.08 mL, 1.08 mmol) were 
combined according to general procedure 7. Treatment with diazomethane and 
purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.10 g, 42% as a 2.25:1 mixture of diastereomers). FTIR 
(film/cm
-1) υmax: 2982.7, 1789.2, 1745.6, 1696.4; 
1
H NMR (500 MHz, CDCl3) 
(2R,3S)-371 : 1.38 (d, 3H, J = 6.3 Hz, OCH(CH3)Ph), 1.52 (s, 18H, (CH3)3COCON), 
3.71 (s, 3H, CO2CH3), 4.35 (d, 1H, J = 6.2 Hz, NCHCO2), 4.56 (q, 1H, J = 6.3 Hz, 
OCH(CH3)Ph), 4.92 - 4.95 (m, 1H, H2C=CHCHO), 5.16 – 5.34 (m ,2H, H2C=CHCHO), 
5.90 (ddd, 1H, J = 17.1, 10.8, 6.7 Hz, H2C=CHCHO), 7.21 -7.36 (m, 5H, Ar-H Ph); 
(2S,3R)-371: 1.35 (d, 1H, J = 6.3 Hz, OCH(CH3)Ph), 1.52 (s, 18H, (CH3)3COCON), 
3.64 (s, 3H, CO2CH3),4.34 (d, 1H, J = 6.2 Hz, NCHCO2), 4.56 (q, 1H, J = 6.3 Hz, 
OCH(CH3)Ph), 4.92 - 4.95 (m, 1H, H2C=CHCHO), 5.37 - 5.42 (m ,2H, H2C=CHCHO), 
5.97 (ddd, 1H, J = 13.8, 10.0, 6.7 Hz, H2C=CHCHO), 7.21 -7.36 (m, 5H, Ar-H Ph); 
13
C 
NMR (125 MHz, CDCl3) (2R,3S)-371: 22.3, 28.0, 51.9, 61.8, 73.2, 75.2, 83.0, 118.0, 
126.2, 126.7, 128.0, 128.5, 137.4, 152.3, 169.4; (2S,3R)-371: 22.1, 27.9, 51.7, 
62.2,73.3, 75.6, 82.8, 118.0, 126.1, 126.8, 128.1, 128.4, 137.5, 151.8, 168.4; HRMS 








) υmax: 2914.3, 2851.5, 1796.6, 1727.8, 1644.8; 
1
H NMR (500 MHz, 
CDCl3) : 1.45 (s, 18H, (CH3)3COCON), 3.81 (s, 3H, CO2CH3), 5.58 (d, 1H, J = 10.8 
Hz, H2C=CHCH=C), 5.71 (d, 1H, J = 17.3 Hz, H2C=CHCH=C), 6.50 (dt, 1H, J = 17.3, 
10.8 Hz, H2C=CHCH=C), 7.17 (d, 1H, J = 10.8 Hz, H2C=CHCH=C); 
13
C NMR (125 
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MHz, CDCl3) : 27.8, 52.3, 83.0, 126.9, 128.0, 130.2, 136.8, 150.4, 165.0; HRMS (ESI, 




(2R,3S)-Methyl 2-(bis(tert-butoxycarbonyl)amino)-3-hydroxypent-4-enoate (373) 
 
To a stirred solution of (2R,3S)-methyl 2-(bis(tert-butoxycarbonyl)amino)-3-((S)-1-
phenylethoxy)pent-4-enoate 371 (0.08 g, 0.17 mmol) in methanol (20 mL) was added 
catalytic palladium on carbon (0.02 g) and stirred under an atmosphere of hydrogen for 
16 hours. The solution was filtered through celite and washed with another 20 mL of 
methanol, dried over Na2SO4, filtered and concentrated in vacuo to afford the title 
compound as a colourless oil (0.04 g, 73%). FTIR (film/cm
-1) υmax: 3428.0, 2980.0, 
1737.2, 1693.7; 
1
H NMR (500 MHz, CDCl3) : 1.00 (t, 3H, J = 7.6 Hz, CH3CH2), 1.49 
– 1.52 (m, 2H, CH3CH2), 1.53 (s, 18H, (CH3)3COCON), 3.78 (s, 3H, CO2CH3), 3.96 (d, 
1H, J = 9.0 Hz, NCHCO2), 4.11 – 4.17 (m, 1H, CH3CH2CHOH); 
13
C NMR (125 MHz, 
CDCl3) : 10.2, 27.5, 27.9, 52.4, 62.4, 72.5, 83.6, 153.4, 169.7; HRMS (ESI, +ve) m/z: 




(2R,3S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-hydroxypentanoate (374) 
 
To a stirred solution of (2R,3S)-methyl 2-(bis(tert-butoxycarbonyl)amino)-3-
hydroxypent-4-enoate 373 (0.07 g, 0.19 mmol, 1 equiv.) in DCM (5 mL) was added 
TFA (0.03 mL, 0.38 mmol, 2 equiv.) at 0 °C. The mixture was stirred for 30 minutes 
before concentrating in vacuo. The residue was taken up in saturated sodium 
bicarbonate solution (10 mL) and extracted with EtOAc (4 × 20 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography (2:1 Pet/EtOAc) to afford the title compound as a colourless oil. (0.04 
g, 78%). [] 20D = +3.2° (c 0.85 EtOH abs.); 
1
H NMR (500 MHz, CDCl3) : 0.94 (t, 3H, J 
= 7.0 Hz, CH3CH2), 1.42 (s, 9H, (CH3)3COCON), 1.51 – 1.55 (m, 2H, CH3CH2), 3.71 
(s, 3H, CO2CH3), 3.97 – 3.99 (m, 1H, CH3CH2CHO), 4.19 (br, 1H, OH), 4.23 (d, 1H, J 
=9.0 Hz, NCHCO2), 5.72 (br, 1H, NH); 
13
C NMR (125 MHz, CDCl3) : 10.0, 27.8, 
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(Z)-Methyl 3-methoxyacrylate ((Z)-223) 
 
To a stirred solution of silver (I) trifluoromethanesulfonate (0.29 g, 1.12 mmol, 0.1 
equiv.) in methanol (15 mL) was added methyl propiolate 232 (0.95 g, 11.2 mmol, 1 
equiv.). The solution was stirred at room temperature for 20 hours and concentrated in 
vacuo. The solution was taken up in chloroform, filtered through celite and concentrated 
to afford the title compound as a pale brown oil (1.10 g, 71%). FTIR (film/cm
-1) υmax: 
2990.0, 2950.5, 2877.1, 2833.7, 1709.4, 1646.2, 1626.2; 
1
H NMR (500 MHz, CDCl3) : 
3.65 (s, 3H, CO2CH3), 3.84 (s, 3H, CH3O), 4.82 (d, 1H, J = 7.1 Hz, 
CH3OCH=CHCO2CH3), 6.43 (d, 1H, J = 7.1 Hz, CH3OCH=CHCO2CH3);
 13
C NMR 
(125 MHz, CDCl3) : 50.8, 62.5, 95.9, 160.1, 165.6; HRMS (ESI, +ve) m/z: calcd. for 






(Z)-Methyl 3-(methoxy)acrylate (Z)-223 (0.51 g, 4.39 mmol) was reduced according to 
general procedure 5 to afford the title compound as a colourless oil (0.13 g, 33%). FTIR 
(film/cm
-1) υmax: 3337.8, 3046.0, 2936.2, 2859.6, 1662.9; 
1
H NMR (300 MHz, d6-
acetone) : 1.85 (br, 1H, CH2OH), 3.63 (s, 3H, CH3O), 4.16 (dd, 2H, J = 6.9, 1.1 Hz, 
CH3OCH=CHCH2OH), 4.64 (q, 1H, J = 6.9 Hz, CH3OCH=CHCH2OH), 6.02 (dt, 1H, J 
= 6.9, 1.2 Hz, CH3OCH=CHCH2OH); 
13
C NMR (75 MHz, d6-acetone) : 56.9, 60.6, 
106.3, 149.2. 
 
(Z)-3-Methoxyallyl 2-(1,3-dioxoisoindolin-2-yl)acetate ((Z)-229) 
 
EDCi.HCl (0.54 g, 2.95 mmol), triethylamine (0.4 mL, 2.95 mmol), phthaloyl glycine  
228 (0.58 g, 2.95 mmol), catalytic DMAP and (Z)-3-(methoxy)prop-2-enol (Z)-224 
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(0.13 g, 1.48 mmol) were combined according to general procedure 3, to afford the title 
compound as a white solid (0.24 g, 60%). MP: 55 - 58 °C; FTIR (film/cm
-1
) υmax: 
2993.7, 2880.3, 1757.6, 1736.1, 1718.0, 1671.7; 
1
H NMR (500 MHz, CDCl3) : 3.58 (s, 
3H, OCH3), 4.43 (s, 2H, NCH2CO2), 4.61 (d, 2H, J = 8.2 Hz, OCH2CH=CHO), 4.92 (dt, 
1H, J = 12.6, 8.2 Hz, OCH2CH=CHO), 6.65 (d, 1H, J = 12.6 Hz, OCH2CH=CHO), 7.77 
– 7.73 (m, 2H, Ar-H Phth), 7.91 – 7.88 (m, 2H, Ar-H Phth); 13C NMR (125 MHz, 
CDCl3) : 39.0, 56.2, 64.2, 96.3, 123.6, 132.1, 134.2, 154.0, 167.3, 167.5; HRMS (ESI, 




(Z)-3-Methoxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate ((Z)-314) 
 
EDCi.HCl (1.06 g, 5.45 mmol), triethylamine (0.76 mL, 5.45 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (1.52 g, 5.45 mmol), catalytic DMAP and (Z)-3-
methoxyprop-2-enol (Z)-224 (0.24 g, 2.72 mmol) were combined according to general 
procedure 3 to afford a yellow oil. Purification by flash chromatography (Al2O, 15:1 
Pet/EtOAc) afforded the title compound as colourless oil (0.28 g, 30%). FTIR (film/cm
-
1) υmax: 2979.6, 2937.6, 1799.3, 1756.9, 1736.0, 1697.7, 1666.7; 
1
H NMR (500 MHz, 
d6-acetone) : 1.48 (s, 18H, (CH3)3COCON), 3.65 (s, 3H, OCH3), 4.28 (s, 2H, 
NCH2CO2), 4.54 – 4.58 (m, 1H, OCH2CH=CHOCH3), 4.67 (dd, 2H, J = 7.8, 0.9 Hz, 
OCH2CH=CHOCH3), 6.21 (dt, 1H, J = 6.3, 1.1 Hz, OCH2CH=CHOCH3); 
13
C NMR 
(125 MHz, d6-acetone) : 32.4, 52.2, 63.3, 64.6, 87.3, 104.6, 156.0, 157.0, 174.1; 







(Z)-3-Methoxyallyl 2-(bis(tert-butoxycarbonyl)amino)acetate (Z)-314 (0.10 g, 0.29 
mmol), TMSCl (0.07 mL, 0.58 mmol) and LiHMDS (0.58 mL, 0.58 mmol) were 
combined according to general procedure 7. Treatment with diazomethane and 
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purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.06 g, 55%, dr 1.5:1). A small fraction of the major anti 
product was isolated for identification. FTIR (film/cm
-1) υmax: 2983.1, 2932.2, 1788.9, 
1745.9, 1695.6; 
1
H NMR (500 MHz, CDCl3) δ anti-330: 1.49 (s, 18H, (CH3)3COCON), 
3.37 (s, 3H, CHOCH3), 3.76 (s, 3H, CO2CH3), 4.28 (t, 1H, J = 8.2 Hz, 
H2C=CHCHOCH3), 4.86 (d, 1H, J = 8.2 Hz, NCHCO2), 5.25 – 5.32 (m, 2H, 
H2C=CHCHOCH3), 5.61 (ddd, 1H, J = 17.9, 9.5, 8.2 Hz, H2C=CHCHOCH3); 
13
C NMR 
(125 MHz, CDCl3) δ anti-330: 28.0, 52.2, 56.5, 60.5, 82.1, 83.3, 120.1, 133.8, 151.6, 




(Z)-2-(tert-Butoxycarbonylamino)penta-2,4-dienoic acid (383) 
 
To a stirred solution of (±)-(2R,3S)-methyl 2-(bis(tertbutoxycarbonyl)amino)-3-
methoxypent-4-enoate 330 (0.04 g, 0.11 mmol, 1 equiv.) in THF (2 mL) was added 
Potassium trimethylsilanolate (0.14 g, 1.11 mmol, 10 equiv.) and the mixture stirred at 
room temperature for 3 hours. Citric acid (0.5 M, 5 mL) was added and the biphasic 
mixture extracted with EtOAc (3 × 10 mL), washed with brine (3 × 10 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography (19:1 DCM/MeOH) to afford the title compound as a colourless oil 
(0.02 g, 100%). FTIR (film/cm
-1) υmax: 3237.1, 2985.4, 1673.9; 
1
H NMR (500 MHz, 
CDCl3) : 1.49 (s, 9H, (CH3)3COCON), 5.54 (d, 1H, J = 10.3 Hz, H2C=CHCH=C), 5.65 
(d, 1H, J = 17.8 Hz, H2C=CHCH=C), 6.44 (br, 1H, NH), 6.63 (dt, 1H, J = 17.8, 10.3 
Hz, H2C=CHCH=C), 7.06 (d, 1H, J = 10.3 Hz, H2C=CHCH=C); 
13
C NMR (125 MHz, 




To a stirred solution of lithium aluminium hydride (0.01 g, 0.26 mmol, 2 equiv.) in 
ether (7 mL) at -78 °C was added a solution of  (±)-(2R,3S)-methyl 2-
(bis(tertbutoxycarbonyl)amino)-3-methoxypent-4-enoate 330 (0.05 g, 0.13 mmol) in 
ether (3 mL). The mixture was stirred at -78 °C for 5 hours before quenching by the 
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addition of EtOAc, then poured onto ice-cold saturated Rochelle salt solution (100 mL) 
followed by the addition of further EtOAc (100 mL). The biphasic mixture was 
vigorously stirred at 0 °C for 2 hours before separating and extracting with EtOAc (3 × 
10 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo  
Purification was achieved by flash chromatography (Pet/EtOAc 10:1) to afford the title 
compound as a colourless oil (0.03 g, 60%, 2:1 rotamers). FTIR (film/cm
-1) υmax: 
3338.7, 2967.3, 2928.0, 2882.8, 1705.4, 1596.4; 
1
H NMR (500 MHz, CDCl3) : 1.49 & 
1.56 (2s, 18H, (CH3)3COCON), 3.29 – 3.32 (m, 1H, NCHCH2OH), 3.34 (s, 3H, 
CH2CHCHOCH3), 3.72 (t, 1H, J = 3.2 Hz, NCHCH2OH), 3.94 (t, 1H, J = 7.9 Hz, 
CH2CHCHOCH3), 4.14 (dd, 1H, J = 7.9, 3.2 Hz, NCHCH2OH), 4.67 (br, 1H, OH), 5.27 
– 5.34 (m, 2H, CH2CHCHO), 5.76 (ddd, 1H, J = 17.5, 9.9, 7.9 Hz, CH2CHCHO); 
13
C 
NMR (125 MHz, CDCl3) : 28.4 (×2), 56.9, 57.0, 57.3(×2), 79.4, 80.5, 119.5, 119.8, 
127.5, 127.6, 133.9, 140.2, 135.8, 135.9, 152.8; 153.2; HRMS (ESI, +ve) m/z: calcd. for 




(±)-(2R,3S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-methoxypent-4-enoate (386) 
 
To a stirred solution of (±)-(2R,3S)-methyl 2-(bis(tertbutoxycarbonyl)amino)-3-
methoxypent-4-enoate 330 (0.07 g, 0.19 mmol, 1 equiv.) in DCM (5 mL) was added 
TFA (0.03 mL, 0.38 mmol, 2 equiv.) at 0 °C. The mixture was stirred for 30 minutes 
before concentrating in vacuo. The residue was taken up in saturated sodium 
bicarbonate solution (10 mL) and extracted with EtOAc (4 × 20 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. Purification was achieved by flash 
chromatography (6:1 Pet/EtOAc) to afford the title compound as a colourless oil. (0.04 
g, 78%) FTIR (film/cm
-1) υmax: 3372.0, 2980.6, 2940.1, 1756.0, 1718.8, 1502.9; 
1
H 
NMR (500 MHz, CDCl3) : 1.45 (s, 9H, (CH3)3COCON), 3.26 (s, 3H, OCH3), 3.78 (s, 
3H, CO2CH3), 4.12 (d, 1H, J = 7.1 Hz, H2C=CHCHOCH3), 4.38 (dd, 1H, J = 7.1, 2.8 
Hz, NH), 5.24 (d, 1H, J = 9.9 Hz, NCHCO2), 5.34 – 5.39 (m, 2H, H2C=CHCHOCH3), 
5.75 (ddd, 1H, J = 17.6, 9.9, 7.1 Hz, H2C=CHCHOCH3); 
13
C NMR (125 MHz, CDCl3) 
: 28.3, 52.4, 56.9, 57.5, 79.9, 82.0, 119.6, 133.8, 155.9, 171.1; HRMS (ESI, +ve) m/z: 









To a solution of (1R,2R)-2-(allyloxy)-1-(1,3-dioxoisoindolin-2-yl)but-3-enyl acetate 
277 (0.14 g, 0.45 mmol, 1 equiv.) in DCM (5 mL) was added 
bis(tricyclohexylphosphine)benzylidine ruthenium(IV) chloride (0.02 g, 0.02 mmol, 
0.05 equiv.) and stirred at room temperature for 24 hours. The mixture was passed 
through a pad of celite and concentrated in vacuo. Purification was achieved by flash 
chromatography (6:1 Pet/EtOAc + 1% NEt3) to afford the title compound as a 
colourless oil (0.11 g, 87%, dr 10:1). FTIR (film/cm
-1) υmax: 2955.0, 2907.9, 2855.2, 
1777.4, 1746.9, 1716.3, 1614.0; 
1
H NMR (500 MHz, CDCl3) syn δ: 3.77 (s, 3H, 
CO2CH3), 4.53 - 4.61 (m, 1H, NCHCO2), 4.77 (d, 2H, J = 8.0 Hz, OCH2CH=CH), 5.51 
- 5.51 (m, 1H, OCHCH=CH), 6.02 - 6.04 (m, 1H, CH=CH), 6.18 - 6.20 (m, 1H, 
CH=CH), 7.72- 7.76 (m, 2H, Ar-H Phth), 7.86 - 7.89 (m, 2H, Ar-H Phth); anti δ: 3.80 
(s, 3H, CO2CH3), 4.53 - 4.61 (m, 1H, NCHCO2), 5.11 (d, 2H, J = 8.0 Hz, 
OCH2CH=CH), 5.65 - 5.69 (m, 1H, OCHCH=CH), 6.02 - 6.04 (m, 1H, CH=CH), 6.18 - 
6.20 (m, 1H, CH=CH), 7.72 - 7.76 (m, 2H, Ar-H Phth), 7.86 - 7.89 (m, 2H, Ar-H Phth); 
13
C NMR (125 MHz, CDCl3) syn δ: 52.7, 55.9, 75.2, 82.8, 123.6, 127.8, 128.9, 131.9, 
134.1, 167.3, 168.0; anti δ: 52.6, 54.8, 75.7, 85.0, 123.6, 126.2, 128.8, 131.7, 134.2, 








To a solution of (2R,3S)-methyl 2-(allyl(tert-butoxycarbonyl)amino)-3-methoxypent-4-
enoate 328 (0.10 g, 0.33 mmol, 1 equiv.) in DCM (5 mL) was added 
bis(tricyclohexylphosphine)benzylidine ruthenium(IV) chloride (0.01 g, 0.02 mmol, 
0.05 equiv.) and stirred at room temperature for 16 hours. The mixture was passed 
through a pad of celite and concentrated in vacuo. Purification was achieved by flash 
chromatography (6:1 Pet/EtOAc + 1% NEt3) to afford the title compound as a 
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colourless oil (0.06 g, 67%, dr 2:1). FTIR (film/cm
-1) υmax: 2954.3, 2907.9, 2855.2, 
1781.2, 1715.3, 1614.0; 
1
H NMR (500 MHz, CDCl3) : 1.48 (s, 9H, (CH3)3COCON), 
3.53 (s, 3H, OCH3), 3.71 (s, 3H, CO2CH3), 3.90 – 4.12 (m, 3H, NCH2CH & 
HC=CHCHOCH3), 5.26 – 5.40 (br m, 1H, NCHCO2), 5.64 – 5.84 (br m, 2H, 
NCH2CH=CH); 
13
C NMR (125 MHz, CDCl3) : 28.3, 42.8, 51.8, 57.4, 74.3, 80.9, 
124.8, 128.6, 134.0, 155.2, 170.4; HRMS (ESI, +ve) m/z: calcd. for C13H21NO5Na 






To a 100 mL Schlenk flask was added copper(I) iodide (0.6 g, 3.0 mmol, 0.02 equiv.) 
and bis(triphneylphosphine)palladium(II) chloride (0.1 g, 0.2 mmol, 0.01 equiv.). The 
flask was evacuated and flushed with nitrogen several times. Freshly distilled 
pyrrolidine (40 mL) was added followed by iodobenzene (3.4 mL, 31.0 mmol, 1.03 
equiv.). The solution was cooled to 0 °C and (S)-butyn-2-ol (S)-189 (2.3 mL, 30.0 
mmol, 1.0 equiv.) was added dropwise. The ice bath was removed and the reaction 
mixture stirred at room temperature for 16 hours. The reaction was quenched by the 
addition of sat. NH4Cl solution. The aqueous was extracted with DCM (3 x 50 mL), 
dried over MgSO4, filtered and concentrated in vacuo. Purification was achieved by 
flash chromatography (DCM) to afford the title compound as a yellow oil (4.4 g, 
100%). [] 20D
 
-29° (c 1, DCM);
 1
H NMR (500 MHz, CDCl3) : 1.57 (d, 3H, J = 6.7 Hz, 
PhC≡CCH(OH)CH3), 1.90 (br, 1H, PhC≡CCH(OH)CH3), 4.78 (q, 1H, J = 6.7 Hz, 
PhC≡CCH(OH)CH3), 7.30 – 7.33 (m, 3H, Ar-H Ph), 7.43 – 7.45 (m, 2H, Ar-H Ph); 
13
C 
NMR (125 MHz, CDCl3) : 24.4, 58.9, 84.0, 90.9, 122.6, 128.3, 128.4, 131.7. All 






To a stirred solution of Red-Al (1.22 mL, 5.44 mmol, 1.6 equiv.) in ether (30 mL) at 0 
°C was added a solution of (S)-4-phenylbut-3-yn-2-ol 432 (0.5 g, 3.4 mmol, 1 equiv.) in 
ether (20 mL) dropwise. After 10 minutes the ice bath was removed and the mixture 
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stirred at room temperature for 4 hours. Saturated NH4Cl (20 mL) was added before 
diluting with ether (10 mL), NaOH (1M, 10 mL) and water (10 mL). The layers were 
separated, and the aqueous phase extracted with ether (3 x 50 mL). Organic phases were 
combined, dried over Na2SO4, filtered and concentrated in vacuo. Purification was 
achieved by flash chromatography (DCM) to afford the title compound as a colourless 
solid (1.62 g, 97%). [] 20D
 
-31° (c 1, DCM); MP: 28 – 29 °C, Lit: 29 – 30 °C; 1H NMR 
(500 MHz, CD2Cl2) : 1.37 (d, 3H, J = 6.6 Hz, PhCH=CHCH(CH3)OH), 4.47 – 4.52 
(m, 1H, PhCH=CHCH(CH3)OH), 6.31 (dd, 1H, J = 15.6, 6.4 Hz, 
PhCH=CHCH(CH3)OH), 6.60 (d, 1H, J = 15.6 Hz, PhCH=CHCH(CH3)OH), 7.25 – 
7.43 (m, 5H, Ar-H Ph); 
13
C NMR (125 MHz, CD2Cl2) : 23.6, 68.7, 126.3, 127.5, 





(E)-Methyl 3-((S,E)-4-phenylbut-3-en-2-yloxy)acrylate (433) 
 
 (S,E)-4-phenylbut-3-en-2-ol 428 (1.62 g, 10.9 mmol, 1.1 equiv.) in THF (400 mL) was 
added DABCO (0.12 g, 0.99 mmol, 0.1 equiv.) and methyl propiolate 232 (1.00 mL, 
9.93 mmol, 1 equiv.) were combined according to the general procedure (reaction time 
2 hours). Purification was achieved by flash chromatography (15:1 Pet/EtOAc) to afford 
title compound as a colorless oil (1.65 g, 65%). [] 20D
 
-191° (c 1, DCM); FTIR (film/cm
-
1) υmax: 3028.5, 2983.8, 2950.9, 1706.9, 1637.8, 1619.2; 
1
H NMR (500 MHz, CDCl3) : 
1.49 (d, 3H, J = 6.4 Hz, PhCH=CHCH(CH3)O), 3.70 (s, 3H, CO2CH3), 4.68 (pent, 1H, J 
= 7.0 Hz, PhCH=CHCH(CH3)O), 5.34 (d, 1H, J = 11.2 Hz, OCH=CHCO2CH3), 6.17 
(dd, 1H, J = 16.0, 7.0 Hz, PhCH=CHCH(CH3)O), 6.61 (1H, J = 16.0 Hz, 
PhCH=CHCH(CH3)O), 7.26 – 7.30 (m, 1H, Ar-H Ph), 7.33 – 7.36 (m, 2H, Ar-H Ph), 
7.39 – 7.41 (m, 2H, Ar-H Ph), 7.60 (d, 1H, J = 11.2 Hz, OCH=CHCO2CH3); 
13
C NMR 
(125 MHz, CDCl3) : 21.1, 51.0, 79.7, 97.8, 126.7, 128.2, 128.4, 128.7, 132.4, 135.8, 











(E)-Methyl 3-((S,E)-4-phenylbut-3-en-2-yloxy)acrylate 433 (0.98 g, 4.22 mmol) was 
reduced according to general procedure 5, to afford the title compound as a colourless 
oil. (0.59 g, 68%). [] 20D
 
-183° (c 1, DCM);
 
FTIR (film/cm
-1) υmax: 3393.9, 3026.0, 
2976.6, 2871.7, 1669.0, 1649.9; 
1
H NMR (500 MHz, d6-acetone) : 1.38 (d, 3H, J = 6.5 
Hz, PhCH=CHCH(CH3)O), 3.97 (d, 2H, J = 7.0 Hz, OCH=CHCH2OH), 4.53 (quin, 1H, 
J = 6.5 Hz, PhCH=CHCH(CH3)O), 5.12 (dt, 1H, J = 12.6, 7.0 Hz, OCH=CHCH2OH), 
6.27 (dd, 1H, J = 15.5, 6.5 Hz, PhCH=CHCH(CH3)O), 6.46 (d, 1H, J = 12.6 Hz, 
OCH=CHCH2OH), 6.64 (d, 1H, J = 15.5 Hz, PhCH=CHCH(CH3)O), 7.26 – 7.47 (m, 
5H, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) :20.7, 59.4, 76.7, 105.8, 126.5, 127.7, 





EDCi.HCl (0.62 g), triethylamine (0.44 mL), 2-(bis(tert-butoxycarbonyl)amido)acetic 
acid 305 (0.89 g) and (E)-3-((S,E)-4-phenylbut-3-en-2-yloxy)prop-2-en-1-ol 434 (0.33 
g) were combined according to general procedure 3, to afford the title compound as a 
yellow oil (0.85 g, 50%). [] 20D
 
-179° (c 1, DCM) ;FTIR (film/cm
-1) υmax: 3024.8, 
2989.7, 2985.2, 1753.7, 1734.4, 1699.3, 1652.4; 
1
H NMR (500 MHz, d6-acetone) : 
1.40 (d, 3H, J = 7.3 Hz, OCH(CH3)CH=CHPh), 1.48 (s, 18H, (CH3)3COCON), 3.00 (d, 
2H, J = 7.7 Hz, OCH2CH=CHO), 4.23 (s, 2H, NCH2CO2), 4.55 (app. d, 2H, J = 7.3 Hz, 
OCH(CH3)CH=CHPh), 5.08 (dt, 1H, J = 12.9, 7.7 Hz, OCH2CH=CHO), 6.27 (dd, 1H, J 
= 16.0, 7.3 Hz, OCH(CH3)CH=CHPh), 6.65 – 6.70 (m, 2H, OCH2CH=CHO & 
OCH(CH3)CH=CHPh), 7.26 – 7.48 (m, 5H, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) : 
20.6, 27.4, 47.1, 62.9, 77.4, 82.0, 99.5, 126.6, 128.6, 130.2, 131.3, 136.6, 152.3, 168.8; 











429 (0.26 g, 0.55 mmol, 1 equiv.), TMSCl (0.14 mL, 1.1 mmol, 2 equiv.) and LiHMDS 
(1.11 mL, 1.1 mmol, 2 equiv.) were combined according to the general procedure. 
Treatment with diazomethane and purification by flash chromatography (15:1 
Pet/EtOAc + 1% NEt3) afforded the title compound as a colourless oil. (0.08 g, 30%). 
FTIR (film/cm
-1) υmax: 3010.7, 2975.0, 1796.7, 1725.3, 1698.9; 
1
H NMR (500 MHz, 
CDCl3) δ: 1.27 (d, 3H, J = 6.6 Hz, OCH(CH3)CH), 1.54 (s, 18H, (CH3)3COCON), 3.72 
(s, 3H, CO2CH3), 4.10 – 4.15 (m, 1H, OCH(CH3)CH), 4.54 (dd, 1H, J = 8.8, 3.7 Hz, 
H2C=CHCHO), 4.88 (d, 1H, J = 8.8 Hz, NCHCO2), 5.01 – 5.17 (m, 2H, 
H2C=CHCH(CH3)O), 5.26 – 5.42 (m, 2H, H2C=CHCHO), 5.65 (ddd, 1H, J = 17.9, 9.9, 
7.4 Hz, H2C=CHCHO), 6.27 (dd, 1H, J = 16.0, 7.3 Hz, OCH(CH3)CH=CHPh), 6.65 – 
6.70 (m, 2H, OCH2CH=CHO & OCH(CH3)CH=CHPh), 7.22 – 7.39 (m, 5H, Ar-H Ph); 
13
C NMR (125 MHz, CDCl3) δ: 20.7, 28.0, 51.9, 62.0, 75.7, 82.8, 82.9, 117.3, 126.4, 
127.4, 128.5, 129.7, 132.4, 138.0, 152.3, 169.4; HRMS (ESI, +ve) m/z: calcd. for 




(S,E)-Methyl 3-(but-3-yn-2-yloxy)acrylate (437) 
 
DABCO (0.40 g, 3.15 mmol) in THF (250 mL), S-butyn-2-ol (S)-189 (2.43 g, 34.7 
mmol) and methyl propiolate 232 (3.1 mL, 31.5 mmol) were combined according to the 
general procedure. Purification was achieved by flash chromatography (15:1 
Pet/EtOAc) to afford the pure vinylogous carbonate as a colourless oil (4.67 g, 87%). 
[] 20D
 
-169° (c 1, DCM); FTIR (film/cm
-1) υmax: 2994.4, 2952.8, 2117.7, 1708.0, 1644.4, 
1623.2; 
1
H NMR (500 MHz, CDCl3) : 1.59 (d, 3H, J = 6.7 Hz, HCCCH(CH3)O), 2.59 
(d, 1H, J = 2.2 Hz, HCCCH(CH3)O), 3.72 (s, 3H, CO2CH3), 4.68 (dq, 1H, J = 6.7, 2.2 
Hz, HCCCH(CH3)O), 5.40 (d, 1H, J = 12.5 Hz, OCHCHCO2CH3), 7.61 (d, 1H, J = 12.5 




C NMR (125 MHz, CDCl3) : 21.6, 51.2, 67.0, 75.4, 80.9, 





(S,E)-Methyl 3-(but-3-en-2-yloxy)acrylate (rac-426) 
 
To a solution of (S,E)-methyl 3-(but-3-yn-2-yloxy)acrylate 437 (1.00 g, 6.49 mmol) in 
EtOAc (40 mL) was added Lindlars catalyst (0.90 g) and quinoline (5 drops) under 1 
atmosphere of hydrogen for 3 hours. The solution was filtered through celite and 
concentrated in vacuo to afford the crude product. Purification was achieved by flash 
chromatography (15:1 Pet/EtOAc) to afford the title compound as a colourless oil. (0.80 
g, .98%). FTIR (film/cm
-1) υmax: 2985.6, 2951.9, 1705.8, 1639.2, 1621.1; 
1
H NMR (500 
MHz, CDCl3) :1.39 (d, 3H, J = 6.1 Hz, CH2CHCH(CH3)O), 3.70 (s, 3H, CO2CH3), 
4.50 (quin, 1H, J = 6.1 Hz, CH2CHCH(CH3)O), 5.23 – 5.30 (m, 3H, CH2CHCH(CH3)O 
& OCHCHCO2CH3), 5.82 (ddd, 1H, J = 17.0, 9.6, 6.1 Hz, CH2CHCH(CH3)O), 7.53 (d, 
1H, J = 12.1 Hz, OCHCHCO2CH3);
13
C NMR (125 MHz, CDCl3) : 20.7, 51.0, 79.6, 





(S,E)-Methyl 3-sec-butoxyacrylate (438) 
 
To a solution of (S,E)-methyl 3-(but-3-yn-2-yloxy)acrylate 437 (0.15 g, 0.94 mmol) in 
EtOAc (10 mL) was added Lindlars catalyst (0.15 g) under 1 atmosphere of hydrogen 
for 3 hours. The solution was filtered through celite and concentrated in vacuo to afford 
the title compound as a colourless oil (0.11 g, 74%). [] 20D
 
+18° (c 1, DCM); FTIR 
(film/cm
-1) υmax: 2987.1, 1706.8, 1635.7, 1631.9; 
1
H NMR (500 MHz, CDCl3) : 1.27 
(d, 3H, J = 6.2 Hz, CH3CH2CH(CH3)O), 1.54 – 1.72 (m, 2H, CH3CH2CH(CH3)O), 3.70 
(s, 3H, CO2CH3), 3.99 (sext, 1H, J = 6.2 Hz, CH3CH2CH(CH3)O), (5.25 (d, 1H, J = 
12.3 Hz, OCHCHCO2CH3), 7.55 (d, 1H, J = 12.3 Hz, OCHCHCO2CH3); 
13
C NMR (125 
MHz, CDCl3) : 9.5, 19.5, 29.1, 51.0, 81.1, 96.7, 162.3, 168.7; HRMS (ESI, +ve) m/z: 
calcd. for C8H14O3Na 181.0841, found 181.0856 (M+Na)
+
. 




To a solution of (S)-butynol (S)-189 (0.07 g, 1.00 mmol) in EtOAc (10 mL) was added 
Lindlars catalyst (0.05 g) under 1 atmosphere of hydrogen for 3 hours. The solution was 
filtered through celite and concentrated in vacuo to afford the title compound as a 
colourless oil (0.0.7 g, 100%). [] 20D
 
+12° (c 1, MeCN); 
1
H NMR (500 MHz, CDCl3) : 
0.93 (t, 3H, J = 7.5 Hz, CH3CH2), 1.18 (d, 3H, J = 6.2 Hz, CH(OH)CH3), 1.40 (br, 1H, 
OH), 1.42 – 1.52 (m, 2H, CH3CH2CH) , 3.67 – 3.78 (m, 1H, CH2CH(OH)CH3); 
13
C 
NMR (125 MHz, CDCl3) : 9.6, 22.3, 31.6, 68.7. All analytical data is in accordance 




(S,E)-Methyl 3-(but-3-en-2-yloxy)acrylate (426) 
 
To a round-bottom flask equipped with a condenser is added lithium aluminium hydride 
(0.95 g, 25.0 mmol, 0.7 equiv.). Ether (50 mL) was added and the resulting suspension 
vigorously stirred and cooled to 0 °C. A solution of (S)-butyn-2-ol (S)-189 (2.83 mL, 
35.7 mmol, 1 equiv.) in ether (20 mL) was added via syringe pump over 5 minutes. The 
solution was brought to a gentle reflux for 48 hours. The mixture was then cooled to 0 
°C and saturated Rochelle’s salt solution was added dropwise until gas evolution 
stopped. A further 60 mL of ether was added and the white precipitate removed by 
filtration through a pad of celite, then washed with an additional 60 mL of ether. The 
resultant filtrate was concentrated in vacuo. Purification was achieved by Kugelrohr 
bulb-to-bulb distillation at 52 °C and 16 torr to afford (S)-3-buten-2-ol as a colourless 
oil (1.00 g, 40%). 
1
H NMR (250 MHz, CDCl3) : 1.30 (d, 3H, J = 6.5 Hz, 
H2C=CHCH(OH)CH3), 4.33 (qt, 1H, J = 6.5, 1.5 Hz, H2C=CHCH(OH)CH3), 5.09 (dt, 
1H, J = 10.8, 1.3 Hz, H2C=CHCH(OH)CH3), 5.24 (dt, 1H, J = 16.6, 1.3 Hz, 
H2C=CHCH(OH)CH3), 5.94 (ddd, 1H, J = 16.6, 10.8, 6.5 Hz, H2C=CHCH(OH)CH3). 
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DABCO (0.13 g, 1.19 mmol) in THF (200 mL), (S)-3-buten-2-ol (1.00 g, 11.9 mmol) 
and methyl propiolate (1.3 mL, 11.9 mmol) were combined according to general 
procedure 4. Purification was achieved by flash chromatography (20:1 Pet/EtOAc) to 
afford the title compound as a colourless oil (1.24 g, 60%). [] 20D
 
-128° (c 1, DCM); 
FTIR (film/cm
-1) υmax: 3085.4, 2985.1, 2952.1, 1708.4, 1639.1, 1620.8; 
1
H NMR (500 
MHz, CDCl3) : 1.38 (d, 3H, J = 6.6 Hz, H2C=CHCH(CH3)O), 3.68 (s, 3H, CO2CH3), 
4.48 (quin, 1H, J = 6.6 Hz, H2C=CHCH(CH3)O), 5.21 – 5.28 (m, 3H, 
H2C=CHCH(CH3)O & OCH=CHCO2CH3), 5.80 (ddd, 1H, J = 17.2, 10.8, 6.6 Hz, 
H2C=CHCH(CH3)O), 7.52 (d, 1H, J = 17.2 Hz, OCH=CHCO2CH3); 
13
C NMR (125 
MHz, CDCl3) : 20.7, 51.1, 79.7, 97.7, 117.2, 137.5, 161.4, 168.4; HRMS (ESI, +ve) 






(S,E)-Methyl 3-(but-3-en-2-yloxy)acrylate 426 (0.85 g, 5.44 mmol) was reduced 
according to general procedure 5, to afford the title compound as a yellow oil (0.56 g, 
80%). [] 20D
 
-129° (c 1, DCM); FTIR (film/cm
-1) υmax: 3348.9, 2980.5, 2871.7, 1669.5, 
1652.1; 
1
H NMR (500 MHz, d6-acetone) : 1.26 (d, 3H, J = 6.6 Hz, 
H2C=CHCH(CH3)O), 3.35 (t, 1H, J = 5.6 Hz, OCH=CHCH2OH), 3.93 (ddd, 2H, J = 
6.9, 5.6, 1.4 Hz, OCH=CHCH2OH), 4.35 (qt, 1H, J = 6.6, 1.3 Hz, H2C=CHCH(CH3)O), 
5.00 – 5.05 (m, 1H, OCH=CHCH2OH), 5.13 (dt, 1H, J = 10.3, 1.3 Hz, 
H2C=CHCH(CH3)O), 5.25 (dt, 1H, J = 17.4, 1.3 Hz, H2C=CHCH(CH3)O), 5.82 (ddd, 
1H, J = 17.4, 10.3, 6.6 Hz, H2C=CHCH(CH3)O), 6.37 (dt, 1H, J = 12.3, 1.3 Hz, 
OCH=CHCH2OH); 
13
C NMR (125 MHz, d6-acetone) : 20.2, 59.3, 76.7, 105.7, 114.9, 
139.5, 147.4. 
 
(S,E)-3-(But-3-en-2-yloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate (424) 
 
EDCi.HCl (0.43 g, 2.24 mmol), triethylamine (0.3 mL, 2.24 mmol), 2-(bis(tert-
butoxycarbonyl)amido)acetic acid 305 (0.62 g, 2.24 mmol) and (S,E)-3-(but-3-en-2-
yloxy)prop-2-en-1-ol 425 (0.14 g, 1.12 mmol) were combined according to general 
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procedure 3, to afford the title compound as a yellow oil (0.45 g, 98%). [] 20D
 
-120° (c.1, 
DCM); 2979.4, 2937.1, 1797.9, 1755.8, 1735.6, 1697.6, 1671.4; 
1
H NMR (500 MHz, 
d6-acteone) : 1.29 (d, 3H, J = 6.2 Hz, OCH(CH3)CH=CH2), 1.49 (s, 18H, 
(CH3)3COCON), 4.28 (s, 2H, NCH2CO2), 4.44 (quin, 1H, J = 6.2 Hz, 
OCH(CH3)CH=CH2), 4.54 (d, 2H, J = 7.8 Hz, OCH2CH=CHO), 5.03 (dt, 1H, J = 12.6, 
7.8 Hz, OCH2CH=CHO), 5.16 (dt, 1H, J = 10.6, 1.2 Hz, OCH(CH3)CH=CH2), 5.27 (dt, 
1H, J = 17.3, 1.2 Hz, OCH(CH3)CH=CH2), 5.84 (ddd, 1H, J = 17.3, 10.6, 6.2 Hz, 
OCH(CH3)CH=CH2), 6.62 (d, 1H, J = 12.6 Hz, OCH2CH=CHO); 
13
C NMR (125 MHz, 
d6-acteone) : 20.1, 27.2, 29.7, 47.0, 62.9, 77.3, 82.1, 99.3, 115.3, 139.0, 151.7, 151.8; 







(S,E)-3-(But-3-en-2-yloxy)allyl 2-(bis(tert-butoxycarbonyl)amino)acetate 424 (0.20 g, 
0.27 mmol), TMSCl (0.07 mL, 0.55 mmol) and LiHMDS (0.55 mL, 0.55 mmol) were 
combined according to general procedure 7. Treatment with diazomethane and 
purification by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) afforded the title 
compound as a colourless oil (0.11 g, 60%, dr 2.5:1). [] 20D
 
-122° (c 1, DCM); FTIR 
(film/cm
-1) υmax: 2981.5, 2938.2, 1751.3, 1699.9; 
1
H NMR (500 MHz, d6-acetone) 
(2R,3S)-423: 1.18 (d, 3H, J = 6.4 Hz, H2C=CHCH(CH3)O), 1.51 (s, 18H, 
(CH3)3COCON), 3.68 (s, 3H, CO2CH3), 3.92 – 3.99 (m, 1H, H2C=CHCH(CH3)O), 4.49 
– 4.53 (m, 1H, H2C=CHCHO), 4.80 (d, 1H, J = 8.4 Hz, NCHCO2), 5.01 – 5.17 (m, 2H, 
H2C=CHCH(CH3)O), 5.26 – 5.42 (m, 2H, H2C=CHCHO), 5.77 (ddd, 1H, J = 16.7, 
10.6, 6.6 Hz, H2C=CHCHO), 6.09 (ddd, 1H, J = 16.3, 10.8, 6.8 Hz, 
H2C=CHCH(CH3)O); (2S,3R)-423: 1.16 (d, 3H, J = 6.4 Hz, H2C=CHCH(CH3)O), 
1.50 (s, 18H, (CH3)3COCON), 3.66 (s, 3H, CO2CH3), 3.92 – 3.99 (m, 1H, 
H2C=CHCH(CH3)O), 4.44 – 4.47 (m, 1H, H2C=CHCHO), 4.80 (d, 1H, J = 8.4 Hz, 
NCHCO2), 5.01 – 5.17 (m, 2H, H2C=CHCH(CH3)O), 5.26 – 5.42 (m, 2H, 
H2C=CHCHO), 5.65 (ddd, 1H, J = 17.9, 9.9, 7.4 Hz, H2C=CHCHO), 6.01 (ddd, 1H, J = 
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17.1, 10.8, 6.4 Hz, H2C=CHCH(CH3)O); 
13
C NMR (125 MHz, d6-acetone) (2R,3S)-
423:19.8, 27.3, 51.3, 62.0, 74.2, 74.8, 82.2, 113.9, 115.8, 138.3, 140.9, 152.3, 168.8; 
(2S,3R)-423: 21.4, 27.2, 51.2, 61.9, 74.0, 75.7, 82.0, 115.9, 116.7, 137.6, 140.5, 152.0, 







To a solution of (2S,3R)-methyl 3-((S)-but-3-en-2-yloxy)-2-(bis(tert-
butoxycarbonyl)amino)pent-4-enoate  423 (0.10 g, 0.25 mmol, 1 equiv.) in DCM (5 
mL) was added bis(tricyclohexylphosphine)benzylidine ruthenium (IV) chloride (0.04 
g, 0.005 mmol, 0.05 equiv.) and stirred at room temperature for 40 hours. The mixture 
was passed through a pad of celite and concentrated in vacuo. Purification was achieved 
by flash chromatography (15:1 Pet/EtOAc + 1% NEt3) to afford the title compound as a 
colourless oil (0.08 g, 85%, dr 2.5:1). [] 20D
 
-70° (c 1, DCM); FTIR (film/cm
-1) υmax: 
2984.6, 1747.1, 1698.8; 
1
H NMR (500 MHz, CDCl3) major: 1.23 (d, 3H, J = 6.4 Hz, 
CH(CH3)O), 1.52 (s, 18H, (CH3)3COCON), 3.73 (s, 3H, CO2CH3), 4.85 (d, 1H, J = 8.7 
Hz, NCHCO2), 4.90 – 4.95 (m, 1H, HC=CHCHO), 5.27 – 5.30 (m, 1H, CHCH(CH3)O), 
5.85 – 5.87 (m, 1H, HC=CHCH(CH3)O), 6.15 – 6.18 (m, 1H, HC=CHCHO); minor: 
1.25 (d, 3H, J = 6.4 Hz, CH(CH3)O), 1.52 (s, 18H, (CH3)3COCON), 3.73 (s, 3H, 
CO2CH3), 4.76 (d, 1H J = 8.4 Hz, NCHCO2), 4.79 – 4.83 (m, 1H, HC=CHCHO), 5.31 – 
5.33 (m ,1H, CHCH(CH3)O), 5.85 – 5.87 (m, 1H, HC=CHCH(CH3)O), 6.15 – 6.18 (m, 
1H, HC=CHCHO); 
13
C NMR (125 MHz, CDCl3) major: 22.1, 28.0, 51.9, 63.3, 82.3, 
83.0, 83.6, 128.7, 132.9, 152.4, 169.6;minor: 21.4, 28.0, 51.9, 62.3, 81.3, 82.9, 83.3, 














To a stirred solution of (S)-methyl 2-(bis(tert-butoxycarbonyl)amino)-2-((2R,5S)-5-
methyl-2,5-dihydrofuran-2-yl)acetate 436 (0.04g, 0.10 mmol, 1 equiv.) in DCM (5 mL) 
was added TFA (0.02 mL, 2 equiv.) at 0 °C. The mixture was stirred for 2 hourd before 
concentrating in vacuo. The residue was taken up in saturated sodium bicarbonate 
solution (10 mL) and extracted with EtOAc (4 × 20 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. Purification was achieved by flash chromatography (4:1 
Pet/EtOAc) to afford the title compound as a colourless oil (0.02 g, 79%).
1
H NMR (500 
MHz, d6-Acetone) major: 1.21 (d, 3H, J = 6.4 Hz, CH(CH3)O), 1.43 (s, 18H, 
(CH3)3COCON), 3.73 (s, 3H, CO2CH3), 4.85 (d, 1H, J = 8.7 Hz, NCHCO2), 4.90 (br, 
1H, NH), 4.92 – 4.95 (m, 1H, HC=CHCHO), 5.27 – 5.30 (m, 1H, CHCH(CH3)O), 5.85 
– 5.87 (m, 1H, HC=CHCH(CH3)O), 6.15 – 6.18 (m, 1H, HC=CHCHO); 
13
C NMR (125 
MHz, d6-Acetone) major: 21.3, 27.6, 51.5, 56.2, 78.6, 82.3, 86.6, 126.5, 133.3, 155.2, 
170.4. 
 
N-Boc furanomycinol (421) 
 
To a stirred solution of lithium aluminium hydride (0.005 g, 0.13 mmol, 2 equiv.) in 
ether (5 mL) at -78 °C was added a solution of (S)-methyl 2-((tert-
butoxycarbonyl)amino)-2-((2R,5S)-5-methyl-2,5-dihydrofuran-2-yl)acetate 442 (0.02 g, 
0.07 mmol) in ether (3 mL). The mixture was stirred at -78 °C for 5 hours before 
quenching by the addition of EtOAc, then poured onto ice-cold saturated Rochelle salt 
solution (100 mL) followed by the addition of further EtOAc (100 mL). The biphasic 
mixture was vigorously stirred at 0 °C for 2 hours before separating and extracting with 
EtOAc (3 × 10 mL). The organics were dried over Na2SO4, filtered and concentrated in 
vacuo. Purification was achieved by flash chromatography (Pet/EtOAc 1:1) to afford the 
title compound as a colourless oil (0.01 g, 65%). FTIR (film/cm
-1) υmax: 3447.8, 3395.6, 
2984.3, 2841.3, 1700.4, 1517.2; 
1
H NMR (500 MHz, CDCl3) major: 1.32 (d, 3H, J = 6.5 
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Hz, CH(CH3)O), 1.43 (s, 9H, (CH3)3COCON), 2.74 (br, 1H, OH), 3.72 – 3.92 (m, 
3H,CHCH2OH & NH)), 4.92 – 5.11 (m, 2H, HC=CHCHO & NCHCO2), 5.76 – 5.89 
(m, 2H, HC=CHCHO); 
13
C NMR (125 MHz, CDCl3) major: 21.8, 28.4, 52.9, 65.1, 79.3, 
82.6, 88.7, 127.5, 132.5, 157.0; HRMS (ESI, +ve) m/z: calcd. for C18H29NO7Na 
394.1842, found 394.1857 (M+Na)
+
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CHAPTER 7 APPENDICES 
 
7.1 AMINO ACIDS 
Table 1: Trivial names and symbols for proteinogenic amino acids
6
 
Trivial Name Symbol  Trival Name Symbol 
Alanine Ala  
Leucine Leu 
Arginine Arg  Lysine Lys 
Asparagine Asn  Methionine Met 
Aspartic Acid Asp  Phenylalanine Phe 
Cysteine Cys  Proline Pro 
Glutamine Gln  Serine Ser 
Glutamic Acid Glu  Theronine Thr 
Glycine Gly  Tryptophan Trp 
Histidine His  Tyrosine Tyr 
Isoleucine Lle  Valine Val 
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7.2 NMR 
7.2.1 NOeSY spectra of (E)- and (Z)-SKA of ester 232 
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7.3 X-RAY 
Table 2: Crystal data and structure refinement for Cs Carboxylate 292 
 
Identification code h08dc1 
Empirical formula C14 H16 Cs N O7 
Formula weight 443.19 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P 21/a 
Unit cell dimensions a = 7.6258(2) Å      = 90° 
 b = 13.1985(3) Å     = 100.5660(10)° 





Calculated density 1.822 Mg/m
3
 




Crystal size 0.45 x 0.25 x 0.15 mm 
Theta range for data collection    3.56 to 27.51° 
Limiting indices -9<=h<=9, -17<=k<=16, -21<=l<=21 
Reflections collected 21615 
Reflections unique 3699 [R(int) = 0.0544] 
Completeness to theta 27.51 (99.5%) 
Max. transmission 0.7217 
Min. transmission 0.4208 
Refinement method Full-matrix least-squares on F
2
 




Final R indices [I>2(I)] R
1
 = 0.0329, wR2 = 0.0774 
R indices (all data) R
1
 = 0.0429, wR2 = 0.0831 
Largest diff. peak and hole 1.494 and -1.189 eÅ
-3
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Table 3: Atomic coordinates ( × 10
4





for 292.U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
Atom X Y Z U(eq) 
Cs 5126(1) 1543(1) 437(1) 39(1) 
N 9057(3) 323(2) 2940(1) 22(1) 
O(1) 7990(3) 1688(2) 2116(1) 29(1) 
O(2) 10603(3) -671(2) 4002(1) 30(1) 
O(3) 7110(3) -438(2) 946(1) 33(1) 
O(4) 9997(3) -168(2) 1403(1) 33(1) 
O(5) 6196(3) -558(2) 3382(1) 31(1) 
O(6) 2796(4) 1172(3) 1762(2) 56(1) 
O(7) 9198(5) 1261(2) 5(2) 50(1) 
C(1) 8911(4) 1347(2) 2744(2) 23(1) 
C(2) 10054(4) 1894(2) 3441(2) 22(1) 
C(3) 10390(4) 2915(2) 3572(2) 26(1) 
C(4) 11481(4) 3193(2) 4316(2) 28(1) 
C(5) 12203(4) 2478(2) 4908(2) 30(1) 
C(6) 11869(4) 1446(2) 4769(2) 28(1) 
C(7) 10798(4) 1172(2) 4028(2) 23(1) 
C(8) 10204(4) 156(2) 3703(2) 24(1) 
C(9) 8196(4) -500(2) 2422(2) 23(1) 
C(10) 8436(4) -350(2) 1506(2) 25(1) 
C(11) 6234(4) -648(2) 2509(2) 23(1) 
C(12) 4439(4) -631(3) 3556(2) 36(1) 
C(13) 5578(4) -1673(2) 2193(2) 32(1) 
C(14) 4100(5) -1828(3) 1656(2) 44(1) 
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Table 4: Bond lengths [Å] for 292 
 
Cs-O(3)#1 2.953(2)  O(7)-H(7B) 0.81(2) 
Cs-O(7)#2 3.036(3)  C(1)-C(2) 1.487(4) 
Cs-O(3) 3.059(2)  C(2)-C(3) 1.381(4) 
Cs-O(6) 3.082(3)  C(2)-C(7) 1.397(4) 
Cs-O(1) 3.183(2)  C(3)-C(4) 1.390(4) 
Cs-O(7) 3.329(3)  C(3)-H(3) 0.9500 
Cs-C(14)#1 3.593(4)  C(4)-C(5) 1.390(5) 
Cs-C(10) 3.749(3)  C(4)-H(4) 0.9500 
Cs-Cs#1 4.3091(4)  C(5)-C(6) 1.397(4) 
Cs-Cs#3 4.5733(3)  C(5)-H(5) 0.9500 
Cs-Cs#2 4.5733(3)  C(6)-C(7) 1.378(4) 
Cs-H(6B) 3.25(6)  C(6)-H(6) 0.9500 
Cs-H(7B) 3.37(5)  C(7)-C(8) 1.482(4) 
N-C(1) 1.388(4)  C(9)-C(11) 1.540(4) 
N-C(8) 1.402(4)  C(9)-C(10) 1.553(4) 
N-C(9) 1.457(3)  C(9)-H(9) 1.0000 
O(1)-C(1) 1.218(4)  C(11)-C(13) 1.500(4) 
O(2)-C(8) 1.211(4)  C(11)-H(11) 1.0000 
O(3)-C(10) 1.239(4)  C(12)-H(12A) 0.9800 
O(3)-Cs#1 2.953(2)  C(12)-H(12B) 0.9800 
O(4)-C(10) 1.256(4)  C(12)-H(12C) 0.9800 
O(5)-C(12) 1.423(4)  C(13)-C(14) 1.311(5) 
O(5)-C(11) 1.436(3)  C(13)-H(13) 0.9500 
O(6)-H(6A) 0.75(7)  C(14)-Cs#1 3.593(4) 
O(6)-H(6B) 0.81(6)  C(14)-H(14A) 0.9500 
O(7)-Cs#3 3.036(3)  C(14)-H(14B) 0.9500 
O(7)-H(7A) 0.842(19)    
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Table 5: Bond angles [°] for 292 
 
O(3)#1-Cs-O(7)#2 102.52(7)  Cs#2-Cs-H(7B) 162.6(7) 
O(3)#1-Cs-O(3) 88.44(6)  H(6B)-Cs-H(7B) 137.6(12) 
O(7)#2-Cs-O(3) 164.15(8)  C(1)-N-C(8) 111.6(2) 
O(3)#1-Cs-O(6) 97.60(7)  C(1)-N-C(9) 125.7(2) 
O(7)#2-Cs-O(6) 100.08(8)  C(8)-N-C(9) 22.7(2) 
O(3)-Cs-O(6) 89.61(7)  C(1)-O(1)-Cs 154.37(19) 
O(3)#1-Cs-O(1) 153.79(6)  C(10)-O(3)-Cs#1 152.8(2) 
O(7)#2-Cs-O(1) 103.69(7)  C(10)-O(3)-Cs 114.66(18) 
O(3)-Cs-O(1) 65.81(5)  Cs#1-O(3)-Cs 91.56(6) 
O(6)-Cs-O(1) 78.29(7)  C(12)-O(5)-C(11) 112.6(2) 
O(3)#1-Cs-O(7) 102.28(7)  Cs-O(6)-H(6A) 120(5) 
O(7)#2-Cs-O(7) 104.16(8)  Cs-O(6)-H(6B) 94(4) 
O(3)-Cs-O(7) 61.82(6)  H(6A)-O(6)-H(6B) 118(6) 
O(6)-Cs-O(7) 144.24(8)  Cs#3-O(7)-Cs 91.75(7) 
O(1)-Cs-O(7) 70.74(7)  Cs#3-O(7)-H(7A) 125(4) 
O(3)#1-Cs-C(14)#1  59.80(7)  Cs-O(7)-H(7A) 129(3) 
O(7)#2-Cs-C(14)#1 75.59(9)  Cs#3-O(7)-H(7B) 120(4) 
O(3)-Cs-C(14)#1 100.88(8)  Cs-O(7)-H(7B) 86(4) 
O(6)-Cs-C(14)#1 154.35(9)  H(7A)-O(7)-H(7B) 101(5) 
O(1)-Cs-C(14)#1 127.37(7)  O(1)-C(1)-N 124.3(3) 
O(7)-Cs-C(14)#1 59.19(8)  O(1)-C(1)-C(2) 129.1(3) 
O(3)#1-Cs-C(10) 105.77(6)  N-C(1)-C(2) 106.6(2) 
O(7)#2-Cs-C(10) 148.57(8)  C(3)-C(2)-C(7) 121.2(3) 
O(3)-Cs-C(10) 17.47(6)  C(3)-C(2)-C(1) 131.2(3) 
O(6)-Cs-C(10) 89.57(7)  C(7)-C(2)-C(1) 107.5(2) 
O(1)-Cs-C(10) 48.83(6)  C(2)-C(3)-C(4) 117.2(3) 
O(7)-Cs-C(10) 56.59(6)  C(2)-C(3)-H(3) 121.4 
C(14)#1-Cs-C(10) 107.39(8)  C(4)-C(3)-H(3) 121.4 
O(3)#1-Cs-Cs#1 45.20(5)  C(3)-C(4)-C(5) 121.8(3) 
O(7)#2-Cs-Cs#1 146.24(6)  C(3)-C(4)-H(4) 119.1 
O(3)-Cs-Cs#1 43.24(4)  C(5)-C(4)-H(4) 119.1 
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O(6)-Cs-Cs#1 94.92(6)  C(4)-C(5)-C(6) 120.8(3) 
O(1)-Cs-Cs#1 108.90(4)  C(4)-C(5)-H(5) 119.6 
O(7)-Cs-Cs#1 79.08(5)  C(6)-C(5)-H(5) 119.6 
C(14)#1-Cs-Cs#1 77.84(6)  C(7)-C(6)-C(5) 117.3(3) 
C(10)-Cs-Cs#1 60.61(4)  C(7)-C(6)-H(6) 121.3 
O(3)#1-Cs-Cs#3 129.59(4)  C(5)-C(6)-H(6) 121.3 
O(7)#2-Cs-Cs#3 68.39(6)  C(6)-C(7)-C(2) 121.6(3) 
O(3)-Cs-Cs#3 95.82(4)  C(6)-C(7)-C(8) 130.2(3) 
O(6)-Cs-Cs#3 132.53(6)  C(2)-C(7)-C(8) 108.2(2) 
O(1)-Cs-Cs#3 61.74(4)  O(2)-C(8)-N 124.7(3) 
O(7)-Cs-Cs#3 41.57(5)  O(2)-C(8)-C(7) 129.3(3) 
C(14)#1-Cs-Cs#3 70.11(6)  N-C(8)-C(7) 106.1(2) 
C(10)-Cs-Cs#3 82.99(4)  N-C(9)-C(11) 112.5(2) 
C(10)-Cs-Cs#3 120.575(7)  N-C(9)-C(10) 110.1(2) 
Cs#1-Cs-Cs#3 84.74(4)  C(11)-C(9)-C(10) 113.1(2) 
O(3)#1-Cs-Cs#2 46.68(6)  N-C(9)-H(9) 106.9 
O(7)#2-Cs-Cs#2 147.43(4)  C(11)-C(9)-H(9) 106.9 
O(3)-Cs-Cs#2 79.08(5)  C(10)-C(9)-H(9) 106.9 
O(6)-Cs-Cs#2 59.97(6)  O(3)-C(10)-O(4) 125.8(3) 
O(1)-Cs-Cs#2 114.02(4)  O(3)-C(10)-C(9) 118.3(2) 
O(7)-Cs-Cs#2 150.69(5)  O(4)-C(10)-C(9) 115.8(2) 
C(14)#1-Cs-Cs#2 102.98(7)  O(3)-C(10)-Cs 47.86(15) 
C(10)-Cs-Cs#2 149.13(4)  O(4)-C(10)-Cs 112.55(19) 
Cs#1-Cs-Cs#2 122.373(7)  C(9)-C(10)-Cs 110.20(16) 
Cs#3-Cs-Cs#2 112.969(9)  O(5)-C(11)-C(13) 110.5(2) 
O(3)#1-Cs-H(6B) 104.5(10)  O(5)-C(11)-C(9) 106.1(2) 
O(7)#2-Cs-H(6B) 86.1(11)  C(13)-C(11)-C(9) 110.6(2) 
O(3)-Cs-H(6B) 102.4(11)  O(5)-C(11)-H(11) 109.9 
O(6)-Cs-H(6B) 14.4(11)  C(13)-C(11)-H(11) 109.9 
O(1)-Cs-H(6B) 77.9(10)  C(9)-C(11)-H(11) 109.9 
O(7)-Cs-H(6B) 48.4(10)  O(5)-C(12)-H(12A) 109.5 
C(14)#1-Cs-H(6B) 151.4(10)  O(5)-C(12)-H(12B) 109.5 
C(10)-Cs-H(6B) 99.7(11)  H(12A)-C(12)-H(12B) 109.5 
Chapter 7  Appendices 
 233 
Cs#1-Cs-H(6B) 108.8(11)  O(5)-C(12)-H(12C) 109.5 
Cs#3-Cs-H(6B) 123.2(11)  H(12A)-C(12)-H(12C) 109.5 
Cs#2-Cs-H(6B) 49.5(10)  H(12B)-C(12)-H(12C) 109.5 
O(3)#1-Cs-H(7B) 104.9(9)  C(14)-C(13)-C(11) 124.3(3) 
O(7)#2-Cs-H(7B) 116.2(6)  C(14)-C(13)-H(13) 117.9 
O(3)-Cs-H(7B) 49.0(5)  C(11)-C(13)-H(13) 117.9 
O(6)-Cs-H(7B) 131.0(4)  C(13)-C(14)-Cs#1 110.4(2) 
O(1)-Cs-H(7B) 62.5(8)  C(13)-C(14)-H(14A) 120.0 
O(7)-Cs-H(7B) 13.9(4)  Cs#1-C(14)-H(14A) 75.8 
C(14)#1-Cs-H(7B) 70.9(6)  C(13)-C(14)-H(14B) 120.0 
C(10)-Cs-H(7B) 42.7(4)  Cs#1-C(14)-H(14B) 84.0 
Cs#1-Cs-H(7B) 73.2(9)  H(14A)-C(14)-H(14B) 120.0 
Cs#3-Cs-H(7B) 49.7(8)    
 
Symmetry transformations used to generate equivalent atoms 
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) for 292. The anisotropic displacement 






 U11 + ... + 2 h k a* b* U12 ] 
 
Atom U11 U22 U33 U23 U13 U12 
Cs 43(1) 36(1) 34(1) -1(1) -5(1) 2(1) 
N 24(1) 21(1) 20(1) -1(1) 3(1) -1(1) 
O(1) 33(1) 28(1) 24(1) 0(1) -2(1) 1(1) 
O(2) 28(1) 28(1) 31(1) 5(1) 3(1) 1(1) 
O(3) 34(1) 39(1) 25(1) -1(1) 3(1) -7(1) 
O(4) 31(1) 38(1) 31(1) -6(1) 13(1) -8(1) 
O(5) 25(1) 47(1) 22(1) -1(1) 8(1) -3(1) 
O(6) 38(2) 41(2) 88(2) -22(2) 11(2) -6(1) 
O(7) 83(2) 34(1) 35(1) 6(1) 22(1) 15(1) 
C(1) 23(1) 26(1) 21(1) -1(1) 6(1) -1(1) 
C(2) 19(1) 27(1) 21(1) -1(1) 5(1) -2(1) 
C(3) 27(1) 26(1) 26(1) -1(1) 7(1) -2(1) 
C(4) 26(1) 29(2) 32(2) -7(1) 8(1) -5(1) 
C(5) 24(1) 41(2) 23(1) -7(1) 4(1) -5(1) 
C(6) 22(1) 37(2) 23(1) 1(1) 3(1) -1(1) 
C(7) 20(1) 29(1) 21(1) 0(1) 6(1) -2(1) 
C(8) 20(1) 29(2) 22(1) 2(1) 6(1) -1(1) 
C(9) 22(1) 22(1) 23(1) -1(1) 2(1) -2(1) 
C(10) 29(1) 20(1) 26(1) -2(1) 7(1) -2(1) 
C(11) 22(1) 26(1) 22(1) 0(1) 4(1) -2(1) 
C(12) 29(2) 48(2) 33(2) -1(1) 13(1) -3(1) 
C(13) 32(2) 27(2) 38(2) -1(1) 12(1) -4(1) 
C(14) 50(2) 46(2) 36(2) 1(2) 6(2) -23(2) 
Chapter 7  Appendices 
 235 
Table 7: Hydrogen coordinates ( × 10
4




) for 292. 
  
Atom x y z U(eq) 
H(6A) 2010(90) 820(50) 1670(40) 80(20) 
H(6B) 2610(70) 1770(50) 1830(40) 75(18) 
H(7A) 9510(60) 940(40) -390(20) 63(15) 
H(7B) 9340(70) 830(30) 370(30) 74(17) 
H(3) 9897 3407 3170 31 
H(4) 11741 3889 4422 34 
H(5) 12933 2694 5413 35 
H(6) 12360 953 5170 33 
H(9) 8842 -1137 2626 27 
H(11) 5477 -108 2191 28 
H(12A) 3647 -169 3191 53 
H(12B) 4455 -447 4139 53 
H(12C) 4005 -1327 3459 53 
H(13) 6278 -2246 2396 38 
H(14A) 3369 -1271 1441 53 
H(14B) 3760 -2498 1481 53 
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